

This is a repository copy of *Digital interventions in mental health : evidence syntheses and economic modelling*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/171555/>

Version: Published Version

---

**Article:**

Gega, Lina [orcid.org/0000-0003-2902-9256](https://orcid.org/0000-0003-2902-9256), Jankovic, Dina [orcid.org/0000-0002-9311-1409](https://orcid.org/0000-0002-9311-1409), Saramago, Pedro [orcid.org/0000-0001-9063-8590](https://orcid.org/0000-0001-9063-8590) et al. (7 more authors) (2022) Digital interventions in mental health : evidence syntheses and economic modelling. Health technology assessment. pp. 1-182. ISSN 2046-4924

<https://doi.org/10.3310/RCTI6942>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

## Health Technology Assessment

Volume 26 • Issue 1 • January 2022

ISSN 1366-5278

# Digital interventions in mental health: evidence syntheses and economic modelling

*Lina Gega, Dina Jankovic, Pedro Saramago, David Marshall, Sarah Dawson, Sally Brabyn, Georgios F Nikolaidis, Hollie Melton, Rachel Churchill and Laura Bojke*





# Digital interventions in mental health: evidence syntheses and economic modelling

Lina Gega<sup>1,2,3\*</sup>  Dina Jankovic<sup>4</sup>  Pedro Saramago<sup>4</sup>   
David Marshall<sup>5</sup>  Sarah Dawson<sup>6,7</sup>  Sally Brabyn<sup>1</sup>   
Georgios F Nikolaidis<sup>4</sup>  Hollie Melton<sup>5</sup>   
Rachel Churchill<sup>5,6</sup>  and Laura Bojke<sup>4</sup> 

<sup>1</sup>Department of Health and Social Care Sciences, University of York, York, UK

<sup>2</sup>Hull York Medical School, University of York, York, UK

<sup>3</sup>Tees, Esk and Wear Valleys NHS Foundation Trust, Middlesbrough, UK

<sup>4</sup>Centre for Health Economics, University of York, York, UK

<sup>5</sup>Centre for Reviews & Dissemination, University of York, York, UK

<sup>6</sup>Common Mental Disorders Group, Cochrane Collaboration, University of York, York, UK

<sup>7</sup>Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK

\*Corresponding author

**Declared competing interests of authors:** Lina Gega report grants from the National Institute for Health Research (NIHR) during the conduct of the study (NIHR201174). Lina Gega also received personal fees from NIHR outside the submitted work. Pedro Saramago reports grants from NIHR during the conduct of the study. Rachel Churchill report grants from NIHR during the conduct of the study (NIHR127810, PB-PG-1217-20041 and NIHR 17/63/130). Laura Bojke report grants from NIHR during the conduct of the study (NIHR128833). Laura Bojke is also a member of the NIHR Health and Social Care Delivery Research Researcher-led Panel.

Published January 2022

DOI: 10.3310/RCTI6942

This report should be referenced as follows:

Gega L, Jankovic D, Saramago P, Marshall D, Dawson S, Brabyn S, *et al.* Digital interventions in mental health: evidence syntheses and economic modelling. *Health Technol Assess* 2022;**26**(1).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



# Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.014

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nihr.ac.uk/hta](http://www.journalslibrary.nihr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 17/93/06. The contractual start date was in September 2018. The draft report began editorial review in June 2020 and was accepted for publication in January 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Gega *et al.* This work was produced by Gega *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <https://creativecommons.org/licenses/by/4.0/>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library ([www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

---

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

## NIHR Journals Library Editors

---

**Professor John Powell** Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Consultant in Public Health, Delta Public Health Consulting Ltd, UK

**Dr Peter Davidson** Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont** Senior Adviser, Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid** Reader in Trials, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein** Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## Digital interventions in mental health: evidence syntheses and economic modelling

Lina Gega<sup>1,2,3\*</sup>, Dina Jankovic<sup>4</sup>, Pedro Saramago<sup>4</sup>, David Marshall<sup>5</sup>, Sarah Dawson<sup>6,7</sup>, Sally Brabyn<sup>1</sup>, Georgios F Nikolaidis<sup>4</sup>, Hollie Melton<sup>5</sup>, Rachel Churchill<sup>5,6</sup> and Laura Bojke<sup>4</sup>

<sup>1</sup>Department of Health and Social Care Sciences, University of York, York, UK

<sup>2</sup>Hull York Medical School, University of York, York, UK

<sup>3</sup>Tees, Esk and Wear Valleys NHS Foundation Trust, Middlesbrough, UK

<sup>4</sup>Centre for Health Economics, University of York, York, UK

<sup>5</sup>Centre for Reviews & Dissemination, University of York, York, UK

<sup>6</sup>Common Mental Disorders Group, Cochrane Collaboration, University of York, York, UK

<sup>7</sup>Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK

\*Corresponding author [lina.gega@york.ac.uk](mailto:lina.gega@york.ac.uk)

**Background:** Economic evaluations provide evidence on whether or not digital interventions offer value for money, based on their costs and outcomes relative to the costs and outcomes of alternatives.

**Objectives:** (1) Evaluate and summarise published economic studies about digital interventions across different technologies, therapies, comparators and mental health conditions; (2) synthesise clinical evidence about digital interventions for an exemplar mental health condition; (3) construct an economic model for the same exemplar mental health condition using the previously synthesised clinical evidence; and (4) consult with stakeholders about how they understand and assess the value of digital interventions.

**Methods:** We completed four work packages: (1) a systematic review and quality assessment of economic studies about digital interventions; (2) a systematic review and network meta-analysis of randomised controlled trials on digital interventions for generalised anxiety disorder; (3) an economic model and value-of-information analysis on digital interventions for generalised anxiety disorder; and (4) a series of knowledge exchange face-to-face and digital seminars with stakeholders.

**Results:** In work package 1, we reviewed 76 economic evaluations: 11 economic models and 65 within-trial analyses. Although the results of the studies are not directly comparable because they used different methods, the overall picture suggests that digital interventions are likely to be cost-effective, compared with no intervention and non-therapeutic controls, whereas the value of digital interventions compared with face-to-face therapy or printed manuals is unclear. In work package 2, we carried out two network meta-analyses of 20 randomised controlled trials of digital interventions for generalised anxiety disorder with a total of 2350 participants. The results were used to inform our economic model, but when considered on their own they were inconclusive because of the very wide confidence intervals. In work package 3, our decision-analytic model found that digital interventions for generalised anxiety disorder were associated with lower net monetary benefit than medication and face-to-face therapy, but greater net monetary benefit than non-therapeutic controls and no intervention. Value for money was driven by clinical outcomes rather than by intervention costs, and a value-of-information analysis suggested that uncertainty in the treatment effect had the greatest value (£12.9B). In work package 4, stakeholders identified several areas of benefits and costs of digital interventions that are important to them, including safety, sustainability and reducing waiting times. Four factors may



## ABSTRACT

influence their decisions to use digital interventions, other than costs and outcomes: increasing patient choice, reaching underserved populations, enabling continuous care and accepting the 'inevitability of going digital'.

**Limitations:** There was substantial uncertainty around effect estimates of digital interventions compared with alternatives. This uncertainty was driven by the small number of studies informing most comparisons, the small samples in some of these studies and the studies' high risk of bias.

**Conclusions:** Digital interventions may offer good value for money as an alternative to 'doing nothing' or 'doing something non-therapeutic' (e.g. monitoring or having a general discussion), but their added value compared with medication, face-to-face therapy and printed manuals is uncertain. Clinical outcomes rather than intervention costs drive 'value for money'.

**Future work:** There is a need to develop digital interventions that are more effective, rather than just cheaper, than their alternatives.

**Study registration:** This study is registered as PROSPERO CRD42018105837.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 1. See the NIHR Journals Library website for further project information.

# Contents

List of tables	xi
List of figures	xiii
List of supplementary material	xv
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
<b>Chapter 1</b> Background	<b>1</b>
Mental health	1
Interventions in mental health	2
Digital interventions	3
Economic evaluations	4
Gaps and limitations	6
Aims and objectives	7
Project design	8
Changes to protocol	8
Patient and public involvement	9
Conclusion	10
<b>Chapter 2</b> Classification of digital interventions in mental health	<b>11</b>
Introduction	11
Classification of digital interventions and their comparators	12
Challenges with classification of comparators within studies of digital interventions	14
<i>When a waiting list goes beyond 'no intervention'</i>	15
<i>When a comparator labelled as 'therapy' is better classified as a 'control'</i>	15
<i>When a technology-enabled intervention is classified as 'non-digital'</i>	16
<i>When unsupported interventions/controls include some type of 'contact'</i>	16
<i>Mixed interventions</i>	16
<i>Granularity of taxonomy</i>	16
Conclusions	16
<b>Chapter 3</b> Review of economic studies	<b>17</b>
Introduction	17
Methods	17
<i>Searches</i>	17
<i>Selection criteria</i>	17
<i>Study selection</i>	18
<i>Data extraction</i>	18
<i>Critical analysis</i>	18
<i>Quality assessment</i>	18

## CONTENTS

Results	19
<i>Summary of available economic evaluations of digital interventions</i>	19
<i>Quality of the included studies under each item of the Drummond checklist</i>	27
<i>Quality of the included studies under each item of the Philips checklist</i>	31
Key challenges and limitations in economic evaluation of digital interventions	31
<i>Estimation of costs and outcomes</i>	31
<i>Use of all available evidence</i>	38
<i>Specification of comparators</i>	38
<i>Time horizon for analysis</i>	39
Cost-effectiveness conclusions	39
<i>Digital interventions were dominant against alternatives</i>	55
<i>Digital interventions achieved better outcomes with higher costs against alternatives</i>	55
<i>Digital interventions were dominated by their alternatives</i>	56
Updated literature searches and additional studies retrieved	57
Discussion	59
Conclusions	60
<b>Chapter 4</b> Review of clinical studies for generalised anxiety disorder	<b>61</b>
Introduction	61
Methods	62
<i>Search strategy</i>	62
<i>Study identification and selection</i>	62
<i>Data extraction and risk-of-bias assessment</i>	63
<i>Data synthesis and statistical analysis</i>	63
<i>Assessment of heterogeneity and consistency</i>	64
<i>Sensitivity analysis</i>	64
Results	64
<i>Included and excluded studies</i>	64
<i>Sample characteristics in randomised controlled trials of digital interventions for generalised anxiety disorder</i>	65
<i>Selection of studies and outcomes for the network meta-analyses</i>	70
<i>Risk-of-bias assessment</i>	70
<i>Classification of digital interventions and comparators</i>	74
<i>Network meta-analysis results: Generalised Anxiety Disorder-7 scores at follow-up</i>	74
<i>Network meta-analysis results: Penn State Worry Questionnaire scores at follow-up</i>	79
<i>Results of between-study heterogeneity and inconsistencies</i>	80
<i>Sensitivity analysis results</i>	80
<i>Comparison of network meta-analysis results on Generalised Anxiety Disorder-7 and Penn State Worry Questionnaire for digital interventions</i>	82
Discussion	82
<i>Summary and interpretation</i>	82
<i>Limitations</i>	86
<i>Recommendations</i>	87
Conclusions	88
<b>Chapter 5</b> Economic modelling for generalised anxiety disorder	<b>89</b>
Introduction	89
Methods	89
<i>Classification of digital interventions and their alternatives</i>	89
<i>Model structure</i>	89
<i>Model parameters</i>	90
<i>Sensitivity analysis</i>	92
<i>Value-of-information analysis</i>	92

Results	93
<i>Generalised anxiety disorder score trajectory</i>	93
<i>Cost and outcomes of digital interventions compared with alternatives</i>	94
<i>Value-of-information analysis</i>	96
<i>Scenario analysis</i>	97
Discussion	98
Conclusions	99
<b>Chapter 6 Knowledge transfer and stakeholder involvement</b>	<b>101</b>
Introduction	101
Stakeholder seminars	101
Summary of feedback	102
Future communication strategies	105
Conclusion	106
<b>Chapter 7 Conclusions and recommendations</b>	<b>107</b>
Future evaluations of costs and outcomes of digital interventions in mental health	107
<i>Populations: reporting subgroup data by diagnosis, severity and comorbidity</i>	107
<i>Digital interventions: granularity of classification</i>	107
<i>Comparators: determined by care pathways</i>	108
<i>Clinical outcomes: choice of standardised measures</i>	109
<i>Cost estimation: reporting all technology-related costs</i>	109
<i>Cost estimation: justifying differences according to perspectives</i>	109
<i>Time horizon: need for long-term data</i>	110
<i>Economic analysis methods: trial based versus economic modelling</i>	110
<i>Research questions: value beyond symptom reduction and cost per unit gained</i>	110
<i>Digital therapeutic alliance: measure and relationship with outcomes</i>	111
Decision-making for digital interventions in mental health	111
Conclusion	113
<b>Acknowledgements</b>	<b>115</b>
<b>References</b>	<b>117</b>
<b>Appendix 1 Methods for statistical analysis and synthesis model</b>	<b>133</b>
<b>Appendix 2 Outcome measures used in randomised controlled trials of digital interventions for generalised anxiety disorder</b>	<b>139</b>
<b>Appendix 3 Results of randomised controlled trials of digital interventions for generalised anxiety disorder synthesised in the network meta-analysis models</b>	<b>143</b>
<b>Appendix 4 Surface under the cumulative ranking curve graphs and rankograms</b>	<b>147</b>
<b>Appendix 5 Assessment of between-study heterogeneity and inconsistencies</b>	<b>157</b>
<b>Appendix 6 Costing the support for digital interventions and controls</b>	<b>159</b>
<b>Appendix 7 Model parameters</b>	<b>161</b>
<b>Appendix 8 Generalised anxiety disorder score trajectory in scenario analysis</b>	<b>167</b>

## CONTENTS

<b>Appendix 9</b> Health-care costs in scenario analysis	<b>169</b>
<b>Appendix 10</b> Cumulative costs and outcomes over time	<b>171</b>
<b>Appendix 11</b> Results from scenario analyses	<b>173</b>

# List of tables

<b>TABLE 1</b> Examples of mental health problems according to <i>International Classification of Diseases</i> , Eleventh Revision, classifications	2
<b>TABLE 2</b> Types of economic evaluations	5
<b>TABLE 3</b> Classification criteria for comparison groups within research studies of DIs	13
<b>TABLE 4</b> Classification groups for DIs and alternatives	14
<b>TABLE 5</b> Economic evaluations of DIs in mental health	21
<b>TABLE 6</b> Quality assessment using the Drummond checklist	28
<b>TABLE 7</b> Quality assessment of structure in economic models of DIs using the Philips checklist	32
<b>TABLE 8</b> Quality assessment of data in economic models of DIs using the Philips checklist	34
<b>TABLE 9</b> Quality assessment of consistency in economic models of DIs using the Philips checklist	37
<b>TABLE 10</b> Classifications and summary of cost-effectiveness conclusions	39
<b>TABLE 11</b> Sample characteristics and outcome measurement in RCTs of DIs for GAD	66
<b>TABLE 12</b> Risk of bias in RCTs of DIs for GAD	71
<b>TABLE 13</b> Characteristics and classifications of interventions and controls in RCTs of DIs for GAD	75
<b>TABLE 14</b> Full meta-analysis results: network and direct pairwise comparisons between all interventions and controls for post-treatment (3–12 weeks) GAD-7 scores adjusted for baseline	78
<b>TABLE 15</b> Full meta-analysis results: network and direct pairwise comparisons between all interventions and controls post treatment (3–12 weeks) on PSWQ scores adjusted for baseline	81
<b>TABLE 16</b> Abridged meta-analysis results: relative treatment effects based on network and direct pairwise comparisons between DIs and alternatives for post-treatment (3–12 weeks) scores on GAD-7 and PSWQ median scores (adjusted for baseline)	83
<b>TABLE 17</b> Mean total cost and effect of DIs and alternatives for GAD (95% confidence interval)	95
<b>TABLE 18</b> Matrix of stakeholder-identified areas of importance for conducting and communicating research on costs and outcomes of DIs in mental health	103

<b>TABLE 19</b>	Description of data sets and variables	<b>136</b>
<b>TABLE 20</b>	Outcome measures used in at least two RCTs	<b>140</b>
<b>TABLE 21</b>	Outcome measures used in only one RCT	<b>141</b>
<b>TABLE 22</b>	Results of RCTs using the GAD-7 as outcome synthesised in the GAD-7 NMA model	<b>143</b>
<b>TABLE 23</b>	Results of RCTs using the PSWQ as outcome synthesised in the PSWQ NMA model	<b>144</b>
<b>TABLE 24</b>	Results from ANCOVA RE NMA consistency and inconsistency models for GAD-7 and PSWQ	<b>157</b>
<b>TABLE 25</b>	Support for DCs	<b>159</b>
<b>TABLE 26</b>	Support for DIs	<b>160</b>
<b>TABLE 27</b>	Distribution of patients across health states, after treatment	<b>161</b>
<b>TABLE 28</b>	Model parameters, with measures of uncertainty	<b>161</b>
<b>TABLE 29</b>	Age- and sex-related utility, and mortality decrements	<b>163</b>
<b>TABLE 30</b>	Generalised anxiety disorder score trajectory in scenario analysis	<b>167</b>
<b>TABLE 31</b>	State-specific health-care costs used in scenario analyses	<b>169</b>
<b>TABLE 32</b>	Mean QALY gains under different model assumptions for GAD score trajectory	<b>176</b>
<b>TABLE 33</b>	Mean total cost (£) under different model assumptions for GAD score trajectory (95% confidence interval)	<b>177</b>
<b>TABLE 34</b>	Mean NMB (£) under different model assumptions for GAD score trajectory (95% confidence interval)	<b>178</b>
<b>TABLE 35</b>	State-specific costs obtained from different sources	<b>179</b>
<b>TABLE 36</b>	Cost and NMB when using alternative health-care cost data	<b>179</b>
<b>TABLE 37</b>	Cost and effects when using alternative health-care cost data	<b>180</b>

# List of figures

<b>FIGURE 1</b> Mental well-being vs. mental health problems	1
<b>FIGURE 2</b> Interventions to prevent or improve mental health problems	3
<b>FIGURE 3</b> Classification of DIs and controls	12
<b>FIGURE 4</b> Combination of interventions vs. controls and digital vs. non-digital	13
<b>FIGURE 5</b> Taxonomy groups based on combinations of intervention vs. control, digital vs. non-digital and supported vs. unsupported	14
<b>FIGURE 6</b> The PRISMA flow diagram for the identification and selection of cost-effectiveness studies relating to DIs in mental health (search 1: up to November 2018)	19
<b>FIGURE 7</b> The PRISMA flow diagram for the identification and selection of cost-effectiveness studies relating to DIs in mental health (search 2: from November 2018 to October 2020)	58
<b>FIGURE 8</b> The PRISMA flow diagram for the identification and selection of clinical trials relating to DIs for GAD	65
<b>FIGURE 9</b> Proportion (%) of RCTs of DIs for GAD with 'low risk', 'high risk' or 'some concerns' in the six domains of the risk-of-bias tool	73
<b>FIGURE 10</b> Network plot for direct pairwise comparisons between all interventions and controls for GAD populations in RCTs with GAD-7 scores as an outcome	77
<b>FIGURE 11</b> Network plot for direct pairwise comparisons between all interventions and controls for GAD populations in RCTs with PSWQ scores as an outcome ( $n$ = number of comparisons available across all RCTs)	79
<b>FIGURE 12</b> Ranking of DIs (SDI and UDI) for GAD relative to NoDIs and controls based on their likelihood of being 'best' for outcomes up to 12 weeks' follow-up (adjusted for baseline)	85
<b>FIGURE 13</b> Ranking of DIs (SDI and UDI) for GAD relative to NoDIs and controls based on SUCRAs for outcomes up to 12 weeks' follow-up (adjusted for baseline)	85
<b>FIGURE 14</b> Decision model for GAD health states based on GAD-7 scores	90
<b>FIGURE 15</b> Movement through Markov states for the initial 5 years without treatment	93
<b>FIGURE 16</b> Change in mean GAD-7 score for the initial 5-year period after starting treatment	94
<b>FIGURE 17</b> Cost-effectiveness acceptability curves for each intervention and control	96



<b>FIGURE 18</b> Cost-effectiveness ranking based on NMB for DIs and controls	97
<b>FIGURE 19</b> The $EVPI_p$ for a range of opportunity costs	97
<b>FIGURE 20</b> Stakeholder groups	101
<b>FIGURE 21</b> Digital interventions and their alternatives in the context of the stepped-care model	108
<b>FIGURE 22</b> Decision-making based on costs and outcomes of DIs compared with alternatives	112
<b>FIGURE 23</b> Ranking of each intervention based on surface under the cumulative ranking curve values for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication	147
<b>FIGURE 24</b> Generalised Anxiety Disorder-7 rankograms: rankogram of each intervention for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication	149
<b>FIGURE 25</b> Penn State Worry Questionnaire surface under the cumulative ranking curves: ranking of each intervention based on surface under the cumulative ranking curve values for the PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI	152
<b>FIGURE 26</b> Penn State Worry Questionnaire rankograms: rankogram of each intervention for PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI	154
<b>FIGURE 27</b> Consistency plot for GAD-7	158
<b>FIGURE 28</b> Consistency plot for PSWQ	158
<b>FIGURE 29</b> Mean cumulative QALY gain over time	171
<b>FIGURE 30</b> Mean cumulative total cost over time	171
<b>FIGURE 31</b> Movement through Markov states without treatment in the initial 10-year period, where GAD-7 scores improve over time (scenarios 1–3)	173
<b>FIGURE 32</b> Movement through Markov states without treatment in the initial 10-year period, where GAD-7 scores are constant (scenarios 4–6)	174
<b>FIGURE 33</b> Generalised Anxiety Disorder-7 scores over time, in six scenarios	175
<b>FIGURE 34</b> Cost-effectiveness acceptability curves without DCs	180
<b>FIGURE 35</b> The $EVPI_p$ for a range of opportunity costs	181

# List of supplementary material

**Report Supplementary Material 1** Literature search for economic evaluations of DIs in mental health

**Report Supplementary Material 2** Excluded studies by reason from review of economic evaluations of DIs in mental health

**Report Supplementary Material 3** Literature search for RCTs of DIs for GAD, mixed anxiety and depression (up to December 2018)

**Report Supplementary Material 4** Literature search for RCTs of DIs (1997 to 7 June 2019)

**Report Supplementary Material 5** Excluded studies by reason from review of RCTs of DIs for GAD

**Report Supplementary Material 6** Targeted searches for informing state-specific costs and utilities for GAD model

Supplementary material can be found on the NIHR Journals Library report page (<https://doi.org/10.3310/RCTI6942>).

Supplementary material has been provided by the authors to support the report and any files provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any supplementary material provided at a later stage in the process may not have been peer reviewed.



## List of abbreviations

ANCOVA	analysis of covariance	GAD	generalised anxiety disorder
BAI	Beck Anxiety Inventory	GAD-7	Generalised Anxiety Disorder-7
BDI	Beck Depression Inventory	GAD-Q-IV	Generalised Anxiety Disorder Questionnaire-IV
BDI-II	Beck Depression Inventory, version 2	GP	general practitioner
CBA	cost–benefit analysis	HAM-A	Hamilton Anxiety Rating Scale
CBT	cognitive–behavioural therapy	HRQoL	health-related quality of life
CCA	cost–consequences analysis	ICER	incremental cost-effectiveness ratio
cCBT	computerised cognitive–behavioural therapy	MBI	mindfulness-based intervention
CDSR	Cochrane Database of Systematic Reviews	MCMC	Markov chain Monte Carlo
CEA	cost-effectiveness analysis	MHF	Mental Health Foundation
CENTRAL	Cochrane Central Register of Controlled Trials	MINI	Mini-International Neuropsychiatric Interview
CINAHL	Cumulative Index to Nursing and Allied Health Literature	NI	no intervention
CMA	cost minimisation analysis	NICE	National Institute for Health and Care Excellence
CrI	credible interval	NIHR	National Institute for Health Research
CUA	cost–utility analysis	NMA	network meta-analysis
CYP	children and young people	NMB	net monetary benefit
DARE	Database of Abstracts of Reviews of Effects	NoDI	non-digital intervention
DC	digital control	OCD	obsessive–compulsive disorder
DI	digital intervention	PHQ-4	Patient Health Questionnaire – 4 items
DIC	deviance information criterion	PHQ-9	Patient Health Questionnaire – 9 items
DoPHER	Database of Promoting Health Effectiveness Reviews	PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
EVPI	expected value of perfect information	PSWQ	Penn State Worry Questionnaire
EVPI <sub>p</sub>	expected value of perfect information at the population level	PSWQ-A	Penn State Worry Questionnaire – abbreviated
EVPPi <sub>p</sub>	expected value of partial perfect information at the population level	QALY	quality-adjusted life-year
FE	fixed effects	RCT	randomised controlled trial
		RE	random effects

## LIST OF ABBREVIATIONS

RR	relative risk	TAU	treatment as usual
SDC	supported digital control	UDC	unsupported digital control
SDI	supported digital intervention	UDI	unsupported digital intervention
SMS	short message service	UNoDC	unsupported non-digital control
SNoDC	supported non-digital control	UNoDI	unsupported non-digital intervention
SNoDI	supported non-digital intervention	VOI	value of information
SSRI	selective serotonin reuptake inhibitor	VR	virtual reality
STAI	State-Trait Anxiety Inventory	WHO	World Health Organization
SUCRA	surface under the cumulative ranking curve	WL	waiting list
		WP	work package

## Plain English summary

**D**igital interventions are activities accessed via technology platforms (e.g. computers, smartphones and virtual reality) that can improve users' mental health and reduce addiction problems. To assess whether or not digital interventions offer 'value for money', we needed to compare their costs and outcomes with the costs and outcomes of alternatives, such as face-to-face therapy and medication. This was done through economic evaluations.

This project consisted of four work packages. In work package 1, we reviewed 76 published economic evaluations of digital interventions for different mental health and addiction problems. We could not directly compare their results because of differences in the methods that were used, but the overall picture suggested that digital interventions could offer good value for money as an alternative to 'doing nothing' or simply monitoring someone or giving them general information.

The picture was unclear when digital interventions were compared with face-to-face therapy. In work package 2, we pooled research studies that evaluated the outcomes of digital interventions in reducing anxiety and worry; the results were inconclusive because we were uncertain about the differences in outcomes between digital interventions and alternatives. In work package 3, an economic model suggested that value for money in digital interventions is driven by how good they are and not by how much they cost. In work package 4, we presented our methods and results to service users, mental health professionals and researchers who wanted to know more about the value of digital interventions for specific groups (e.g. children and older adults) and for outcomes other than reducing symptoms (e.g. reducing waiting times for treatment and improving attendance for therapy). Finally, the stakeholders highlighted four factors that may influence their decisions to use digital interventions, other than costs and outcomes: increasing choice, reaching underserved populations, enabling continuous care and accepting the 'inevitability of going digital'.



# Scientific summary

## Background

Digital interventions use software programs, accessed via computers, tablets, smartphones and virtual reality equipment, to deliver therapeutic activities that aim to prevent and improve the symptoms and disability associated with mental health and addiction problems. There is an assumption that using technology can save time and money because it enables self-care and allows clinicians to deliver therapy remotely. Economic evaluations can provide evidence on whether or not digital interventions offer good value for money, based on their costs and outcomes relative to the costs and outcomes of alternatives.

## Objectives

Our aim was to review all published economic studies on digital interventions for mental health and addiction problems and then use an exemplar clinical condition to produce an economic model that demonstrates how we can bring together evidence from different sources to assess the cost-effectiveness of digital interventions compared with all possible alternatives. To do this, we aimed to develop classification criteria for categorising digital interventions and their alternatives, so that they could be reasonably pooled together in an evidence synthesis. To inform our economic model, we also aimed to conduct a quantitative synthesis of clinical outcomes from studies comparing digital interventions with alternatives for the exemplar clinical condition. We chose generalised anxiety disorder as our index condition for the clinical evidence synthesis and economic modelling because it has the highest weekly prevalence among all other mental health diagnoses and lends itself well to treatment with digital interventions, yet it is under-researched and under-reported. Finally, we aimed to explore how evidence on costs and outcomes, as well as other factors, can influence stakeholder decisions about the development, evaluation and adoption of digital interventions in mental health.

## Methods

The project comprised four work packages completed in 18 months. The first was a systematic review, critical appraisal and summary of economic evaluations of digital interventions across all mental health conditions. The second was a systematic review and two network meta-analyses of randomised controlled trials on digital interventions for generalised anxiety disorder. The third was the economic modelling and value-of-information analysis of digital interventions for generalised anxiety disorder. The final work package was a series of seminars with service users, professionals and researchers.

To be able to draw comparisons and conclusions across different economic evaluations, we classified digital interventions and their comparators into different groups based on three criteria: (1) therapeutic intent (intervention vs. control), (2) software processing (digital vs. non-digital) and (3) interpersonal communication (supported vs. unsupported). We used 10 classification groups to pool and compare costs and outcomes of digital interventions and alternatives: medication, supported non-digital intervention, supported digital intervention, unsupported digital intervention, supported digital control, unsupported digital control, no intervention, unsupported non-digital intervention, unsupported non-digital control and supported non-digital control.

We conducted a first literature search in December 2018, which was updated in October 2020 for the economic studies in work package 1, and in June 2019 for the clinical studies in work package 2. We searched the following databases: MEDLINE, PsycInfo® (American Psychological Association,



Washington, DC, USA), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Plus, Database of Abstracts of Reviews of Effects (DARE), EMBASE™ (Elsevier, Amsterdam, the Netherlands), Web of Science™ (Clarivate Analytics, Philadelphia, PA, USA) Core Collection, the Health Technology Assessment database and the National Institute for Health Research Journals Library, and the Database of Promoting Health Effectiveness Reviews (DoPHER). We also searched the NHS Economic Evaluation Database (NHS EED) for economic studies and two clinical trial registries for ongoing studies: ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform (ICTRP) portal. We searched the National Institute for Health Research portfolio and conducted web searches using Google (Google Inc., Mountain View, CA, USA) and Google Scholar (Google Inc.) using simplified search terms. We searched the reference lists of previous systematic reviews and of our included studies. We conducted forward citation chasing on all identified protocols, conference abstracts and the included studies using Google Scholar for any relevant publications. We also contacted researchers in the field for unpublished studies.

For work package 1, eligible economic evaluations included participants with emerging or existing mental health conditions. Studies were excluded if the primary diagnosis of the participants was a physical condition (e.g. cancer or insomnia). Interventions based on software were included, but technologies simply used for telecommunication without any software processing (e.g. telephones or videoconferencing) were excluded. We included economic evaluations conducted alongside trials and modelling studies, as long as they compared two or more options and considered both costs and consequences (i.e. cost-minimisation, cost-effectiveness, cost-utility and cost-benefit analyses).

For work package 1, we assessed the quality of the identified studies using standardised checklists that focused on the clarity of the research questions, the quality and completeness of data used, the methods used to characterise uncertainty in the evaluation model, and the interpretation of the results. We summarised cost-effectiveness conclusions, as reported by the reviewed studies, into three groups according to whether the studies found that (1) digital interventions dominated their alternatives (i.e. digital interventions had a lower cost and a better outcome), (2) digital interventions were dominated by their alternatives (i.e. digital interventions had a higher cost and a worse outcome) or (3) digital interventions achieved better outcomes with higher costs, so decisions about their cost-effectiveness depended on willingness-to-pay thresholds and the level of uncertainty associated with the results.

For work package 2, eligible clinical studies included participants with emerging or existing generalised anxiety disorder as determined by a standardised diagnostic interview or a score on a standardised measurement tool with an accepted cut-off value. Mixed populations of patients with generalised anxiety disorder and those with other conditions were included when clinical outcomes were reported separately for the subsample of participants with generalised anxiety disorder. We included digital interventions that were software based for patient-facing activity rather than systems that were only for administration, training or telecommunication. We included only randomised controlled trials.

For work package 2, we combined all trial-based effectiveness evidence in a single modelling framework allowing the estimation of relative treatment effects for all relevant comparisons between digital interventions and alternatives. Using an analysis of covariance framework for two outcome measures separately (i.e. the Generalised Anxiety Disorder 7-item questionnaire and the Penn State Worry Questionnaire), two network meta-analyses (one for each outcome) pooled post-treatment scores on each outcome, adjusted for baseline scores on the same outcome. We also carried out a risk-of-bias assessment for each study, checked for treatment effect modifiers, carried out several sensitivity analyses and evaluated network consistency. We presented the estimated results as relative treatment effect scores (and associated 95% credibility intervals) in the selected outcome measures. Finally, we estimated the probability of a treatment being the 'best', presented rankograms for all interventions and reported the surface under the cumulative ranking curve.

For work package 3, we used a Markov model, with 3-month cycles over the lifetime of an individual, to evaluate the cost-effectiveness of digital interventions for generalised anxiety disorder, across different types of technologies and therapeutic modalities, and for different comparators, from the perspective of the UK's health-care system. The model structure was based on anxiety severity, in which patients start in one of four health states: no, mild, moderate or severe anxiety. At each cycle of the model, patients can remain in a health state or transition to another, better or worse, health state. The intended effect of digital interventions was to reduce the severity of anxiety and move patients to less severe anxiety states. Model parameters included intervention effectiveness, state-specific utilities and costs, mortality and intervention costs. Patients' costs and health-related quality of life were tracked over the course of an individual's lifetime. The cumulative costs and quality-adjusted life-years gained or lost were then used to derive the net monetary benefit conditional on the marginal productivity of the health system. Probabilistic uncertainty analysis was conducted to characterise the uncertainty associated with input parameters to the model, and their impact on cost-effectiveness. One-way scenario analysis was performed to evaluate the sensitivity of the model results to our assumptions. The results from the probabilistic uncertainty analysis were used to estimate the value of information.

We held seven seminars with groups of stakeholders, which included commissioners who make funding decisions about services, practitioners and service managers who provide services, individual users who seek to improve or promote their mental health, and technologists and researchers who develop and evaluate digital interventions. Each seminar had two parts. The first part was the communication of our methods and findings through an interactive presentation. The second part was a question-answer and discussion session in which we asked the audience to identify the highlights of our findings that were important to them and any aspects of the presentation that were not clear, and to offer comments and feedback in general. We kept detailed notes and summarised and reflected on the key discussion points that arose from the seminars.

## Results

In work package 1, we identified 76 economic evaluations (11 were economic models and 65 were within-trial evaluations). The studies did not capture all relevant comparators or the long-term impact of mental health problems. Given that digital interventions are complex and heterogeneous, there are specific challenges to their economic evaluation and the synthesis of economic evidence, including the estimation of all costs and outcomes, conditional on the analysis viewpoint, and identification of appropriate and clinically useful comparators. Although the results of the economic evaluations are not directly comparable because of their different methods, the overall picture suggests that digital interventions are likely to be cost-effective against no intervention and non-therapeutic controls, whereas the value of digital interventions compared with face-to-face therapy or printed manuals is unclear.

In work package 2, we carried out two network meta-analyses of 20 randomised controlled trials that included a total of 2350 participants with emerging or diagnosable generalised anxiety disorder. The majority of comparisons were between supported digital interventions and waiting lists or usual care; there were no trials using individual therapy (rather than group therapy) or manual-based self-help as comparators. Owing to very wide confidence intervals, the results of our network meta-analyses were inconclusive as to whether or not digital interventions are better than no intervention or than non-therapeutic active controls, or whether or not they confer any benefit over and above group therapy. One of the network meta-analyses included a study comparing a digital intervention with medication; based on this study, we found that medication was associated with lower anxiety scores at follow-up relative to all other interventions and controls. Medication also ranked first in terms of its likelihood of being most effective, which considered the uncertainty in relative effect estimates. Supported digital interventions were not necessarily 'better' than unsupported (pure self-help) digital interventions.

In work package 3, a decision-analytic model found that digital interventions for generalised anxiety disorder were associated with lower net monetary benefit than for medication and group therapy, but greater net monetary benefit than for non-therapeutic and no intervention controls. Supported digital interventions may offer better value than unsupported ones for higher investment; however, if investment is zero, unsupported digital interventions may be a better option. The net monetary benefit of digital interventions and their alternatives was driven by health-care resource use and health-related quality of life, which, in turn, were driven by anxiety severity, both directly and through morbidity. This means that value for money was driven by clinical outcomes rather than by intervention costs. A value-of-information analysis suggested that uncertainty in the treatment effect had the greatest value (£12.9B), whereas parameters defining the effect of generalised anxiety on costs and health-related quality of life (state-related costs and utilities, and excess mortality) had low or negligible value.

In work package 4, discussions with stakeholders identified several areas of importance for conducting and communicating research on costs and outcomes of digital interventions in mental health:

- What is the added value of digital interventions for children and young people, people living in rural areas and older adults?
- In what way do digital interventions make a difference to individual users rather than just populations?
- What is the role of the therapeutic relationship?
- What are the non-specific effects of technology beyond the therapeutic content?
- What are the safety risks and adverse effects?
- Are digital interventions sustainable?
- Can we use digital interventions for tracking and monitoring?
- How can digital interventions improve communication with clinicians?

To gauge the value of digital interventions, the stakeholders were interested in 10 key outcomes: relapse occurrence, risk increase, attendance and completion of sessions, waiting time, admission rates, remission and recovery rates, re-admission rates, treatment duration and discharge rates, transition experience and number of patients per clinician.

## Conclusions

When it comes to value for money, digital interventions may be preferred to 'doing nothing' or 'doing something non-therapeutic' (e.g. monitoring or having a general discussion); however, there is uncertainty around their added value against medication, face-to-face therapy and printed manuals. With digital interventions for generalised anxiety disorder as a case in point, value for money is driven by clinical outcomes rather than intervention costs, and treatment effects have a very high value of information in resolving uncertainty of economic outcomes. This points to future research focusing on developing digital interventions that are more effective, rather than just cheaper, than their alternatives. To enhance their clinical effectiveness, we can improve the design and technology of digital interventions to enable them to achieve better outcomes as pure self-help tools and/or we can optimise the interpersonal support offered to patients to achieve better outcomes in the context of clinician-led treatment or supported self-help. Stakeholder feedback suggested that the value of future research is in demonstrating that digital interventions can increase patient choice, reach underserved populations and enable continuous care. The decision-making of stakeholders is also influenced by the 'inevitability of going digital'. With this in mind, strengthening the clinical and economic body of evidence on digital interventions is important not only to inform decisions about whether or not we should adopt them, but also to inform how we can make the most of them once they become an established and ubiquitous part of mental health care.

## Study registration

This study is registered as PROSPERO CRD42018105837.

## Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 1. See the NIHR Journals Library website for further project information.



# Chapter 1 Background

## Mental health

We can begin to understand mental health with two related, yet independent, concepts. Mental well-being (*Figure 1*, blue circle) refers to our sense of self, our ability to meet our potential and develop relationships, and our ability to do things that we consider important and worthwhile. Mental health problems (see *Figure 1*, purple circle) refer to the presence of specific signs and symptoms that indicate a diagnosable condition that affects our emotional state, physical function, behaviour and thinking.

The diagnosis of mental health problems is based on specific signs and symptoms that follow the World Health Organization (WHO)'s classification criteria,<sup>1</sup> which help clinicians group different types of mental health problems into specific diagnostic categories (*Table 1*). Clinical guidelines are also helpful to group different problems when they follow similar care pathways, for example the National Institute for Health and Care Excellence (NICE)'s clinical guidelines on common mental health problems.<sup>2</sup> Different mental health problems often coexist as comorbidities. In addition, the severity of mental health problems varies along a continuum not only between individuals, but also at different times in the same person; some people are more vulnerable than others, and the same person is more vulnerable at certain times in their lives, because of an accumulation of risk factors (e.g. family history of mental illness, abuse or bullying, and poverty). At any particular time, some susceptible individuals will be at one end of the continuum, with no symptoms and no risk of any mental health problems, while others will be further along the continuum, experiencing some degree of vulnerability to a specific mental health problem or exhibiting emerging or warning symptoms to some degree (see *Figure 1*, black arrow). Some people will move along the continuum to experience acute symptoms or a crisis, and, of those, some will recover and others will experience life-long and recurrent problems. This continuum gives a useful context to our work, as we will explore research studies in mental health, not only across different clinical populations, but also at different stages in the continuum for a specific clinical population represented by mild, moderate, severe or subthreshold states.

So, what is the difference, and the relationship, between mental well-being and mental health problems? Although diagnosable mental health problems are a risk factor for poor mental well-being, a diagnosis does not necessarily lead to poor mental well-being; many people with diagnosable mental health




FIGURE 1 Mental well-being vs. mental health problems.

**TABLE 1** Examples of mental health problems according to *International Classification of Diseases, Eleventh Revision, classifications*

Classification group	Examples of conditions
Schizophrenia/psychosis	Schizophrenia, schizoaffective disorder, delusional disorder
Mood disorders	Bipolar affective disorder, depressive episodes
Anxiety or fear-related disorders	Generalised anxiety disorder, panic disorder, agoraphobia, specific phobia, social anxiety, separation anxiety, selective mutism
Obsessive-compulsive or related disorders	Obsessive-compulsive disorder, body dysmorphic disorder, health anxiety, body-focused repetitive behaviour
Disorders associated with stress	Post-traumatic stress disorder, prolonged grief disorder, adjustment disorder
Feeding or eating disorders	Anorexia, bulimia, binge eating disorder, avoidant-restrictive food intake, pica
Disorders of bodily distress or bodily experience	Bodily distress disorder, body integrity dysphoria
Disorders due to substance use or addictive behaviours	Disorders due to substance use: alcohol drugs, sedatives, hypnotics or anxiolytics, caffeine, nicotine, other psychoactive and non-psychoactive substances  Disorders due to addictive behaviours: gambling disorder, gaming disorder
Impulse control disorders	Pyromania, kleptomania, compulsive sexual behaviour
Personality disorders and related traits	Personality disorder, prominent personality traits or patterns
Mental or behavioural disorders associated with pregnancy, childbirth and the puerperium	Post-natal depression, post-natal psychosis

problems flourish and maintain strong mental well-being. In contrast, the absence of diagnosable mental health problems does not guarantee strong mental well-being, as people have reported poor mental well-being without a diagnosis. This is an important distinction to delineate the scope of this work, which relates to emerging or existing diagnosable mental health problems and is not about general mental well-being.

## Interventions in mental health

Interventions to promote or improve mental health can be mapped onto the two concepts of mental health – mental well-being and mental health problems – and across the four key points of the continuum in *Figure 1* (at risk, emerging, acute problems, chronic problems). Interventions to support and improve mental well-being (*Figure 2*, the purple circle that sits in the background) are the foundation of good mental health for any population. This includes having an active lifestyle, eating and sleeping well, safeguarding people from abuse and bullying, providing good education, reducing poverty, ensuring equality and justice, and having meaningful relationships. Such activities are the foundation of mental well-being for any population, but they are beyond the scope of this work, unless they are specifically developed, implemented and evaluated in the context of preventing or improving emerging or existing mental health problems.

Typically, interventions within the scope of our work, that is interventions that aim to prevent or improve emerging or existing mental health problems, are either pharmacological (i.e. prescribed psychiatric medication indicated for a specific diagnosis) or non-pharmacological (i.e. psychological




FIGURE 2 Interventions to prevent or improve mental health problems.

therapies, social interventions, physical and occupational therapies, behavioural interventions). The aims of these interventions, as shown in *Figure 1*, are to:

- reduce the likelihood of occurrence of future mental illness among those at risk (targeted prevention)
- reduce emerging and early symptoms before these manifest as a diagnosable illness (early intervention)
- improve acute symptoms and manage crisis (treatment)
- improve and manage chronic symptoms to minimise the likelihood of recurrence (relapse prevention).

Our project focused on mental health outcomes associated with an intervention, in the form of reducing the incidence/occurrence of mental health problems and the severity of clinical symptoms associated with those. Mental health interventions could instigate behaviour change, improve physical health outcomes and have a positive impact on proxy indicators and factors associated with mental well-being (e.g. employment and poverty). These are important outcomes but beyond the scope of this project.

## Digital interventions

Digital interventions (DIs) use software programs that are accessed via computers, tablets, smartphones, audio-visual and virtual reality (VR) equipment, gaming consoles, robots and other devices to deliver interventions that aim to prevent or improve mental health problems, including depression, anxiety disorders, addictive behaviours and eating disorders.<sup>3</sup> DIs collect, store and retrieve clinical information: deliver standardised instructions via text, voice files or video clips: and guide users in the application of therapeutic activities. DIs can include varying levels of standardisation, self-help and clinician involvement; some are entirely self-administered by service users, whereas others are completely reliant on a clinician/therapist.

Digital interventions are often standardised, automated, user-directed, psychological therapies that use technology to help users work through a therapeutic activity either independently of, or alongside, a clinician or therapist. One common mental health therapy that features heavily in DIs, because of its structured approach, is cognitive-behavioural therapy (CBT). CBT treats a physical or mental health problem by identifying and changing certain beliefs and behaviours that maintain the problem. CBT places emphasis on activities completed by users outside therapy sessions; this is commonly referred to as 'homework', which fits in well with the self-directed nature of DIs.



An example of a DI is an internet-based self-help programme evaluated by Christensen *et al.*<sup>4</sup> The intervention was a 10-week structured therapy consisting of psychoeducation (weeks 1 and 2), CBT (weeks 3–7), relaxation (weeks 8 and 9) and physical activity (week 10). The psychoeducation section provided information on worry, stress, fear and anxiety; how to differentiate between types of anxiety disorders; risk factors for anxiety; comorbidity; consequences of anxiety; and available treatments. The CBT toolkit addressed typical anxious thoughts and included sections on dealing with the purpose and meaning of worry, the act of worrying and the content of worry. The relaxation modules guided participants on how to progressively tense and relax different muscle groups to induce relaxation and how to become aware of their breathing and body, acknowledging thoughts and external distractions but remaining focused on the present. The physical activity gave tailored advice depending on the level of the participant's motivation and ability.

Another example of a DI is a mobile app (application) in a study by Pham *et al.*,<sup>5</sup> which engaged users in a series of minigames to learn and practise diaphragmatic breathing to alleviate symptoms of anxiety, in line with NHS protocols and evidence-based literature. The minigames had various themes, from sailing a boat down a river to flying balloons into the sky. Users touched the screen with their finger as they inhaled and removed their finger from the screen as they exhaled to control the gaming mechanics. A breathing indicator visually represented a full breath; users saw a circle expanding as they inhaled and contracting as they exhaled. This indicator provided a visual guide of a breathing retraining exercise. The goal of each minigame was to correctly follow the breathing indicator to progress in the game narrative; users progressed through levels and achieved goals by breathing correctly and staying calm.

### Economic evaluations

Digital interventions are particularly important for mental health care in locations where access to services is limited and face-to-face contact with psychiatrists and psychologists is at a premium. The decision to adopt DIs into a health-care system is, at least in part, informed by an assessment of value for money. There is an assumption that DIs offer 'good value for money' because they have the potential to save clinician time and make clinical work more efficient by encouraging patient self-management, allowing remote delivery of interventions, enabling a less specialised workforce to deliver complex interventions, enhancing outcomes for the same level of therapeutic input and reducing waiting lists (WLs).

Economic evaluations can provide evidence to support or refute the assumption that DIs are good value for money, by comparing the costs and outcomes of DIs relative to the costs and outcomes of relevant alternatives. Economic evaluations are often built within clinical evaluations or trials, which compare the outcomes of a new intervention/service with the outcomes of a control (e.g. usual or standard care) over a specific period of time. Randomised controlled trials (RCTs) are considered the 'gold standard' of clinical evaluations because changes in the selected outcome measures are likely to be due to the effect of the intervention itself, rather than be due to chance or other confounding variables (e.g. spontaneous remission of symptoms over time, attention or measurement effects).

Outcomes in economic evaluations are often expressed in terms of quality-adjusted life-years (QALYs), which are generated by multiplying years of life by the utility scores associated with the specific health states experienced by the person. Costs are calculated by multiplying resources used (resource utilisation) over an appropriate time horizon by the price attached to each unit of that resource (unit cost). The costs can include direct costs (e.g. for medication, therapies, social services and transportation), indirect costs (e.g. productivity loss due to time off work and criminal justice expenditure) and intangible costs (e.g. impaired quality of life and distress of living with pain).

The type of resources included in the final cost calculation depends on the perspective of the economic evaluation, that is who pays for or saves from the resources used that we are interested in, such as the

society in general or the health service in particular. This is important when the intervention is expected to have different impacts on different sectors and stakeholders (e.g. one sector incurred the majority of the costs and another yields the benefits of an intervention). The perspective of an economic evaluation can be as narrow as a particular agency or government department (e.g. ministry of health) or can be broader to include the statutory/public sector as a whole (e.g. all health and social care services).

There are five common types of economic evaluations that compare costs and outcomes between different interventions: cost minimisation analysis (CMA), cost-consequences analysis (CCA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA). All five types are similar in the way they measure costs, but they differ in the ways they measure health outcomes and combine these with costs to reach decisions about value for money.

Cost-minimisation analysis starts from the basis that two interventions have similar outcomes (in terms of effectiveness and safety) but different costs; however, the lack of a statistically significant difference in outcomes does not mean that the interventions are equivalent.<sup>6</sup> A CCA considers all the health and non-health impacts and costs of different interventions across different sectors; it then lists or tabulates these in a disaggregated form for each intervention and does not attempt to synthesise the costs and outcomes within and between interventions.

Cost-effectiveness analysis, CBA and CUA are three types of economic evaluations that compare the costs and outcomes of an intervention with the costs and outcomes of its alternatives. Outcomes are measured in their natural units (e.g. symptom-free days, depression score) in a CEA; in units of utility or preference, often as a QALY, in a CUA; and in monetary units in a CBA. The relative costs and outcomes of an intervention and an alternative are then summarised into one number, known as an incremental cost-effectiveness ratio (ICER), by dividing the difference in costs (incremental cost) by the difference in outcomes (incremental effect).

Table 2 provides an overview of how the five types of economic evaluations differ in terms of outcomes and their synthesis with costs.

These five types of economic evaluations are informed by short- or medium-term clinical outcomes (in mental health usually up to 2 years) when they are based on a within-trial analysis, depending on the length of time during which participants in a RCT are followed up. Within-trial CEAs, or 'piggy-back' economic evaluations as they are known, have limitations, for example the atypical nature of trial setting, inappropriate clinical alternatives, inadequate length of follow-up, inadequate sample size for economic analysis, protocol-driven costs and benefits, and inappropriate range of end points (for both costs and outcomes). Health economic decision models are used to guide the choice of interventions for a clinical population on the basis of expected benefits and costs, commonly over a lifetime.<sup>7</sup> Decision models are

TABLE 2 Types of economic evaluations

Analysis	Expression of outcomes	Synthesis of costs and outcomes
CMA	Outcomes are shown to be similar	Only costs are compared
CCA	A group of different outcomes expressed in their natural units	Not applicable – costs and outcomes are not combined but presented in separate tables for qualitative comparison
CEA	A single condition-specific outcome expressed in its natural units (e.g. points on a depression scale)	ICER: cost per natural unit
CUA	Utilities: QALYs or disability-adjusted life-years	ICER: cost per utility
CBA	Money	Net monetary benefit or cost

often implemented by using either decision trees or Markov models. In Markov models, patients move between clinical states of interest in discrete time periods. Each state is associated with certain costs and outcomes. Decision models are defined by parameters that include probabilities of transition between clinical states, costs and outcomes associated with each state, treatment effects and other covariates (e.g. comorbidities and age). All available relevant evidence should be used to inform these parameters, which may include RCTs and population observational studies.

Once the costs and outcomes of competing alternatives have been estimated, either through a within-trial economic evaluation or through modelling, standard decision rules can be used to conclude whether or not a DI should be adopted.<sup>8</sup> If CEAs demonstrate that DIs are likely to be both more effective and less costly than the alternatives, then DIs are the preferred option in terms of 'value for money'. Decision-making is more complex if DIs yield better outcomes for a greater cost than their alternatives. Where costs are higher and outcomes better, or costs lower and outcomes poorer, the incremental gain for a DI (costs saved or QALYs gained) must be assessed according to the marginal productivity of the health-care system (i.e. how much health is gained with an increase in expenditure at the margin or how much health is lost with a decrease in expenditure at the margin). An acceptable cost per QALY is health system specific, and is estimated at £15,000 in the UK,<sup>9</sup> although alternative figures of £50,000<sup>10</sup> and £20,000–30,000 have been used in decision-making.<sup>11</sup>

Making a choice in favour of DIs (even when they are likely to be cost-effective) may imply the sacrifice of alternative options, which may not always be possible for ethical, clinical or feasibility reasons (e.g. we cannot replace the family doctor with digital self-management, but we can use the latter in addition to visits to the family doctor). Moreover, the cost of software and hardware for DIs is often frontloaded, whereas savings (or improved outcomes) are accrued in the long run, so those paying for DIs need to have the money to invest up front. Finally, costs incurred for DIs and benefits accrued from DIs may relate to different budgets (e.g. DIs are paid for by the health service that looks after the employees of a company but savings are accrued in the employment sector by reducing absenteeism of these employees).<sup>12</sup> Health-care providers and users may not adopt DIs even when they are proven to be cost-effective, because this will require either disinvesting from existing care options that cannot be forgone, or generating 'new monies' to add DIs to existing care options.

An additional consideration for decision-making utilising cost-effectiveness evidence is uncertainty. This uncertainty pertains to the evidence base used to generate estimates of cost-effectiveness as well as assumptions that are required in compiling this evidence. To inform decision-making, we need to characterise this uncertainty appropriately, for example using probabilistic sensitivity analysis and/or scenario analyses, and we need to explore the implications of this uncertainty in terms of adoption decisions and recommendations for further research.<sup>13</sup> Although decisions are binary (yes/no) in terms of cost-effectiveness, the evidence underpinning decisions may be uncertain, and so there is a probability of making the 'wrong decision'. The evidence base to support assessments of cost-effectiveness for DIs is likely to be less developed than, for example, pharmaceuticals because of different regulatory requirements associated with the adoption of digital health interventions compared with pharmaceuticals. This implies that an assessment of cost-effectiveness for DIs should reflect this uncertainty and communicate it appropriately to decision-makers.

## Gaps and limitations

The first systematic review of economic evidence for DIs was published by NICE more than 10 years ago<sup>14</sup> and included only one CEA available at the time, which was on computerised CBT (cCBT).<sup>15</sup> Recent syntheses of economic evidence relating to DIs have focused on a specific technology (e.g. the internet)<sup>16,17</sup> or a specific intervention (e.g. CBT)<sup>18</sup> or a combination of both (e.g. internet CBT).<sup>18-21</sup> Some reviews<sup>22,23</sup> include a wider range of interventions, such as online problem-solving therapy and positive psychology interventions. Most reviews are of studies of the most common

mental health problems, namely depression and anxiety, but, increasingly, more reviews of economic evidence relevant to psychological and behavioural interventions include addictive behaviours (e.g. smoking<sup>24</sup>) and physical health/somatic problems.<sup>25,26</sup>

The number of economic evaluations is a fraction of the number of clinical trials of DIs. Reviews of economic evidence for the use of digital technologies to support mental health care (irrespective of the targeted population or type of technologies and interventions used) are useful, not least because the potential investment in digital technologies is large and irreversible. The economic evidence base for DIs is uncertain, so we need to understand under what circumstances these technologies are conducive to efficient delivery of care and the degree of certainty in the conclusions regarding cost-effectiveness. There may also be particular core assumptions that are key to determining the cost-effectiveness of DIs, such as engagement with DIs by patients (which can considerably change outcomes) and variable provision of personal support as an adjunct to DIs (which can considerably change the cost, e.g. if support is given by specialist clinicians or laypeople).

Previous work<sup>27</sup> has concluded that economic evaluations for DIs (not specific to, but including, mental health) may require more flexible approaches to reflect the complexity of the intervention and its outcomes. Data to inform CEAs may not capture all the information required to assess cost-effectiveness. In most CEAs for DIs, time horizons are short, and the full opportunity costs of DIs, such as development costs, are not usually captured. Wider social costs, including productivity losses, presenteeism and other intangible costs, which carry weight in mental health, are also inconsistently measured. In addition, CEAs rarely estimate the investment sum needed for implementing DIs or the budgetary impact of their implementation against existing alternatives.

To our knowledge, there is no consideration of the appropriateness of existing methods of CEA to assess the value of DIs. To do so requires a comprehensive overview and critique of the cost-effectiveness evidence relating to the use of digital technologies to promote or improve mental health outcomes. Such a review will help to highlight the key conditions that make DIs cost-effective based on current evidence, as well as to identify key issues for consideration in establishing their cost-effectiveness. The results of a review and critique can be used to generate guidance and a checklist for future CEAs of DIs.

## Aims and objectives

Our main aim was to make best use of existing evidence so that we could (1) inform practice and future research about which DIs are likely to represent a good use of health-care resources, (2) evaluate how uncertain the evidence regarding their cost-effectiveness is and (3) determine what drives variation in their value for money. Our secondary aim was to explore how current economic and clinical evidence is understood and used by key stakeholders in making decisions about the future development, evaluation and adoption of DIs.

Our objectives were to:

- identify and summarise all published and unpublished CEAs comparing the costs and outcomes of DIs for the prevention and treatment of any mental health condition to the costs and outcomes of relevant alternatives [e.g. interventions that do not involve digital technologies or no intervention (NI)]
- identify key drivers of variation in the effects and costs of DIs (e.g. for different population subgroups, delivery methods, economic perspectives or outcome measures)
- develop classification criteria to inform the categorisation of DIs and their comparators
- critically evaluate the quality and appropriateness of the methods used by existing CEAs to establish the cost-effectiveness of DIs
- determine what cost-effectiveness judgements can be made for DIs given current evidence from economic evaluations

- conduct an exploratory analysis to quantify the short- and long-term cost-effectiveness of DIs using a de novo decision-analytic model informed by a systematic review and quantitative data synthesis of clinical trials on common mental health problems
- conduct a value-of-information (VOI) analysis based on the decision model findings and make recommendations as to what further research is necessary to inform future decisions
- suggest how the methods of future CEAs for DIs can be improved by producing a step-by-step guide and a quality assessment checklist
- investigate how the results on CEAs of DIs can be most effectively communicated to and inform decision-making by:
  - commissioners to fund services that use DIs
  - practitioners and service managers to provide DIs in routine care
  - service users to engage with DIs to improve or promote their mental health
  - technologists and researchers to further develop and optimise DIs.

## Project design

The project had four work packages (WPs):

1. WP1 was a systematic review, critical appraisal and narrative synthesis of economic evaluations of DIs across all mental health conditions.
2. WP2 was a systematic review and network meta-analysis (NMA) of RCTs on DIs for a selected mental health condition.
3. WP3 was the economic modelling and VOI analysis of DIs for the selected mental health condition.
4. WP4 was a series of knowledge exchange seminars with stakeholders focusing on costs and outcomes of DIs.

We have reported our methods and findings of the systematic reviews in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.<sup>28,29</sup> We have reported our economic modelling in accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.<sup>30</sup>

## Changes to protocol

The protocol initially stated that the systematic review in WP2 and the model in WP3 would focus on depression and anxiety under the umbrella 'common mental health problems'. These conditions were chosen because most of the available and best-quality clinical evidence relates to common mental health problems, as opposed to psychosis, eating disorders or autism.<sup>31-35</sup> During the course of the project, we concluded that the disease and treatment pathways across the group of conditions included under the original umbrella term of common mental health problems were too disparate to analyse in a single model. Related to this point, the international classification manuals removed some of the conditions that were previously considered under 'anxiety disorders', such as obsessive-compulsive disorder (OCD) and post-traumatic stress disorder, to their own diagnostic groups, making them even more disparate. Consequently, we refined the scope of the review in WP2 and the model in WP3 to an exemplar mental health condition, and the changes were approved by the project steering group's independent members. The decision to focus on one exemplar condition, and that this condition should be generalised anxiety disorder (GAD) as opposed to a group of common mental health problems or a single condition other than GAD (e.g. depression), was based on the following factors:

- Different common mental health problems have different illness trajectories and different treatment pathways, so they cannot be reasonably analysed in one model.

- GAD is the most prevalent and least studied condition among other common mental health problems; its point prevalence is nearly double that of depression and it is often confused with panic disorder or depression when self-reported by survey participants. It is also commonly comorbid with other physical and mental health problems.
- A substantial proportion of the papers identified in WP1 targeted GAD and related conditions, such as worry and stress, and so there was value in synthesising the findings from multiple studies and using this synthesis to inform the economic model.
- We have not identified any anxiety models with an analysis time horizon > 18 months, and so a long-term model would provide a useful contribution to the body of evidence. In contrast, several long-term economic models for depression already exist, some of which have been used as a basis to assess the cost-effectiveness of DIs.

In the original protocol we thought that WP4 would require ethics approval by the University of York and the Health Research Authority. In the end, ethics approval was not necessary because our WP4 seminars were conducted as consultations and educational seminars, and we did not collect or report any information from individual participants. We did not record the sessions and we did not use any quotations or individual contributions, but reported only on general discussion themes across seminar groups. This was because our engagement with the stakeholders was an iterative process and it became apparent that it had to be embedded within the routine professional development activities of the stakeholders, such as clinical seminars and advisory group meetings, rather than as separate 'research focus groups'.

## Patient and public involvement

The patient and public involvement/service user member of our steering group attended all steering groups meetings and gave feedback during and after the meetings about how the project can lead to clear messages about the value for money of digital mental health interventions, especially 'long-term' value. He suggested that 6 months is a meaningful period of time to measure benefits and costs from a service user's perspective as a way of distinguishing short-term and medium-term outcomes. We liaised regularly with him outside the steering group meetings to discuss decisions about literature search terms, inclusion/exclusion criteria and ways of organising information to carry out dissemination activities for our findings as part of WP4.

We have also had patient and public representation through our partners at the Mental Health Foundation [(MHF); London, UK], whom we met on a regular basis. Josefien Breedvelt, the Research Manager at the MHF at the time, acted as a conduit between the MHF's regular patient and public consultations and this project. MHF is a public champion of mental health promotion and illness prevention, which has been a 'grey area' in our literature review for which we sought the MHF's steer. DIs for mental health promotion and prevention were represented in a large and often overinclusive body of literature that could mean anything from universal emotional well-being initiatives to targeted or indicated interventions for populations with established symptoms or risk factors. The MHF participated in discussions about inclusion/exclusion criteria for our review in terms of appropriate interventions and outcomes around mental health promotion and prevention. One of the conclusions was that 'prevention of mental health problems' rather than 'mental health promotion' better described the focus of our review.

We have also had public involvement activities through the Closing the Gap network (University of York); one of the network's themes, which was led by this project's chief investigator, focused on improving physical outcomes in people with mental illness through digital technologies. Our project included only mental health outcomes and not physical health outcomes, but this was a point that we had to decide on early in the project so that we could agree on inclusion/exclusion criteria for the retrieved literature. The patient and public involvement members of the Closing the Gap network suggested that certain outcomes are directly related to physical health but can also be considered as

mental health outcomes, such as smoking cessation and alcohol detoxification ('addiction outcomes'). This was suggested as a good base for our review, which in the future can be extended to include physical health outcomes separate to mental health outcomes.

## Conclusion

Digital interventions use software programs, accessed via computers, smartphones, audio-visual equipment and other devices, to deliver therapeutic activities that aim to make a difference to the symptoms and functioning of people with mental health and addiction problems. Economic evaluations can provide evidence as to whether or not DIs offer value for money, based on their costs and outcomes relative to the costs and outcomes of alternative care options. Our first aim was to review all published economic studies on DIs for mental health and addiction problems. Our second aim was to use an exemplar clinical condition to conduct a synthesis of clinical evidence, which would then inform our third aim of constructing an economic model that demonstrates how we can bring together evidence from different sources to assess the cost-effectiveness of DIs compared with all possible alternatives. To this end, we also aimed to develop classification criteria for categorising DIs and their alternatives so that they could be reasonably pooled together. Finally, we aimed to explore how evidence on costs and outcomes, as well as other factors, may influence stakeholder decisions to adopt DIs in mental health.

# Chapter 2 Classification of digital interventions in mental health

## Introduction

Systematic reviews can provide a comprehensive picture of the currently available evidence on DIs, but the way they often lump or split this evidence does not always lead to meaningful or useful conclusions. For example, technology-mediated interventions in mental health can include internet consultations [clinician–patient telecommunication by e-mail or via Skype™ (Microsoft Corporation, Redmond, WA, USA)] and internet therapy (self-help with no support or some brief support from a clinician or lay person). These two types of interventions are ‘apples and oranges’ when it comes to funding and delivery of services, because internet consultations need a clinician to deliver them but do not require sophisticated software (so costs are mostly for human resources), whereas internet therapy needs software but can be delivered without clinician input (so costs are mostly for technology development and maintenance).

Using a classification system can help an evidence synthesis make best use of the currently available evidence by grouping together DIs that share key characteristics. Different stakeholders may have different views about how DIs should be lumped or split based on their key characteristics. For developers, the type of technology used [e.g. web based, mobile apps (applications) or artificial intelligence] may be the most important characteristic, whereas for clinicians the type of therapeutic approach may have an over-riding significance. For managers, DIs that increase service capacity are different from DIs that enhance usual care, whereas service users may consider it important to differentiate between DIs that enable them to stay in contact with clinicians and peers and DIs that are entirely automated self-help.

The WHO<sup>1</sup> has produced a classification system for digital health interventions (not specific to mental health) according to four stakeholder groups (i.e. clients, health-care providers, health system managers and data services). The WHO classification groups reflect the different functions of DIs for each stakeholder group (e.g. self-monitoring for clients, training for health-care providers, management of budget and expenditures for managers, and data storage and aggregation for data services). The WHO system uses the term ‘intervention’ in a broad sense to include administrative activities and training that are important for health care but are not designed as patient-facing therapeutic activities to directly prevent or improve clinical symptoms.

For this project, we developed classification criteria that we could apply to the comparators used across the economic evaluations reviewed in WP1 and the RCTs reviewed in WP2. Using these criteria, we aimed to allocate each comparator (e.g. internet therapy, face-to-face therapy, control website and usual care) to a classification group. This would enable us to aggregate many complex and diverse comparators to a contained number of classification groups. Our evidence synthesis pooled together the costs and outcomes of comparators within the same classification group and compared the costs and outcomes of comparators in different classification groups. The granularity and number of classification groups aimed to strike a balance between the number of studies that could inform each classification group and the number of distinctive comparisons between groups; too many classification groups would have limited the number of combined studies within each group, whereas too few classification groups would have diluted the distinctiveness of comparisons between groups.



## Classification of digital interventions and their comparators

We followed a five-step process for the allocation of comparators into classification groups. First, we extracted the key characteristics of comparison groups as reported in the reviewed studies. These comparison groups included at least one DI. We used existing frameworks of reporting complex interventions<sup>36</sup> to ensure that we captured all the necessary components for each comparison group, as reported by the studies. Second, we identified common and differentiating features of the comparison groups between and within studies. Third, we consulted the literature and an advisory group of researchers, clinicians and service users about features within the available comparison groups that could be important for the relative costs and outcomes of DIs and their comparators. Fourth, we classified each comparison group in the reviewed studies based on specific criteria. Finally, we used combinations of these criteria to arrive at a list of classification groups.

We used three criteria, as shown in *Figure 3*, to classify each comparison group: (1) whether the group was an intervention or a control – the intervention could be either psychosocial/behavioural (I) or medication (M), and the control could be either a non-therapeutic control (C) or NI; (2) whether the intervention/control was digital (D) or non-digital (NoD); and (3) whether the intervention/control was supported (S) or unsupported (U). The criteria are defined in *Table 3*.

Using a combination of two criteria (intervention vs. control and digital vs. non-digital), we arrived at six comparison groups: DI, digital control (DC), non-digital intervention (NoDI), non-digital control (NoDC), NI and medication (*Figure 4*). In the context of this report, NoDI infers that the intervention is psychosocial/behavioural in nature. It is worth reiterating that we merged WL and usual care into ‘no intervention’ to mean that no additional activities or input were offered as part of a research study over and above interventions and resources that were routinely accessible to all participants irrespective of group allocation. We have further addressed this by grouping usual care or WL interventions into active controls when they included activities over and above what would be expected in routine care, or when usual-care activities were not accessible to the intervention group.

Using a combination of the three criteria (i.e. intervention vs. control, digital vs. non-digital and supported vs. unsupported), we arrived at 10 classification groups: medication (M), supported non-digital intervention (SNoDI), supported digital intervention (SDI), unsupported digital intervention (UDI), supported digital control (SDC), unsupported digital control (UDC), NI, unsupported non-digital intervention (UNoDI), unsupported non-digital control (UNoDC) and supported non-digital control (SNoDC) (*Figure 5*).

*Table 4* provides examples for each classification group.




FIGURE 3 Classification of DIs and controls.

TABLE 3 Classification criteria for comparison groups within research studies of DIs

Group classification	Criteria
Psychosocial/behavioural intervention (I)	An activity offered as part of a research protocol for therapeutic purposes (i.e. we expect it to make a difference in a mental health problem by improving clinical symptoms and functioning, based on psychological, behavioural, social or educational theories, evidence and/or experience)
Medication (M)	A pharmacological agent (pills, injections, etc.) offered as part of a research protocol
Non-therapeutic control (C)	An activity offered as part of a research protocol that we do not expect to make a clinically important difference to a mental health problem. This may be a psychological placebo, an attention control, or a change in usual care introduced by the research team to keep participants safe and minimise attrition
Digital (D)	Interventions/controls that include software processing of patient information to guide an activity
Non-digital (NoD)	Interventions/controls that do not involve any technology; for example, they are delivered by printed materials or during face-to-face meetings, or involve telecommunications technology without software-led activities (e.g. consultations by e-mail, Skype or telephone)
No intervention (NI)	No protocolled research activity and no changes in usual care introduced by the research team; this is typically when participants are placed on a WL or receive usual care. We used NI rather than 'WL/usual care' to differentiate from a 'non-therapeutic control' in which WL/usual care is enhanced by research activities (e.g. weekly contact for assessment)
Supported (S)	Interventions/controls that include scheduled or regular reciprocal/two-way person-to-person interactions (e.g. between service user and clinician or researcher, or peer to peer)
Unsupported (U)	Interventions/controls with no person-to-person interaction or ad hoc interaction (e.g. telephoning a helpline if any problems as a one-off) or non-reciprocal communication (e.g. reminders, posted or telephone messages without the expectation that there will be a conversation with the patient)




FIGURE 4 Combination of interventions vs. controls and digital vs. non-digital. M, medication.




FIGURE 5 Taxonomy groups based on combinations of intervention vs. control, digital vs. non-digital and supported vs. unsupported. M, medication.

TABLE 4 Classification groups for DIs and alternatives

Acronym	Classification of intervention/control	Examples
M	Medication	Antidepressants, anxiolytics
SDI	Supported digital intervention	Computerised CBT with weekly telephone support, clinician-delivered therapy with VR, mobile app with SMS communication with a facilitator
UDI	Unsupported digital intervention	Internet self-help without any clinician contact, mobile app with automated reminders but without any two-way interaction with a facilitator
SNoDI	Supported non-digital intervention	Individual or group therapy, telephone brief therapy
UNoDI	Unsupported non-digital intervention	Stand-alone self-help using a treatment manual, bibliotherapy
SDC	Supported digital control	Access to a general health education website with weekly check-in calls, computer-delivered 'sham' experiment
UDC	Unsupported digital control	Access to an educational website with reminder e-mails
SNoDC	Supported non-digital control	WL with weekly check-in communication with a person, usual care with weekly researcher assessments
UNoDC	Unsupported non-digital control	General self-help (e.g. leaflets with health advice not specific to the mental health problem targeted)
NI	No intervention	WL, usual care

SMS, short message service.

### Challenges with classification of comparators within studies of digital interventions

We resolved discrepancies between reviewers who attributed the same comparators to different classification groups by refining and expanding the definitions of our classification criteria until two reviewers could independently arrive at the same classification for every comparator within the selected studies. The discrepancies between reviewers highlighted some of the difficulties in classifying

complex interventions and some of the gaps in reporting comparators to a sufficient detail to enable us to classify them appropriately. Below, we discuss some of the challenges in the classification of comparators across the economic evaluations reviewed in WP1 and in the RCTs reviewed in WP2.

### ***When a waiting list goes beyond 'no intervention'***

By default, we have classified WL as 'no intervention', assuming no regular input from the research team and no changes in usual care because of the research study. If a WL (or usual care) was enhanced through regular contact or therapeutic materials from the research team then we classified it as 'non-therapeutic active control'. For example, in Johansson *et al.*,<sup>37</sup> participants on the WL received weekly assessments and substantial non-directive support via an online system by therapists, so this was classified as SDC. Teng *et al.*<sup>38</sup> invited all WL participants to have a weekly face-to-face assessment with a research assistant in a laboratory, which was classified as SNoDC.

In Pham *et al.*,<sup>5</sup> patients on the WL also received a weekly newsletter with curated content on breathing retraining exercises, matching content to the intervention they were to receive after coming off the WL, and e-mail reminders to complete assessments, albeit without any personal interaction; this was classified as UDC, although we could argue that the extent and therapeutic content of the information was on a par with an intervention. As the authors called this a 'waiting list', and the participants knew that they were being given information while waiting to receive an intervention, irrespective of the potential therapeutic effect of the WL, it could be classified only as a control.

In a study by Lovell *et al.*,<sup>39</sup> WL was a period of NI followed by individual high-intensity CBT. As the majority of the participants randomised to WL/usual care received treatment within the duration of the study, the comparator for internet CBT was more akin to a standard therapy than to NI. This raises the importance of monitoring and reporting what usual care is within RCTs so that sensitivity analyses can take into account the actual interventions that were received by the control group, rather than making assumptions about what the control group received.

There are occasions<sup>40,41</sup> when participants on the WL engage in a research activity that would not be available to those receiving usual care (e.g. the provision of weekly online ratings or the option to telephone the research team if they encounter problems). In this case, 'no intervention' is still the appropriate classification because these participants in such a group receive no regular input from the research team (e.g. measurement of outcomes or scheduled 'check-ins' with participants).

### ***When a comparator labelled as 'therapy' is better classified as a 'control'***

It can be difficult to classify an activity as 'therapy' or 'control' when the same activity could be therapeutic in some contexts but not in others. For example, in a study reported by McCrone *et al.*,<sup>42</sup> one of the randomisation arms was a computerised relaxation programme that was delivered in the same way as the intended intervention (i.e. cCBT for OCD) in a clinic using a self-administered software-based programme. Although applied relaxation can be used as a treatment for some conditions, such as GAD, there is no evidence or indication that it is a bona fide treatment for OCD, so the study used this as a psychological placebo.

In another study by Andersson *et al.*,<sup>43</sup> internet CBT was compared with 'internet support therapy', which was intended as a 'control over attention effects and possible alleviating effects in having contact with a professional therapist'. The internet CBT was a self-help intervention that included 100 pages of materials and worksheets with established therapy components as well as weekly homework and written feedback from therapists through an integrated treatment platform. Internet support therapy included supportive communication with a therapist via the same integrated treatment platform but without the CBT content or homework. Interacting with a therapist via an online platform in a supportive way could have been classified as a therapeutic activity for a condition such as depression but not for OCD; therefore, the internet support therapy on this occasion was a control rather than an intervention.

***When a technology-enabled intervention is classified as 'non-digital'***

We have made the distinction between DIs and telecommunication media that may use a digital interface (e.g. a computer or a mobile phone) without information processing. For example, short message service (SMS) texts or e-mails between a therapist and a user are not classified as 'DIs', whereas an online or telephone-based messaging system, as used in Johansson *et al.*,<sup>37</sup> that includes specially constructed backend software to provide a bespoke therapy environment with message encryption and centralised monitoring is classified as a DI. In another scenario, videoconferencing is not a DI unless it is part of a platform with software processing that guides some elements of the intervention.

***When unsupported interventions/controls include some type of 'contact'***

In their most basic form, unsupported interventions do not involve any interpersonal contact but are entirely self-administered. Some unsupported interventions may include one-way reminders, postcards or telephone messages, or a helpline to call if there are any problems. What differentiates these from supported interventions is that, in the case of supported interventions, there is a regular and expected two-way interaction between the user and a facilitator or between peers.

***Mixed interventions***

Interventions could be a mix of medication and psychosocial/behavioural interventions (e.g. when a DI is used to assist a participant in taking their medication and to monitor adherence). Medication that is a usual/routine care intervention may still be part of a 'psychosocial intervention' group, a 'no intervention' group or an 'active control' group. If participants are offered psychosocial support as part of a controlled medication trial, then the intervention is classified as 'medication'. Participants may still be offered medication as part of usual care in addition to the psychosocial intervention (the medication is not a 'research intervention').

***Granularity of taxonomy***

Digital interventions are complex and may include different therapeutic components (e.g. psychoeducation, cognitive techniques, behavioural techniques and motivational interviewing) and different layers of intensity (e.g. weekly 1-hour sessions or brief interventions). In addition, DIs increasingly follow a mixed model in which one intervention may include different types of technologies (e.g. telephone, website, biofeedback) and different types of personal support (e.g. face-to-face sessions with a therapist, telephone calls for technical support or standardised texts and e-mails from an assistant).

**Conclusions**

We propose a classification system for DIs and their alternatives based on three criteria: therapeutic intent (intervention vs. control), software processing (digital vs. non-digital) and interpersonal communication (supported vs. unsupported). Such classification requires a judgement based not only on predefined criteria, but also on understanding the nuances of technology-enabled interventions in the context of specific clinical applications. Distinguishing between digital and non-digital interventions is not always straightforward, especially as technologies can be used for patient-clinician telecommunication or for patient-directed activities, or for a blend of both. Classifying a DI as an intervention or control could also be complicated when interventions for one clinical condition may not be considered therapeutic for another. WLs and usual care are classified by default as 'no intervention'; however, they may be more accurately described as 'active controls' (when the research design introduces additional processes such as monitoring) or as 'interventions' (when participants receive routine treatments such as medication or face-to-face therapy). The relative effects of DIs depend on how tough their comparators are (e.g. DIs may perform 'better' than 'no intervention' but perform less well against 'gold standard' treatments). To enable the appropriate analysis and meaningful interpretation of evidence syntheses, research studies need to describe in detail the comparators of DIs in accordance with existing frameworks for reporting complex interventions, including any support that participants have received in a WL or usual care.

# Chapter 3 Review of economic studies

## Introduction

To inform decision-makers about which DIs (under what circumstances) may offer good value for money, we needed to review the relevant body of economic evidence that currently exists in the form of economic evaluations. In addition, we needed to critically appraise whether or not the economic evidence takes into account all relevant costs and outcomes, for the full range of possible alternative interventions and care options, and over an appropriate time horizon, for the mental health conditions of interest.<sup>44</sup>

This systematic review aimed to identify all economic evaluations of DIs and extract common themes, focusing on the methods used in the economic analyses and their appropriateness for decision-making. The review also considered whether methods have yet to be developed or utilised, and what further research is needed to inform economic analysis in the context of DIs.

## Methods

### Searches

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

In December 2018, the following databases were searched to identify published and unpublished studies: MEDLINE, PsycInfo® (American Psychological Association, Washington, DC, USA), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus, Database of Abstracts of Reviews of Effects (DARE), EMBASE™ (Elsevier, Amsterdam, the Netherlands), Web of Science™ (Clarivate Analytics, Philadelphia, PA, USA) Core Collection, NHS Economic Evaluation Database (NHS EED), the Health Technology Assessment database and the National Institute for Health Research (NIHR) Journals Library and the Database of Promoting Health Effectiveness Reviews (DoPHER). The full search strategy is presented in *Report Supplementary Material 1*.

We also searched two clinical trial registries for ongoing studies (ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform portal), searched the NIHR portfolio and conducted web searches using Google (Google Inc., Mountain View, CA, USA) and Google Scholar (Google Inc.) using simplified search terms. After searches were completed, we searched the studies included in the relevant systematic reviews identified as well as the references cited in the included studies and conducted forward citation chasing on all identified protocols and conference abstracts. We also contacted researchers in the field and searched the reference lists of the selected studies.

The searches were conducted from 1997, as no relevant studies of DIs could have been published before this date. Searches were restricted to studies written in English, as we anticipated that most economic studies written in other languages would also have a version published in English (e.g. the South Asia Cochrane Group).<sup>46</sup>

### Selection criteria

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

Eligible studies included participants with symptoms or at risk of mental health problems as defined by the *International Classification of Diseases, Eleventh Revision*,<sup>1</sup> criteria for mental, behavioural or neurodevelopmental disorders, with the exception of the conditions listed under the categories of neurodevelopmental, neurocognitive and disruptive behaviour or dissocial disorders. Studies were also excluded if the primary diagnosis of the participants was a physical or other condition other than those listed (e.g. cancer or insomnia). All DIs that expressly targeted mental health outcomes and patient-facing therapeutic activities were included, with the exception of those that were simply a communication medium (e.g. telephones or videoconferencing). A broad range of studies was considered in the review, including economic evaluations conducted alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations that compared two or more options and considered both costs and consequences (i.e. CMA, CEA, CUA and CBA) were included in the review. No studies were excluded on the basis of their comparator group. Study protocols, abstracts and reviews were marked to facilitate follow-up as described in *Searches*.

### **Study selection**

Two reviewers, one of whom had expertise in health economics, independently assessed all titles and abstracts for eligibility. If either reviewer indicated that a study could be relevant, the full text for that study was sought and again assessed independently by two reviewers, with disagreements resolved through discussion or with a third reviewer.

### **Data extraction**

The purpose of data extraction was to summarise methodology and identify challenges common in the evaluation of DIs. To do so, we extracted information reported in the studies on the population, intervention (underpinning principles, delivery mode, level of support, treatment duration) comparators, outcomes (clinical and economic outcomes, and the economic end point), study design, analytical approach (within-trial analysis, decision model, statistical model, epidemiological study), analysis time horizon, setting (country and analytical perspective), analytical framework (CMA, CEA, CUA, CCA or CBA) and methods employed to characterise uncertainty.

### **Critical analysis**

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

The identified studies were critically reviewed, to assess whether or not the existing evidence meets the requirements for decision-making in health care<sup>44</sup> and to assess the challenges in generating cost-effectiveness evidence in this context. The following questions were asked of the methods used in the included studies:

- Does the economic analysis estimate both costs and effects?
- Does the analysis appropriately synthesise all of the available evidence?
- Are the full ranges of possible alternative interventions and clinical strategies included?
- Are costs and outcomes considered over an appropriate time horizon?

### **Quality assessment**

Checklists are useful tools to assess the quality and applicability of economic evaluations. They also provide a framework for summarising the methods and results of economic evaluations in a consistent manner. Having an appropriate quality assessment checklist for economic evaluations of DIs in mental health can improve reporting standards and encourage harmonisation of key methods likely to drive heterogeneity in results from different economic evaluations. Following a checklist can help structure the narrative synthesis of results and critique of the methods used. This process helps the comparison of results across different studies, which are likely to be driven by methods employed to determine cost-effectiveness.


There are several checklists used in reviews of health economic evaluations, as summarised by Watts and Li.<sup>47</sup> Their paper notes that the Drummond<sup>48</sup> checklist [or *BMJ (British Medical Journal)* checklist, as Watts and Li call it] and the Philips<sup>49</sup> checklist are the most commonly used and are well regarded by the health economics community. Using the Drummond<sup>48</sup> checklist, we assessed the included studies according to the clarity of their research questions, the quality and completeness of data used in the economic evaluation, the methods used to characterise uncertainty in the evaluation model, and the interpretation of their results. We have also used the Philips<sup>49</sup> checklist, which is specific to model-based economic evaluations and describes attributes of good practice and questions for critical appraisal according to the model's structure, data and consistency.

## Results

### Summary of available economic evaluations of digital interventions

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

Our systematic literature search and study selection identified 63 primary studies,<sup>15,39,42,43,50-108</sup> whose results were reported in 67 papers,<sup>15,39,42,43,50-112</sup> as shown in *Figure 6*. After the removal of duplicates, 6931 of the 10,764 records originally identified remained and were screened, of which 6645 were excluded by title and abstract and 286 were assessed for eligibility by reviewing their full text. A total of 219 papers were excluded because the primary diagnosis was not a mental health problem ( $n = 27$ );



**FIGURE 6** The PRISMA flow diagram for the identification and selection of cost-effectiveness studies relating to DIs in mental health (search 1: up to November 2018). HE, health economic. Reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.



the intervention was not a mental health intervention ( $n = 13$ ); the study did not include health economic outcomes ( $n = 36$ ); it was not an economic evaluation, or it was a review rather than a primary study ( $n = 10$ ); it was a conference abstract rather than a peer-reviewed paper ( $n = 26$ ); or it was a duplicate reference ( $n = 4$ ) or a protocol ( $n = 103$ ). *Report Supplementary Material 2* gives the references of the excluded studies and the reasons for exclusion.

Two papers<sup>89,109</sup> reported the results of identical analyses from the same study; therefore, the paper by Duarte *et al.*<sup>109</sup> was incorporated in the summary with Littlewood *et al.*<sup>89</sup> to avoid duplicate reporting. Two papers<sup>62,112</sup> reported results from the same economic evaluation using different perspectives: the employer's<sup>62</sup> and the societal.<sup>112</sup> Three papers<sup>69,110,111</sup> used the same sample and interventions but different economic evaluation methods: El Alaoui *et al.*'s<sup>110</sup> paper was based on the provider's perspective and a 4-year time horizon, Hedman *et al.*<sup>69</sup> adopted a societal perspective and a 6-month time horizon, and Hedman *et al.*'s<sup>111</sup> paper was based on a societal perspective and a 4-year time horizon. It is worth highlighting that two papers<sup>43,51</sup> were considered as reporting separate studies, although they used the same sample, as the study reported in the second paper<sup>51</sup> was an extension of that reported in the first.<sup>43</sup> In conclusion, there were 66 papers with unique economic analyses and 63 studies with separate samples and interventions (hereafter referred to as 66 economic evaluations and 63 studies).

Approximately two-thirds of the studies (45/63) evaluated interventions that target anxiety and/or depression. Other conditions included suicidal ideation ( $n = 1$ ), child disruptive behaviour ( $n = 1$ ), eating disorders ( $n = 3$ ), schizophrenia ( $n = 3$ ) and addiction, including drug and alcohol addiction ( $n = 3$  and  $n = 2$ , respectively) and smoking cessation ( $n = 8$ ) (*Table 5*).

The interventions varied both between and within individual conditions, in terms of their underlying principles (e.g. CBT, guided relaxation, self-help, exposure therapy, motivational support for smoking cessation), content (e.g. the number of modules), mode of delivery (e.g. mobile, computer or text based, or completed at home or at clinic), type of support (e.g. online chat, telephone, face to face), frequency of support (e.g. weekly, ad hoc), person delivering support (e.g. clinician, assistant, lay person) and extent of support (e.g. administrative support only, additional counselling) (see *Table 10*).

Comparators can be broadly categorised as NI, which could be WL or usual care, active non-therapeutic controls or standard therapy. There is limited reporting of what interventions patients had access to, or received, when allocated to a WL or to usual care. Non-therapeutic controls were designed as 'psychological placebos' or attention controls; they encourage patients to spend the same amount of time on treatment as active interventions, but without the 'active' component, such as CBT or problem-solving therapy. Non-therapeutic comparators included websites, printed reading and online relaxation not indicated as a 'treatment' for the condition under study (see *Table 10*).

Methods for costing interventions varied. The majority of the evaluations (50/66)<sup>15,39,42,43,50-75,77,80,82-84, 88-90,92,95-98,100-106,110-112</sup> included the cost of staff time required to deliver the intervention. Some studies included variable equipment costs and website maintenance and hosting, whereas very few considered the cost of development, capital costs or patient recruitment (or technology dissemination).

Most evaluations (52/66)<sup>15,39,42,43,50-75,77,80,82-84,88-90,92,95-98,100-106,110-112</sup> were within-trial analyses, and one<sup>59</sup> included a temporal extrapolation. A further three studies<sup>76,93,107</sup> were within-pilot evaluations<sup>76,93</sup> and feasibility trials,<sup>107</sup> although one study<sup>79</sup> used observational data. Ten studies<sup>67,78,81,85-87,91,94,99,108</sup> used decision models to evaluate interventions. Eight<sup>78,81,85-87,91,94,99</sup> of the 10 studies<sup>67,78,81,85-87,91,94,99,108</sup> that used modelling to evaluate DIs did so because of the absence of head-to-head trial data, and used individual trials or non-comparative data sources to inform the treatment effect of DIs. The model for eating disorders used synthesised evidence of the treatment effect to derive the cost of different treatment options.

TABLE 5 Economic evaluations of DIs in mental health

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean <sup>a</sup> (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/ number completed	Perspective	Time horizon
Aardoom 2016 <sup>50</sup>	4-arm RCT	Eating disorder	The Netherlands	≥ 16 years	None reported	354 (4)	152/202	Societal	3 months
Andersson 2015 <sup>43</sup>	2-arm RCT	OCD	Sweden	Adults	(Mean, SD not reported), 18–67	101 (34)	2/99	Societal	10 weeks (for economic outcomes, 4 months for clinical outcome)
Andersson 2015 <sup>51</sup>	2-arm RCT	OCD	Sweden	Adults	(Mean, SD not reported), 20–70	93 (32)	11/82	Societal	24 months
Axelsson 2018 <sup>52</sup>	4-arm RCT	Health anxiety	Sweden	Adults	38 (13), 20–72	132 (34)	5/127	Health system, societal	12 weeks (post treatment)
Bergman Nordgren 2014 <sup>53</sup>	2-arm RCT	Anxiety (not specified)	Sweden	Adults	35 (SD not reported), 19–68	100 (37)	21/79	Societal	1 year
Bergström 2010 <sup>54</sup>	2-arm RCT	Panic disorder	Sweden	Adults	Not reported	113 (40)	26/87	Health system	6 months
Bolier 2014 <sup>55</sup>	2-arm RCT	Depression	The Netherlands	≥ 21 years	43 (12), (range not reported)	264 (58)	86/198	Societal	6 months
Brabyn 2016 <sup>56</sup>	2-arm RCT	Depression	UK	Adults	41 (14), 8–77	369 (131)	95/274	Health system	12 months
Budney 2015 <sup>57</sup>	3-arm RCT	Cannabis addiction	USA	Adults	None reported	75 (gender not reported)	30/45	Provider	9 months
Buntrock 2017 <sup>58</sup>	2-arm RCT	Depression	Germany	Adults	45 (12) (range not reported)	406 (106)	118/288	Health system, societal	12 months
Burford 2013 <sup>59</sup>	2-arm RCT	Smoking	Australia	Adults	(Mean, SD not reported), 18–30	160 (60)	38/122	Health system	6 months
Calhoun 2016 <sup>60</sup>	2-arm RCT	Smoking	USA	Not specified	43 (14), (range not reported)	413 (343)	105/308	Health-care provider	12 months follow-up (lifelong QALY gain modelled)

continued

TABLE 5 Economic evaluations of DIs in mental health (continued)

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean <sup>a</sup> (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/ number completed	Perspective	Time horizon
Dear 2015 <sup>61</sup>	2-arm RCT	Stress, anxiety, worry	Australia	≥ 60 years	(Mean, SD not reported), 60–81	72 (28)	10/62	Health system	12 weeks
Ebert 2018 <sup>62</sup> (linked with Kahlke 2019 <sup>112</sup> )	2-arm RCT	Stress	Germany	Adults	43 (10), (range not reported)	264 (71)	26/87	Employer	6 months
El Alaoui 2017 <sup>110</sup>	2-arm RCT	Social anxiety	Sweden	Adults	(Mean, SD not reported), 18–64	126 (81)	25/101	Provider	4 years
Garrido 2017 <sup>63</sup>	2-arm RCT	Schizophrenia	Spain	Adults	33 (SD not reported), 18–55	67 (49)	34/33	Health system	36 months
Geraedts 2015 <sup>64</sup>	2-arm RCT	Depression	The Netherlands	Adults	None reported	231 (87)	106/125	Societal, employer	12 months
Gerhards 2010 <sup>65</sup>	3-arm RCT	Depression	The Netherlands	18- to 65-year olds	None reported	303 (131)	28/275	Societal	12 months
Graham 2013 <sup>66</sup>	3-arm RCT	Smoking	USA	Adults	36 (11), (range not reported)	2005 (981)	637/1368	Payer	18 months
Guerrero 2013 <sup>67</sup>	Modelling study based on pilot RCT	Smoking	UK	Not specified	Not applicable	200 (gender not reported)	16/184	Health system	31 weeks
Hedman 2011 <sup>69</sup>	2-arm RCT	Social anxiety	Sweden	Adults	(Mean, SD not reported), 18–64	126 (81)	25/101	Societal	6 months
Hedman 2013 <sup>68</sup>	2-arm RCT	Health anxiety	Sweden	Adults	(Mean, SD not reported), 25–69	81 (21)	6/75	Societal	12 weeks (post treatment)
Hedman 2014 <sup>111</sup>	2-arm RCT	Social anxiety	Sweden	Adults	(Mean, SD not reported), 18–64	126 (81)	Not reported	Societal	4 years
Hedman 2016 <sup>70</sup>	2-arm RCT	Health anxiety	Sweden	Adults	(Mean, SD not reported), 21–75	158 (33)	16/142	Societal	12 weeks (post treatment)
Hollinghurst 2010 <sup>71</sup>	2-arm RCT	Depression	UK	18- to 75-year-olds	35 (12), (range not reported)	297 (95)	87/210	Health system	8 months

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean* (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/number completed	Perspective	Time horizon
Holst 2018 <sup>72</sup>	2-arm RCT	Depression	Sweden	Adults	37 (11), (range not reported)	90 (38)	25/65	Health system, societal	9 months
Hunter 2017 <sup>73</sup>	2-arm RCT	Alcohol addiction	Italy	Adults	None reported	763 (469)	143/620	Health system	12 months
Joesch 2012 <sup>74</sup>	2-arm RCT	Anxiety (mixed)	USA	Adults	None reported	690 (195)	Not reported	Health system	18 months (including treatment)
Jolstedt 2018 <sup>75</sup>	2-arm RCT	Anxiety (mixed)	Sweden	8- to 12-year-olds	10 (1), (range not reported)	131 (61)	18/113	Societal	12 weeks (3 month follow-up but with crossover)
Jones 2001 <sup>77</sup>	3-arm RCT	Schizophrenia	UK	Adults aged < 65 years	(Mean, SD not reported), 18–65	112 (gender not reported)	56/66	Societal	3 months
Jones 2014 <sup>76</sup>	2-arm RCT	Child disruptive disorder	USA	Children aged 3–8 years	6 (SD, range not reported)	22 (gender not reported)	7/15	Provider	Not reported
Kählke 2019 <sup>112</sup>	2-arm RCT	Stress	Germany	Adults	43 (10), (range not reported)	264 (71)	26/87	Employer	6 months
Kass 2017 <sup>78</sup>	Modelling study	Eating disorder	USA	Not specified	Not applicable	Not applicable	Not applicable	Payer	Unclear (lifetime?)
Kenter 2015 <sup>79</sup>	2-arm observational study	Depression and anxiety	The Netherlands	Adults	None reported	4448 (2006)	Not reported	Provider	Varied (observational data)
Kiluk 2016 <sup>80</sup>	3-arm RCT	Alcohol addiction	USA	Adults	43 (12), (range not reported)	68 (44)	4/62	Not reported	6 months
Koeser 2013 <sup>81</sup>	Modelling study based on multiple studies	Depression	UK	Not specified	Not applicable	Not applicable	Not applicable	Health system	8 months

continued

TABLE 5 Economic evaluations of DIs in mental health (continued)

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean <sup>a</sup> (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/ number completed	Perspective	Time horizon
Kolovos 2016 <sup>82</sup>	2-arm RCT	Depression	The Netherlands	Adults	38 (11), (range not reported)	269 (124)	158/111	Health system, provider, societal	12 months
König 2018 <sup>83</sup>	2-arm RCT	Binge eating disorder	Germany and Switzerland	Adults	None reported	178 (gender not reported)	31/147	Societal	18 months
Kraepelien 2018 <sup>84</sup>	3-arm RCT	Depression	Sweden	Adults	(Mean, SD not reported), 18–67	945 (250)	717/228	Health system, societal	Health-care perspective: 3 months. Societal perspective: 12 months
Kumar 2018 <sup>85</sup>	Modelling study based on multiple studies	GAD	USA	Adults	Not applicable	Not applicable	Not applicable	Payer, societal	Not reported
Lee 2017 <sup>87</sup>	Modelling study from multiple sources	Depression	Australia	Adolescents aged 11–17 years	Not applicable	Not applicable	Not applicable	Health system	10 years
Lee 2017 <sup>86</sup>	Modelling study from multiple sources	Depression and anxiety	Australia	Adults aged < 60 years	None reported	Not applicable	Not applicable	Health system	12 months
Lenhard 2017 <sup>88</sup>	2-arm RCT	OCD	Sweden	Adolescents aged 12–17 years	15 (2), (range not reported)	67 (36)	7/60	Societal	12 weeks
Littlewood 2015 <sup>89</sup> and Duarte 2017 <sup>109</sup>	3-arm RCT	Depression	UK	Adults	40 (13), (range not reported)	691 (229)	230/461	Health system	24 months
Lovell 2017 <sup>39</sup>	3-arm RCT	OCD	UK	Adults	33 (SD not reported), 18–77	475 (178)	141/334	Health system, societal	12 months
McCrone 2004 <sup>15</sup>	2-arm RCT	Depression and anxiety	UK	Adults	(Mean, SD not reported), 18–75	274 (72)	12/262	Health system, societal	6 months

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean <sup>a</sup> (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/number completed	Perspective	Time horizon
McCrone 2007 <sup>42</sup>	3-arm RCT	OCD	USA and Canada	Adults	None reported	218 (gender not reported)	42/176	Provider	Not reported
McCrone 2009 <sup>90</sup>	3-arm RCT	Panic disorder	UK	Adults	38 (13), (range not reported)	90 (28)	30/60	Health system	1 month
Mihalopoulos 2005 <sup>91</sup>	Modelling study from multiple sources	Panic disorder	Australia	Not specified	None reported	Not applicable	Not applicable	Health system	12 months (reported in original model paper)
Murphy 2016 <sup>92</sup>	2-arm RCT	Addiction to substances (mixed)	USA	Adults	35 (11), (range not reported)	507 (315)	Not reported	Payer, provider	36 weeks
Naughton 2017 <sup>93</sup>	2-arm RCT	Smoking	UK	Not specified	27 (6), (range not reported)	407 (gender not reported)	146/261	Payer	11–36 weeks (final follow-up at 36 weeks of gestation)
Naveršnik 2013 <sup>94</sup>	Modelling study based on pilot trial	Depression	Slovenia	Adults	Not applicable	46 (gender not reported)	24/22	Health system	6 months
Olmstead 2010 <sup>95</sup>	2-arm RCT	Addiction (mixed)	USA	Adults	42 (10) (range not reported)	77 (46)	23/54	Payer	Unclear (appears to be 8 weeks)
Phillips 2014 <sup>96</sup>	2-arm RCT	Depression and/or anxiety	UK	Adults	None reported	637 (296)	406/231	Not reported	12 weeks (total)
Romero-Sanchiz 2017 <sup>97</sup>	3-arm RCT	Depression	Spain	18- to 65-year-olds	43 (SD, range not reported)	296 (70)	83/203	Societal	12 months
Smit 2013 <sup>98</sup>	3-arm RCT	Depression	Australia	Adults	None reported	414 (165)	183/231	Health system	6 months
Solomon 2015 <sup>99</sup>	Modelling study from multiple sources	Smoking	Australia	Adults	Not applicable	Not applicable	Not applicable	Societal	12 months

continued

TABLE 5 Economic evaluations of DIs in mental health (continued)

Study (first author and year)	Design	Condition	Country	Target age group	Sample age: mean <sup>a</sup> (SD), range (years)	Number randomised (number of men)	Number lost to follow-up/ number completed	Perspective	Time horizon
Španiel 2012 <sup>100</sup>	2-arm RCT	Schizophrenia	Czech Republic and Slovakia	18- to 60-year-olds	None reported	158 (90)	63/95	Not reported	12 months
Stanczyk 2014 <sup>101</sup>	3-arm RCT	Smoking	The Netherlands	Adults	None reported	2551 (1273)	1342/1209	Health system, societal	12 months
Titov 2009 <sup>102</sup>	2-arm RCT	Social anxiety	Australia	Adults	None reported	193 (gender not reported)	22/171	Other	10 weeks
Titov 2015 <sup>103</sup>	2-arm RCT	Depression	Australia	Elderly (no age specified)	(Mean, SD not reported), 61–78	54 (14)	2/52	Health system	8 weeks
van Spijker 2012 <sup>104</sup>	2-arm RCT	Suicidal ideation	The Netherlands	Adults	41 (14), (range not reported)	236 (80)	25/111	Societal	6 weeks
Warmerdam 2010 <sup>105</sup>	3-arm RCT	Depression	The Netherlands	Adults	45 (12), (range not reported)	263 (76)	112/151	Societal	12 weeks
Wijnen 2018 <sup>106</sup>	2-arm RCT	Depression	The Netherlands	Adults	(Mean, SD not reported), 18–81	329 (80)	92/237	Health system, societal	3 months
Wright 2017 <sup>107</sup>	2-arm RCT	Depression	UK	12- to 18-year-olds	None reported	91 (gender not reported)	36/55	Provider, societal	4 months
Wu 2014 <sup>108</sup>	Modelling study based on RCT	Smoking	UK	Adults	45 (12), (range not reported)	6911 (3163)	1737/5174	Health system	Lifetime

SD, standard deviation.

<sup>a</sup> Rounded to the nearest integer.

The vast majority of the papers reported some form of sensitivity analysis, with only 11 studies<sup>57,63,74,77,79,80,85,97,100,102,107</sup> not reporting having conducted any. In total, 50 studies<sup>15,39,42,43,50-75,77,80,82-84,88-90,92,95-98,100-106,110-112</sup> used both probabilistic and deterministic sensitivity analyses. Deterministic sensitivity analysis involved exploring alternative scenarios and assumptions; the most common parameter value that was varied was the cost of intervention. Other common scenarios included alternative methods for dealing with missing data or for estimating costs and effect.

### Quality of the included studies under each item of the Drummond checklist

Table 6 reports the outcomes of the quality assessment for each economic study based on the Drummond *et al.*<sup>48</sup> checklist, which comprises 10 items that assess the following domains: (1) question definition, (2) description of competing alternatives, (3) established effectiveness, (4) inclusion of costs and consequences, (5) measurement of costs and consequences, (6) valuation of cost and consequences, (7) adjustment of costs and consequences for differential timing, (8) incremental analysis, (9) allowance for uncertainty and (10) presentation and discussion of results.

#### Item 1: clarity of research question

The majority of the economic evaluations were conducted alongside trials and had the primary aim of establishing clinical effectiveness, with determination of cost-effectiveness being a secondary objective. Most studies (48/66)<sup>39,43,50-53,55-62,64-66,68-73,75,81-89,91-95,97,98,101,103,105,106,108,110-112</sup> had a clearly defined objective (to compare costs and outcomes of DIs with the costs and outcomes of other treatment options), and the majority stated or implied their perspective (64/66).<sup>15,39,42,43,50-79,81-95,97-108,110-112</sup> The decision-making context was not always clear in the included economic evaluations. Each trial implied a different role for DIs, reflected in their approach to recruiting patients. Recruitment methods included self-referral; referral by clinician, whereby patients are identified 'on the job' and recruitment requires no additional resources; recruitment by screening medical records; and proactively inviting patients to participate. Target populations and recruitment methods were appropriate for the purpose of using DIs in the mental health care pathway. For example, recruitment of self-referred patients came with a role for DIs in the diagnosis and treatment of patients who may not have otherwise sought treatment, whereas targeting diagnosed patients implied that DIs were administered instead of or alongside existing treatment. Patients to whom DIs were offered for suicidal ideation and eating disorders were predominantly recruited by self-referral; all remaining conditions employed multiple methods, suggesting a varied role for DIs.

#### Item 2: description of competing alternatives

Digital interventions and their competing NoDIs were by and large described in sufficient detail to understand the underlying principles and modus operandi of the interventions. WL controls and treatment as usual (TAU) were very broad, and the difference between them was often not clear, particularly when participants had self-referred (recruited via adverts), as it is not possible to determine if TAU would have involved any care had the participants not signed up to the trials. We also assessed whether or not any important alternatives were omitted, or if treatment should have been considered, based on the proposed role of the intervention, and the role of the chosen comparator. In 41 of the trials<sup>15,42,52,54,55,57,58,60,64,65,67,69,72-74,76,77,79-87,89,90,92-100,104,105,110,111</sup> the comparator was judged to be appropriate, being TAU or any other comparator justified in the study. In 21 trials<sup>39,61-63,66,68,70,71,75,88,101-103,106-108</sup> it was not clear whether or not the comparator of choice was appropriate. This occurred when the study used a specific comparator (e.g. no treatment, attention control as opposed to TAU) without providing justification of whether or not this was a plausible treatment option.

#### Item 3: establishing effectiveness of the programme or services

The majority of the economic evaluations (53/66)<sup>15,39,42,43,50-66,68-75,77,80,82-84,88-90,92,95-99,101,103-106,108,110-112</sup> established the effectiveness through a single trial; of these, 47<sup>15,39,42,43,50-66,68-75,77,80,82-84,88-90,92,95-99,101,103-106,108,110-112</sup> included only within-trial analyses, two<sup>59,69</sup> extrapolated the results over time and four<sup>59,77,86,100</sup> used the treatment effect observed in a trial to populate a decision model. All these studies were assessed to have established the effectiveness of the programme in the appraisal. Seven papers<sup>67,76,79,81,93,94,107</sup> used



TABLE 6 Quality assessment using the Drummond checklist

Study (first author and year)	Drummond checklist item									
	1	2	3	4	5	6	7	8	9	10
Aardoom 2016 <sup>50</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Andersson 2015 <sup>43</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	No	Yes	Yes	Partial
Andersson 2015 <sup>51</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Partial	Yes	Partial
Axelsson 2018 <sup>52</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Partial	Yes	Partial
Bergman Nordgren 2014 <sup>53</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Bergström 2010 <sup>54</sup>	Partial	Yes	Yes	Partial	Yes	Yes	NA	Partial	Partial	Partial
Bolier 2014 <sup>55</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Brabyn 2016 <sup>56</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Budney 2015 <sup>57</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	No	No	Yes
Buntrock 2017 <sup>58</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Burford 2013 <sup>59</sup>	Yes	Partial	Yes	Yes	Yes	Partial	Yes	Partial	Partial	Yes
Calhoun 2016 <sup>60</sup>	Yes	Yes	Yes	Partial	Yes	Yes	Partial	No	No	Partial
Dear 2015 <sup>61</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Partial	Partial
Ebert 2018 <sup>62</sup> (linked with Kählke 2019 <sup>112</sup> )	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
El Alaoui 2017 <sup>110</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Garrido 2017 <sup>63</sup>	Partial	Unclear	Yes	Partial	Yes	Yes	No	No	No	Yes
Geraedts 2015 <sup>64</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Gerhards 2010 <sup>65</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Graham 2013 <sup>66</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	No	Partial	No	Partial
Guerrero 2013 <sup>67</sup>	Partial	Yes	Partial	Yes	Yes	Yes	Partial	Yes	Yes	Yes
Hedman 2011 <sup>69</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Hedman 2013 <sup>68</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Hedman 2014 <sup>111</sup>	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Partial
Hedman 2016 <sup>70</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Hollinghurst 2010 <sup>71</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Holst 2018 <sup>72</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Hunter 2017 <sup>73</sup>	Yes	Yes	Yes	Partial	Unclear	Yes	NA	Yes	Yes	Yes
Joesch 2012 <sup>74</sup>	Partial	Yes	Yes	Partial	Partial	Yes	No	Yes	No	Partial
Jolstedt 2018 <sup>75</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Partial	Partial
Jones 2001 <sup>77</sup>	Partial	Yes	Yes	Unclear	Unclear	Unclear	Partial	No	Partial	Partial
Jones 2014 <sup>76</sup>	Partial	Yes	Partial	Partial	Yes	Yes	NA	No	No	Yes
Kählke 2019 <sup>112</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Kass 2017 <sup>78</sup>	Partial	No	No	No	Unclear	Partial	Unclear	No	No	Partial
Kenter 2015 <sup>79</sup>	Partial	Yes	Partial	Yes	Yes	Partial	Unclear	No	No	Yes
Kiluk 2016 <sup>80</sup>	No	Yes	Yes	Unclear	Yes	Unclear	NA	No	No	Yes
Koeser 2013 <sup>81</sup>	Yes	Yes	Partial	Yes	Yes	Yes	NA	Yes	Yes	Yes

TABLE 6 Quality assessment using the Drummond checklist (continued)

Study (first author and year)	Drummond checklist item									
	1	2	3	4	5	6	7	8	9	10
Kolovos 2016 <sup>82</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
König 2018 <sup>83</sup>	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Kraepelien 2018 <sup>84</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Partial
Kumar 2018 <sup>85</sup>	Yes	Yes	No	Partial	Partial	Partial	Yes	Partial	Partial	Partial
Lee 2017 <sup>87</sup>	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Partial
Lee 2017 <sup>86</sup>	Yes	Yes	No	Partial	Yes	Unclear	NA	Yes	Partial	Yes
Lenhard 2017 <sup>88</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Partial	Yes	Partial
Littlewood 2015 <sup>89</sup> and Duarte 2017 <sup>109</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lovell 2017 <sup>39</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
McCrone 2004 <sup>15</sup>	Partial	Yes	Yes	Yes	Yes	Yes	NA	Partial	Partial	Yes
McCrone 2007 <sup>42</sup>	Partial	Yes	Yes	Yes	Unclear	Yes	Unclear	Yes	Yes	Yes
McCrone 2009 <sup>90</sup>	Partial	Yes	Yes	Partial	Yes	Yes	NA	Yes	Partial	Partial
Mihalopoulos 2005 <sup>91</sup>	Yes	Partial	No	Unclear	Yes	Unclear	NA	No	Partial	Partial
Murphy 2016 <sup>92</sup>	Yes	Yes	Yes	Partial	Yes	Yes	NA	Yes	Yes	Yes
Naughton 2017 <sup>93</sup>	Yes	Yes	Partial	No	Yes	Yes	NA	Yes	Yes	Yes
Naveršnik 2013 <sup>94</sup>	Yes	Yes	Partial	Unclear	Unclear	Yes	NA	Yes	Yes	Partial
Olmstead 2010 <sup>95</sup>	Yes	Yes	Yes	Partial	Yes	Yes	Unclear	Yes	Yes	Yes
Phillips 2014 <sup>96</sup>	No	Yes	Yes	Unclear	Yes	Yes	NA	No	Yes	Yes
Romero-Sanchiz 2017 <sup>97</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	No	Yes
Smit 2013 <sup>98</sup>	Yes	Yes	Yes	Partial	Partial	Yes	NA	Yes	Yes	Yes
Solomon 2015 <sup>99</sup>	Partial	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Španiel 2012 <sup>100</sup>	Partial	Yes	No	Partial	Yes	Yes	NA	No	Partial	Yes
Stanczyk 2014 <sup>101</sup>	Yes	Unclear	Yes	Partial	Partial	Yes	NA	Yes	Yes	Partial
Titov 2009 <sup>102</sup>	Partial	Unclear	Yes	No	Unclear	Partial	NA	Yes	No	No
Titov 2015 <sup>103</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Partial	Yes
van Spijker 2012 <sup>104</sup>	Partial	Yes	Yes	Unclear	Yes	Yes	NA	Yes	Yes	Partial
Warmerdam 2010 <sup>105</sup>	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Wijnen 2018 <sup>106</sup>	Yes	Unclear	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Wright 2017 <sup>107</sup>	Partial	Unclear	Partial	Yes	Yes	Yes	NA	No	No	Yes
Wu 2014 <sup>108</sup>	Yes	Unclear	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes
<b>Total</b>										
N/A	0	0	0	0	0	0	47	0	0	0
Yes	48	41	53	42	56	57	6	45	42	35
Partial	16	3	7	15	4	5	3	8	12	30
No	2	1	6	3	0	0	6	13	12	1
Unclear	0	21	0	6	6	4	4	0	0	0
NA, not applicable.										

feasibility, pilot and observational studies, whereas another five<sup>85-87,91,100</sup> used non-comparative data (single-arm studies or registry data) to inform the treatment effect in decision models; these were judged in the appraisal as having partially established and having not established the effectiveness of the programme, respectively. Finally, one study<sup>78</sup> established the effectiveness of the programme through a systematic review and evidence synthesis, but the method of incorporating the findings into the decision model was not clear.

#### **Item 4: identifying relevant costs and consequences**

This item explored whether or not the range of costs and effects measured and included in the analysis was wide enough, whether or not they covered all relevant viewpoints, and whether or not they included capital costs as well as operating costs. The outcome measures and the included costs varied greatly between the studies. Admittedly, it was difficult to judge what was relevant. The majority of studies included some operating costs, such as staff time and website maintenance. Many recruited patients through public advertising, yet they did not include recruitment costs. If the interventions were to be rolled out, reaching out to the same patient population would incur costs, and so the cost of recruitment would potentially be relevant. In terms of effects, most trials included relevant effects for that trial. Effectiveness measured in terms of disease-specific outcome measures makes sense, but on a wider scale (e.g. if societal and health-care perspective are used) it is not clear how to judge whether or not an intervention is cost-effective, unless it is dominant or dominated.

#### **Item 5: accuracy of measurement of costs and consequences**

The majority of the studies (56/66)<sup>15,39,43,50-72,75,76,79-84,86-93,95-97,99,100,103-108,110-112</sup> accurately measured costs and consequences. Six studies<sup>42,73,77,78,94,102</sup> did not report sufficient detail about the costs and consequences included and, therefore, were assessed as 'unclear' on this item, and a further four studies<sup>74,85,98,101</sup> omitted potentially relevant costs or outcomes, leading this item to be assessed as 'partial'.

#### **Item 6: were costs and consequences valued credibly?**

This item explored the extent to which the sources of all values were clearly defined, market values were employed and the valuation of consequences was appropriate for the question posed. Overall, the majority of the studies included sufficient detail, with five studies<sup>59,78,79,85,102</sup> providing partial information and four studies<sup>77,80,87,91</sup> not stating clearly whether or not market values were employed.

#### **Item 7: adjusting costs and consequences for differential timing**

A total of 47 studies<sup>15,39,50-58,61,62,64,65,68-73,75,76,80-82,84,87,88,90-94,96-107,112</sup> had an analysis time horizon shorter than 1 year, and so discounting was not required. Ten studies, reported in 11 papers,<sup>51,63,66,74,83,87,89,108,111</sup> reported a time horizon longer than 12 months. Of those, six studies<sup>59,85,86,89,108,110</sup> discounted both costs and effects, and two provided justification for the discount rate they used.<sup>89,108</sup> Six studies<sup>51,63,66,68,74,83</sup> were assessed as 'not discounted for differential timing': one study reported a relatively short time horizon (18 months) as justification,<sup>74</sup> whereas a further five studies<sup>51,63,66,68,83</sup> did not report any discounting. Three studies<sup>60,67,77</sup> were assessed as 'partial', one of which discounted only effects, because it did not model long-term costs,<sup>60</sup> and the other two discounted only costs because it did not model long-term effects.<sup>67,77</sup> Finally, four studies<sup>42,78,79,95</sup> had an unclear analysis time horizon. Of those, one discounted costs but not effects,<sup>78</sup> and the other three did not report discounting.<sup>42,79,95</sup> These last three studies were assessed as 'unclear' as we could not tell whether or not discounting was required.

#### **Item 8: incremental analysis of costs and outcomes**

The majority of the studies (45/66)<sup>39,42,43,53,55,56,58,61,62,64,65,67-75,78,81-84,87,89,90,92-95,97-99,101-106,108,110-112</sup> compared incremental costs with incremental outcomes. Twelve studies<sup>57,60,63,76,77,79,80,86,91,96,100,107</sup> reported costs and outcomes separately, although the reported outcomes can be used to derive incremental costs and outcomes. Eight studies<sup>15,51,52,54,59,66,85,88</sup> were assessed as partially reporting incremental analysis of costs and outcomes. Of these, three reported ICERs but for a limited range of scenarios (e.g. analysis

assumptions, comparators or perspectives),<sup>52,59,66</sup> whereas the remaining five estimated the incremental costs and effects but either did not report them (because they were not statistically significant<sup>51,88</sup> or because one of the comparators was dominant<sup>85</sup>), reported non-incremental cost-effectiveness ratio and the incremental cost-effectiveness plane graphically<sup>54</sup> or reported outcomes in terms of the probability that an intervention would be cost-effective.<sup>15</sup>

### Item 9: evaluation of uncertainty

The assessment of sensitivity analyses was based on whether or not the authors conducted any sensitivity analysis and provided the rationale for the types of sensitive analyses they conducted. The most common scenarios were alternative intervention costs and methods for dealing with missing data.

### Item 10: discussion

The assessment of discussions was based on the extent to which the conclusions of the analysis were correctly drawn and interpreted intelligently and were compared with broader literature, and whether or not the discussion included generalisability of the findings, and implementation. In total, 35 studies<sup>15,39,42,50,56–59,63,67,71,73,76,79–83,87,89,92,93,95–100,103,105–108,110,112</sup> included a satisfactory discussion, whereas a further 30 studies included a partial discussion.<sup>43,51–55,60–62,64–66,68–70,72,74,75,77,78,84–86,88,90,91,94,101,104,111</sup> Discussions were judged to be partial when they excluded at least one of the above criteria. Only one study<sup>102</sup> was considered not to have critiqued methods for evaluation or discussed the generalisability and implications of the findings.

### Quality of the included studies under each item of the Philips checklist

Tables 7–9 summarise the quality assessment for each model-based study based on the Philips *et al.*<sup>49</sup> checklist. The analysis methods are generally good; for example, in the majority of the studies the objective was clear (item S1), the choice of model was appropriate (item S6), structural assumptions were transparent and appropriate (items S3 and S4) and the sources of data for baseline outcomes were clear and justified (item D2a). The most common limitations were associated with the comparators (item S5), the time horizon (item S7) and the treatment effect (D2b). Specifically, none of the studies provided a systematic comparison of all possible comparators; the time horizon was either incomplete (potentially failing to capture the long-term effect of DIs) or unclear in 8<sup>78,81,85–87,91,94,99</sup> out of the 10 studies,<sup>67,78,81,85–87,91,94,99,108</sup> and the treatment effect was synthesised from multiple trials in only one study<sup>78</sup> (although the methods were not explicitly reported). In the remaining models, four studies<sup>87,91,99,108</sup> informed the treatment effect using a single RCT, three studies<sup>81,85,86</sup> used indirect evidence and two studies<sup>67,94</sup> used a hypothetical treatment effect.

## Key challenges and limitations in economic evaluation of digital interventions

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

The critical review of the studies identified a range of challenges arising from the complexity of DI interventions and the heterogeneity of evidence; we describe each in turn.<sup>45</sup>

### Estimation of costs and outcomes

The included studies use a variety of methods to measure costs and outcomes of DIs. Benefits were measured in terms of QALYs, disability-adjusted life-years, life-years, disease-free days, disease-specific outcome measures, response or clinical improvement, inpatient days avoided or days of abstinence in interventions that target addiction. Costs attributed to DIs included the cost of staff time required to deliver the intervention, a range of equipment costs, website maintenance and hosting, the cost of development, capital costs and the costs of patient recruitment (or technology dissemination).

TABLE 7 Quality assessment of structure in economic models of DIs using the Philips checklist

Checklist item	Study (first author and year)									
	Guerriero 2013 <sup>67</sup>	Kass 2017 <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>S1 statement of decision problem/objective</b>										
Is there a clear statement of the decision problem?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Is the objective of the evaluation and model specified and consistent with the stated decision problem?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Is the primary decision-maker specified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>S2 statement of scope/perspective</b>										
Is the perspective of the model stated clearly?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Are the model inputs consistent with the stated perspective?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Has the scope of the model been stated and justified?	Yes	Partial	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes
Are the outcomes of the model consistent with the perspective, scope and overall objective of the model?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>S3 rationale for structure</b>										
Is the structure of the model consistent with a coherent theory of the health condition under evaluation?	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Are the sources of data used to develop the structure of the model specified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Are the causal relationships described by the model structure justified appropriately?	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>S4 structural assumptions</b>										
Are the structural assumptions transparent and justified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Are the structural assumptions reasonable given the overall objective, perspective and scope of the model?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Checklist item	Study (first author and year)									
	Guerriero 2013 <sup>67</sup>	Kass 2017 <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>S5 strategies/comparators</b>										
Is there a clear definition of the options under evaluation?	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Have all feasible and practical options been evaluated?	No	Unclear	Yes	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Is there justification for the exclusion of feasible options?	No	No	NA	No	No	Yes	No	No	No	No
<b>S6 model type</b>										
Is the chosen model type appropriate given the decision problem and specified causal relationships within the model?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>S7 time horizon</b>										
Is the time horizon of the model sufficient to reflect all important differences between options?	Yes	Unclear	Partial	Unclear	Unclear	Partial	Unclear	Unclear	Partial	Yes
Are the time horizon of the model, the duration of treatment and the duration of treatment effect described and justified?	Yes	No	Partial	No	Partial	Partial	Partial	Partial	Partial	Yes
<b>S8 disease states/pathway</b>										
Do the disease states (state transition model) or the pathways (decision tree model) reflect the underlying biological process of the disease in question and the impact of interventions?	Unclear	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Yes
<b>S9 cycle length</b>										
Is the cycle length defined and justified in terms of the natural history of disease?	Yes	NA	NA	Yes	No	NA	Unclear	NA	NA	Yes
NA, not applicable.										
<b>Note</b> Adapted by permission from Springer Nature: Springer Nature, <i>Pharmacoeconomics</i> , Good practice guidelines for decision-analytic modelling in health technology assessment, Philips <i>et al.</i> <sup>49</sup> copyright 2006.										

TABLE 8 Quality assessment of data in economic models of DIs using the Philips checklist

Checklist item	Study (first author and year)									
	Guerrero 2013 <sup>67</sup>	Kass 2017 <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>D1 data identification</b>										
Are the data identification methods transparent and appropriate given the objectives of the model?	Yes	Partial	Partial	Yes	Yes	Partial	Yes	Yes	Yes	Yes
Where choices have been made between data sources, are these justified appropriately?	No	Yes	Yes	Yes	Yes	Partial	Yes	Yes	No	Yes
Has particular attention been paid to identifying data for the important parameters in the model?	Unclear	Partial	Partial	No	Partial	Partial	Partial	Yes	Yes	Yes
Has the quality of the data been assessed appropriately?	Unclear	Partial	Yes	Partial	Yes	Partial	Partial	Yes	Unclear	Yes
Where expert opinion has been used, are the methods described and justified?	NA	NA	NA	Yes	NA	NA	NA	NA	NA	Yes
<b>D2 data modelling</b>										
Is the data modelling methodology based on justifiable statistical and epidemiological techniques?	Implied	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Implied	Yes
<b>D2a baseline data</b>										
Is the choice of baseline data described and justified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Are transition probabilities calculated appropriately?	Yes	NA	NA	Yes	Yes	NA	NA	NA	Unclear	Yes
Has a half-cycle correction been applied to both cost and outcome?	Unclear	NA	NA	No	No	NA	NA	NA	Unclear	No
<b>D2b treatment effect</b>										
If relative treatment effects have been derived from trial data, have they been synthesised using appropriate techniques?	NA	Unclear	NA	NA	NA	NA	NA	NA	NA	NA
Have the methods and assumptions used to extrapolate short-term results to final outcomes been documented and justified?	Yes	NA	NA	Yes	Yes	NA	NA	Yes	NA	Yes
Have alternative assumptions been explored through sensitivity analysis?	No	Partial	No	Partial	Yes	Yes	No	Yes	Yes	No
Have assumptions regarding the continuing effect of treatment once treatment is complete been documented and justified? Have alternative assumptions been explored through sensitivity analysis?	No	No	No	Partial	Yes	NA	No	Yes	Unclear	No

Checklist item	Study (first author and year)									
	Guerrero 2013 <sup>67</sup>	Kass 2017 <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>D2c costs</b>										
Are the costs incorporated into the model justified?	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Partial
Has the source for all costs been described?	Yes	Yes	Yes	Yes	Yes	No	Yes	Partial	Yes	Yes
Have discount rates been described and justified given the target decision-maker?	Yes	No	Yes	Yes	Yes	No	Yes	No	NA	Yes
<b>D2d quality-of-life weights (utilities)</b>										
Are the utilities incorporated into the model appropriate?	Implied	NA	Yes	Unclear	Yes	Yes	Yes	Yes	Implied	Yes
Is the source for the utility weights referenced?	Yes	NA	Yes	Partial	Yes	Yes	Yes	Yes	Yes	Yes
Are the methods of derivation for the utility weights justified?	Unclear	NA	Yes	Unclear	Yes	Yes	Yes	Yes	Unclear	Yes
<b>D3 data incorporation</b>										
Have all data incorporated into the model been described and referenced in sufficient detail?	Unclear	Partial	Yes	Yes	Yes	Yes	Yes	Yes	Implied	Yes
Has the use of mutually inconsistent data been justified (i.e. are assumptions and choices appropriate)?	NA	NA	NA	NA	NA	Partial	NA	NA	Unclear	NA
Is the process of data incorporation transparent?	Yes	Partial	Yes	Partial	Yes	Partial	Yes	Yes	Partial	Yes
If data have been incorporated as distributions, has the choice of distribution for each parameter been described and justified?	Yes	NA	Yes	NA	Yes	NA	Yes	Yes	Yes	Yes
If data have been incorporated as distributions, is it clear that second order uncertainty is reflected?	Yes	NA	Yes	NA	Yes	NA	Yes	Yes	Yes	Yes
<b>D4 assessment of uncertainty</b>										
Have the four principal types of uncertainty been addressed?	No	No	Partial	No	Partial	No	Partial	Yes	No	Partial
If not, has the omission of particular forms of uncertainty been justified?	Partial	No	No	No	No	No	No	NA	Partial	

continued



TABLE 8 Quality assessment of data in economic models of DIs using the Philips checklist (continued)

Checklist item	Study (first author and year)									
	Guerrero 2013 <sup>67</sup>	Kass 2017 <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>D4a methodological</b>										
Have methodological uncertainties been addressed by running alternative versions of the model with different methodological assumptions?	No	No	No	No	No	No	No	Yes	No	Yes
<b>D4b structural</b>										
Is there evidence that structural uncertainties have been addressed via sensitivity analysis?	No	Partial	Partial	Partial	Yes	Yes	No	Yes	No	No
<b>D4c heterogeneity</b>										
Has heterogeneity been dealt with by running the model separately for different subgroups?	No	Partial	No	Partial	Yes	No	Partial	No	No	No
<b>D4d parameter</b>										
Are the methods of assessment of parameter uncertainty appropriate?	Yes	NA	Partial	NA	Yes	NA	Yes	Yes	Yes	Yes
If data are incorporated as point estimates, are the ranges used for sensitivity analysis stated clearly and justified?	Yes	NA	NA	NA	NA	Partial	NA	NA	Yes	NA
NA, not applicable.										
<b>Note</b> Adapted by permission from Springer Nature: Springer Nature, <i>PharmacoEconomics</i> , Good practice guidelines for decision-analytic modelling in health technology assessment, Philips <i>et al.</i> <sup>49</sup> copyright 2006.										

TABLE 9 Quality assessment of consistency in economic models of DIs using the Philips checklist

Checklist item	Study (first author and year)									
	Guerriero 2013 <sup>67</sup>	Kass (2017) <sup>78</sup>	Koeser 2013 <sup>81</sup>	Kumar 2018 <sup>85</sup>	Lee 2017 <sup>87</sup>	Lee 2017 <sup>86</sup>	Mihalopoulos 2005 <sup>91</sup>	Naveršnik 2013 <sup>94</sup>	Solomon 2015 <sup>99</sup>	Wu 2014 <sup>108</sup>
<b>C1 internal consistency</b>										
Is there evidence that the mathematical logic of the model has been tested thoroughly before use?	No	No	No	No	Yes	No	Yes	No	No	No
<b>C2 external consistency</b>										
Are any counterintuitive results from the model explained and justified?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
If the model has been calibrated against independent data, have any differences been explained and justified?	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Have the results of the model been compared with those of previous models and any differences in results explained?	Yes	No	Yes	Yes	Yes	No	Yes	Yes	No	Yes
NA, not applicable.										
<b>Note</b> Adapted by permission from Springer Nature: Springer Nature, <i>PharmacoEconomics</i> , Good practice guidelines for decision-analytic modelling in health technology assessment, Philips <i>et al.</i> <sup>49</sup> copyright 2006.										

The optimal method for measuring outcomes ultimately depends on the analysis perspective. An employer may be interested in measuring the effect of the intervention on productivity, a mental health-care provider may include a narrow range of benefits specific to the mental health condition targeted by the intervention and costs that fall on that provider, whereas a health system may aim to improve overall health, and so requires a broader health measure such as health-related quality of life (HRQoL) to allow comparison across different fields of medicine.

Although the majority of the studies that were identified in this review reported a range of different costs and outcomes, seven studies,<sup>52,54,59,66,74,86,90</sup> evaluated interventions from a health-care system or payer perspective, but measured outcomes in terms of changes in clinical scores,<sup>59,66,86,90</sup> clinical improvement/response/remission<sup>52,54</sup> or disease-free days.<sup>74</sup> It is not clear how health gains in such disease-specific outcome measures can be used by decision-makers to allocate resources across different disease areas.

Similarly, the appropriate methods for measuring costs depend on the analysis perspective (e.g. whether to include the cost to employer, service provider, broader health system or the society), as well as the role of the intervention. When interventions target undiagnosed patients who would not have sought care otherwise, dissemination (e.g. advertising or public health campaigns) is an integral part of the intervention that is likely to affect its outcomes, and so the cost of dissemination should be included in the cost of the intervention. Conversely, when an intervention targets diagnosed patients, and is prescribed by clinicians, the dissemination costs are likely to be negligible. Studies that recruit self-referred patients through advertising rarely include recruitment costs in their analysis. Furthermore, the costs of developing and maintaining DIs are highly uncertain because very few studies included capital costs (e.g. computers, staff training or one-off software purchases), or costs for website maintenance and hosting. The subsequent cost per patient depends on the scale of roll-out, where wider delivery (e.g. providing an intervention nationally) is likely to dilute such fixed costs.

### ***Use of all available evidence***

Evidence synthesis is more complex for DIs than for interventions such as medication, as DIs are multilayered and subject to external factors, and, therefore, it is difficult to ensure uniform delivery or to disentangle the impact of each layer on outcomes. There is significant heterogeneity likely between interventions, the populations they target and the settings in which they are delivered; even when interventions target the same condition, they tend to vary in their underlying principles, content, and the type and extent of support. It is not clear whether each of the characteristics affect the treatment effect, or whether evidence from similar interventions can be reasonably pooled to make an overall recommendation about their cost-effectiveness.

Furthermore, interventions for the same mental health disorder can target different patient populations (e.g. according to disease severity). The population in which an intervention is evaluated can affect its comparability with other trials (i.e. it may not be appropriate to generalise costs and treatment effect observed in one target population to another, or to attempt to synthesise effectiveness of interventions observed in different patients populations).

Finally, DIs as well as comparators that involve behavioural therapy are likely to vary between settings (clinics and countries) in the referral system, capacity, waiting times and frequency of contact, and so synthesising evidence on resource use may not be appropriate.

### ***Specification of comparators***

Comparators included supported and unsupported DIs, medication, different types of face-to-face therapy, WL and usual care. The majority of economic evaluations were based on two-arm RCTs. WLs and usual care were the most common comparators. Their description was often limited and the distinction between them was not always clear. Treatment of mental health conditions tends to vary between health providers, and between different patient populations (e.g. diagnosed vs. undiagnosed), so a lack of understanding of a comparator in a trial can limit generalisability of the findings, as well as comparability of results across trials.

### Time horizon for analysis

The majority of the evaluations were conducted alongside a trial or used retrospective data from a single study. Most economic evaluations did not explore the results beyond the trial end point, potentially failing to capture long-term costs and effects of DIs. This is considered inadequate for decision-making owing to the truncated time horizon. Mental illness is a lifetime condition for many patients, with periods of respite and relapse during which costs and outcomes can be influenced by any potential treatment received. Limiting the time horizon of an analysis can generate inaccurate estimates of cost-effectiveness. The lack of long-term modelling is likely to be due, in part, to the lack of reliable data about the long-term performance of DIs. In many cases, there are no empirical data on the duration of treatment effects and how these relate to a changing baseline (i.e. how illness progresses in the population that does not receive the treatment). This issue is likely to be confounded by comorbidities and future events, making long-term extrapolation challenging.

### Cost-effectiveness conclusions

Cost-effectiveness results, which comprise estimates such as ICERs and net benefits, as reported in the reviewed studies, are summarised in *Table 10*. This table also shows which comparisons were between DIs (UDI, SDI) and non-digital psychological interventions (SNoDI, UNoDI), non-therapeutic controls (SDC, UDC, SNoDC, UNoDC) and NI. Only two studies<sup>86,99</sup> reported cost-effectiveness comparisons with medication.

TABLE 10 Classifications and summary of cost-effectiveness conclusions

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Aardoom 2016 <sup>50</sup>	UDI	1. Featback (FB) with no support: internet psychoeducation and automated monitoring and feedback system	Probability cost-effective when cost-effectiveness threshold = £0 per QALY: FB, > 20%; FBL, > 30%; FBH, ≈ 30%; WL, ≈ 0%
	SDI-1	2. Featback with low-intensity support (FBL): internet psychoeducation and automated monitoring and feedback system, with weekly therapist support via e-mail, chat and/or teleconference	Probability cost-effective when cost-effectiveness threshold > £20,000 per QALY: FB, 42–54%; FBL, 1–17%; FBH, 30–38%; WL, 5–15%
	SDI-2	3. Featback with high-intensity support (FBH): internet psychoeducation and automated monitoring and feedback system, with therapist support three times per week via e-mail, chat and/or teleconference	
	NI	4. WL with crossover (WL): waiting 5 months before receiving Featback with low-intensity therapist support	
Andersson 2015 <sup>43</sup>	SDI	1. ICBT: internet CBT with weekly therapist support and reminders. ICBT content tailored to OCD type and included homework exercises. Therapist support was feedback on homework exercises. SMS reminders and telephone calls used when patients had not logged in for ≥ 1 week	ICER = US\$931 per remission
	SDC	2. Internet-based support therapy (active control): online non-directive supportive therapy. Access to an e-mail function integrated in the treatment platform, through which participants could communicate with a therapist. No CBT component. No active treatment components such as self-help texts or worksheets	

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Andersson 2015 <sup>51</sup>	SDI	1. ICBT booster: manual-based CBT with therapist support via an e-mail-type online platform for 3 weeks given at 6 months after completion of a 10-week ICBT programme	Societal ICER = US\$1489/relapse avoided. Provider ICER = US\$1066/relapse avoided
	NI	2. No booster	
Axelsson 2018 <sup>52</sup>	SDI	1. Therapist-guided internet CBT (G-ICBT): 12-week internet CBT for health anxiety, completed in patient's own time. Access to a therapist through a secure online contact system	ICERs from societal perspective (per responder): G-ICBT vs. U-CBT, £12,671; G-ICBT vs. BIB-CBT, £542,471; G-ICBT vs. WL, £416; U-ICBT vs. BIB-CBT, dominated; U-ICBT vs. WL, dominant; BIB-CBT vs. WL, £273
	UDI	2. Unguided internet CBT (U-ICBT): 12-week internet CBT for health anxiety, completed in patient's own time. No access to therapist	
	UNoDI	3. Unguided CBT (BIB-CBT): 12 weeks of paper version of unguided internet CBT without any therapist involvement	ICERs from health-care perspective (per responder): G-ICBT vs. U-CBT, £2902; G-ICBT vs. BIB-CBT, £290,670; G-ICBT vs. WL, £640; U-ICBT vs. BIB-CBT, dominated U-ICBT vs. WL, £80; BIB-CBT vs. WL, dominant
	NI	4. WL: 12 weeks of no treatment, followed by TAU	
Bergman Nordgren 2014 <sup>53</sup>	SDI	1. ICBT: internet-based CBT, completed in own time, including homework. Therapists provided feedback via e-mail on homework and were advised to spend no more than 15 minutes per participant per week	Dominant (when outcome is CORE-OM score or QALY gain)
	SNoDC	2. Attention control: participants asked about their well-being weekly by therapist but were generally not given any specific feedback on the answers unless the therapist judged the answer to warrant further action	
Bergström 2010 <sup>54</sup>	SDI	1. ICBT: internet CBT completed in own time. Supported by psychologist by e-mail (feedback on exercises, enabled access as participants progressed, answers to specific questions via online messaging system)	Dominant
	SNoDI	2. Group CBT: same modules as in ICBT but delivered by two psychologists in 2-hour group sessions	
Bolier 2014 <sup>55</sup>	UDI	1. Psyfit: based on positive psychology principles. Included lessons and homework. Fully automated, without any therapist support but with access to an online community	ICER = €21,319 per response
	NI	2. WL: participants told they were on a WL for 6 months before they received their login codes for Psyfit. They were free to seek professional help (care as usual), if needed	

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Brabyn 2016 <sup>56</sup>	UDI	1. MoodGym – telephone-facilitated: free-to-use, internet-based, interactive CBT program. Weekly telephone calls with therapist to (1) facilitate the use of the program and (2) engage in between-session exercises with problem formulation and adherence to CBT principles. All participants were offered usual GP care	Telephone-facilitated MoodGym dominates minimally supported MoodGym
	SDI	2. MoodGym – minimally supported: free-to-use, internet-based, interactive CBT program. No therapist support but given a technology support number. All participants were offered usual GP care	
Budney 2015 <sup>57</sup>	SDI	1. Computer-assisted motivational enhancement therapy, CBT and abstinence-based contingency management (computer MET, CBT + CM): nine sessions delivered via an internet-delivered programme delivered in a clinic with therapist support	Cost of computer and brief counselling significantly lower than therapist. Abstinence significantly higher after computer and therapist than brief counselling. ICERs not reported
	SNoDI	2. Standard counselling: nine sessions of individual counselling that was based on MET, CBT + CM	
	SNoDI	3. Brief counselling: two individual MET counselling sessions plus a 12-week incentive programme that encouraged attendance at sessions and substance testing appointments	
Buntrock 2017 <sup>58</sup>	SDI	1. GET.ON Mood Enhancer: online multimedia interactive intervention based on behavioural activation and problem-solving therapy, with homework. Option to receive standardised text messages helping participants to integrate the learnt techniques into their lives. Participants supported by an online trainer, who provided written feedback after each session and encouraged adherence	Health system ICER = £13,500 per QALY, £1125/depression-free day  Societal ICER = £13,400 per QALY, £1117/depression-free days
	UDC	2. Web-based psychoeducation: usual care (unspecified), plus access to a web-based psychoeducational intervention without support	
Burford 2013 <sup>59</sup>	UDI	1. Photoaging: in addition to standard smoking cessation advice, internet-based three-dimensional age progression software package that creates a stream of aged images of faces from a standard digital photograph. The resulting aged images can be adjusted to compare how a person will age as a smoker vs. as a non-smoker	ICER = AU\$46 per additional quitter
	NI	2. Standard smoking cessation advice (details not given)	

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Calhoun 2016 <sup>60</sup>	SDI	1. QuitNet: tailored, online tobacco cessation support, with direct access to online smoking cessation counsellors, access to interactive features that offer assistance in selecting a quit date and choosing medications, unlimited access to social support features (e.g. forums, buddies, chat rooms) and access to proactive e-mail support	Mean cost in intervention arm: US\$178. Mean cost in control arm: US\$26  Outcomes in intervention arm: 28 quits, 0.51 life-years and 0.27 QALYs gained  Outcomes in control arm: 32 quits, 0.48 life-years and 0.27 QALYs gained
	SNoDI	2. Specialist clinic-based smoking cessation: group and telephone counselling by doctoral-level psychologists, based on QuitSmart program, with medication management provided by psychiatrist. NRT provided as usual	ICERs not reported
Dear 2015 <sup>61</sup>	SDI	1. e-Managing Stress and Anxiety Course: internet-based CBT completed in own time. Five online lessons, homework assignments and several detailed case stories. Regular automatic reminder and notification e-mails. Regular support from a clinical psychologist via a secure e-mail system and telephone	ICER = £8806 per QALY
	NI	2. WL with crossover: delayed treatment after follow-up	
Ebert 2018 <sup>62</sup> (linked with Kählke 2019) <sup>112</sup>	SDI	1. GET.ON stress: internet-based training in problem-solving and emotion regulation; included text, audio and video clips, exercises and testimonials. Adaptive training: content determined by previous responses. Participants could receive motivational text messages (1–3 per day). Participants supported by e-coach, up to 30 minutes per session (maximum 3 hours in total)	Dominant
	NI	2. WL: no details reported	
El Alaoui 2017 <sup>110</sup>	SDI	1. ICBT: internet-delivered CBT modules with homework. Patients received supportive e-mail feedback from a psychologist after each module. Therapists were instructed to restrict time spent on each patient to approximately 10 minutes per week	Dominant
	SNoDI	2. Group CBT: one initial individual session followed by 14 2.5-hour group sessions with six or seven participants facilitated by therapists	
Garrido 2017 <sup>63</sup>	SDI	1. CACR (computer-assisted cognitive remediation therapy): cognitive remediation therapy accessed individually in clinic via computer exercises for 1 hour twice per week for 6 months (48 sessions). Content: neurocognitive exercises adapted to the patient's neuropsychological profile according to standardised scores. Therapist support for motivation, skills transfer and to reinforce learning and guide action	Cost significantly higher in the active control group. Observed improvement in four cognitive domains with treatment (ICERs not reported)

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
	SNoDC	2. Attention control: watching a documentary (not clear about content of documentary), played for 1 hour twice per week for 6 months (48 sessions) on same computer as the CACR. Participants invited to complete a questionnaire about the documentary. Therapist interactions during the documentary to maintain attention and subsequent feedback regarding the written answers	
Geraedts 2015 <sup>64</sup>	SDI	1. Happy at Work: six weekly self-directed lessons via the internet. Participants received feedback on assignments from a coach. Participants free to seek any additional (mental) health care	Societal ICER = £532,959 per QALY, £314 per 1-point reduction in CES-D. Employer ICER = £382,354 per QALY, £223/CES-D point reduction
	NI	2. Usual care: advised to consult with (occupational) physician or psychologist. Participants free to seek any additional (mental) health care	
Gerhards 2010 <sup>65</sup>	UDI	1. Colour Your Life: internet CBT; nine sessions of an online, multimedia, interactive computer program, completed at home, including homework exercises and a mood diary. No therapist involvement	Cost of cCBT compared with TAU = -€711 (-€3111 to €1780). Cost of cCBT + TAU compared with TAU = €738 (€71871 to €3477). Effect not significant for either intervention
	SDI	2. Colour Your Life plus GP treatment: internet CBT; nine sessions of online, multimedia, interactive computer program, completed at home, including homework exercises and a mood diary. Participants encouraged to contact their own GP to receive four or five consultations and antidepressants. A letter was sent to GP advising to follow the depression guideline as described by the Dutch College of General Practitioners	
	SNoDI	3. GP treatment: participants encouraged to see their GP. A letter was sent to GP advising to follow the depression guideline as described by the Dutch College of General Practitioners. Usual care as such can consist of four or five biweekly consultations in combination with antidepressant treatment if indicated. In practice, however, usual care is whatever the GP prescribes	
Graham 2013 <sup>66</sup>	UDI	1. Enhanced internet smoking cessation programme (QuitNet): advice and assistance in accordance with evidence-based guidelines; includes interactive features and a large online social network. No therapist involvement	3 months: enhanced vs. basic internet ICER = US\$4227/quitte; enhanced internet + telephone vs. enhanced internet ICER = US\$1197/quitte; 6 months: enhanced vs. basic internet ICER = US\$2305/quitte; enhanced

continued



TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
	SDI	2. Enhanced internet smoking cessation programme plus telephone counselling: advice and assistance in accordance with evidence-based guidelines; includes interactive features and a large online social network. Supported by proactive telephone counselling provided by trained cessation counsellors who reinforced and encouraged use of QuitNet	internet + telephone vs. enhanced internet ICER = US\$1841/quitter; 12 months: enhanced vs. basic internet ICER = dominated; enhanced internet + telephone vs. enhanced internet ICER = US\$1528/quitter; 18 months: enhanced vs. basic internet ICER = dominated; enhanced internet + telephone vs. enhanced internet ICER = US\$3781/quitter
	UDC	3. Basic website: content from interactive webpage made available to read via basic website. No interactive features and no online social network. Created for the trial to mimic no treatment	
Guerriero 2013 <sup>67</sup>	UDI	1. text2stop: motivational text messages – five per day for the first 5 weeks and three per week for the next 26 weeks	Service with text-based support dominant
	NI	2. Usual care: participants free to participate in any other smoking cessation service or support that they wished to use; they were offered the QUIT and NHS smoking cessation helpline numbers	
Hedman 2011 <sup>69</sup>	SDI	1. ICBT: internet-based CBT with homework exercises and e-mail support by therapist for up to 10 minutes per week	ICBT dominant
	SNoDI	2. GCBT: one individual and 14 group CBT sessions	
Hedman 2013 <sup>68</sup>	SDI	1. ICBT: internet-based CBT over 12 weekly modules. Regular e-mail support from a clinical psychologist via a secure e-mail system	ICBT dominant (per response and QALY gain)
	SNoDC	2. Online discussion forum: participants could send messages anonymously to each other over a period of 12 weeks to discuss their health anxiety and helpful ways of coping with it, and for general peer support. No therapeutic content or trained peers as ‘supporters’	
Hedman 2014 <sup>111</sup>	SDI	1. ICBT: internet-based CBT completed in own time. Included homework exercises. Supported by therapist via e-mail (up to 10 minutes per week)	ICBT dominant
	SNoDI	2. GCBT: one individual and 14 group CBT sessions	
Hedman 2016 <sup>70</sup>	SDI-1	1. ICBT: internet-based CBT completed in own time. Regular support from a clinical psychologist via a secure e-mail system and telephone	ICER = US\$10,000 per QALY, US\$2124 per case improved
	SDI-2	2. Internet-delivered behavioural stress management (active control): online modules on applied relaxation and stress management strategies. Access to a therapist through online contact (like e-mail) system	

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Hollinghurst 2010 <sup>71</sup>	SDI	1. Online CBT: 10 sessions of internet-based CBT. Supported online by therapists (via instant messaging service)	ICER = £17,173 per QALY, £3528 per recovery
	NI	2. WL with crossover: participants were reassessed after 8 months, and those on the WL who were still eligible were offered the intervention at that time	
Holst 2018 <sup>72</sup>	SDI	1. Depressionshjälpen: ICBT seven modules with regular therapist contact to reinforce progress and encourage participation (15 minutes per week)	Health system ICER = €537 per QALY, €41/BDI-II point reduction. Societal ICER = €5387 per QALY, €411/BDI-II point reduction
	NI	2. Usual care: treatment typically provided at a specific primary care centre consisting of visits to a GP (58%), or nurse (18%), antidepressants (50%), face-to-face psychotherapy (39%), sick leave certification (32%) or combinations of these	
Hunter 2017 <sup>73</sup>	SDI	1. Facilitated access brief intervention: 'Down your drink' interactive website signposted by the GP without therapist support	Probability that INHS is cost-effective: 70% if costs include intervention delivery, training and website development; 84% if only the cost of training (excluding website development costs) is included;
	SNoDI	2. Face-to-face brief intervention: advice and monitoring for hazardous and harmful drinkers delivered by a GP	75% if English NHS costs are used and intervention costs only are included
Joesch 2012 <sup>74</sup>	SDI	1. Coordinated Anxiety Learning and Management (CALM): treatment model that offered patients the choice of CBT, medication or both. To enhance treatment decisions, CALM included real-time, web-based clinical outcome monitoring and a computer-assisted programme to optimise CBT delivery by non-expert care managers	Incremental net benefit positive when cost-effectiveness threshold > US\$5000 per QALY  Incremental net benefit positive when cost-effectiveness threshold > US\$4/anxiety-free day
	NI	2. Usual care: could include medication, counselling (7/17 clinics had limited in-clinic mental health resources), or referral to a mental health specialist. After the eligibility diagnostic interview, the only contact between usual-care participants and study personnel was for assessment by telephone	
Jolstedt 2018 <sup>75</sup>	SDI	1. ICBT: 12 web-based CBT modules, completed in own time, included text, films, illustrations and exercises. Limited weekly asynchronous support from a clinician, mainly messages and comments on worksheets within the programme	ICBT dominant (when outcome is response)
	SDC	2. Internet-delivered child-directed play (ICDP): 12 modules of a web-based programme intended as an active control aimed to improve parent-child relationships and increase child self-esteem without directly targeting anxiety. Directed at parents only	

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Jones 2001 <sup>77</sup>	SDI-1	1. Computer education with researcher: five sessions aiming to increase patients' knowledge about schizophrenia, delivered at a clinic with assistance from a researcher	No significant difference in effect for a range of outcomes No cost-saving with DI
	SDI-2	2. Combination of computer education with researcher and nurse feedback: five sessions, aiming to increase patients' knowledge about schizophrenia, delivered at a clinic. Two sessions were delivered by nurses (first and last), middle three were assisted by a researcher	
	SNoDI	3. Sessions with a community psychiatric nurse. Covered the same content as the computer system. Personal issues could be introduced by the patient	
Jones 2014 <sup>76</sup>	SDI	1. TE-HNC (Technology Enhanced Helping the Noncompliance Child): Helping the Noncompliant Child clinic-based programme with smartphone app support and therapist video calls and feedback. Uses videos, daily survey of skills practice, midweek video calls with therapist, videotaped home practice used by therapists to assess skill development, and motivational messages and reminders	TE-HNC had no significant effect, led to higher cost
	SNoDI	2. HNC (Helping the Non-compliance Child): clinic-based, individual family-focused, behavioural parent training (BPT) programme supported weekly by therapists	
Kass 2017 <sup>78</sup>	SDI	1. Online guided self-help, online preventative intervention, stepped-care approach (theoretical, no particular intervention)	Cost of prevention: US\$505.86. Cost of 'wait and treat': US\$508.76. In-person therapy with prevention: 241 individuals per 1000 at risk. In-person therapy with wait and treat: 310 individuals per 1000 at risk. Clinical outcomes not considered
	NI	2. No prevention (WL): TAU	
Kenter 2015 <sup>79</sup>	SDI	1. Blended CBT: online CBT (disorder specific), supported online (feedback on homework, motivational techniques) plus face-to-face CBT	Incremental cost = €585. Effect not significant
	SNoDI	2. Face-to-face CBT: individual CBT that could vary depending on the preference of the therapist and patient	
Kiluk 2016 <sup>80</sup>	SDI-1	1. CBT4CBT + monitoring: online CBT modules completed in a private room within the clinic, plus brief (10-minute) weekly clinical monitoring provided in person by a doctoral-level psychologist	Costs CBT4CBT + TAU: US\$410.83 CBT4CBT + monitoring: US\$273.12

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Koeser 2013 <sup>81</sup>	SDI-2	2. CBT4CBT plus face-to-face therapy plus psychiatric services: online CBT modules completed in a private room within the clinic, in addition to face-to-face therapy + psychiatric services	TAU: US\$318.85 Significant reductions in alcohol found across all comparators. CBT4CBT + TAU demonstrated greater abstinence than TAU (numbers not reported, only <i>p</i> -values)
	SNoDI	3. Face-to-face therapy plus psychiatric services: weekly group or individual psychotherapy delivered by Master's-level counsellors at the outpatient facility plus psychiatric services	
	UDI	1. Beating the Blues: computerised CBT with no therapist support. Patients allowed to receive pharmacotherapy, physical investigations, general support or advice but no face-to-face psychological interventions	Beating the Blues: £2430 in moderate depression; £3016 in severe depression Guided self-help: £2488 in moderate depression; £4739 in severe depression TAU: £1510 in moderate depression; £2575 in severe depression
Kolovos 2016 <sup>82</sup>	SNoDI	2. Positive Mental Training (PosMT): self-help audio-based psychosocial therapy, unguided. Standard GP and nurse supervision and monitoring maintained, but antidepressants not allowed	
	NI	3. Usual care: at GPs' discretion – medication, physical investigations, general support or advice but no face-to-face psychological interventions	
	SDI	1. Taking control: structured five-session online intervention supported by therapist (in form of feedback on exercises) via e-mail	ICER = £3222/unit reduction in CES-D score. Intervention dominated by usual care when health effect measured in terms of QALYs and remission
König 2018 <sup>83</sup>	UNoDI	2. Bibliotherapy: usual care, plus self-help book mailed to home address. The book, <i>Everything Under Control: Overcome Your Problems and Worries by Self-analysis</i> , had therapy content but the research team expected it to have only a small effect because there was no therapist guidance with it	
	SDI	1. GSH-I (therapist-guided internet-based self-help): 11 online modules combining behavioural interventions and homework exercises. Includes two face-to-face coaching sessions and therapist support by e-mail and telephone over 4 months	ICER = €63 per binge-free day; intervention dominated by guided self-help when health effect measured in terms of QALYs
Kraepelien 2018 <sup>84</sup>	SNoDI	2. Individual CBT: up to 20 individual therapy sessions (50 minutes each) over 4 months	
	SDI	1. ICBT: internet CBT and behavioural activation with online therapist support given as written messages in the treatment platform. Allowed to utilise primary care services	Health system ICERs: ICBT vs. TAU: €8817 per QALY; €3666/responder. Exercise vs. TAU: €14,571 per QALY; €7157/responder

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Kumar 2018 <sup>85</sup>	SNoDI	2. Physical exercise: maximum of 36 supervised group exercise sessions (three times per week), a weekly meeting with a trainer or physiotherapist and telephone calls to monitor adherence and encourage participation. Telephone reminders were scheduled once per week, if needed	Societal ICERs: ICBT vs. TAU: €31,471 per QALY; €13,084/responder. Exercise vs. TAU: €37,974 per QALY; €18,652/responder
	NI	3. Usual care: the treatment the participant received at their primary care unit, determined by the participant's primary care physician. In many cases this included counselling, but not all participants received any depression treatment at their primary care unit	
	SDI	1. Mobile CBT: mobile telephone-based CBT – combination of education and practice, including daily audio-guided or self-guided interactive and personalised CBT techniques. A trained coach (with health and wellness coaching or psychology background) provided support and motivational enhancement via asynchronous in-app messages	ICBT dominant relative to face-to-face CBT and status quo
Lee 2017 <sup>87</sup>	SNoDI	2. CBT: clinical outcomes with face-to-face CBT derived from the Cochrane review of CBT in GAD <sup>127</sup>	
	NI	3. Status quo: assumed 58.6% on pharmacotherapy, based on literature, no treatment for remaining 41.4%	
	SDI	1. Internet-delivered psychological interventions for the prevention of major depression in young people	Not available (effectiveness of DIs not measured, but is assumed to be 50% and 100% of face-to-face therapy)
Lee 2017 <sup>86</sup>	SNoDI	2a. Universal psychological intervention: group-based psychological interventions delivered to all participating school students	
	SNoDI	2b. Indicated psychological intervention: group-based psychological interventions delivered to students with subthreshold depression	
	SNoDI	2c. Indicated bibliotherapy: self-help bibliotherapy (reading) delivered to students with subthreshold depression	
Lee 2017 <sup>86</sup>	UDI	1. MindSpot: online course (condition specific), completed in own time, with homework assignments. Available on self-referral or recommendation via health professionals (such as GPs). Therapist involvement not reported	Intervention dominant
	SNoDI	2. Usual care – CBT: one of the following three: CBT alone, CBT and at least two consultations with the same type of health professional, or CBT and at least three consultations with the same type of health professional	

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
	M	3. Usual care – medication: one of the following three: medication alone, medication and at least two consultations with the same type of health professional, or medication and at least three consultations with the same type of health professional	
Lenhard 2017 <sup>88</sup>	SDI	1. Child Internet Project: web-based therapist-guided and parent-assisted CBT. Includes homework exercises. Therapist guided (clinical psychologist provides asynchronous written feedback 5 days per week via messages and telephone calls), parent assisted	ICBT dominant
	NI	2. WL – continued use of ongoing medication and psychosocial care (not CBT)	
Littlewood 2015 <sup>89</sup> Duarte 2017 <sup>109</sup>	SDI-1	1. MoodGym plus usual GP care: free-to-use computerised CBT, accessed from home or at community venues or GP surgery. Weekly telephone support for administration and general encouragement by trained researchers. Participants had access to usual GP care, including medication and therapy	Beating the Blues vs. TAU: dominated MoodGym vs. TAU: £6933 per QALY
	SDI-2	2. Beating the Blues plus usual GP care: pay-to-use computerised CBT, accessed from home or at community venues or GP surgery. Weekly telephone support for administration and general encouragement by trained researchers. Participants had access to usual GP care, including medication and therapy	
	NI	3. Usual GP care: no restrictions on usual GP care, including the use of medication or therapy. Letter sent to GP	
Lovell 2017 <sup>39</sup>	SDI	1. OCFighter: online CBT completed in own time. Supported by low-intensity therapists in six 10-minute scheduled telephone calls, for a brief risk assessment, administrative support, reviewing progress and solving any difficulties that were impeding progress	Health system ICERs supported cCBT vs. WL, £32,857 per QALY at 3 months, dominant after 12 months; supported cCBT vs. guided self-help, £94,167 per QALY at 3 months, dominant after 12 months; guided self-help vs. WL, £55,152 per QALY at 3 months, £3934 per QALY at 12 months
	SNoDI	2. Guided self-help: participants provided self-help book. Receive weekly guidance from a PWP supported in using CBT (ERP), reviewing progress, pre-empting difficulties as they arose and engaging the participants in collaborative problem-solving as required	Societal perspective ICERs supported cCBT vs. WL, £48,095 per QALY at 3 months, dominant after 12 months; supported cCBT vs. guided self-help, £45,417 per QALY at 3 months, £21,778 per QALY at 12 months; guided self-help vs. WL, £46,970 per QALY at 3 months, dominant after 12 months
	NI	3. WL with individual therapy at some point: participants receive high-intensity CBT at some point during the trial (not necessarily at the end of the follow-up period)	

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
McCrone 2004 <sup>45</sup>	UDI	1. Beating the Blues plus TAU: online CBT delivered at clinic. Includes videos, reading and homework. Sessions and homework projects are customised to the patient's specific needs and each session builds on the one before. Practice nurses provided administrative support	Probability of cost-effectiveness: 85% if cost-effectiveness threshold = £0 per QALY 99% if cost-effectiveness threshold = £15,000 per QALY
	NI	2. TAU: whatever therapy the GP prescribed. A variety of interventions, including discussions with the GP, referral to a counsellor, practice nurse or mental health professional, and treatment of physical conditions	14.5% if cost-effectiveness threshold = £0/depression-free day > 80% if cost-effectiveness threshold = £5/depression-free day 14% if cost-effectiveness threshold = £0/point reduction in the Beck Depression Inventory > 80% if cost-effectiveness threshold = £0/point reduction in the Beck Depression Inventory
McCrone 2007 <sup>42</sup>	SDI	1. BTSteps: interactive-voice-response automated system accessed from a telephone at home. Based on exposure and response prevention (CBT). Therapists monitored progress and gave feedback	BTSteps vs. relaxation: £64/point reduction. Clinician-guided ERP vs. relaxation: £90/point reduction. Clinician-guided ERP vs. BTSteps: £133/point reduction
	SNoDI	2. Clinician-guided ERP: 1-hour sessions of individual exposure and response prevention (CBT)	
	UNoDC	3. Relaxation: attention placebo, manualised and audiotape-guided applied muscle relaxation	
McCrone2009 <sup>90</sup>	SDI	1. FearFighter (FF): computerised self-directed graded exposure therapy (CBT), completed on stand-alone computer terminals at a clinic. Brief face-to-face support by a clinician at the start and end of sessions	FF vs. relaxation: £64/point decrease in main problem. FF vs. clinician-led therapy: dominant
	SNoDI	2. Clinician-led exposure therapy: therapist-delivered graded exposure therapy (CBT) at a clinic	
	SDC	3. Computer-guided relaxation therapy: applied muscle relaxation self-directed and guided by a computer accessed at a clinic (no exposure element)	
Mihalopoulos 2005 <sup>91</sup>	SDI-1	1. Panic Online – psychologist delivered: 12 sessions of internet modules supported by psychologist online (via e-mails) and one consultation with GP	Psychologist delivered vs. TAU: AU\$4300 per QALY. GP delivered vs. TAU: AU\$3200 per QALY
	SDI-2	2. Panic Online – GP delivered: 12 sessions of internet modules supported by GP in six consultations	
	SNoDI	3. Evidence-based GP care: primarily CBT (which was assumed to be face to face)	
	NI	4. General practice care (not including evidence-based interventions for panic)	

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Murphy 2016 <sup>92</sup>	SDI	1. Therapeutic Education System (TES) plus usual care: computer program with 62 interactive, self-directed multimedia modules based on community reinforcement approach and an integrated contingency management program accessed on any internet device, in own time. Incentives provided for engagement (module completion) and performance (drug-free urine sample). Level of guidance unclear	ICER = £9073/abstinent year. Intervention dominated by usual care when effect measured in QALYs
	NI	2. Usual care: primarily therapeutic groups, with some individual counselling dependent on GP clinic	
Naughton 2017 <sup>93</sup>	UDI	1. MiQuit plus TAU: automated 12-week SMS tailored advice and support, including motivational messages, advice about quit attempt preparation, managing cravings and withdrawal. Tailored to patients based on 14 characteristics	ICER = £133.53 per additional quitter
	NI	2. Usual care: participants were signposted (NHS booklet) to smoking cessation services offered as part of routine antenatal care	
Naveršnik 2013 <sup>94</sup>	SDI	1. Improvehealth.eu: a web-based information and communication technology system, designed to support collaborative care management and active patient engagement. Included online- (and telephone-) based care management performed by trained psychologists	€1400 per QALY
	NI	2. Usual care: physician visits and antidepressant treatment	
Olmstead 2010 <sup>95</sup>	SDI	1. CBT4CBT plus counselling: online CBT modules completed in a private room within the clinic twice per week. Administrative support provided by research associate. One individual (45 minutes) and one group (90 minutes) counselling session per week. Counselling included the application of the principles of basic drug counselling, including facilitation of self-help involvement (no CBT)	Clinic perspective: US\$21 per drug-free specimen. Patient perspective: US\$15 per drug-free specimen
	SNoDI	2. Counselling: one individual (45 minutes) and one group (90 minutes) counselling session per week. Counselling included principles of basic drug counselling, including facilitation of self-help involvement (no CBT)	
Phillips 2014 <sup>96</sup>	SDI	1. MoodGym: five 1-hour weekly online CBT modules with weekly telephone calls (10 minutes) by clinical studies officers to maintain engagement with the study, to screen for risk and to collect service use data for costing purposes	Comparable QALY gain in two interventions; lower loss of employment and absence from work with intervention

continued



TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
	SDC	2. Attention control: access to five websites with information and advice on mental health and stress. Weekly telephone calls (10 minutes) by clinical studies officers to maintain engagement with the study, to screen for risk and to collect service use data for costing purposes	
Romero-Sanchiz 2017 <sup>97</sup>	SDI	1. Smiling is Fun with therapist support: internet-based CBT, 10 modules; supported by therapist, who checked progress, enhanced motivation, offered administrative support and answered technical questions	TSG vs. TAU: dominant (for all outcomes). LITG vs. TAU: dominant (for all outcomes). TSG vs. LITG: not reported
	UDI	2. Smiling is Fun without therapist support: internet-based CBT, 10 modules, totally self-guided, help available for technical questions	
	NI	3. Improved usual care: provided by GPs who participated in a 3-hour training programme to update their knowledge of how to treat depression in primary care based on the NICE recommendation. The programme included the use of antidepressants in adequate doses and lengths of time	
Smit 2013 <sup>98</sup>	SDI	1. MT (multiple tailoring) with counselling: internet-based multiple computer-tailored smoking cessation programme with feedback letters, counselling and telephone support	MT vs. UC: €5100/quit (MTC dominated by UC). MTC vs. UC: €40,300 per QALY (MT dominated by UC)
	UDI	2. MT only: internet-based multiple computer-tailored smoking cessation programme with automated feedback letters	
	NI	3. Usual care: receipt of smoking cessation guidance in accordance with participating practice nurses' standard practice. Care can vary between nurses and practices	
Solomon 2015 <sup>99</sup>	UDI	1. MyCompass: internet CBT with real-time self-monitoring of symptoms (e.g. problem moods, thoughts and behaviours) via mobile phone and/or computer is a key therapeutic feature. No therapist support	MyCompass vs. CBT: AU\$2966.37 per QALY. MyCompass vs. M: dominant
	M	2. Medication: drug treatment with a prescribed antidepressant for an acute depressive episode, plus a 21-week maintenance phase of drug therapy after remission	
	SNoDI	3. Face-to-face CBT: with a clinical psychologist during acute phase	

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
Španiel 2012 <sup>100</sup>	SDI	1. Information Technology-Aided Program of Relapse Prevention in Schizophrenia (ITAREPS): weekly 10-item monitoring and prompting automated programme. Early Warning Signs Questionnaire to patients (EWSQ-10P) and their family members (EWSQ-10FM) delivered via mobile phones. Responses fed back to the treating psychiatrist for monitoring. Psychiatrist reacted when scores reached prespecified threshold	Intervention ineffective, cost not reported
	SDC	2. 'Dummy' ITAREPS: as ITAREPS but ALERT e-mails to investigators (when the patient deteriorates) were disabled, so the investigators detected and reacted to potential signs of psychotic relapse as they would have done prior to study	
Stanczyk 2014 <sup>101</sup>	UDI-1	1. I-Change text based: web-based multiple computer-tailored smoking cessation intervention with automated feedback received via video (e.g. graphics and images). The video messages were presented by five different adults in a television 'news programme' format. Tailored feedback was on smoking attitude, behaviour, perceived social influence, perceived self-efficacy and on how to plan a quit date	Video vs. control: €1500/abstinence; €60,000 per QALY. Text vs. control: €50,400/abstinence; text dominated by control (when outcome measured in QALYs). Video dominant over text (for both outcomes)
	UDI-2	2. I-Change video based: web-based multiple computer-tailored smoking cessation intervention with automated feedback received via text (no graphics or animations)	
	UDC	3. Control condition: respondents received brief general text advice about quitting	
Titov 2009 <sup>102</sup>	SDI	1. Shyness: six online clinician-assisted CBT self-help sessions with feedback from therapist via e-mails within 24 hours, along with weekly reminder e-mails; if necessary, participants were telephoned by the therapist	AU\$5686 per year lived with disability gained
	NI	2. WL with crossover: access to Shyness after follow-up was completed	
Titov 2015 <sup>103</sup>	SDI	1. Managing Your Mood: five internet-based CBT sessions with feedback from therapist via e-mails, along with regular automated reminder and notification e-mails	AU\$4392 per QALY
	NI	2. WL with crossover: access to Managing Your Mood after follow-up was completed	

continued

TABLE 10 Classifications and summary of cost-effectiveness conclusions (continued)

Study (first author and year)	Classification	Description of DIs and comparators	Results of economic evaluations
van Spijker 2012 <sup>104</sup>	UDI	1. Online, unguided, self-help intervention aimed at decreasing the frequency and intensity of their suicidal ideation: based on CBT (DBT, PST, and MBCT). Available via an online suicide-prevention platform. Six weekly modules	Intervention dominant
	UDC	2. Signposting to websites: link to a website created for the study that provided information on suicidality, such as prevalence, warning signs and risk factors. In addition, links and advice to use relevant mental health organisations. Option to cross over to intervention 6 weeks from randomisation (end of active intervention)	
Warmerdam 2010 <sup>105</sup>	SDI-1	1. ICBT: internet-delivered self-help programme based on CBT with e-mail support from life coach (average 20 minutes per week)	CBT vs. WL: €22,609 per QALY. PST vs. WL: €11,523 per QALY. CBT dominated by PST (when using QALYs). CBT vs. WL: €1817 per additional reliably improved patient. PST vs. WL: €1248/change in depressive symptoms. CBT dominated by PST (when effect measured in change in depressive symptoms)
	SDI-2	2. Internet Based Problem-Solving Therapy (IPST): internet-delivered self-help programme with e-mail support from life coach (average 20 minutes per week)	
	NI	3. WL with crossover: crossover to ICBT or IPST after follow-up	
Wijnen 2018 <sup>106</sup>	UDI	1. Complaint-directed mini-intervention (CDMI): three or four online modules completed in own time. Largely based on CBT but also incorporates elements from solution-focused therapy, mindfulness and positive psychology. No support; a reminder sent if participants did not log in within 1 week after registration	Web-based self-help dominant for all outcomes
	NI	2. WL with crossover: treatment offered after follow-up	
Wright 2017 <sup>107</sup>	SDI	1. Stressbusters: cCBT designed for 12- to 18-year-olds, eight sessions, includes videos, animations, graphics and printouts. Completed at prearranged time (at participant's choice of venue). Administrative support provided in person	Stressbusters had no effect, led to reduction in costs
	UDC	2. Attention control: directed to available self-help websites about general mental health	
Wu 2014 <sup>108</sup>	SDI	1. Computer-tailored smoking cessation advice: computer-tailored advice report based on the information obtained at baseline and an additional assessment to generate a progress report 4 weeks after the baseline	Short-term: £14,527 per QALY. Long term: £9700 per QALY
	UNoDI	2. Stop Smoking Start Living booklet: posted to participants	

BDI-II, Beck Depression Inventory-II; CM, contingency management; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure; DBT, dialectical behaviour therapy; ERP, exposure and response prevention; GCBT, group cognitive-behavioural therapy; GP, general practitioner; ICBT, internet cognitive-behavioural therapy (internet based/delivered/mediated); INHS, Italian National Health Service; LITG, low-intensity therapist-guided; MET, motivational enhancement therapy; NRT, nicotine replacement therapy; MBCT, mindfulness-based cognitive therapy; PST, problem solving therapy; PWP, psychological well-being practitioner; TSG, totally self-guided; UC, usual care.

Comparisons of summary estimates, such as ICERs and their constituent parts (i.e. costs and outcomes), across economic evaluations of DIs would be misleading given their methodological differences, as described in *Key challenges and limitations in economic evaluation of digital interventions*. Our review focused on the appropriateness of the methods used to establish the cost-effectiveness of DIs to inform health-care decision-making, and identified areas for improving consistency in future studies on key methods, including time horizon, included costs, expression of outcomes and description of comparators.

We give an overview of the results of the studies into three groups according to whether or not the studies found that: (1) DIs dominated their alternatives (i.e. DIs had a lower cost and a better outcome), (2) DIs were dominated by their alternatives (i.e. DIs had a higher cost and a worse outcome) or (3) DIs achieved better outcomes with higher costs and, therefore, their cost-effectiveness depended on willingness-to-pay thresholds and the level of uncertainty associated with the results. As stated in *Key challenges and limitations in economic evaluation of digital interventions*, we do not attempt to directly compare summary estimates, such as ICERs, across different economic evaluations, but instead aim to provide a panoramic overview of the landscape of economic evaluations on DIs.

### **Digital interventions were dominant against alternatives**

- DIs were dominant against NI for:
  - depression<sup>97,106</sup>
  - health anxiety<sup>52</sup> (only from societal perspective and not from a health-care perspective)
  - OCD<sup>39,88</sup> (only at 12 months' follow-up)
  - stress<sup>62,112</sup>
  - smoking.<sup>67,99</sup>
- DIs were dominant against non-therapeutic controls for:
  - anxiety<sup>53</sup> (against attention placebo)
  - suicidal ideation<sup>104</sup> (against information websites)
  - health anxiety<sup>68</sup> (against online forum without therapeutic elements)
  - schizophrenia<sup>63</sup> (against watching a video; this study suggested lower costs with better outcomes but did not calculate ICERs).
- DIs were dominant against NoDIs for:
  - panic disorder (Bergström *et al.*<sup>54</sup> against group CBT, McCrone *et al.*<sup>90</sup> against individual CBT)
  - social anxiety<sup>69,110,111</sup> (against face-to-face CBT; note, the three economic evaluations were based on the same clinical trial)
  - GAD<sup>85</sup> (against face-to-face CBT or medication)
  - mixed depression and anxiety<sup>86</sup> (against medication and face-to-face CBT)
  - binge eating disorder<sup>83</sup> (against face-to-face CBT when outcomes were expressed in QALYs rather than number of binge-free days)
  - OCD<sup>39</sup> (against manual-based self-help at the 12-month but not 3-month follow-up).

### **Digital interventions achieved better outcomes with higher costs against alternatives**

- DIs achieved better outcomes with higher costs against NI for:
  - addiction<sup>80,95</sup>
  - depression<sup>15,55,64,71,72,81,84,89,103,105</sup>
  - eating disorders<sup>50,78</sup>
  - health anxiety<sup>52</sup> (from a health-care but not a societal perspective)

- OCD<sup>43,51</sup>
  - panic disorder<sup>91</sup>
  - smoking<sup>59,93,94</sup>
  - social anxiety<sup>102</sup>
  - stress/worry/anxiety<sup>61,74</sup>
- DIs achieved better outcomes with higher costs against non-therapeutic controls for:
    - depression<sup>58</sup> (against non-specific education)
    - smoking<sup>108</sup> (against non-specific education).
  - DIs achieved better outcomes with higher costs against NoDIs for:
    - health anxiety<sup>52</sup> (against manualised self-help).

### *Digital interventions were dominated by their alternatives*

- DIs were dominated by NI for:
  - depression<sup>89</sup> (Beating the Blues only)
  - substance misuse<sup>92</sup> (when outcomes were measured in QALYs rather than abstinent years).
- DIs were dominated by NoDIs for:
  - health anxiety<sup>52</sup> (against manual-based self-help)
  - depression<sup>82</sup> (against bibliotherapy).

It is worth noting that the following studies found that DIs did not confer any added value in terms of outcomes against their alternatives:

- DIs compared with NI for:
  - OCD<sup>39</sup> (at 3-month follow-up).
- DIs compared with non-therapeutic controls for:
  - depression and/or anxiety<sup>96,107</sup> (against attention control)
  - schizophrenia<sup>100</sup> (against a 'dummy' version of the DI).
- DIs compared with NoDIs for:
  - child disruptive disorder<sup>76</sup> (against clinic-based parenting programme)
  - depression and anxiety<sup>79</sup> (against individual CBT)
  - eating disorder<sup>83</sup> (against individual CBT when outcome was number of binge-free days)
  - OCD<sup>39</sup> (against manualised self-help at 3-month follow-up)
  - schizophrenia<sup>77</sup> (against clinician sessions)
  - severe depression<sup>81</sup> (against audio-based self-help)
  - smoking<sup>60</sup> (against specialist clinic smoking cessation programme).

This panoramic overview of the results of individual studies reiterates the complexity in interpreting the results of economic evaluations; even within the same study, results were different depending on how outcomes were expressed (e.g. QALYs rather than abstinent years<sup>92</sup> or binge-free days<sup>83</sup>), the different time horizons (e.g. 12 months rather than 3 months<sup>39</sup>) or the different perspectives

(e.g. societal vs. health care<sup>52</sup>). When DIs were compared with NI or non-therapeutic controls, individual studies suggested that the DIs either were dominant or achieved better outcomes with higher costs. When DIs were compared with NoDIs, such as individual or group CBT, several studies indicated dominance of the DIs studied, but equally as many studies found that DIs did not confer any added value.

## Updated literature searches and additional studies retrieved

As the systematic literature searches were conducted > 1 year before the completion of all WPs and submission of the report, we conducted an updated literature search to capture new economic evaluations published after November 2018 (when our first literature search was carried out) up to October 2020. We searched the same databases using the same search terms as in our first literature search (see *Searches*), and we applied the same inclusion/exclusion criteria (see *Selection criteria*) and the same identification and selection process with the same reviewers (see *Study selection*). We have included the details of our updated literature search in *Report Supplementary Material 1*.

After duplicates were removed, 2422 of the 4740 records identified remained and were screened, of which 2292 were excluded by title and abstract and 130 were assessed for eligibility by full text. A total of 120 papers were excluded because the primary diagnosis was not a mental health problem ( $n = 5$ ), the intervention was not a mental health intervention ( $n = 10$ ), the study did not include health economic outcomes ( $n = 48$ ), it was not an economic evaluation ( $n = 5$ ), it was a review rather than a primary study ( $n = 4$ ), it was a conference abstract rather than a peer-reviewed paper ( $n = 12$ ), or it was duplicate reference ( $n = 3$ ) or a protocol ( $n = 33$ ). *Report Supplementary Material 2* gives the references of the excluded studies and the reasons for exclusion.

As a result of the updated literature search, we identified 10 additional studies that met the inclusion criteria of our review and had been published over the preceding 2 years,<sup>113-122</sup> as shown in *Figure 7*. All 10 additional studies used DIs based on CBT delivered via the web/internet<sup>113,114,116-119,121,122</sup> or via VR<sup>120</sup> or a mobile app.<sup>115</sup> One study used a non-CBT DI (progressive muscle relaxation).<sup>119</sup> The comparators against which the DIs were evaluated included NI,<sup>114,115,117,120-122</sup> non-therapeutic controls<sup>118</sup> and NoDIs including face-to-face CBT.<sup>113,116,119</sup>

With the exception of one study that recruited adolescents with anxiety,<sup>118</sup> the rest related to adult populations with depression,<sup>113-116</sup> mixed depression and anxiety,<sup>122</sup> social anxiety,<sup>121</sup> OCD,<sup>119</sup> paranoia in psychosis<sup>120</sup> and stress-related disorders (i.e. adjustment disorder and exhaustion disorder).<sup>117</sup> The evaluations were conducted across six high-income countries: two in Germany,<sup>113,114</sup> three in the Netherlands,<sup>115,116,120</sup> one in Sweden,<sup>117</sup> one in Canada,<sup>118</sup> one in Australia<sup>119</sup> and two in the UK.<sup>121,122</sup>

One study was a model-based economic evaluation<sup>113</sup> and the other nine used within-trial analyses.<sup>114-122</sup> It is worth noting that one within-trial analysis<sup>119</sup> used a direct comparison between two DIs (CBT and relaxation) from a two-arm RCT benchmarked against a third intervention (face-to-face CBT) in an indirect comparison with data from previous meta-analyses. The time horizon across the 10 studies ranged from 8 weeks<sup>118</sup> to 3 years.<sup>113</sup>

The analytical framework used in the studies included CMA,<sup>114</sup> CCA,<sup>118</sup> CEA,<sup>113,115-117,119</sup> CUA<sup>115-117,120-122</sup> and CBA.<sup>119</sup> The perspectives adopted were either societal<sup>113,115-117,119,120</sup> or that of the health-care provider.<sup>114,116,117,119,121,122</sup> One study<sup>118</sup> did not report the relevant perspectives.

The model-based evaluation<sup>113</sup> synthesised evidence from multiple sources (including 17 clinical trials meta-analysed to inform the treatment effect) to evaluate the cost-effectiveness of a DI (internet CBT) for the treatment of depression, compared with a NoDI (face-to-face CBT) from the societal perspective in Germany. It found that the internet CBT dominated face-to-face CBT, on the assumption that internet




FIGURE 7 The PRISMA flow diagram for the identification and selection of cost-effectiveness studies relating to DIs in mental health (search 2: from November 2018 to October 2020).

CBT had reduced waiting times compared with face-to-face CBT. This assumption was based on indirect evidence: the waiting time for face-to-face CBT was informed by average waiting times in Germany, whereas waiting time for internet CBT was based on a clinical trial among patients with OCD in Sweden. Sensitivity analysis suggested that internet CBT was less effective than face-to-face CBT when waiting times for the two treatments were equal.

Of the nine trial-based evaluations, the only one<sup>118</sup> that compared a DI against a non-therapeutic control did not report any economic results because of low response rates and loss of data. Of the six studies that used NI as the comparator for DIs,<sup>114,115,117,120-122</sup> one<sup>121</sup> found a DI for social anxiety dominant at 12 months' follow-up; three<sup>117,120,122</sup> demonstrated that DIs for stress-related disorders, psychosis and depression/anxiety achieved better outcomes with higher cost; one<sup>114</sup> found reduced costs for similar outcomes between a DI and usual care for depression; and one<sup>115</sup> did not find a DI for depression cost-effective. Two studies compared DIs with face-to-face CBT and suggested that DIs are likely to be cost-effective for OCD<sup>119</sup> and potentially for depression<sup>116</sup> from a health-care perspective but not from a societal perspective.

The nature and results of these additional 10 economic evaluations are consistent with our findings from our earlier review of the 66 economic evaluations. Studies reported limited detail on comparators, making it difficult to distinguish between TAU and WL, or to determine similarity between comparators (e.g. TAU) in different settings. The use of trial-based analyses meant that the studies included a limited number of comparators, and a finite analysis time horizon. The findings could not be directly compared, as studies showed heterogeneity in terms of the target condition, population, analytical perspective,

outcome measures and analysis time horizons. A panoramic overview of individual study results is consistent with the previous observation that DIs are dominant or achieve better outcomes with higher cost than NI, whereas the results of face-to-face comparisons of DIs and CBT are not consistent. The methods used in the model-based evaluation<sup>113</sup> are comparable to those we used in our model in WPs 2 and 3 to analyse the cost-effectiveness of DIs for GAD, compared with all other treatment options.

## Discussion

Material in this section has been reproduced with permission from Jankovic *et al.*, Systematic review and critique of methods for economic evaluation of digital mental health interventions, *Applied Health Economics and Health Policy*, published 2020.<sup>45</sup> Copyright © 2020, Springer Nature Switzerland AG.

Despite a growing literature on economic evaluation of DIs, including several systematic reviews, there is no conclusive evidence regarding their cost-effectiveness. The lack of consensus is often attributed to the heterogeneity in the interventions, the conditions they target and the methods used to evaluate them. This chapter aimed to assess the appropriateness of the methodology used to determine the cost-effectiveness of DIs and the challenges associated with estimating cost-effectiveness.

The review identified 66 economic evaluations from searches up to November 2018 and 10 additional economic evaluations up to October 2020. Our findings support conclusions from previous reviews that the methods used to evaluate DIs are heterogeneous.<sup>14,18,19,21</sup> The majority of trial-based economic evaluations are limited for decision-making purposes because of their truncated time horizon and inability to include the full range of possible alternative interventions and to incorporate all available evidence into the analysis.<sup>44</sup> The majority of the studies were conducted in high-income countries, so the results may not be readily generalisable to low- and middle-income countries. Differences in health systems (e.g. the US health system being primarily driven by insurance/private policies and the UK being supported by the NHS) is a contextual factor that affects the transferability of results across countries.

To draw conclusions regarding the cost-effectiveness of DIs, a synthesis of all available evidence is required, and in a way that models the long-term trajectory of mental health problems and includes all relevant comparators. Previous reviews have focused on specific types of DIs (e.g. internet-delivered CBT<sup>14,18,19,21</sup> or guided internet interventions<sup>123</sup>) or on DIs for specific conditions (e.g. depression<sup>19,23,123</sup> or anxiety disorders<sup>16</sup>). Given the complexity of DIs, their evaluation needs to be preceded by a taxonomy to inform what interventions can reasonably be pooled together and compared with groups of alternatives.

Decisions made about the appropriate method of CEA are, at least in part, driven by the intended role of the analysis. The role of some DIs reviewed in this study was unclear; studies recruited patients through self-referral or referral by clinician in which patients are identified 'on the job', by screening medical records and by proactively inviting patients to participate. Different target populations suggest different aims of interventions. Interventions that target self-referred patients have a role in the diagnosis and treatment of patients who may not have otherwise sought treatment, whereas those that target diagnosed patients imply that DIs are administered in addition to, or alongside, existing treatment. The role of therapy can affect whether or not evidence from different studies can be pooled and how we measure costs and effects, as well as what the appropriate comparators are.

The appropriate perspective for the evaluation of DIs can also vary according to the decision-making context. Evaluations can be commissioned at a local level (e.g. clinics, regional decision-makers), at a national level (e.g. NHS) or by employers and individuals themselves. Therefore, the costs and outcomes included in the analysis and the 'decision rule' used to interpret whether or not an intervention is cost-effective can also vary. An employer may be interested in measuring the effect



of the intervention on productivity and a mental health care provider may include a narrow range of benefits specific to the mental health condition targeted by the intervention and the costs that fall on that provider, whereas a health system may aim to improve overall health, and therefore requires a broader health measure, such as HRQoL, to allow comparison across different fields of medicine. Furthermore, although NICE has an explicit decision rule (£20,000–30,000 per QALY), in other perspectives it is not clear how to interpret health gains that result in an additional cost, particularly when health benefits are measured using disease-specific outcomes; for example, how much should a provider spend on a 1-point increase in Generalised Anxiety Disorder-7 (GAD-7) score?

## Conclusions

In this systematic review, we identified 76 economic evaluations of DIs, mostly conducted alongside trials with short-term follow-ups. Given that DIs are complex and heterogeneous, there are challenges specific to their economic evaluation and the synthesis of economic evidence, including estimation of all relevant costs and outcomes, analysis from different viewpoints and identification of relevant comparators. A classification system informed how DIs and comparators could be reasonably pooled together and compared in terms of cost-effectiveness, with the caveat of the different economic evaluation methods used and the diverse clinical problems addressed. The majority of studies that compared DIs with NI or with non-therapeutic controls found that DIs either achieved better outcomes at lower costs, and therefore were cost-effective, or achieved better outcomes with higher costs, in which case their cost-effectiveness would depend on how much we are willing to pay for them. When DIs were compared with NoDIs (e.g. individual or group CBT), several studies found DIs to be better and less costly, but an equal number found that DIs did not confer any added value in terms of outcomes and had no significant differences in costs.

## Chapter 4 Review of clinical studies for generalised anxiety disorder

Parts of this chapter have been reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

### Introduction

Generalised anxiety disorder is the most common mental health condition in the UK, with 6% point-prevalence (measured over the preceding week), nearly double that of depression (3.3%).<sup>125</sup> It is often confused with panic disorder or depression when self-reported by survey participants.<sup>125</sup> GAD is characterised by excessive worry that persists for several months and leads to significant distress or impairment in everyday life and functioning.<sup>1</sup> Other typical characteristics include free-floating anxiety and physical symptoms, such as muscle tension, headaches, restlessness, difficulty concentrating, irritability or sleep problems. GAD is associated with a low quality of life and high health-care costs.<sup>126</sup>

Psychological interventions can be effective, especially CBT<sup>127</sup> and applied relaxation.<sup>128</sup> Antidepressant medication can also be effective<sup>129</sup> and is often the first choice for treatment by clinicians in view of limited access to psychological interventions. DIs, defined as software-based therapeutic activities accessed via technology platforms, such as the internet, VR and mobile phones, have been used as alternatives, or as add-ons, to conventional psychological therapies to improve access and increase patient choice.<sup>3,130</sup> DIs are included in the UK's clinical guidelines for GAD<sup>2</sup> in the context of a stepped-care model, in which patients are offered 'self-help' before medication or therapist-delivered CBT/applied relaxation.

Previous reviews of the effectiveness of DIs for GAD<sup>131,132</sup> have included mixed populations of anxiety disorders and depression without reporting outcomes separately for GAD subgroups within these mixed samples. Reporting a disorder-specific outcome for mixed samples can be misleading because it implies that if an intervention works for the mixed sample it will also work for each of its constituent populations. Reviews and primary studies that include mixed samples do not answer the question of whether or not DIs are effective for GAD to inform disorder-specific clinical guidelines. To achieve this, we need to analyse GAD outcomes reported separately for GAD populations and for GAD subsamples within mixed populations.

Over the last two decades, NMA methods<sup>133</sup> (also known as mixed treatment comparisons<sup>134,135</sup>) have enabled researchers to extend standard (pairwise) meta-analysis so that they can simultaneously compare interventions of interest and their alternatives within a single coherent analysis, even in the absence of direct comparisons from primary studies. Such an approach is being increasingly used in health technology assessments to inform the optimal intervention strategy for a given medical condition.<sup>136</sup> NMAs have been often used to inform estimates of cost-effectiveness and commissioning decisions.

This is a systematic review and quantitative synthesis of RCTs that compared DIs with other interventions and controls for GAD populations of varying severity (i.e. subthreshold, mild, moderate and severe). The review has five objectives:

1. categorise the DIs and its comparators into groups that can be pooled together
2. compare the pooled outcomes of DIs for GAD symptoms with the pooled outcomes of NoDIs, medication, non-therapeutic controls and NI

3. compare the pooled outcomes of different types of DIs against each other
4. identify limitations and gaps in the existing research on DIs for GAD
5. inform an economic model by using the pooled clinical evidence on effectiveness to assess the cost-effectiveness of DIs and alternative care options.

## Methods

### Search strategy

In December 2018, the following databases were searched to identify published and unpublished studies: MEDLINE, PsycInfo, CENTRAL, CDSR, CINAHL Plus, DARE, EMBASE, Web of Science Core Collection, DoPHER and ProQuest® (ProQuest LLC, Ann Arbor, MI, USA).

We searched two clinical trial registries for ongoing studies: ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform portal. We also searched the NIHR portfolio, and conducted web searches using Google and Google Scholar using simplified search terms. After these searches were complete, we scanned the lists of included studies of relevant systematic reviews identified by the searches and the reference lists of all included studies; conducted forward citation chasing on all identified protocols, conference abstracts and the included studies using Google Scholar for any relevant publications; and contacted the authors of included studies for information on any other work in the field they were aware of.

The searches were conducted from 1997, as we did not anticipate finding relevant DIs from before that date, and were restricted to those written in English, as we anticipated that most studies written in other languages would also have a version published in English (e.g. the South Asia Cochrane Group<sup>46</sup>).

In June 2019, the searches were updated and widened to included terms based on unspecified anxiety disorders. At this time, we also conducted an additional pilot search using terms based on 'worry' and 'anxiety prevention' using only the Cochrane Library and PsycInfo databases to ensure that no articles were being missed. As no new included articles emerged from this pilot search, it was not deemed necessary to expand this to all the databases. The full search terms and outputs of the database searches are provided in *Report Supplementary Material 3 and 4*.

### Study identification and selection

Two reviewers independently screened all titles and abstracts of the identified studies against our inclusion/exclusion criteria. If either reviewer thought that a study could be relevant, we retrieved the full text. The same two reviewers independently assessed the full texts against our inclusion/exclusion criteria. A third reviewer resolved any disagreements through discussion and arrived at the final list of included and excluded studies.

Eligible studies included those that featured the following:

- Participants with symptoms or who were at risk of GAD within mental health populations or within the general population; we defined this as a certified diagnosis using a standardised diagnostic interview or a score above an accepted cut-off point for diagnosable GAD in standardised questionnaires.
- Software-based systems and technology platforms designed for patient-facing delivery of a mental health intervention (i.e. an intervention to improve mental health outcomes).
- All comparisons relevant to DIs, even when two or more DIs were compared with each other without other comparators.
- GAD-specific measures of anxiety or worry, reported for GAD populations or GAD subsamples within mixed populations.
- Randomised controlled trials to minimise risk of bias and confounding variables.

We excluded studies that featured the following:

- Mixed populations of GAD with other conditions, when the outcomes were not reported separately for GAD subgroups.
- Technology used as a means for telecommunication (e.g. e-mail, telephone or video) without any software-based processing.
- Software-based systems designed for the training of health professionals or for administration without any patient-facing intervention components.
- Outcomes that were not mental health related.
- Study protocols, abstracts and reviews; these were marked so that we could check for RCTs that we may have missed in the database searches.

### **Data extraction and risk-of-bias assessment**

Two researchers independently extracted data from published and unpublished study reports. Data were extracted on the sample, study design, intervention and comparator characteristics, baseline characteristics and results. Any discrepancies were resolved by a third reviewer. The same two reviewers who completed the data extraction (DM and HM) independently assessed the risk of bias of each study using the Cochrane risk-of-bias tool (RoB 2)<sup>137</sup> and resolved disagreements by discussion with a third reviewer (RC). We assessed the risk of bias for each outcome measure reported in a study in the following six domains: randomisation process, deviations from intended interventions, missing outcome data, measurement of the outcome, selection of the reported results and overall bias. The risk-of-bias tool<sup>137</sup> classifies each study as high risk, posing some concerns, or low risk based on responses to each domain.

### **Data synthesis and statistical analysis**

An analysis of covariance (ANCOVA) modelling framework was used, in which the final measurement is synthesised, adjusting for baseline outcome measurements. With the 'change from baseline' approach, the ANCOVA avoids guessing within-patient correlation to enable the calculation of the standard error of change and subsequent sensitivity analyses for different correlation values. Treatment effect estimates based on ANCOVA methods have been shown to be more efficient, less biased and robust to chance baseline imbalance.<sup>138-143</sup> Hence, ANCOVA is the preferred method for estimating treatment effects from continuous outcomes.<sup>144-147</sup>

A modelling approach in line with parameterisation for continuous data with normal likelihood and identity link used by Dias *et al.*<sup>138,139</sup> is taken throughout. Fixed-effects (FE) and random-effects (RE) models (accounting for potential correlation within multiarm trials) were fitted to the data, with each outcome of interest being modelled independently. In the model, patients who did not receive any treatment are expected to neither improve nor worsen during treatment (i.e. null placebo effect). In addition, it was assumed that the effect of the baseline measurement is common across all treatments, in other words that, when two active treatments are compared in a trial, the baseline effects are cancelled out.

All analyses were conducted within a Bayesian Markov chain Monte Carlo (MCMC) approach and fitted using WinBUGS software version 1.4.3, 2007 [Medical Research Council (UK) and Imperial College (UK)]<sup>148</sup> and linked to the freely available software R (version 3.6.0; The R Foundation for Statistical Computing, Vienna, Austria) through the package R2WinBUGS.<sup>149</sup> In all models the MCMC Gibbs sampler was initially run for 10,000 iterations, and these were discarded as 'burn-in'. Models were run for at least a further 5000 iterations, on which inferences were based. Chain convergence was checked using autocorrelation and Brooks–Gelman–Rubin diagram diagnostics.<sup>150-152</sup> Goodness of fit was assessed using the DIC (deviance information criterion) (with differences of  $\geq 3$  assumed to be important) and posterior mean residual deviance.<sup>153,154</sup>

We presented the estimated results as relative treatment effect scores [and associated 95% credible intervals (CrIs)] in the selected outcome measures. We have estimated the probability of a treatment being the 'best' (i.e. being the most clinically effective),<sup>155</sup> and presented rankograms for all interventions, which provide the probabilities of an intervention being ranked 1 (the highest) to 7 (the lowest). Finally, we reported the surface under the cumulative ranking curve (SUCRA), which is a numerical presentation of the overall ranking of each intervention. SUCRA values range from 0% to 100%: interventions are more likely to be placed towards the top ranks the closer their SUCRA value is to 100% and towards the bottom ranks the closer their SUCRA value is to 0%.<sup>138,156</sup>

*Appendix 1* gives further details on the analysis, including annotated synthesis WinBUGS code, sample data and initial values for the main synthesis model used (see *Table 19*).

### **Assessment of heterogeneity and consistency**

For both end points, the model was extended to include study-level covariates as potential treatment effect modifiers. Clinical expectations were that potential sources of heterogeneity could include disease severity, concomitant medication and comorbidities. Meta-regression is the most commonly employed method to explore the influence of particular study-level covariates on the relative effect. However, this method requires that all studies report data on the covariate(s) in question. For the trials informing the NMA, complete data for disease severity (as a binary covariate mild to moderate/moderate to severe) were obtained, but not for the other two potential effect modifiers. To preserve all studies (and treatments), when a covariate was not reported by some studies, we allowed the model to impute missing covariate information (multiple imputation procedure assuming 'missingness' mechanism of 'missing at random').

As per guidance by Dias *et al.*,<sup>156,157</sup> inconsistency was assessed by comparing the DIC of our primary analyses (based on NMA models that assume consistency between direct and indirect evidence) and the DICs yielded by inconsistency models (which provide effect estimates based on direct evidence only). Results were assessed for coherence by qualitatively comparing estimates of pairwise ANCOVA meta-analysis (direct) and ANCOVA RE NMA (direct and indirect).

### **Sensitivity analysis**


We conducted two types of sensitivity analysis. First, we evaluated how sensitive the networks were to individual trials. When network links were informed by more than one trial, we removed each trial one at a time (giving  $n - 1$  for each analysis) and investigated the impact on the probability of each intervention being 'best'. Second, we assessed the robustness of the synthesis results by repeating the analysis while excluding studies of fewer than 30 patients.

## **Results**

### **Included and excluded studies**

Initial systematic searches of bibliographic databases identified 16,272 records; in addition, 32 records were identified through secondary searches (e.g. citation searching of protocols and abstracts). After duplicates were removed, a total of 8920 records were screened by title and abstract, and 8543 records were excluded. We retrieved the full-text papers for the remaining 377 records and, as a result of further screening, 352 articles were excluded. In total, 21 studies (reported in 25 papers) were included in the review. The PRISMA flow diagram (*Figure 8*) summarises the number of records retrieved and selected at different stages of identification and screening.

At the stage of full-text screening, we excluded 18 records because they were reviews, 14 that were abstract only and 116 that were protocols, and 10 duplicates that had not been picked up in the previous screening. We also excluded six studies that did not recruit GAD populations and 88 studies that recruited mixed populations, which may have included GAD among other conditions (e.g. depression) but did not



**FIGURE 8** The PRISMA flow diagram for the identification and selection of clinical trials relating to DIs for GAD. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

report separate outcomes for the GAD sample. We excluded a further 61 studies in which the participants did not meet GAD criteria, 10 studies because the intervention was not digital (software based), 11 studies that reported no anxiety outcomes and 18 studies that were not RCTs. *Report Supplementary Material 5* provides a full reference list of the excluded studies grouped according to reasons for exclusion.

### **Sample characteristics in randomised controlled trials of digital interventions for generalised anxiety disorder**

The 21 RCTs included in the review,<sup>4,5,37,38,40,41,158-172</sup> as detailed in *Table 11*, were conducted over 10 years, between 2009 and 2019, in 10 countries [Sweden, Australia, USA, UK, Canada, Spain, Italy, Ireland, Taiwan (Province of China) and the Netherlands] and involved 2547 randomised participants. Most participants were recruited from the general adult population, except in four studies<sup>161,163,168,172</sup> that recruited students/young adults and one study<sup>164</sup> involving the over-60s. GAD populations were defined as either meeting the criteria of an established diagnostic tool, such as the Mini-International Neuropsychiatric Interview (MINI),<sup>177</sup> or scoring above an accepted cut-off value for diagnosable GAD in standardised questionnaires, such as the GAD-7 questionnaire<sup>178</sup> or the Penn State Worry Questionnaire (PSWQ).<sup>179</sup>

TABLE 11 Sample characteristics and outcome measurement in RCTs of DIs for GAD

Study (first author and year)	RCT design	Comparison groups	Country	Population	Entry criteria	Number randomised	Number analysed	Treatment duration	Follow-up time points	Outcomes of interest	Other reported outcomes
Andersson 2012 <sup>158</sup>	3-arm	SDI vs. SDI vs. NI	Sweden	General – adults	GAD diagnosis on SCID-I	81	59	8 weeks	8 weeks 3 months 18 months	PSWQ	BAI, BDI-II, GAD-Q-IV, MADRS-S, QOLI, SCID-I, STAI-S, STAI-T
Andersson 2017 <sup>40</sup>	2-arm	SDI vs. NI	Sweden	General – adults	PSWQ score > 56	140	132	10 weeks	10 weeks 4 months 12 months	PSWQ	BBQ, CAQ, HADS-A, IOU, MADRS-S, MCQ-30
Christensen 2014 <sup>4</sup>	5-arm	UDI vs. SDI vs. UDI vs. UDC vs. SDC	Australia	General – adults	GAD-7 score > 5	558	264	10 weeks	10 weeks 6 months 12 months	GAD-7 PSWQ	ASI, CES-D, days out of role, MINI
Christensen 2014 <sup>159</sup>	3-arm	SDI vs. SDC vs. M	Australia	General – adults	GAD diagnosis on ADIS-IV	21	11	10 weeks	10 weeks 6 months 12 months	GAD-7	CES-D, CGI
Dahlin 2016 <sup>41</sup>	2-arm	SDI vs. NI	Sweden	General – adults	GAD diagnosis on SCID-I; PSWQ score > 45	103	85	9 weeks	9 weeks 6 months	GAD-7 PSWQ	BAI, GAD-Q-IV, MADRS-S, PHQ-9, QOLI
<sup>a</sup> Dear 2015 <sup>160</sup>	2 × 2 factorial	SDI vs. SDI vs. UDI vs. UDI	Australia	General – adults	GAD diagnosis on MINI  GAD-7 score > 5	338	260	8 weeks	9 weeks 3 months 12 months 24 months	GAD-7	K-10, MINI, Mini-SPIN, NEO-FFI-3, PDSS-SR, PHQ-9, SDS

Study (first author and year)	RCT design	Comparison groups	Country	Population	Entry criteria	Number randomised	Number analysed	Treatment duration	Follow-up time points	Outcomes of interest	Other reported outcomes
Hazen 2009 <sup>161</sup>	2-arm	SDI vs. SDC	USA	University students	PSWQ score > 60	24	23	3–6 weeks	3–6 weeks	PSWQ	BDI, STAI-T
<sup>b</sup> Hirsch 2018 <sup>162</sup>	3-arm (analysed as 2-arm)	SDI vs. SDI vs. SDC	UK	General – adults	Mixed sample anxiety/depression <sup>c</sup>  GAD diagnosis on SCID-I; GAD-7 score > 10	64	64	3–4 weeks	3–4 weeks 1 month	GAD-7 PSWQ	PHQ-9, RRS
<sup>d</sup> Howell 2018 <sup>163</sup>	2-arm	UDI vs. UDC	USA	University students	Mixed sample non-clinical (GAD < 4) and clinical mild GAD (4 < GAD-7 score < 10) <sup>e</sup>	197	NR	4 weeks	3 months	GAD-7 <sup>d</sup>	None
Johansson 2013 <sup>37</sup>	2-arm	SDI vs. SDC	Sweden	General – adults	Mixed sample anxiety/depression <sup>c</sup>  GAD diagnosis on MINI GAD-7 score > 10	43	NR	10 weeks	10 weeks 3 months	GAD-7	PHQ-9
Jones 2016 <sup>164</sup>	2-arm	SDI vs. NI	Canada	Over 60s	GAD diagnosis or threshold subclinical on MINI; GAD-7 score > 10	46	41	7–10 weeks	7–10 weeks 1 month	GAD-7	ACES, GAI, GDS, PHQ-9, PSWQ-A, WHOQOL
Navarro-Haro 2019 <sup>165</sup>	2-arm	SNoDI vs. SDI	Spain	Primary care – adults	GAD diagnosis on MINI	42	30	12 weeks	7–12 weeks	GAD-7	DERS, FFMQ, HADS, MAIA

continued



TABLE 11 Sample characteristics and outcome measurement in RCTs of DIs for GAD (continued)

Study (first author and year)	RCT design	Comparison groups	Country	Population	Entry criteria	Number randomised	Number analysed	Treatment duration	Follow-up time points	Outcomes of interest	Other reported outcomes
Paxling 2011 <sup>166</sup>	2-arm	SDI vs. NI	Sweden	General – adults	GAD diagnosis on SCID-I; PSWQ score > 53  GAD-Q-IV > 5	89	72	8 weeks	8 weeks 1 year 3 years	PSWQ	BAI, BDI-II, GAD-Q-IV, MADRS-S, QOLI, STAI-S, STAI-T
Pham 2016 <sup>5</sup>	2-arm	UDI vs. UDC	UK	General – adults	Mixed sample common mental health problems <sup>f</sup>  GAD-7 score > 6, OASIS > 8, ASI > 16	63	42	4 weeks	4 weeks	GAD-7	Acceptability, ASI-3, OASIS, PDSS-SR, Q-LES-Q-SF
Repetto 2013 <sup>167</sup> (linked with Gorini 2010, <sup>173</sup> Gorini 2010 <sup>174</sup> and Pallavicini 2009 <sup>175</sup> )	3-arm	SDI vs. SDI vs. NI	Italy	Primary care – adults	GAD diagnosis (unspecified tool used)	25	24	NR	NR	GAD-7 PSWQ	BAI, HAM-A, STAI
Richards 2016 <sup>168</sup>	2-arm	SDI vs. NI	Ireland	University students	GAD-7 score > 10	137	112	6 weeks	6 weeks	GAD-7 PSWQ	BDI-II, WASAS
Robinson 2010 <sup>169</sup>	3-arm	SDI vs. SDI vs. NI	Australia	General – adults	GAD diagnosis on MINI	150	138	10 weeks	11 weeks 3 months	GAD-7 PSWQ	K-10, PHQ-9, SDS
Teng 2019 <sup>38</sup>	3-arm	SDI vs. SDC vs. SNoDC	Taiwan (Province of China)	General – adults	GAD diagnosis on DIS-IV  PSWQ score > 60	93	82	4 weeks	4 weeks 1 month	PSWQ	BAI, BDI, STAI-S, STAI-T
Titov 2009 <sup>171</sup> (linked with Lorian 2012 <sup>176</sup> )	2-arm	SDI vs. NI	Australia	General – adults	GAD diagnosis on MINI	34	NR	8 weeks	9 weeks	GAD-7 PSWQ	K-10, PHQ-9, SDS

Study (first author and year)	RCT design	Comparison groups	Country	Population	Entry criteria	Number randomised	Number analysed	Treatment duration	Follow-up time points	Outcomes of interest	Other reported outcomes
Titov 2010 <sup>170</sup>	2-arm	SDI vs. NI	Australia	General - adults	Mixed sample anxiety/depression <sup>f</sup>  GAD diagnosis on MINI	48	19	9 weeks	9 weeks  3 months	PSWQ	DASS-21, K-10, NEO-FFI-3, PDSS-SR, PHQ-9, SDS, SPSQ
Topper 2017 <sup>172</sup>	3-arm	SNoDI vs. SDI vs. NI	The Netherlands	15- to 22-year-olds	PSWQ score above 66th percentile (score 38)	251	218	8-10 weeks	8-10 weeks  3 months  12 months	PSWQ	BDI-II, EDI-2-BU, GAD-Q-IV, MASQ-D30, PTQ, QDS, RRS

ACES, Anxiety Change Expectancy Scale; ASI, Anxiety Sensitivity Index; ASI-3, Anxiety Sensitivity Index-3; BAI, Beck Anxiety Inventory; BBQ, Brunnsvikien Brief Quality of Life Scale; CAQ, Cognitive Avoidance Questionnaire; CES-D, Center for Epidemiologic Studies Depression Scale; CGI, Clinical Global Improvement Scale; DASS-21, Depression Anxiety Stress Scales - 21 items; DERS, Difficulties in Emotion Regulation Scale; EDI-2-BU, Eating Disorder Inventory-2 Bulimia; FFMQ, Five Facet Mindfulness Questionnaire; GAD-Q-IV, Generalised Anxiety Disorder Questionnaire-IV; GAI, Geriatric Anxiety Inventory; GDS, Geriatric Depression Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale - Anxiety Subscale; HAM-A, Hamilton Anxiety Rating Scale; IOU, Intolerance of Uncertainty Scale; K-10, Kessler Psychological Distress Scale; M, medication; MADRS-S, Montgomery-Åsberg Depression Rating Scale Self-rated; MAIA, Multidimensional Assessment of Interoceptive Awareness; MASQ-D30, Mood and Anxiety Symptoms Questionnaire - short form; Mini-SPIN, Mini-Social Phobia Inventory; MCQ-30, Metacognition Questionnaire-30; NEO-FFI-3, NEO Five-Factor Inventory-3; NR, not reported; OASIS, Overall Anxiety Severity and Impairment Scale; PDSS-SR, Panic Disorder Severity Scale - Self-Report version; PHQ-9, Patient Health Questionnaire - 9 items; PSWQ-A, Penn State Worry Questionnaire - abbreviated; PTQ, Perseverative Thinking Questionnaire; QDS, Quick Drinking Screen; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form; QOLI, Quality of Life Inventory; RRS, Ruminative Response Scale; SCID-I, Structured Clinical Interview for *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Axis I Disorders; SDS, Sheehan Disability Scale; SPSQ, Satisfaction with Performance Scaled Questionnaire; STAI-S, State-Trait Anxiety Inventory - State; STAI-T, State-Trait Anxiety Inventory - Trait; WASAS, Work and Social Adjustment Scale; WHOQOL, World Health Organization Quality of Life.

- a 2 × 2 factorial RCT, so outcomes reported in two groups (SDI vs. UDI for both GAD-specific and transdiagnostic groups).  
 b Outcomes reported as a single group across both interventions (SDI with or without repetitive negative thinking).  
 c Outcomes reported separately for GAD subgroup.  
 d Study not included in the meta-analysis because it reported only categorical GAD-7 outcomes.  
 e Outcomes reported separately for mild GAD subgroup (4 < GAD-7 < 10).  
 f Outcomes reported for the whole mixed sample of common mental health problems, but all participants had a GAD-7 score of > 6.

#### Note

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.

### ***Selection of studies and outcomes for the network meta-analyses***

A total of 45 different outcome measures were reported in the included RCTs, as shown in *Appendix 2*. All 21 RCTs<sup>4,5,37,38,40,41,158-172</sup> used either the GAD-7 (14 studies)<sup>4,5,37,41,159,160,162-165,167-169,171</sup> or the PSWQ (14 studies),<sup>4,38,40,41,158,161,162,166-172</sup> with seven studies<sup>4,41,162,167-169,171</sup> using both to measure symptoms at baseline and outcomes at follow-up. *Table 11* shows which studies reported GAD-7 and/or PSWQ scores. Apart from GAD-7 and PSWQ, the two most frequently reported outcomes were for depression, the Patient Health Questionnaire – 9 items (PHQ-9)<sup>180</sup> and the Beck Depression Inventory, version 2 (BDI-II),<sup>181</sup> which were reported in eight and six RCTs, respectively (see *Appendix 2, Table 20*). We focused on GAD-7 and PSWQ as our outcomes of choice for the NMAs because other commonly used GAD outcomes, such as the Beck Anxiety Inventory (BAI) and State-Trait Anxiety Inventory (STAI), were used in only five RCTs. An additional 25 outcome measures, including the Hamilton Anxiety Rating Scale (HAM-A)<sup>182</sup> used in a recent NMA on medication for GAD,<sup>129</sup> appeared only once in the included RCTs (see *Appendix 2, Table 21*).

Our first NMA was based on the GAD-7, a seven-item anxiety scale described in the literature as a valid and efficient tool to screen for GAD and assess symptom severity in clinical practice and research.<sup>178</sup> Our second NMA was based on the PSWQ, a measure that focuses on worry, which is one of the central features of GAD.<sup>183</sup> The measure is designed to capture the generality, excessiveness, and uncontrollability dimensions of pathological worry.

Our NMA for GAD-7 included 13 studies.<sup>4,5,37,41,159,160,162,164,165,167-169,171</sup> One study<sup>163</sup> used GAD-7 but it was not included in the meta-analysis because it reported only categorical outcomes (i.e. mild, moderate, severe) rather than continuous scores. Another study<sup>164</sup> reported the Penn State Worry Questionnaire – abbreviated (PSWQ-A), the abbreviated version of the PSWQ, so it was included only in the GAD-7 model. The measurement period ranged from 3 to 12 weeks because longer follow-ups were available for only a very few studies (e.g. for GAD-7, only four studies<sup>4,35,159,160</sup> reported outcomes at 6 and/or 12 months, and one study<sup>160</sup> reported outcomes at 24 months). Even when longer follow-ups were available, the control group had already crossed over to the intervention, so the randomisation was lost.

### ***Risk-of-bias assessment***

All but one<sup>161</sup> of the 21 included studies were judged to have a high risk of bias in at least one domain of assessment for at least one outcome measure. This was largely because of outcome measurement, as all studies used self-reported (albeit standardised) questionnaires. The reason why self-reported outcomes are considered to have a high risk of bias in these studies is that participants are not masked to their allocation group, namely whether they have been allocated to a psychological intervention or to a WL or medication or a psychological placebo that is self-evidently non-therapeutic (e.g. a website with advice on general health rather than a sophisticated web-based programme specific to GAD).

The one study using self-reported measures that was assessed to be at low risk of bias involved the inclusion of a ‘sham arm’ very similar to the experimental arm,<sup>161</sup> which made it more difficult for the participants to guess whether the arm to which they were allocated was an intervention or a control. One other study<sup>37</sup> was assessed to be at low risk of bias but only for its researcher-administered diagnostic measure, the MINI.<sup>177</sup> Although researcher-administered outcomes are less open to inter-rater bias because they are completed by one person, or a few researchers who receive standardised training, a high risk of bias for the study remains if the researchers who administer the interviews are not masked to the participant’s allocation.

With regard to risk of bias, most studies were considered to be at a low risk for the randomisation process in general, although over half did not provide enough detail of allocation concealment to make an assessment. Similarly, most studies were rated as being at low risk of bias as a result of deviations from the intended intervention. Missing outcome data were of considerable concern with respect to bias, with over half the studies being rated as having a high risk of bias in this domain. Concerns about missing outcome data included high rates of withdrawals or exclusions at follow-up, differential attrition between groups and limited use of appropriate statistical procedures to mitigate these issues. The risk-of-bias outcome for each study under each domain is shown in *Table 12* and a visual description of the risk-of-bias assessment across all studies is shown in *Figure 9*.

TABLE 12 Risk of bias in RCTs of DIs for GAD

Study (first author and year)	Outcomes assessed individually for risk of bias	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of outcome	Selection of the reported result	Overall bias
Andersson 2012 <sup>158</sup>	Anxiety (GAD-Q-IV, STAI), worry (PSWQ), QoL (QOLI) Depression (MADRS-S, BDI-II), diagnosis (SCID-I)	Low	Low	High	High	High	High
Andersson 2017 <sup>40</sup>	Worry (PSWQ), depression (MADRS-S, HADS-D), diagnosis (MINI) QoL (BBQ)	Low	Low	Low	High	Concerns High	High
Christensen 2014 <sup>4</sup>	Anxiety (GAD-7), worry (PSWQ), depression (CES-D)	Low	Low	High	High	High	High
Christensen 2014 <sup>159</sup>	Anxiety (GAD-7), worry (PSWQ), depression (CES-D)	Low	Concerns	High	High	Low	High
Dahlin 2016 <sup>41</sup>	Anxiety (GAD-7, GAD-Q-IV, BAI), worry (PSWQ), QoL (QOLI), depression (MADRS-S, PHQ-9)	Concerns	Low	Low	Low	Concerns	Concerns
Dear 2015 <sup>160</sup>	Anxiety (GAD-7, PDSS) depression (PHQ-9), distress (K-10), diagnosis (MINI)	Low	High	High	High	Concerns	High
Hazen 2009 <sup>161</sup>	Anxiety (STAI), worry (PSWQ), depression (BDI)	Concerns	Low	Low	High	Concerns	High
Hirsch 2018 <sup>162</sup>	Anxiety (GAD-7), worry (PSWQ, RRS), depression (PHQ-9)	Low	High	High	High	Concerns	High
Howell 2018 <sup>163</sup>	Anxiety (GAD-7)	Concerns	High	High	High	High	High
Johansson 2013 <sup>37</sup>	Anxiety (GAD-7), depression (PHQ-9), diagnosis (MINI)	Concerns	Low	Low	High	Concerns	High
Jones 2016 <sup>164</sup>	Anxiety (GAD-7, GAI, ACES), depression (GDS, PHQ-9), worry (PSWQ-A), QoL (WHOQOL)	Low	Low	Low	High	Concerns	High
Navarro-Haro 2019 <sup>165</sup>	Anxiety (GAD-7, HADS-A), depression (HADS-D)	Concerns	Concerns	High	High	Concerns	High
Paxling 2011 <sup>165</sup>	Anxiety (GAD-Q-IV, STAI, BAI), worry (PSWQ), QoL (QOLI), depression (MADRS-S, BDI)	Concerns	Low	High	High	Low	High

continued


TABLE 12 Risk of bias in RCTs of DIs for GAD (continued)

Study (first author and year)	Outcomes assessed individually for risk of bias	Randomisation process	Deviations from intended interventions	Missing outcome data	Measurement of outcome	Selection of the reported result	Overall bias
Pham 2016 <sup>5</sup>	Anxiety (GAD-7, PDSS), QoL (Q-LES-Q-SF)	Concerns	Low	High	High	Concerns	High
Repetto 2013 <sup>167</sup>	Anxiety (GAD-7, HAM-A, STAI, BAI), worry (PSWQ)	Concerns	Concerns	High	High	High	High
Richards 2016 <sup>168</sup>	Anxiety (GAD-7), worry (PSWQ), depression (BDI-II)	Concerns	Low	Concerns	High	Low	High
Robinson 2010 <sup>169</sup>	Anxiety (GAD-7), worry (PSWQ), depression (PHQ-9), general distress (K-10), disability (SDS)	Concerns	Low	Concerns	Low	Low	High
Teng 2019 <sup>38</sup>	Anxiety (STAI, BAI), worry (PSWQ), depression (BDI)	Concerns	Concerns	High	High	High	High
Titov 2009 <sup>171</sup>	Anxiety (GAD-7), worry (PSWQ)	Low	Low	Concerns	Low	High	High
Titov 2010 <sup>170</sup>	Anxiety (PDSS, SPSQ), stress (PSWQ), depression (PHQ-9)	Low	Low	Concerns	Low	High	High
	General distress (K-10), disability (SDS)	Low	Low	Concerns	Low	Concerns	High
Topper 2017 <sup>172</sup>	Anxiety (GAD-7, MASQ-A), worry (PSWQ, RRS, PTQ), general distress (MASQ-GD), depression (BDI-II)	Low	Concerns	High	Low	High	High

ACES, Anxiety Change Expectancy Scale; BBQ, Brunsviken Brief Quality of Life Scale; CES-D, Center for Epidemiologic Studies Depression Scale; GAD-Q-IV, Generalised Anxiety Disorder Questionnaire-IV; GAI, Geriatric Anxiety Inventory; GDS, Geriatric Depression Scale; HADS-A, Hospital Anxiety and Depression Scale – Anxiety Subscale; HADS-D, Hospital Anxiety and Depression Scale – Depression Subscale; K-10, Kessler Psychological Distress Scale; MADRS-S, Montgomery-Åsberg Depression Rating Scale; MASQ-A, Mood and Anxiety Symptoms Questionnaire – anxiety; MASQ-GD, Mood and Anxiety Symptoms Questionnaire – general distress; PDSS, Panic Disorder Severity Scale; PTQ, Perseverative Thinking Questionnaire; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; QoL, quality of life; QOLI, Quality of Life Inventory; RRS, Ruminative Response Scale; SCID-I, Structured Clinical Interview for DSM-IV Axis I Disorders; SDS, Sheehan Disability Scale; SPSQ, Satisfaction with Performance Scaled Questionnaire; WHOQOL, World Health Organization Quality of Life.

#### Note

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.



**FIGURE 9** Proportion (%) of RCTs of DIs for GAD with 'low risk', 'high risk' or 'some concerns' in the six domains of the risk-of-bias tool. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

### **Classification of digital interventions and comparators**

We classified DIs and their alternatives according to three criteria: (1) whether they were a psychological/behavioural intervention (I) or a non-therapeutic psychological/behavioural control (C); (2) whether they were digital (D) or non-digital (NoD); and (3) whether they were supported (S) or unsupported (U). WLs and usual care were classified under NI unless an active component (e.g. monitoring, sham activity) was introduced, in which case the WL/usual care was classified as non-therapeutic psychological/behavioural control. An additional classification group was included for pharmacological interventions, called medication (M).

The interventions and controls of the 21 included RCTs were allocated to one of the following eight classification groups: medication (M), NI, SDC, SDI, SNoDC, SNoDI, UDC and UDI. There were no available clinical studies that included UNoDIs or UNoDCs.

*Table 13* describes all the interventions and controls included in each classification group for each study. The majority of DIs were supported (in 19 RCTs)<sup>4,37,38,40,41,158-162,164-172</sup> and were compared against NI (in 12 RCTs)<sup>5,40,41,158,164,166-172</sup>. Only three RCTs<sup>4,5,160</sup> included UDIs; two were web-based CBT<sup>4,160</sup> and one<sup>5</sup> was a mobile game to practise breathing retraining. The only NoDI represented in two RCTs<sup>165,172</sup> was group therapy [one CBT and one mindfulness-based intervention (MBI) and there was only one RCT that included medication (an antidepressant, sertraline)].<sup>159</sup> Most of the non-therapeutic active controls reported in eight RCTs<sup>4,5,37,38,159,161-163</sup> included a digital element, whereas only one RCT<sup>38</sup> had a non-digital control in the form of a weekly face-to-face assessment with a research assistant in a laboratory.

### **Network meta-analysis results: Generalised Anxiety Disorder-7 scores at follow-up**

Generalised Anxiety Disorder-7 scores were reported in 13 out of 20 studies ( $n = 1613$  patients)<sup>4,5,37,38,40,41,158-162,164-172</sup>. Each of these studies reported short-term outcomes (up to 12 weeks), with very few studies reporting outcomes beyond 12 weeks post treatment initiation. In those that did, crossovers were allowed at follow-up, biasing any long-term treatment effect.<sup>184</sup> Ten direct treatment comparisons were made in the 13 trials included in the GAD-7-based NMA; four of the 13 trials were multiarm trials (three three-arm trials<sup>159,167,169</sup> and one five-arm trial<sup>4</sup>); five comparisons were informed by more than one trial when a pairwise ANCOVA meta-analysis was conducted (ANCOVA FE and ANCOVA RE models when  $n > 3$ ).

We constructed a network plot to illustrate which interventions had been compared head to head (direct pairwise comparisons) for GAD-7 in the 13 included RCTs. An overview of these pairwise comparisons is shown in *Appendix 3, Table 22*. The structure of the network for GAD-7 is shown in *Figure 10*.

Fixed-effects and RE models were employed with minimal difference in mean residual deviances and DIC between the models tested. However, posterior estimates of between-study heterogeneity suggested considerable variability across studies, which was in line with the assessment made of the studies within the evidence base. Hence, a RE approach was preferred. There was a high degree of uncertainty in the network, especially links that were not informed by direct comparisons. *Table 14* presents the full results of the NMA based on GAD-7 scores. Negative values suggest a positive effect for the first intervention in the direct pairwise comparisons, and that the intervention on the left column is 'better' in the NMA. GAD-7 score differences should be assessed in the light of the GAD-7 score range 0–21, from mild to severe.

Medication was the intervention associated with the largest decrease in GAD-7 median scores, although uncertainty was high in the NMA estimates, with all 95% CrIs including zero. These results were driven by the outcomes of a small ( $n = 21$ ), three-arm trial<sup>159</sup> that compared medication supplemented with scheduled face-to-face meetings with psychologists and general practitioners (GPs) with SDC (a general health website with scheduled meetings with psychologists and GPs) and SDI (a web-based CBT self-help programme with scheduled meetings with psychologists and GPs).

TABLE 13 Characteristics and classifications of interventions and controls in RCTs of DIs for GAD

Study (first author and year)	Intervention or control description (mode of delivery, therapy/control method, type of interpersonal contact/support)	Classification
Andersson 2012 <sup>158</sup>	Web-based psychodynamic therapy + weekly online support by psychology students/qualified psychologist	SDI
	Web-based CBT + weekly online support by psychology students/qualified psychologists	SDI
	WL (crossover to web-based CBT at 3 months)	NI
Andersson 2017 <sup>40</sup>	Web-based extinction therapy + daily online support by psychology students	SDI
	WL (+ weekly online <sup>a</sup> PSWQ ratings and option to telephone if symptoms worsen – crossover to web-based extinction therapy at 10 weeks)	NI <sup>b</sup>
Christensen 2014 <sup>4</sup>	Web-based CBT – no interpersonal communication	UDI
	Web-based CBT + weekly telephone calls by ‘casual interviewers’	SDI
	Web-based CBT + weekly reminder e-mail similar in content to telephone calls by ‘casual interviewers’ but no two-way communication	UDI
	Control website (information about general health) – no interpersonal communication	UDC
	Control website (information general health) + weekly telephone calls by ‘casual interviewers’	SDC
Christensen 2014 <sup>159</sup>	Web-based CBT + scheduled on-site meetings with psychologists/GPs	SDI
	Control website (information about general health) + scheduled meetings with psychologists/GPs	SDC
	Medication (SSRI – 25 mg of sertraline up to 100 mg per day) + scheduled meetings with psychologists/GPs	M
Dahlin 2016 <sup>41</sup>	Web-based MBT and ACT + weekly messages via a secure messaging system by psychology students	SDI
	WL (+ weekly online <sup>a</sup> GAD-7 and PSWQ ratings – contact with administrator implied for weekly measure completion but unclear – crossover to modified web-based MBT and ACT at 9 weeks)	NI <sup>b</sup>
Dear 2015 <sup>160</sup>	Web-based CBT (transdiagnostic model focusing on mental well-being) + weekly telephone/e-mail contact with qualified psychologists	SDI
	Web-based CBT (GAD-specific focusing on worry control) + weekly telephone/e-mail contact with qualified psychologists	SDI
	Web-based CBT (transdiagnostic model focusing on mental well-being) + standardised weekly e-mail reminders and option to telephone/e-mail for technical support or other problems – no scheduled or regular interpersonal contact	UDI
	Web-based CBT (GAD-specific focusing on worry control) + standardised weekly e-mail reminders and option to telephone/e-mail if needed technical support or had other problems – no scheduled or regular interpersonal contact	UDI
Hazen 2009 <sup>161</sup>	Computer-delivered attentional retraining + ‘non-therapy’ meetings with ‘experimenters’ every 6 days	SDI
	Sham training + ‘non-therapy’ meetings with ‘experimenters’ every 6 days	SDC
Hirsch 2018 <sup>162</sup>	Web-based CBM + one initial on-site meeting + regular (unspecified) contact by telephone/e-mail/SMS with researchers (unspecified qualifications) + RNT priming	SDI
	Web-based CBM + one initial on-site meeting + regular (unspecified) contact by telephone/e-mail/SMS with researchers (unspecified qualifications) – no RNT priming	SDI
	Control website (neutral scenarios) + one initial on-site meeting + regular (unspecified) contact by telephone/e-mail/SMS with researchers (unspecified qualifications)	SDC

continued



TABLE 13 Characteristics and classifications of interventions and controls in RCTs of DIs for GAD (continued)

Study (first author and year)	Intervention or control description (mode of delivery, therapy/control method, type of interpersonal contact/support)	Classification
Howell 2018 <sup>163</sup>	Web-based CBT + standardised weekly e-mail reminders with information – no interpersonal contact	UDI
	Control website (online assessment and resources) + standardised weekly e-mail reminders with substantial information – no interpersonal contact	UDC
Johansson 2013 <sup>37</sup>	Web-based psychodynamic therapy + weekly written messages via online messaging system by therapists (unspecified qualifications)	SDI
	WL + weekly assessment and non-directive support via online messaging system with therapists (unspecified qualifications) matching therapist support in the intervention	SDC <sup>c</sup>
Jones 2016 <sup>164</sup>	Web-based CBT + weekly messages via online messaging system by therapists (unspecified qualification)	SDI
	WL (crossover after 7–10 weeks) – no monitoring or other input specified	NI
Navarro-Haro 2019 <sup>165</sup>	Group MBI in weekly on-site meetings with a therapist	SNoDI
	VR mindfulness skills + group MBI in weekly on-site meetings with a therapist	SDI
Paxling 2011 <sup>166</sup>	Web-based CBT (like an online book) + weekly online/e-mail contact with therapist	SDI
	WL (crossover after 8 weeks) – no monitoring or other input specified	NI
Pham 2016 <sup>5</sup>	Mobile game of breathing retraining – no interpersonal contact	UDI
	WL + weekly newsletter with curated content on breathing retraining exercises, matching content to mobile game, mindfulness meditation (assumed via mobile but not clear) + e-mail reminders to complete assessments (crossover to access the mobile game after 4 weeks)	UDC <sup>d</sup>
Repetto 2013 <sup>167</sup>	VR relaxation during weekly meetings with therapist + mobile phone home access of VR environments	SDI
	VR relaxation during weekly meetings with therapist + mobile phone home access of VR environments + biofeedback machine for therapist to adapt VR environments according to participant's heart rate	SDI
	WL (no monitoring or any other input specified)	NI
Richards 2016 <sup>168</sup>	Web-based CBT + weekly online messages by psychologists	SDI
	WL (crossover at week 7 – no monitoring or other input)	NI
Robinson 2010 <sup>169</sup>	Web-based CBT + weekly telephone/e-mail contact by a 'clinician' (clinical psychologist)	SDI
	Web-based CBT + weekly telephone/e-mail contact by a 'technician' (administrative clinic manager)	SDI
	WL (crossover at week 11 – no monitoring or other input)	NI
Teng 2019 <sup>38</sup>	Mobile app – home-delivered ABM + weekly 'lab' meeting with assistant + telephone call if missed sessions	SDI
	Mobile app – attention training + weekly 'lab' meeting with assistant + telephone call from the assistant if missed sessions	SDC
	WL + weekly meetings with research assistant for matching assessment in a 'lab'	SNoDC <sup>e</sup>
Titov 2009 <sup>171</sup>	Web-based CBT + moderated online discussion forum + instant online messaging + one initial telephone contact + subsequent e-mail/telephone weekly contact with clinical psychologist	SDI
	WL (crossover at week 11 – no monitoring or other input)	NI
Titov 2010 <sup>170</sup>	Web-based CBT + moderated online discussion forum + instant online messaging + one initial telephone contact + subsequent e-mail/telephone weekly contact with clinical psychologist	SDI
	WL (+ unclear if contact with psychologist – crossover at week 9)	NI

TABLE 13 Characteristics and classifications of interventions and controls in RCTs of DIs for GAD (continued)

Study (first author and year)	Intervention or control description (mode of delivery, therapy/control method, type of interpersonal contact/support)	Classification
Topper 2017 <sup>172</sup>	Group CBT in weekly meetings with psychologists	SNoDI
	Web-based CBT + weekly online personalised feedback from psychologists (unclear whether or not there was two-way communication between participant and psychologist in response to feedback)	SDI
	WL (crossover at 12 months – no monitoring or other input from the research team)	NI

ABM, attentional bias modification; ACT, acceptance and commitment therapy; M, medication; MBT, mindfulness-based therapy; RNT, repetitive negative thinking; SSRI, selective serotonin reuptake inhibitor.

- a Not clear whether online measures were sent by e-mail or were automated and delivered via a platform.
- b ‘Waiting list’ classified as ‘no intervention’ because the online weekly ratings were self-completed without any further input from the research team.
- c ‘Waiting list’ classified as ‘supported digital control’ because there was substantial and regular non-specific support and monitoring via an online messaging system with a therapist that matched the duration of therapeutic support in the intervention arm.
- d ‘Waiting list’ classified as ‘unsupported digital control’ because there was substantial and regular information and therapeutic advice similar to that of the intervention – via the mobile (inferred) (hence ‘digital’); standardised materials without two-way interaction with a therapist (hence ‘unsupported’).
- e ‘Waiting list’ classified as ‘supported non-digital control’ because there were substantial and regular face-to-face assessments with a researcher that matched the assessments of the intervention groups.

**Note**

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.




FIGURE 10 Network plot for direct pairwise comparisons between all interventions and controls for GAD populations in RCTs with GAD-7 scores as an outcome. Line thickness around the node is proportional to the number of patients contributing to each intervention/control group. Line thickness connecting nodes is proportional to the number of patients contributing to each pairwise comparison between interventions/controls. n = number of trials informing each comparison. M, medication. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

TABLE 14 Full meta-analysis results: network and direct pairwise comparisons between all interventions and controls for post-treatment (3–12 weeks) GAD-7 scores adjusted for baseline

GAD-7 network	Comparator							
	GAD-7 direct pairwise, <sup>a,b</sup> median (95% CrI)							
	NI	UDC	SDC	UDI	SDI			M
					FE	RE	SNoDI	
NI		Not available	Not available	Not available	-3.65 (-8.19, 0.9)	-1.26 <sup>b</sup> (-43.8, 40.93)	Not available	Not available
UDC	-0.26 (-16.82, 16.42)		-0.80 <sup>a</sup> (-12.30, 10.70)	-0.77 (-7.81, 6.26)	-1.50 <sup>a</sup> (-11.34, 8.34)		Not available	Not available
SDC	-0.14 (-15.52, 15.30)	0.12 (-9.84, 10.05)		-0.51 (-31.75, 28.95)	-8.16 (-26.57, 13.04)	-1.07 <sup>b</sup> (-30.2, 27.19)	Not available	-8.20 <sup>a</sup> (-22.07, 5.67)
UDI	<b>-0.96</b> (-16.43, 14.54)	<b>-0.7</b> (-9.10, 7.58)	<b>-0.83</b> (-8.82, 7.29)	-	-0.14 (-8.85, 8.89)	-1.38 <sup>b</sup> (-26.23, 23.62)	Not available	Not available
SDI	<b>-1.75</b> (-15.72, 12.26)	<b>-1.49</b> (-10.51, 7.47)	<b>-1.61</b> (-8.03, 4.82)	<b>-0.79</b> (-7.39, 5.80)			<b>-0.71<sup>a</sup></b> (-14.03, 12.61)	<b>-2.70<sup>a</sup></b> (-9.80, 4.40)
SNoDI	-2.41 (-22.34, 17.46)	-2.21 (-18.69, 14.5)	-2.28 (-17.66, 13.16)	<b>-1.45</b> (-16.92, 14.03)	-	<b>-0.65</b> (-14.67, 13.23)		Not available
M	-4.95 (-21.09, 11.26)	-4.69 (-16.62, 7.11)	-4.81 (-14.59, 4.83)	<b>-3.97</b> (-14.3, 6.20)	-	<b>-3.18</b> (-11.32, 4.76)	-2.56 (-18.71, 13.54)	

M, medication.

a Non-pooled data for when  $n = 1$  ( $n$  is number of studies).

b Pairwise ANCOVA RE meta-analysis when  $n > 3$  for contrasts with intervention SDI ( $n$  is number of studies).

Lower-left triangle (unshaded area): NMA results (ANCOVA RE). Upper-right triangle (shaded area): direct pairwise meta-analysis results (ANCOVA FE). Cells with bold font: available comparisons between DIs (supported and unsupported) and alternatives.

#### Note

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.


Based on SUCRA rankings and rankograms for each intervention (as detailed in *Appendix 4*), SDIs were estimated to be more effective than UDIs, which included unsupported web-based CBT<sup>4,160</sup> and an unsupported mobile breathing retraining game;<sup>5</sup> however, SDIs were less effective than SNoDI, which was a weekly group MBI with a therapist.<sup>165</sup> The adjustment for baseline scores indicated that the baseline effect on the final outcome was small with a 95% CrI including zero (median  $-0.14$ , 95% CrI  $-1.10$  to  $0.82$ ).

The results of independently pooling direct evidence for each contrast (but not pooling when  $n = 1$ ), were found to be generally consistent with the NMA results in terms of both direction and magnitude of the estimates (see *Table 14*; upper-right triangle, shaded). Of note are the differences in the estimates found when applying a FE and a RE ANCOVA meta-analysis model to direct evidence for the comparisons of SDIs and SDCs ( $n = 4$ ) and of SDIs and NI ( $n = 8$ ), evidencing non-negligible variability across the studies and the importance of accounting for between-study heterogeneity.

### Network meta-analysis results: Penn State Worry Questionnaire scores at follow-up

The PSWQ follow-up scores were reported in 14 out of 20 studies<sup>4,31,40,41,158,161,162,166-172</sup> ( $n = 1776$  patients). Using these studies, we constructed a network plot to illustrate which interventions have been compared head to head (direct pairwise comparisons) for PSWQ score. An overview of these pairwise comparisons is shown in *Appendix 3*, *Table 23*. The structure of the network is shown in *Figure 11*.

Eleven direct treatment comparisons were made in the 14 trials<sup>4,31,40,41,158,161,162,166-172</sup> included in the NMA; 6 of the 14 trials were multiarm trials (five three-arm trials<sup>38,158,167,169,172</sup> and one five-arm trial),<sup>4</sup> five comparisons were informed by more than one trial in which pairwise ANCOVA meta-analysis was conducted (ANCOVA FE models and ANCOVA RE when  $n > 3$ ).



**FIGURE 11** Network plot for direct pairwise comparisons between all interventions and controls for GAD populations in RCTs with PSWQ scores as an outcome ( $n =$  number of comparisons available across all RCTs). Line thickness around the node: proportional to the number of patients contributing to each intervention/control group. Line thickness connecting nodes: proportional to the number of patients contributing to each pairwise comparison between interventions/controls.  $n =$  number of trials informing each comparison. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

Fixed-effects and RE models were employed with minimal difference in mean residual deviances and DIC between them. However, posterior estimates of between-study heterogeneity suggested considerable variability across studies, which was in line with the assessment made of the studies within the evidence base. Hence, a RE approach was preferred. *Table 15* presents the full results of the NMA based on PSWQ scores. Negative values suggest a positive effect for the first intervention in the direct pairwise comparison, and that the intervention on the left column achieves better outcomes in the NMA. The PSWQ score differences should be assessed in the light of the PSWQ score ranging from 16 to 80, that is from mild to severe.

Uncertainty was high for all comparisons, with all 95% CrIs including zero. We observed no difference in median PSWQ scores between the SNoDI, which was a weekly group CBT with a therapist,<sup>172</sup> and the UDI, an internet CBT self-help programme without therapist support.<sup>4</sup> Based on SUCRA rankings and rankograms for each intervention, as detailed in *Appendix 4*, SNoDI and UDI were estimated to be more effective than the remaining interventions and controls, including SDIs; however, SDIs were associated with larger median score reduction on the PSWQ than NI and UDC, which was a general health website without any personal communication.<sup>4</sup>

Unexpectedly, SNoDC, a WL control supplemented by weekly face-to-face assessment with research assistant,<sup>38</sup> was 'worse' than all other comparators, with similar effectiveness to NI. One explanation may be that repeated assessment without any supportive elements during interactions with the researcher may have accentuated participants' awareness of their anxiety symptoms.

Adjustment for baseline in the PSWQ indicated that baseline effect on final outcome is negligible, with a 95% CrI including zero (median 0.01, 95% CrI -0.44 to 0.45). The results of independently pooling direct evidence on the PSWQ for each contrast (but not pooling when  $n = 1$ ) were generally consistent with the NMA results (see *Table 15*; upper-right triangle, shaded).

### **Results of between-study heterogeneity and inconsistencies**

Three sources of heterogeneity were considered relevant: disease severity, concomitant medication and comorbidities. Using data relating to disease severity and comorbidities was not feasible (see *Appendix 1* for further details); therefore, only data on concomitant medication were included as a covariate in the synthesis modelling. For both outcomes, when this covariate was included, the between-study heterogeneity parameter was not reduced, suggesting that heterogeneity is not explained by this covariate. Crucially, even if the proportion receiving concomitant medication was found to be an important effect modifier, the meta-regression model is not necessarily suited to detect this intervention-covariate interaction, as patients were receiving medication before trial entry. Therefore, medication may have already exerted an effect on patients, being captured by the ANCOVA baseline adjustment component.

Several data loops existed in the networks for GAD-7 and PSWQ, where both direct and indirect data informed intervention effectiveness estimates; the possibility of inconsistencies was investigated. *Tables 14* and *15* show no evidence of substantial discrepancies between the direct and the NMA results for both outcomes; given the uncertainty in the data, only very large differences were likely to result in statistical significance. The results of the consistency and inconsistency models for both outcomes indicated the existence of overall model consistency, as detailed in *Appendix 5*.

### **Sensitivity analysis results**

The sensitivity of networks to specific studies was investigated. In total, 10 analyses with 12 (rather than the total 13) included studies for GAD-7, and 11 analyses with 13 (rather than the total 14) included studies for PSWQ were performed, and the probability of each intervention being the best was assessed. For GAD-7, the selective serotonin reuptake inhibitor (SSRI) and group CBT continued to have the highest chances of being 'best', with probabilities of around 43% and 30%, respectively. Similar results to the primary analysis were obtained for PSWQ. The exception was when a three-arm

TABLE 15 Full meta-analysis results: network and direct pairwise comparisons between all interventions and controls post treatment (3–12 weeks) on PSWQ scores adjusted for baseline

PSWQ network	Comparator							
	PSWQ direct pairwise, <sup>a,b</sup> median (95% CrI)							
	NI				SDI			
	NI	UDC	SDC	UDI	FE	RE	SNoDC	SNoDI
NI		Not available	Not available	Not available	-5.23 (-12.91, 2.39)	4.76 <sup>b</sup> (-51.7, 59.53)	Not available	-6.51 <sup>a</sup> (-30.24, 17.22)
UDC	-2.13 (-45.14, 41.05)		-2.60 <sup>a</sup> (-37.39, 32.19)	-6.73 (-33.99, 21.37)	-3.60 <sup>a</sup> (-35.42, 28.22)		Not available	Not available
SDC	-3.76 (-46.77, 32.38)	-1.76 (-32.27, 28.68)		-2.52 (-26.55, 22.31)	-2.93 (-20.90, 15.00)	0.95 <sup>b</sup> (-77.24, 80.71)	3.15 <sup>a</sup> (-20.58, 26.88)	Not available
UDI	-7.13 (-37.55, 24.61)	-4.96 (-35.07, 24.94)	-3.36 (-28.72, 21.82)		1.53 (-21.48, 24.93)	–	Not available	Not available
SDI	-6.43 (-39.63, 39.15)	-4.35 (-34.27, 25.6)	-2.65 (-15.95, 10.74)	0.67 (-23.71, 25.41)			6.75 <sup>a</sup> (-20.97, 34.47)	-0.58 <sup>a</sup> (-24.74, 23.58)
SNoDC	-0.39 (-53.64, 39.29)	1.87 (-35.41, 38.99)	3.51 (-19.87, 26.64)	6.81 (-26.18, 39.67)	–	6.15 (-18.36, 30.39)		Not available
SNoDI	-7.14 (-32.27, 28.68)	-4.98 (-44.2, 33.81)	-3.42 (-31.40, 24.76)	-0.06 (-34.59, 34.83)	–	-0.710 (-25.34, 23.9)	-6.91 (-41.53, 27.92)	

a Non-pooled data when  $n = 1$  ( $n$  is number of studies).

b Pairwise ANCOVA RE meta-analysis when  $n > 3$  ( $n$  is number of studies).

Lower-left triangle (unshaded area): NMA results (ANCOVA RE). Upper-right triangle (shaded area): direct pairwise meta-analysis results (ANCOVA FE). Cells with bold font: available comparisons between DIs (supported and unsupported) and alternatives.

#### Note

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.

study comparing SDIs with NI was removed,<sup>158</sup> which resulted in increased uncertainty around PSWQ scores for all active interventions.

Two studies<sup>159,167</sup> in the evidence base informing the network for the GAD-7 outcome had included fewer than 30 patients. Not considering these studies from the network implied the exclusion of medication from the comparator set, altering the network structure. As expected, with the reduction in the number of studies informing the network, the uncertainty in the posterior effect distributions increased further. However, no significant changes were observed compared with the main model results. For PSWQ, two studies<sup>161,167</sup> were also excluded from the network on the basis of lower patient numbers, with the comparator set prevailing. The ranking of active interventions in terms of median PSWQ score decrease compared with NI was unaltered, although higher score decreases were estimated.

### **Comparison of network meta-analysis results on Generalised Anxiety Disorder-7 and Penn State Worry Questionnaire for digital interventions**

To compare the results of the NMAs across both outcome measures (i.e. GAD-7 and PSWQ), and only for comparisons between DIs and their alternatives (rather than between alternatives, e.g. medication vs. group therapy), we present an abridged version of the NMA results in *Table 16*. The table shows the network comparisons and the direct pairwise comparisons between DIs and alternatives for post treatment (3–12 weeks) scores on GAD-7 and PSWQ median scores (adjusted for baseline).

Comparing the direction and magnitude of differences in median scores at follow-up between the GAD-7 and PSWQ results (where available for both) in *Table 16*, we make three observations. First, the difference in GAD-7 median scores at follow-up between medication and DIs is the largest across all comparators, and favours medication. Second, no data were available for comparisons between DIs and individual therapy, either face to face or by telephone, or between DIs and manualised guided self-help (which is the non-digital counterpart of most DIs). Third, the direction of effect favoured SDIs for GAD-7 and UDIs for PSWQ.

To compare the ranking of DIs relative to their comparators across both GAD-7 and PSWQ we produced two figures. *Figure 12* shows the ranking of DIs (SDI and UDI) for GAD relative to NoDIs and controls based on their likelihood of being 'best' for outcomes up to 12 weeks' follow-up (adjusted for baseline). *Figure 12* shows the average ranking of each intervention based on SUCRAs. *Appendix 4* shows in detail the SUCRA graphs and rankograms for each intervention and control for GAD-7 and PSWQ.

From *Figure 13* we make three observations. First, medication and group therapy have a higher probability than DIs of being 'best' (i.e. they are associated with lower GAD-7 and PSWQ scores at 3–12 weeks' follow-up). Second, UDIs are more likely than SDIs to be 'best'. Third, several non-therapeutic controls (SDC, UDC and SNoDC) rank above SDIs for both GAD-7 and PSWQ.

## **Discussion**

### **Summary and interpretation**

Our systematic review retrieved 21 studies<sup>4,5,37,38,40,41,158–172</sup> and our analysis was based on 20 RCTs,<sup>4,5,37,38,40,41,158–162,164–172</sup> which included 2325 adults with emerging or diagnosable GAD allocated to DIs or an alternative pathway of care, including NI. Comparisons varied depending on whether the intervention or control was digital or non-digital and supported or unsupported by clinicians or laypeople; the majority of comparisons were between SDIs and NI. Using an ANCOVA framework, our two NMAs pooled together post-treatment scores (adjusted for baseline) for two outcome measures: GAD-7 and PSWQ. In addition, the existence of treatment effect modifiers was assessed, several sensitivity analyses were carried out and network consistency was evaluated.

**TABLE 16** Abridged meta-analysis results: relative treatment effects based on network and direct pairwise comparisons between DIs and alternatives for post-treatment (3–12 weeks) scores on GAD-7 and PSWQ median scores (adjusted for baseline)

Comparators	GAD-7 <sup>a</sup> score (95% confidence interval)		PSWQ <sup>a</sup> score (95% confidence interval)	
	Network	Direct pairwise	Network	Direct pairwise
<b>Medication</b>				
M vs. SDI	-3.18 (-11.32 to 4.76)	-2.70 <sup>b</sup> (-9.80 to 4.40)	Not available	Not available
M vs. UDI	-3.97 (-14.30 to 6.20)	Not available	Not available	Not available
<b>NI</b>				
SDI vs. NI	-1.75 (-15.72 to 12.26)	-3.66 (-8.19 to 0.90) FE; -1.26 <sup>c</sup> (-43.8 to 40.93) RE	-6.43 (-39.63 to 39.15)	-5.23 (-12.91 to 2.39) FE; 4.76 <sup>c</sup> (-51.7 to 59.53) RE
UDI vs. NI	-0.96 (-16.43 to 14.54)	Not available	-7.13 (-37.55 to 24.61)	Not available
<b>Group therapy</b>				
SNoDI vs. SDI	-0.65 (-14.67 to 13.23)	-0.71 <sup>b</sup> (-14.03 to 12.61)	-0.71 (-25.34 to 23.90)	-0.58 <sup>b</sup> (-24.74 to 23.58)
SNoDI vs. UDI	-1.45 (-16.92 to 14.03)	Not available	-0.06 (-34.59 to 34.83)	Not available
<b>Non-therapeutic controls</b>				
<i>Digital</i>				
SDI vs. SDC	-1.61 (-8.03 to 4.82)	-8.16 (-26.57 to 13.04) FE; -1.07 <sup>c</sup> (-30.2 to 27.19) RE	-2.65 (-15.95 to 10.74)	-2.93 (-20.90 to 15.00) FE; 0.95 <sup>c</sup> (-77.24 to 80.71) RE
SDI vs. UDC	-1.49 (-10.51 to 7.47)	-1.50 <sup>b</sup> (-11.34 to 8.34)	-4.35 (-34.27 to 25.60)	-3.60 <sup>b</sup> (-35.42 to 28.22)
UDI vs. SDC	-0.83 (-8.82 to 7.29)	-0.51 (-31.75 to 28.95)	-3.36 (-28.72 to 21.82)	-2.52 (-26.55 to 22.31)
UDI vs. UDC	-0.70 (-9.10 to 7.58)	-0.77 (-7.81 to 6.26)	-4.96 (-35.07 to 24.94)	-6.73 (-33.99 to 21.37)

continued



TABLE 16 Abridged meta-analysis results: relative treatment effects based on network and direct pairwise comparisons between DIs and alternatives for post-treatment (3–12 weeks) scores on GAD-7 and PSWQ median scores (adjusted for baseline) (continued)

Comparators	GAD-7 <sup>a</sup> score (95% confidence interval)		PSWQ <sup>a</sup> score (95% confidence interval)	
	Network	Direct pairwise	Network	Direct pairwise
<i>Non-digital</i>				
SNoDC vs. SDI	Not available	Not available	6.15 (–18.36 to 30.39)	6.75 <sup>b</sup> (–20.97 to 34.47)
SNoDC vs. UDI	Not available	Not available	6.81 (–26.18 to 39.67)	Not available
<i>Variants of DIs</i>				
SDI vs. UDI	–0.79 (–7.39 to 5.80)	–0.14 (–8.85 to 8.89) FE; –1.38 (–26.23 to 23.62) RE	0.67 (–23.71 to 25.41)	1.53 (–21.48 to 24.93) FE

M, medication.

a The GAD-7 and PSWQ results are not directly comparable as they express mean differences but refer to different scales.

b Non-pooled data when  $n = 1$ .

c Pairwise ANCOVA RE meta-analysis when  $n > 3$ , for contrasts with intervention SDI.

Only comparisons that include DIs are presented.

#### Note

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.




FIGURE 12 Ranking of DIs (SDI and UDI) for GAD relative to NoDIs and controls based on their likelihood of being 'best' for outcomes up to 12 weeks' follow-up (adjusted for baseline). Dotted line, top rank; bold line, middle rank; and dashed line, bottom rank. M, medication. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.




FIGURE 13 Ranking of DIs (SDI and UDI) for GAD relative to NoDIs and controls based on SUCRAs for outcomes up to 12 weeks' follow-up (adjusted for baseline). Dotted line, top rank; bold line, upper-middle rank; double line, lower-middle rank. M, medication. Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The figure includes minor additions and formatting changes to the original figure.

Our NMA results suggest that medication is associated with lower anxiety scores at follow-up relative to all other interventions and controls. Medication also ranks first in terms of its likelihood of being most effective, which considers the uncertainty in relative effect estimates. Medication results are supported by data from one study reporting GAD-7 and not PSWQ. Antidepressant medication as a treatment for GAD is supported by clinical guidelines<sup>2</sup> and previous evidence syntheses. A large NMA<sup>129</sup> of six trials comparing sertraline with placebo for the treatment of GAD found that sertraline (the same antidepressant used in the study by Christensen *et al.*<sup>159</sup> included in our NMA) resulted in a greater improvement in HAM-A scores compared with baseline than did placebo (mean difference -2.88, 95% CrI -4.17 to -1.59). Another meta-analysis<sup>131</sup> favoured a combined treatment of psychological therapy and medication for all anxiety disorders and depression, except GAD, where the direction of effect favoured antidepressant medication (venlafaxine) alone.

Our NMA makes best use of all currently available RCT-based evidence on DIs for GAD. Despite the sparsity and low quality of the data, a statistical synthesis can still be useful for mental health professionals who use DIs for GAD anyway, so that they can be informed about the current evidence base, understand which DIs have been shown to be more effective in reducing GAD and prioritise future research. Previous reviews of DIs that reported GAD-related outcomes<sup>131,132</sup> used mixed samples of anxiety disorders and depression without reporting separate outcomes for GAD subgroups. There are no RCTs carried out in GAD populations comparing DIs with non-digital self-help interventions based on a manual rather than a web-based program. Nor are there any RCTs comparing DIs with individual therapy, either face to face or by telephone, as the only available comparisons within the literature are between DIs and group therapy.

Owing to very wide confidence intervals, our NMA results were inconclusive as to whether DIs for GAD are better than NI and non-therapeutic active controls, or whether they confer an additional benefit to standard therapy. Previous meta-analyses suggested that supported DIs could be as good as face-to-face therapy across depression, anxiety and somatic disorders.<sup>185</sup> Yet the mixed samples in these meta-analyses without separate analysis or reporting for GAD subsamples do not allow any conclusions to be drawn about the relative efficacy of DIs specific to the treatment and prevention of GAD.

Our NMA results about the comparative effectiveness of supported and unsupported DIs for GAD were counterintuitive, as we would expect SDIs to rank higher in terms of likelihood of being 'best', based on a previous meta-analysis in which SDIs were found to be four times more effective than DIs without any therapist contact.<sup>186</sup> We found that UDIs rank higher than SDIs in terms of being best, but the converse is true based on all rankings (SUCRAs). This is consistent with a recent review<sup>187</sup> that reported mixed findings regarding guided versus unguided DIs and human versus automated support for DIs. This suggests that the design, content, technology platform and type of reinforcement offered in lieu of personal support in UDIs may bear more weight and account for greater variability in their outcomes.

The evidence base available in this setting is complex. In particular, the sheer volume of anxiety metrics (45 in total) being reported across the available studies suggests a lack of consensus on which measures to use in evaluating GAD outcomes. GAD-7 and PSWQ are commonly used and well-validated outcomes to capture change in GAD symptoms. The use of GAD-7 or PSWQ or both as outcome measures across all the included studies further strengthens our review, as we did not need to exclude any of the retrieved studies from the meta-analysis on the basis that it did not use GAD-7 or PSWQ. The only excluded study<sup>163</sup> used GAD-7, but reported only categorical outcomes. It is worth noting that the HAM-A used in the large meta-analysis on medication for GAD<sup>129</sup> featured in only one<sup>167</sup> of our included studies, showing a discrepancy in the choice of outcomes for psychological and pharmacological interventions.

### Limitations

There was substantial uncertainty around effect estimates of DIs against alternatives for GAD-7 and PSWQ. This was driven by the small number of studies informing most comparisons, as well as the

small samples in some of these studies and their high risk of bias, limiting our confidence in any observed differences in anxiety scores between interventions and controls. These observed differences may simply be due to chance; therefore, we cannot make clear recommendations about the relative value of DIs compared with their comparators, but we can make recommendations for future research (both for primary studies and evidence synthesis) in view of the current evidence.

Caution is needed when interpreting the results of our NMA across all different interventions for GAD. Our review has been completed in the context of DIs; it included only RCTs in which at least one of the randomisation arms was a DI. Therefore, we cannot draw any conclusions about the comparative merit of NoDIs (psychological or pharmacological) for GAD when these are considered separately from DIs (e.g. group CBT vs. medication). To be able to do this, we would need to include RCTs in a NMA that would enable second or third order contrasts (e.g. RCTs comparing NI and medication), which was beyond the scope of this review. In addition, ranking based on likelihood of being best and on SUCRAs does not reflect differences in effectiveness estimates between interventions and controls and CrIs, that is, we cannot tell whether or not the differences between ranking position (e.g. between first, second, third and fourth) are clinically meaningful.

Another point of caution, as it is with all evidence synthesis, relates to pooling DIs and their alternatives into groups for analysis based on our classification criteria. Any classification implies interpretation and judgement, which is conditional on attained information from studies. We note the insufficient reporting of details about 'non-therapeutic controls' and WLs in some studies. Furthermore, we could have split DIs into further categories according to the technology used (e.g. VR, internet, mobile app), the function of the technology (e.g. adjunct to clinician-delivered therapy vs. patient self-help) or the type of support (e.g. telephone calls vs. meetings). This would have created more 'nodes' in the NMA models but also more uncertainty because comparisons between DIs and their alternatives within each subgroup would have been informed by fewer studies.

Many of our included RCTs had small samples and multiple arms, comparing different versions of the same intervention, thereby reducing the power of the study. Our evidence synthesis also shows that in the majority of RCTs either the time frame for follow-up is short (up to 12 weeks) or the control group has already crossed over to the intervention at the point of a longer follow-up (up to 2 years), which cancels the randomised comparison. Consequently, we did not include observations for further follow-up time points, when these were available, nor did we account for time differences in the short-term reporting (the timing of assessments post treatment varied from 3 to 12 weeks). Our NMA results reflect the short-term impact of DIs as there is scant evidence to inform randomised comparisons about effects beyond 12 weeks.

### **Recommendations**

As GAD is the most prevalent and least studied condition among other common mental health problems, future evidence syntheses will be helpful to focus on GAD populations and GAD subgroups within mixed populations as a means of informing GAD-specific future research and clinical guidelines.<sup>2</sup> Feasibility and pilot studies, as well as user involvement in the development of the intervention and delivery protocols, could ensure that the final RCT tests the best possible intervention for GAD. Adaptive designs with improved intervention features and boosted recruitment numbers to a fully powered RCT are preferable to underpowered studies with multiple arms testing increments of the same DI.

Our NMAs and previous literature suggest that antidepressants are an important factor to consider in future studies on DIs for GAD. Studies of psychological interventions (whether digital or non-digital) often include participants who are taking medication as part of their routine care. It is difficult to disentangle the effects of medication and psychological support for GAD, and future RCTs need to report medication details (name, dose and duration) and include it as a covariate in their analysis to establish how outcomes with DIs and controls are influenced by concurrent medication use.

Having a consensus about GAD-specific outcome measures can prevent participant fatigue from completing batteries of different questionnaires and enable comparisons across studies and data syntheses. GAD-7 is more sensitive to changes associated with treatment and therefore may be more suitable for longitudinal clinical research.<sup>188</sup> Reporting continuous data on GAD-7 as a common measure in RCTs with GAD populations will make more studies available for a future statistical synthesis. Including HAM-A in studies of psychological therapies will enable us to compare results with those of pharmacological studies. Future analyses using multivariate models may be in a position to make better use of the available evidence by borrowing strength across different outcomes.

Many studies that include long-term follow up of participants offer the intervention to those randomised to the control group at a crossover point. Participants are also likely to receive some treatment as part of usual care the longer they remain on WLs or non-therapeutic controls, so studies cannot withhold interventions to enable long-term follow-up. As the typical duration of DIs is 3–12 weeks, the follow-up period of future RCTs needs to be longer than this, for example at least 6 months, to get a sense of the 'stickiness' of DIs beyond their delivery period. Usual care and WLs are poorly reported in RCTs, and the RCTs do not include data on concurrent interventions accessed by participants, including openly available self-help, which can influence the difference in outcomes between DIs and NIs.

## Conclusions

To our knowledge, this study is the first to evaluate the effectiveness of DIs specifically in a GAD population. Using two outcome measures (GAD-7 and PSWQ), it is also the first to combine all the RCT-based effectiveness evidence from DIs and key comparators in a single modelling framework, allowing the estimation of relative treatment effects for all relevant comparisons. Our results suggest that medication is associated with lower anxiety scores at follow-up relative to all other interventions and controls. Results were inconclusive as to whether DIs are better than NI and non-therapeutic active controls for GAD, or whether they confer an additional benefit to standard therapy.

Future primary studies and meta-analyses need to focus on GAD populations rather than use mixed samples, or report outcomes specifically for GAD subsamples if they intend to answer questions about the comparative effectiveness of DIs for GAD. Comparing DIs with manualised (non-digital) self-help, for which there are no current RCTs for GAD populations, will be useful in the context of stepped care. Antidepressant medication as a first-line treatment for GAD compared with DIs deserves further research and economic modelling. As many decisions to use interventions are driven by 'value for money', and in the light of the scarcity of data on the costs and outcomes of DIs compared with non-digital alternatives for the treatment of GAD, it is necessary to assess the VOI to guide decisions of further research. To inform commissioning and potential disinvestment from non-digital alternatives, we need to put the findings of this evidence synthesis into context together with an assessment of the costs of developing and implementing DIs in clinical practice.

# Chapter 5 Economic modelling for generalised anxiety disorder

Parts of this chapter have been reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

## Introduction

Previous studies that evaluated the cost-effectiveness of DIs with GAD populations<sup>61,85</sup> compared a specific DI against usual care or individual therapy. To our knowledge, no studies synthesised evidence on all DIs for GAD to evaluate their cost-effectiveness across different technologies and therapeutic modalities. Reviews of cost-effectiveness of DIs were for mixed mood and anxiety disorders, so they were dominated by DIs for depression and did not report outcomes for GAD populations separately.<sup>16,20</sup>

This WP aims to evaluate the cost-effectiveness of DIs, across different types of technologies and therapeutic modalities, compared with (1) conventional therapy (without any digital components), (2) medication, (3) non-therapeutic controls and (4) NI, from the perspective of the UK's health-care system. The analysis constitutes a cost-effectiveness model, specifically a Markov model, with 3-month cycles over the lifetime of an individual with GAD.

## Methods

### *Classification of digital interventions and their alternatives*

We compared seven types of interventions and controls for GAD based on our classification criteria: medication (M), SNoDI, SDI, UDI, SDC, UDC and NI. There were no available clinical studies that included UNoDIs or UNoDCs, and no studies of SNoDCs that used GAD-7 as an outcome. DCs identified in WP2 (see *Classification of digital interventions and comparators*) were included in the analysis, as patients are occasionally signposted to information sources in reputable websites when waiting times are long. Their exclusion from the analysis was explored in *Scenario analysis*.

### *Model structure*

The CEA methods followed the NICE reference case.<sup>11</sup> An NHS and Personal Social Services perspective was used for the analysis. A full incremental analysis was undertaken comparing all seven interventions/controls simultaneously over a patient's lifetime.

The model structure was based on GAD severity determined by the GAD-7 questionnaire, in which the scores denote no (scores 0–4), mild (5–9), moderate (10–14) or severe (15–21) anxiety.<sup>178</sup> A Markov cohort model was used, following the structure adapted from Kumar *et al.*<sup>85</sup> The health states included are shown in *Figure 14*.

At the start of the model, patients are in one of four health states. At each subsequent cycle of the model, they can remain in this health state or transition to another, better or worse, health state. Health-care resource use and HRQoL are driven by GAD severity, both directly and through comorbidities. The intended effect of DIs was to reduce the severity of GAD, thereby reducing the number of patients in moderate and severe GAD states, with an associated impact on costs and HRQoL.




FIGURE 14 Decision model for GAD health states based on GAD-7 scores. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

### Model parameters

#### Intervention effectiveness

Changes in GAD-7 scores as a result of the seven interventions were informed by our NMA reported in *Chapter 4*. Using an ANCOVA framework,<sup>138</sup> the meta-analysis reported median GAD-7 scores after treatment (3–12 weeks), adjusted by baseline scores. GAD-7 scores were modelled as a continuous variable. When scores generated in the ANCOVA model were between severity states (e.g. GAD-7 score 4.5), the score was rounded up.

Baseline and post-treatment GAD-7 scores were used to inform the model baseline GAD-7 scores and transitions after the first model cycle, respectively (see *Appendix 7, Table 27*). Changes in GAD-7 scores in the remaining cycles were estimated based on evidence from the literature. It was assumed that, without treatment, patients' GAD symptoms would, on average, improve over time, as reported by Yonkers *et al.*<sup>190</sup> Specifically, 15% of patients recovered in the first year, a further 10% recovered in the second year and a further 5% recovered in the third year. In the model, recovery was defined as a 5-point reduction in GAD-7 scores in the corresponding proportion of iterations with mild, moderate or severe anxiety, consistent with a move to a lower anxiety state. In the base case, the treatment effect was assumed to remain constant relative to no treatment indefinitely. Thus, the shift to lower GAD scores remained over a patient's lifetime, although some patients were assumed to improve over time at the same rate as those in the base case.

#### State-specific utilities and costs

Targeted searches were conducted to inform state-specific health-care costs and utilities. To identify published economic evidence, we searched MEDLINE [via Ovid®; (Wolters Kluwer, Alphen aan den Rijn, the Netherlands)], EMBASE and PsycInfo. (Details of the searches, including the number of studies retrieved, are provided *Report Supplementary Material 6*.) The searches identified one study<sup>126</sup> that reported state-specific utilities (no, mild, moderate and severe anxiety) with a measure of uncertainty (standard deviation). The utilities were derived from the Short Form questionnaire-6 Dimensions (SF-6D) scores using the UK scoring algorithm. The states were defined by the HAM-A<sup>182</sup> score, an assessment tool highly correlated with the GAD-7 questionnaire ( $r = 0.852$ ),<sup>191</sup> which we used to inform the utilities in the model. Uncertainty in utilities was derived by fitting a beta distribution to the reported mean and standard error, using the method of moments.<sup>192</sup> The HRQoL/utility scores

associated with the GAD-7 states were assumed to follow an underlying age depreciation over time, in accordance with UK population utility score norms (per year of age).<sup>193</sup>

The targeted searches identified two studies that reported state-specific health-care resource use,<sup>85,194</sup> and one further study reported state-specific costs in patients with anxiety and/or depression.<sup>14</sup> Study details are provided in *Appendix 9, Table 30*. Given the variation in the delivery of mental health services across settings, the UK-based study<sup>14</sup> was used to inform health-care resource use in the base case, whereas the remaining two studies were used in scenario analyses. The costs from Kaltenthaler *et al.*<sup>14</sup> were adjusted to 2019 Great British pounds using the overall Consumer Price Index.<sup>195,196</sup> Costs and benefits were discounted at 3.5% over the time horizon of the model.<sup>11</sup>

## Mortality

Age- and sex-dependent mortality risk in patients with no anxiety was obtained from the Office for National Statistics.<sup>197</sup> Excess mortality in mild, moderate and severe anxiety states was derived from Michal *et al.*,<sup>198</sup> who reported the impact of anxiety or depression on all-cause mortality in cardiovascular outpatients on long-term oral anticoagulation, adjusted for age, sex, high school graduation, partnership, smoking, obesity and frailty in patients with mild, moderate and severe anxiety or depression, defined by Patient Health Questionnaire – 4 items (PHQ-4) scores. The excess mortality was assumed to capture deaths by suicide and due to GAD-related comorbidities. The reported risk ratios were applied to mortality without GAD.

## Intervention cost

The intervention costs were derived from published literature. The cost of NI/WL was assumed to be £0. The only medication for which data were available was a SSRI. The cost of pharmacotherapy was assumed to represent the cost of medication (£16.42, representing the mean cost of all SSRIs<sup>199</sup> weighted by the volume dispensed, as reported by OpenPrescribing.net<sup>200</sup> in January 2020), the dispensing fees for SSRIs (12 prescriptions dispensed annually, at £1.26 each<sup>199</sup>) and GP appointments (7.5 in the first year of treatment and 4 thereafter, as per guidance for prescribing SSRIs from NICE,<sup>2</sup> at £42.60 each). Medication was assumed to be prescribed for 5 years as a conservative estimate to prevent underestimating its cost. Antidepressant medication may be given for up to 2 years in the first instance, but relapse is common within the first year of stopping the medication, which may lead to another 2 years of prescription.

The cost of non-digital psychological interventions (SNoDI) was based on the time spent with a therapist multiplied by the cost of the therapist's time (£53 per hour<sup>201</sup>). The SNoDI interventions in this evaluation used group therapy (group sizes of five to nine people) lasting 9–10.5 hours.<sup>165,172</sup> The intervention was therefore costed at 1.5 hours of therapist time per patient (based on 10.5 hours for seven patients). Non-attendance was assumed not to result in cancellation of the group session, and so this did not affect the average cost of therapy per patient.

The digital component of interventions/controls was assumed to carry no cost, on the basis that, if the intervention were rolled out nationally, the marginal cost per patient would be negligible. Alternative assumptions were explored in the sensitivity analysis. UDIs and UDCs were assumed to incur no additional costs. The cost of support for DCs and interventions was calculated separately, based on the level of support typically required to deliver them, as detailed in *Appendix 6*.

## Cost-effectiveness analysis

Patients' costs and HRQoL were tracked over time, until all patients in the cohort died. The cumulative costs and QALYs were then used to derive the net monetary benefit (NMB) conditional on the marginal productivity of the health system. NMB represents the difference between the benefit incurred by the intervention and the benefit forgone by displacing the resources elsewhere in the health system to fund the intervention.<sup>48</sup> The intervention with the highest NMB was the most cost-effective one.



## Sensitivity analysis

### Probabilistic analysis

Probabilistic uncertainty analysis was conducted to characterise the uncertainty associated with input parameters to the model and their impact on cost-effectiveness. Each parameter was sampled 25,000 times from its probability distribution. The number of iterations was chosen to match the number of random samples of the treatment effect generated in the meta-analysis. The model parameters and the probability distribution parameters are shown in *Appendix 7* (see *Tables 28* and *29*).

### Deterministic scenario analysis

A one-way scenario analysis was performed to evaluate the sensitivity of the model results to our assumptions. The following scenarios were explored regarding the GAD score trajectory, health-care resource use and intervention costs:

- Five additional scenarios regarding the GAD score trajectory (see *Appendix 8*).
- Two alternative scenarios regarding health-care resource use, in which state-specific health-care costs were informed using alternative studies (i.e. Vera-Llonch *et al.*<sup>194</sup> and Kumar *et al.*<sup>85</sup>). The cost of health care was derived by multiplying the reported resource use by the unit costs available from the NHS England tariff for the year 2018/19<sup>201</sup> (see *Appendix 9, Table 31*).
- Alternative DI costs, where a threshold analysis was performed to identify the maximum cost of DIs that would make them good value for money.
- Alternative levels of support in SDCs (5 minutes per patient, delivered by non-clinical staff or by clinical psychologists).
- Exclusion of DCs (UDCs and SDCs) from the analysis.

### Value-of-information analysis

The results of the probabilistic uncertainty analysis were used to estimate the VOI. The maximum value of further research per patient treated [expected value of perfect information (EVPI)] was derived from the difference between the NMB under perfect information (i.e. where the optimum treatment is known with certainty) and existing information (i.e. the expected net benefit from the treatment that is the most cost-effective under current knowledge).<sup>202</sup>

The value of further research at population level [expected value of perfect information at the population level (EVPI<sub>p</sub>)] was then estimated by multiplying EVPI by the effective population size (*Equation 1*):<sup>202</sup>

$$\text{Effective population} = \sum_{t=1}^T \frac{I_t}{(1 + dr)^t} \quad (1)$$

where  $I_t$  represents GAD incidence in year  $t$ ,  $T$  is the total number of years for which information from the research would be useful (usually representing the technology lifetime) and  $dr$  is the discount rate, set at 3.5%.

The incidence of GAD was 4.9% of the population in the UK in 2008<sup>203</sup> and 4.3% in Germany in 2008.<sup>204</sup> Therefore, in the VOI analysis, the incidence was set at 250,000, representing a conservative estimate in which < 10% of patients in England (population of  $\approx$  55.9 million) who acquire GAD would receive the intervention. The relevant technology lifetime was assumed to be 5 years.

Finally, the expected value of partial perfect information at the population level (EVPPi<sub>p</sub>) was derived to understand the parameters in the model driving uncertainty relevant to the adoption decision. The non-parametric method developed by Strong *et al.*<sup>205</sup> was used. The method, conducted using the Sheffield Accelerated Value of Information (SAVI) interface (URL: <http://savi.shef.ac.uk/SAVI/>; accessed 7 September 2021), regresses random samples of all uncertain parameters against the net benefit of each intervention to derive the impact of uncertainty about individual parameters on the model results.

All uncertain parameters in the model were used to derive EVPPI<sub>p</sub> for the following five groups of parameters: treatment effect (GAD-7 scores after the first cycle, seven parameters), state-specific costs (four parameters), state-specific utilities (four parameters), excess death [three parameters – relative risk (RR) of death in mild, moderate and severe anxiety] and age-related utility decrements (54 parameters, utility decrements every year until all patients in the model die).

The opportunity cost was assumed to be £15,000 per QALY, in line with the empirical estimate by Claxton *et al.*<sup>206</sup>

## Results

### Generalised anxiety disorder score trajectory

Figure 15 shows the proportion of patients in each GAD-7 health state for the initial 5 years, without treatment. At the start of treatment almost 80% of patients had moderate GAD, a further 20% had mild GAD and the proportion with no and severe GAD was < 0.05. In the base case, for the first 3 years of the model, patients' GAD was assumed to improve spontaneously, resulting in a decrease in the proportion who had moderate and severe GAD, and an increase in the proportion with no or mild GAD. After 3 years the proportions remained constant (in the living population). The proportion in each anxiety state after treatment is shown in Appendix 8.

The reduction in GAD-7 scores after receiving treatment with the seven treatment options compared in the model is shown in Figure 16. The initial reduction in GAD-7 reflects the effect of treatment, as determined by our meta-analysis. The treatment effect was assumed to remain constant indefinitely, and after 1 year GAD-7 scores decreased further as patients' symptoms continued to improve at the same rate as without treatment. However, the GAD-7 reduction decreased, as, following treatment, the number of patients who could recover spontaneously was lower than if no treatment had been received. The rate of decrease in GAD-7 score varied between interventions, depending on the magnitude and uncertainty of the treatment effect. More effective treatments were associated with fewer patients in mild, moderate and severe anxiety states, and so the spontaneous symptoms improvement affected fewer patients. Wider confidence intervals led to a higher probability of patients




FIGURE 15 Movement through Markov states for the initial 5 years without treatment. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.




FIGURE 16 Change in mean GAD-7 score for the initial 5-year period after starting treatment. M, medication. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

being in the no anxiety state, and so the spontaneous symptoms improvement affected fewer patients; this is why the reduction in GAD-7 scores after 1 year was higher in SDIs than in UDIs, despite SDIs being more effective. After 3 years, the reduction in GAD-7 remained constant.

#### Cost and outcomes of digital interventions compared with alternatives

Table 17 shows the costs and outcomes associated with each of the seven comparators. The differences in QALY and life-years follow the same pattern; the differences between comparators were small and uncertain, reflected in wide and overlapping confidence intervals. The QALY and life-year gains reflect the results from the meta-analysis: on average, the greatest reduction in post-treatment anxiety scores was associated with medication, followed by SNoDIs, then by SDIs and then by UDIs. Both SDIs and UDIs were associated with lower scores post treatment than SDCs, UDCs and no treatment.

Health-care costs were highly uncertain, with overlapping confidence intervals. Differences in health-care costs largely followed the reverse order of QALY gains; health-care costs were lowest for patients taking medication and highest for patients who received NI. This was due to the correlation between health-care costs and GAD severity (see Appendix 7).

Supported digital interventions and SNoDIs were associated with the same intervention costs, as they include the same level of human resources. Medication was more expensive, as it is administered over 5 years (and so requires contact with health-care professionals for 5 years), and, unlike other interventions, the costs were uncertain because the proportion of patients who were alive and taking medication was uncertain. The total costs of different comparators follow the same order as health-care costs, except SDIs that incur a higher total cost than UDIs owing to the higher intervention cost.

Table 17 shows the incremental costs and effects and the net benefit of all seven comparators, whereas Figure 17 shows the cost-effectiveness acceptability curves for each intervention and control, and how their probability of cost-effectiveness changes for different opportunity costs. In Table 17, net benefit and the probability of cost-effectiveness are shown for two opportunity costs: £0 per QALY, representing a decision-maker who will implement only cost-saving interventions, and £15,000 per QALY, close to the empirical estimate of the opportunity cost in England.<sup>9</sup> The model results did not change significantly at opportunity costs higher than £15,000 per QALY (as seen in Figure 17).


TABLE 17 Mean total cost and effect of DIs and alternatives for GAD (95% confidence interval)

Outcome	Options						
	M	SNoDI	UDI	SDI	SDC	UDC	NI
QALYs	12.9 (11.5 to 14.3)	12.2 (10.4 to 14.2)	11.8 (9.7 to 14.1)	11.9 (10.5 to 13.7)	11.6 (9.2 to 14.0)	11.5 (8.9 to 14.1)	11.1 (9.4 to 12.4)
Life-years	37.2 (34.1 to 38.6)	36.4 (32.09 to 38.6)	36.0 (31.4 to 38.8)	36.4 (32.5 to 39.0)	35.7 (31.0 to 38.7)	35.6 (30.5 to 38.6)	34.9 (30.9 to 38.6)
Health-care cost (£)	10,640 (725 to 45,948)	12,362 (49 to 59,092)	14,114 (25 to 68,008)	14,218 (139 to 63,152)	14,605 (13 to 74,297)	14,822 (18 to 75,923)	16,069 (1 to 87,123)
Intervention cost (£)	1115 (1113 to 1115)	80	0	80	18	0	0
Total cost (£)	11,754 (1839 to 47,063)	12,442 (128 to 59,171)	14,114 (25 to 68,008)	14,298 (218 to 63,232)	14,623 (31 to 74,315)	14,822 (18 to 75,923)	16,069 (1 to 87,123)
Incremental cost compared with M (£)	-	688 (-38,229 to 49,867)	2360 (-37,391 to 57,798)	25,43 (-36,862 to 51,940)	2868 (-37,785 to 63,454)	3067 (-38,072 to 65,451)	4315 (-38,184 to 75,859)
Incremental QALYs compared with M	-	-0.7 (-3.4 to 2.2)	-1.2 (-3.6 to 1.8)	-1.0 (-3.0 to 0.8)	-1.4 (-3.8 to 1.4)	-1.4 (-4.5 to 1.8)	-1.9 (-3.9 to 0.3)
Mean ICER (£ per QALY)	Dominant	Dominated	Dominated	Dominated	Dominated	Dominated	Dominated
<i>k</i> = £0 per QALY							
NMB (£)	-11,754 (-47,063 to -1839)	-12,442 (-59,171 to -128)	-14,114 (-68,008 to -25)	-14,298 (-63,232 to -218)	-14,623 (-74,315 to -31)	-14,822 (-75,923 to -18)	-16,069 (-87,123 to -1)
PCE	0.051	0.129	0.151	0.107	0.159	0.165	0.238
<i>k</i> = £15,000 per QALY							
NMB (£)	181,975 (131,817 to 209,180)	171,033 (110,947 to 208,548)	162,334 (97,837 to 205,226)	164,551 (111,833 to 197,813)	158,586 (88,232 to 203,339)	158,335 (81,276 to 205,462)	149,671 (74,016 to 180,051)
PCE	0.342	0.232	0.111	0.089	0.085	0.105	0.035

*k*, opportunity cost; M, medication; PCE, probability cost-effective.

#### Note

Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.



**FIGURE 17** Cost-effectiveness acceptability curves for each intervention and control. M, medication. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

The intervention most likely to be cost-effective depends on the opportunity cost. The most cost-effective intervention is NI for an opportunity cost of £0 per QALY, SNoDIs for an opportunity cost of £1000 per QALY and medication for an opportunity cost of £2000 per QALY or higher.

Medication was dominant, resulting in the highest NMB at all opportunity costs, followed by group therapy, as both led to lower total costs and greater QALY gains than DIs. NI had the lowest NMB because of the lower QALY gains and higher health-care costs. DIs (UDIs and SDIs) had a higher NMB than DCs (UDC and SDC) as they were associated with better outcomes and lower health-care costs. SDIs had greater QALY gains but also higher costs than UDIs, so their NMB depended on the opportunity cost of the health system. When the opportunity cost is £0 per QALY, UDIs are ranked above SDIs, whereas the opposite is the case when the opportunity cost increases to £15,000 per QALY.

These results are uncertain, which is reflected in the wide confidence intervals associated with NMB and the probability of each intervention being the most cost-effective (see *Table 17* and *Figure 18*). For example, although medication has the highest NMB, there is a high probability that it is not the most cost-effective comparator: 0.949 probability at £0 per QALY opportunity cost and 0.658 at £15,000 per QALY.

Accumulation of costs and outcomes over time is shown in *Appendix 10*. The longer the analysis time horizon, the greater the differences in the QALY gain (see *Appendix 10, Figure 29*), as the benefits accrue over time. Differences in health-care cost are driven by the clinical effectiveness of interventions, and so, as for QALY gains, the longer the time horizon the greater the cost differences (see *Appendix 10, Figure 30*), but the rate of change is diminishing. Medication is the most expensive intervention in the short term, but, as health-care cost savings accrue over time, and treatment cost reduces after 5 years, the total cost for medication increases at a lower rate than for other comparators, eventually becoming the second-cheapest treatment option, after SNoDI.

### Value-of-information analysis

*Figure 19* shows EVPI<sub>p</sub> over a range of opportunity costs. Even at its lowest, when opportunity cost is £4000 per QALY, the value of uncertainty is high (£11.4B), increasing to £16.2B and £19B when opportunity costs are £15,000 and £20,000 per QALY, respectively. The EVPI<sub>p</sub> analysis suggested that uncertainty in the treatment effect had the greatest value, £12.9B. Parameters defining the effect




FIGURE 18 Cost-effectiveness ranking based on NMB for DIs and controls. Values in brackets are 95% CIs. k, opportunity cost; M, medication.




FIGURE 19 The EVPI<sub>p</sub> for a range of opportunity costs. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

of GAD on costs and HRQoL (state-related costs and utilities, and excess mortality) had low or negligible value, whereas age-related utility decrements were uncertain, valued at £6.8B.

### Scenario analysis

Scenario analyses were performed to explore the sensitivity of the findings to assumptions made regarding the GAD score trajectory, health-care costs and interventions costs. Appendix 11 shows the movement through Markov states, and the changes in GAD-7 scores in the initial 10-year period is shown in Appendix 11, Figures 31–33. The results were not sensitive to any of the alternative scenarios; the order of cost-effectiveness did not change, only the magnitude of the difference. Pharmacotherapy dominates all other interventions, and SDIs are more effective and costlier than UDIs (see Appendix 11). As DIs were costlier than face-to-face therapy and medication, the effect of increasing their cost further was not explored.

## Discussion

To understand whether or not DIs represent value for money in the treatment of GAD, we constructed a decision-analytic model to evaluate the cost-effectiveness of supported and unsupported DIs, from the perspective of the UK health-care system, in comparison with group therapy, antidepressant medication, non-therapeutic controls and NI. The expected net benefit was the highest for medication followed by group therapy. All DIs and non-therapeutic controls led to higher net benefit than NI. SDIs led to higher costs than UDIs, but NMB was higher when the opportunity cost was  $\geq$  £5000 per QALY.

These results are highly uncertain, with the VOI estimated to be  $>$  £11B. The VOI represents not only the value of further research in resolving model uncertainty, but also the scale of the loss of QALYs and incurred costs if the decision about whether to fund DIs, based on existing evidence, is incorrect. The EVPPi<sub>p</sub> analysis found that the effectiveness of DIs is highly uncertain. It is also a parameter fundamental to establishing the cost-effectiveness of DIs for GAD, given that costs are driven by clinical outcomes (better GAD outcomes lead to lower total health-care costs, compensating for higher DI costs). Therefore, the value of further research to establish the effectiveness of DIs for GAD is substantial: at least £12.9B.

We synthesised evidence on all DIs for GAD populations to evaluate the cost-effectiveness of these, whereas previous economic studies evaluated one specific DI for GAD using a single source for clinical data. Kumar *et al.*<sup>85</sup> evaluated the cost-effectiveness of a SDI (mobile self-directed cognitive-behavioural therapy: CBT) against individual CBT and NI, and found the SDI to be cost-saving against both comparators; however, clinical data came from a single-arm pilot study for the SDI and from a previous systematic review for the individual CBT, rather than from a RCT comparing SDI with individual CBT. In addition, Kumar *et al.*'s<sup>85</sup> CEA did not explore probabilistic uncertainty. Dear *et al.*<sup>61</sup> evaluated the cost-effectiveness of a SDI (internet-based self-directed CBT) compared with NI, using outcomes from a RCT. The authors found that the SDI was more effective but also costlier than NI, with a high probability of being cost-effective when the opportunity cost was AU\$40,000 per QALY ( $\approx$  £20,000 per QALY). Our analysis supports the findings by Kumar *et al.*<sup>85</sup> and by Dear *et al.*<sup>61</sup> that SDIs may be more cost-effective than NI, albeit with great uncertainty. No clinical studies included head-to-head comparisons between DIs and individual CBT for GAD populations (only group CBT), so we could not confirm or refute the finding by Kumar *et al.*<sup>85</sup> that DIs are more cost-effective than individual CBT.

Limitations in data availability led to several assumptions regarding model parameters. Utilities and excess mortality in different severity states were informed by studies that used measures other than GAD-7 (i.e. HAM-A<sup>126</sup> and PHQ-4<sup>198</sup>), but these measures have been found to be highly correlated with GAD-7.<sup>191</sup> Furthermore, excess mortality was estimated from the impact of anxiety and/or depression in cardiovascular outpatients with long-term oral anticoagulation; it is not clear how closely this relates to excess mortality from GAD in the general population, but the relatively small effect means that it is unlikely to have a large impact on the results. The cost of health care for different levels of GAD severity was based on data collected in 2005 (adjusted for inflation) in patients with anxiety and/or depression<sup>14</sup> and on non-UK health-care resource use in the scenario analysis.<sup>85,194</sup> All three studies led to similar conclusions in terms of ranking and uncertainty regarding the cost-effectiveness of DIs and their alternatives.

Finally, the meta-analysis in WP2 did not provide information about relapse rates for each intervention and therefore it was not possible to include this potential impact of interventions. The relapse was assumed to be comparable across all comparators, and the rate of relapse was assumed to be lower than the rate of spontaneous improvement (as described in *Model parameters*), leading to a positive net change in symptoms. In the sensitivity analysis (see *Appendix 11, Table 34*), medication had a higher net benefit (£171,866, 95% CI £112,948 to £204,345) than other interventions in the base case when a constant treatment effect was assumed and, thus, we conclude that the results are not sensitive to assumptions about the rate of relapse.

Our model compared the lifetime effect of single treatments for GAD, whereas, in practice, patients can receive multiple cycles of the same therapy or a combination of therapies concurrently or in sequence. We did not model the cost-effectiveness of sequential or combined treatments owing to lack of data; therefore, we do not know whether or not DIs may be cost-effective as a first-line treatment in a stepped-care model before medication and individual or group therapy is offered to those who do not respond to DIs. The lack of GAD-specific cost data is another limitation, so having more up-to-date estimates of resource use for GAD patients as they move through a stepped-care pathway would enable more accurate estimates of cost-effectiveness.

## Conclusions

As far as we are aware, this is the first study to evaluate the cost-effectiveness of DIs for GAD, across all types of DIs and in comparison to all types of alternatives, using a decision-analytic model. DIs are associated with a lower NMB than medication and group therapy, but with a higher NMB than non-therapeutic controls and NI. SDIs may be of better value than UDIs, but only for higher investment; if investment is zero, UDIs may be a better alternative. The high uncertainty of these results does not allow for any conclusions about the cost-effectiveness of DIs. NMB is driven by health-care resource use and HRQoL, which in turn are driven by GAD severity, both directly and through morbidity. This means that value for money is driven by clinical outcomes rather than intervention costs; therefore, focusing on treatment effects of DIs for GAD populations in future clinical studies will enable more certain results from cost-effectiveness evaluations.





# Chapter 6 Knowledge transfer and stakeholder involvement

## Introduction

We do not know how stakeholders, such as commissioners, practitioners, managers, patients, technologists and researchers, make sense of economic evidence about DIs and how they may use this evidence to inform their decisions to adopt, or not, certain DIs. Many concepts in economic evaluations (e.g. QALYs, uncertainty and ICERs) cannot be easily understood (or can be easily misunderstood) by audiences who are not health economists. For example, even the most basic message of an intervention being ‘cost-effective’ is often (mis)taken as the equivalent of being ‘cheap’ or ‘cost saving’. In a series of stakeholder seminars, we explored how individuals and organisations may understand, interpret and potentially use economic information to inform their decision-making about DIs, and how researchers can tailor knowledge transfer activities of economic evidence synthesis to fit the interests and priorities of each stakeholder group.

## Stakeholder seminars

We have held seven seminars with groups of stakeholders (*Figure 20*), which included:

- commissioners who may fund services that use DIs
- practitioners and service managers who may provide DIs in routine care
- service users who may engage with DIs to improve or promote their mental health
- technologists and researchers who may further develop and optimise DIs.

The groups were mixed to reflect the multidisciplinary nature of teams within health and community settings where DIs may be implemented. The seminars involved 2–18 participants and were delivered both via telecommunication [Skype, Zoom (Zoom Video Communications, San Jose, CA, USA) and Microsoft Teams (Microsoft Corporation, Redmond, WA, USA)] and in person by visiting NHS premises and holding classes at the University of York. We did not record the sessions but we took detailed notes. Most of the seminars were part of education and continuous professional development for health-care staff and students. The occurrence of the COVID-19 pandemic in the middle of our knowledge transfer activities meant that we had to be flexible about the way in which we carried out the seminars; we included as many representative stakeholders as possible within a naturalistic setting and with the




FIGURE 20 Stakeholder groups.

changing priorities of the NHS. We did not cite any quotations from individual stakeholders, we summarised and reflected on only the key discussion points that arose from the seminars.

The seminars took into consideration a science communication framework<sup>207,208</sup> and involved the following steps:

- We presented a summary of our methods and findings in an appropriate way so that the audience could make sense of the presented information. To enable this, we used colour-coded diagrams and figures as much as possible, rather than tables with numbers or long narratives.
- We discussed how the summary of evidence may speak to the values and intentions of stakeholders and how their decisions to invest time and resources in DIs may be supported or challenged in view of this evidence.
- We listened to the audience to understand the decisions they have to make about DIs and the values and intentions that underpin these decisions.
- We discussed how we can improve the understanding and use of economic evidence by stakeholders.

Each seminar had two parts. The first part was the communication of our methods and findings through an interactive presentation. The second part was a question–answer and discussion session when we asked the audience to identify the highlights of our findings that were important to them, identify any aspects of the presentation that were not clear, and offer comments and feedback in general. We did not follow a structured discussion topic guide so that we could understand, in the first instance, what areas the stakeholders identified as important without being prompted or coached in a certain direction. Using a thematic analysis,<sup>209</sup> we identified key themes and were able to draw comparisons about the understanding and potential use of our evidence within and between the different stakeholder groups. In our final expert oversight group, which included health economists, statisticians, researchers and a representative from Public Health England, we presented the findings of the stakeholder workshops and a proposal of how a series of future evidence briefings will be structured and communicated to a broader audience.

### Summary of feedback

We produced a matrix (*Table 18*) to map out the areas of importance for conducting and communicating research on costs and outcomes of DIs in mental health that emerged from the stakeholder seminars within and between the four stakeholder groups.

Some stakeholders questioned what we really mean by ‘digital interventions’. A lot of people confuse digital platforms (e.g. Skype and smartphones) with DIs (i.e. an activity underpinned by a clinical rationale). There is also the added complication of social media, which are sometimes used as platforms to increase awareness, reduce stigma and encourage help-seeking in mental health, but are not really DIs. Although an important function of digital media is to start a conversation about mental health and encourage help-seeking, they may also have the inadvertent effect of medicalising normal emotional responses and inflating the demand for mental health services.

When we talked about DIs in mental health, some of the stakeholders reflected that it is important to differentiate whether these are for specific diagnosable mental health problems or for factors that may contribute to mental health problems, such as isolation, loneliness, lack of well-being or lack of awareness. In our evidence synthesis, we included DIs only for specific mental health problems, because we wanted to make it relevant to health services that fund and deliver DIs to those with emerging or existing diagnosable conditions, rather than to the general population.

Stakeholders’ experiences of recovery with DIs indicated that their effects were much lower in real life and within health-care services than is reported in research and evaluation studies. This is not surprising given that many of the studies we reviewed had a high risk of bias due to the ways in which the results

TABLE 18 Matrix of stakeholder-identified areas of importance for conducting and communicating research on costs and outcomes of DIs in mental health

Areas of importance for conducting and communicating research on DIs	Stakeholders			
	Those who fund DIs	Those who deliver DIs	Those who use DIs	Those who develop and evaluate DIs
<b>Populations</b>				
Children and young people		X		
Rural vs. urban areas	X			
Older adults		X	X	
<b>Interventions</b>				
Making a difference			X	
Therapeutic relationship		X		
Non-specific effect of technology		X		
Safety and adverse effects	X	X		X
Meaning, ubiquity		X		X
Sustainability	X			X
Tracking/monitoring		X		X
Communication with peers			X	
Communication with clinicians		X		
<b>Outcomes and service use</b>				
Relapse occurrence		X		
Risk increase		X		
Attendance/completion of sessions		X		
Waiting time			X	
Admission rates	X	X		
Remission and recovery rates		X		
Re-admission rates	X	X		
Treatment duration and discharge rates	X			
Transition experience		X	X	
Number of patients per clinician		X		
<b>Values</b>				
Choice		X	X	
Inevitability		X	X	X
Access/reach		X		X
Continuity of care		X		

were reported. In the seminars, we discussed what we would want to see reported in research studies, which is not there now, to enable us to make better use of the available evidence. One of the areas for improvement is reporting rates of remission and recovery, for example the percentage of people who score below 'caseness', as well as reporting outcomes according to 'health states' (e.g. not only the mean scores at follow-up but also the percentage of people with no symptoms and with mild, moderate and severe symptoms).

With regard to the role of DIs for different age groups, a popular view is that DIs lend themselves better to the mental health care of children and young people (CYP). Are CYP more likely to engage with DIs because they are used to technology and because they enjoy it more? Stakeholders reported that this is not always the case as young people may prefer something different from technology, if they associate 'digital' with schoolwork or social peer pressure. Misconceptions of older generations not wishing or being able to use technology may also raise barriers and lead to patronising attitudes in the way DIs are designed for and offered to older generations.

Can technology alone be therapeutic for CYP who use it simply because it is enjoyable (e.g. children who enjoy playing computer games may find that their mood improves with a game-based DI because they find it enjoyable rather than because of the therapy techniques included in it)? We discussed the value of non-therapeutic DCs as a way of testing the differential effects of technology over therapy, by having a 'control' game without any therapeutic content. In our review, we found that some of the DCs ranked higher than interventions in terms of the probability of being effective, which may be explained by the non-specific effect of the technology itself (e.g. enjoyable, distracting and novel) rather than the content of the technology. Based on this question, future research will be helpful if it focuses on comparisons between DIs and their non-digital counterpart interventions, for example self-help using a digital medium and a non-digital one (a book or a manual). In this way, we can understand whether or not the digital element adds value over and above the content of the intervention.

Given the inconclusive evidence of our review that SDIs may not necessarily be better than UDIs, a member of the audience in one of our seminars asked whether or not the therapeutic relationship is still important. We discussed that the therapeutic relationship may contribute to clinical outcomes in SDIs, but that, equally, the therapeutic ingredients of UDIs may be independent mediators of outcomes. The assumption that the therapeutic relationship synergistically contributes to change in clinical outcomes alongside the therapeutic ingredients of an intervention is challenged by our findings that UDIs may yield similar outcomes as supported ones. This does not minimise the role of the therapeutic relationship but, rather, it emphasises the fact that various elements of DIs make independent contributions. Yet SDIs are advocated by service users, who value the experience of having a person to communicate with, and by clinicians, who suggest that fulfilling patients' needs and preferences to have a person to communicate with at low-intensity care (when DIs are commonly offered) may lead to less need for high-intensity treatment.

In the seminars, we discussed what factors may influence adoption of DIs by decision-makers, other than costs and outcomes. The stakeholders identified two contexts that may drive investment in DIs: first, the belief that technology has the ability to provide a solution to complex mental health problems and, second, the desire to invest in technology to overcome severe NHS staff shortages and vacancies. Some seminar audiences raised concerns that investing in technology has happened on the basis of assumptions and wishful thinking (and also political agendas), rather than on clinical evidence that technology can indeed be a solution to complex problems, and without economic evidence that money is better spent on technology rather than, for example, workforce and care environment. Clinicians spoke of valuing patient choice and the fact that logistically DIs have proven a good way of making interventions available at all times, so that people can access them from their home, outside working hours (e.g. if they are young parents or work shifts). Service users can also use DIs to suit their pace, go over therapeutic activities again and again and, more importantly, have access to interventions well beyond their discharge from the service.

Relapse prevention following discharge from a hospital or a community care team was raised as a potential area in which DIs have a role to play. We discussed service users valuing continuing contact with clinicians after discharge, but also having access to entirely self-administered interventions. We also discussed that most DIs in the reviewed literature have been for common mental health problems

in primary care, but for mental health professionals who care for people with severe mental illness, DIs have most value when incorporated within secondary care pathways as a means of relapse prevention. This is an important point given that very few studies have implemented and evaluated DIs for relapse prevention, and relapse is rarely used as a research outcome metric. Having longer-term follow-ups after the end of an intervention during the 'relapse period' has also been flagged by researchers as a way of improving data availability for the potential long-term modelling of intervention effectiveness and cost-effectiveness.

Although relapse prevention is an important area for DI use, and sleep disturbance is a warning of relapse, we did not include sleep-tracking devices in our current reviews, because their reported outcomes do not capture the occurrence or deterioration of symptoms of mental illness; they detect only changes in sleep patterns. There is a whole body of literature around behaviour change and physical health outcomes in psychiatric populations that is beyond the scope of this work but could be explored in future evidence synthesis. In addition, stakeholders mentioned the value of having an overview of mental health outcomes for people with physical problems (such as depression in people with sleep disorders); this was not within the remit of the current review but could be considered in a future evidence synthesis that focuses on mental health outcomes with DIs used by people with a primary medical/physical problem.

## Future communication strategies

The communication of our findings involving stakeholders is ongoing. The next step is to carry out a webinar involving a panel of representative stakeholders in a facilitated discussion. This builds on a model we have already applied in Cochrane Common Mental Disorders and which is becoming the cornerstone for our knowledge mobilisation on selected reviews. The webinar will be widely advertised with an open invitation, but with some targeted approaches to key individuals as part of the audience, including members of the research team, researchers working in the field, commissioners, clinicians and service users. Following the panel discussion, the audience will be invited to ask questions, contribute information and offer ideas for next steps.

This webinar discussion will provide the foundation from which we will develop more tailored dissemination products for each of our target stakeholder audiences. When appropriate, the contents of the webinar will be used to shape the outputs targeting different audiences. The advantage of this approach is that it provides a neutral space, largely independent of the research team, in which the findings of our evidence synthesis can be discussed and interpreted by representatives of different stakeholder groups, and in which the positions of each can be explored both independently and together. This is especially important when the findings are not obviously conclusive, when different stakeholder groups hold different perspectives or assumptions and when the interpretation of findings is nuanced. The webinar will be recorded and made publicly available as part of the project outputs materials on an appropriate digital platform.

As a follow-on, we will produce bespoke outputs for each audience, which summarise the key findings of our review but, in addition, provide specific stakeholder commentary (preferably submitted by the panellist following the discussion) to better engage and enable decision-makers to consider and use the findings. We have a variety of 'briefing' templates for policy-makers and commissioners that we can build on, although the key issue is that these are brief (preferably one page), clearly laid out and not too dense. We will consider something different for service users and the public; brief plain-language summaries are useful and well-established methods, but blogs, infographics and short podcasts can be much more appealing for broad audiences, and can be easily shared via social media [Twitter (Twitter, Inc., San Francisco, CA, USA; [www.twitter.com](https://www.twitter.com)) is a key channel for both non-academic and academic audiences, and is also a place for the webinar recording link to be shared].

## Conclusion

A series of seminars with stakeholders (i.e. individuals and organisations who would potentially fund, deliver, develop, evaluate and use DIs) helped inform the interpretation of our findings; raised questions for future research; highlighted limitations in our evidence syntheses; and helped us expand, clarify and add to the discussion of our results. An aspect of our findings that was not picked up by the seminar audiences was the role of medication as a comparator or a mediator of outcomes for research on DIs in mental health, or even the role of DIs to support medication use (e.g. using software-based activities to monitor benefits and side-effects or to ensure appropriate and consistent use of medication). DIs are seen as a platform to psychological therapies, and, as such, they may be perceived as separate to medication. This is reflected in the limited research and reporting of medication alongside DIs, despite medication being one of the most commonly offered interventions for mental health problems.

# Chapter 7 Conclusions and recommendations

## Future evaluations of costs and outcomes of digital interventions in mental health

### *Populations: reporting subgroup data by diagnosis, severity and comorbidity*

Many studies and reviews on DIs that we retrieved through our literature searches included mixed populations (e.g. mixed anxiety disorders, or mixed anxiety and depression) without reporting outcomes separately for each diagnostic subgroup. Reporting outcomes for mixed samples, even if the outcome is measured by a disorder-specific tool, such as the GAD-7, can be misleading because it implies that if an intervention works for the mixed sample, then it will also work for each of its constituent populations. Mixed samples do not answer the question of whether or not DIs are effective with a view to informing condition-specific clinical guidelines. To achieve this, future studies with mixed samples need to report outcomes separately for condition-specific subgroups; even if the sample size is not sufficiently large to explore differences by condition within a study, reporting the data by the condition will facilitate data synthesis across studies.

Apart from reporting outcomes for condition-specific subgroups in mixed populations, symptom severity is another important variant for which outcomes need to be reported for 'mild, moderate and severe' subgroups in future studies using established cut-off scores for the chosen outcome measure. This is important for two reasons. First, policy decisions may be based on symptom severity in addition to mental health condition, for example recommending the use of DIs only for patients with mild to moderate depression or GAD. Second, any participant heterogeneity needs to be reflected in the analysis of effectiveness data, as we did in WP2, particularly when pooling data from multiple studies with different distributions of symptom severity. Reporting data on patient subgroups by symptom severity will enable more accurate synthesis of evidence for economic modelling in the future.

Related to the issue of heterogeneity in patient characteristics, many study participants are affected by comorbidities in the form of multiple mental health problems (e.g. substance misuse and depression), but also in the form of mixed physical and mental health problems (e.g. chronic pain and depression). Each of these comorbidities acts as a competing risk, and, as such, it should be accounted for when determining the effectiveness of DIs. Techniques are available to do this, including the use of meta-regression adjusting for differences in the proportions of patients with comorbidities that have been pooled together from individual studies, as we have done in WP2. To be able to achieve this, data on key comorbidities need to be reported in a systematic manner, for example clearly reporting the proportion of patients with chronic pain or with substance misuse within a group of participants with depression. Many studies included in WP2 did not include this detail, and future research needs to collect and report data on the mental and physical health conditions that participants experience in addition to the condition under investigation.

### *Digital interventions: granularity of classification*

We developed a classification system in which interventions were grouped according to whether they were psychological or pharmacological (medication), and controls were grouped according to whether they were non-therapeutic activities (e.g. monitoring) or NI. By 'no intervention' we mean that no additional activities or input were offered as part of the research study over and above interventions and resources that were routinely accessible to all participants irrespective of group allocation. Psychological interventions and non-therapeutic controls were further classified as (1) either digital (software driven) or non-digital (lack of technology, or use of technology only for telecommunication, such as speaking on the telephone or via Skype) and (2) either supported (involving interpersonal communication) or unsupported (pure self-help).



This classification system helped us pool DIs and their comparators in the evidence synthesis for WPs 1 and 2. Our classification system did not differentiate between different types of technology platforms (e.g. computer or smartphone) or different types of therapies (e.g. CBT or psychodynamic). This would have made us lose sight of the bigger picture and diluted the evidence synthesis with too few studies in each group. Moreover, DIs using the same technology are not necessarily more alike than those using different technologies; for example, the same self-help programme may be delivered via a computer or a smartphone, whereas an internet platform for live teleconsultation with a therapist is entirely different from an internet self-help programme. The optimal level of granularity for future reviews needs to be driven by its research questions; reviews that focus on incremental iterations of DIs to inform their future development need greater granularity, whereas reviews that are interested in a panoramic overview of DIs to inform pathways of care need to group DIs and their alternatives using higher-order characteristics.

**Comparators: determined by care pathways**

The DIs evaluated in WP1 reflect the use of such treatments at different points in the clinical pathway for people experiencing mental health problems. DIs can be used to identify risk, using either a targeted or a universal population approach, and to prevent the onset, deterioration or relapse of mental health and addiction problems. Given the heterogeneity of DIs in their functions, delivery setting and targeted clinical conditions, decisions are often made in the context of the services and care pathways within which DIs are implemented. On this basis, future within-trial economic evaluations need to use appropriate alternatives, which would be displaced by a potentially cost-effective DI in a specific care pathway.

Figure 21 depicts the four levels of an inverse pyramid representing the care options within a stepped-care model. The care options that feature at each level should act as alternatives in future economic evaluations of DIs. Step 1, or ‘watchful waiting’, includes alternatives such as assessment, education and monitoring (typically delivered in the community) for populations with subthreshold or mild symptoms or who are at risk of developing a mental health problem. Step 2 includes ‘low-intensity’ interventions in the form of supported and unsupported self-help, as well as education groups. Step 3, or ‘high-intensity’ interventions, includes individual or group therapy and medication. Both step 2 and step 3 are typically delivered in primary care. Step 4, or ‘specialist’ interventions, includes crisis and hospital care as well as complex therapy and medication regimes, typically delivered in secondary care.




FIGURE 21 Digital interventions and their alternatives in the context of the stepped-care model.

Future research needs to consider the role of DIs in clinician-led therapy, especially as this was discussed by our stakeholders, who suggested that DIs are underused in level 3 (high-intensity interventions) and level 4 (specialist interventions) of the stepped-care model when clinicians are at the forefront of treatment delivery. Supported DIs were valued by service users who participated in our stakeholder groups, reflecting their preference for communicating with a professional rather than doing pure self-help. Future economic studies need to address the evidence gap in comparing DIs with individual therapy and to evaluate how individual therapy and DIs may complement one another, especially at levels 3 and 4 of the stepped-care model. Given our conclusion that the effectiveness of DIs drives their value for money, future research should explore whether or not the synergy of DIs and individual therapy in a blended approach can improve clinical outcomes, and, in turn, the cost-effectiveness of DIs, in the context of clinician-led treatment or supported self-help.

### **Clinical outcomes: choice of standardised measures**

In WP2 we used a NMA to combine multiple sources of evidence into a single estimate. This allows the body of evidence to be reflected in a way that accounts for any underlying trends in treatment effect, but also captures heterogeneity between studies. The challenge in such a synthesis of evidence is that clinical outcomes have to be measured by the same standardised tool. As we found in WP2, 45 different outcome measures were used across 20 studies, but only two of those (the GAD-7 and the PSWQ) were used in enough studies (14 in each case) to enable us to carry out a meta-analysis. In addition, standardised tools measure different constructs (e.g. clinical symptoms in GAD-7 and worry in PSWQ), so the conclusions of the two meta-analyses were not directly comparable. Future studies of DIs need to include outcome measures that will enable comparisons and synthesis of evidence with other studies for the same clinical population. As there is no consensus on recommended outcome measures for specific conditions, a literature review should inform the selection of at least one measure by individual studies on the basis that it will allow comparisons and integration of results with those of other studies.

### **Cost estimation: reporting all technology-related costs**

In determining cost-effectiveness, we often need to consider multiple forms and sources of evidence to estimate the costs of the interventions and their comparators. DIs are difficult to establish a cost for, as discussed by McNamee *et al.*<sup>27</sup> For example, there may be significant costs of software development and regular maintenance of digital platforms, which are difficult to disentangle and allocate on a per-patient basis. There are two types of costs that have been under-reported in current economic studies of DIs, and which need to be included in future research studies, or at least reasons for exclusion reported: costs associated with the use of technology (e.g. cost of having Wi-Fi, cost of a computer/smartphone and cost of licences to access software, website maintenance and staff training) and costs associated with reaching potential users (e.g. the cost of advertising if recruiting among the general public and the cost of clinician time if recruitment requires assessment and signposting within clinical services).

### **Cost estimation: justifying differences according to perspectives**

The perspectives of future economic evaluations on DIs will determine which costs should be included in their final cost estimation. For example, costs to develop the technology may be incurred by private companies and not by the health service that adopts the DI; therefore, such costs may be included only if the evaluation is conducted from a societal perspective rather than from a health-care perspective. Future studies need to explicitly discuss how the perspective they used influenced their cost estimation, especially for costs that are technology specific but under-reported, such as capital costs (computers, staff training, one-off software purchases) or costs for website maintenance. Furthermore, future economic studies need to explain and discuss the costs that account for differences in cost-effectiveness results driven by different perspectives, as we have seen in the results of many economic studies in WP1.

***Time horizon: need for long-term data***

Owing to the chronic nature of mental health problems, it is useful to model the impact of short-term interventions over a longer time horizon to understand how differences in treatments translate to differences in costs and outcomes over the lifetime of individuals. Unfortunately, there are few data to support assumptions regarding the 'stickiness' of DIs in mental health beyond the initial treatment period. In addition, there are sparse long-term data regarding the trajectory of mental health conditions, such as GAD, over the longer term. To establish cost-effectiveness over an appropriate time horizon, some extrapolation of shorter-term trial evidence over a longer time horizon is necessary. This leads to assumptions about longer-term treatment effect and the natural history of mental health conditions, which must be validated or tested using sensitivity analysis.

Available data on outcomes and resource use within RCTs are typically short term. This is because of the high costs of long-term follow-ups as part of a research trial, but also because the longer the follow-up, the more likely it is that the trial will lose participants. Our meta-analysis in WP2 showed that typical follow-up was 3–12 weeks before the control group crossed over to an active intervention; this limited the usefulness of longer-term data in estimating treatment effects because the groups were no longer randomised. Although crossover for the control group from 'no intervention' to an active intervention may seem reasonable, especially when studies recruit from the general public and use the crossover as enticement for randomisation, it limits the value of the research study for long-term outcomes. Our modelling study in WP3 relied on assumptions regarding long-term effectiveness in the absence of longer-term trial data. Determining how effective DIs are over the longer term, even with extrapolation, is possible only with longer follow-up in primary studies. Future RCTs on DIs should have at least a 6-month follow-up and avoid crossover designs, especially when participants in the usual-care control group are likely to have access to routine interventions anyway.

***Economic analysis methods: trial based versus economic modelling***

Future economic evaluations of DIs need to take into account the body of existing evidence and how the planned evaluation will contribute towards the literature. To inform decision-making, new evidence on DIs must be put into context with the existing relevant evidence. Trial-based evaluations are often insufficient in follow-up and cannot capture all the relevant differences in costs and outcomes between alternatives, for example between DIs and NoDIs, medication or usual care. The requirement to include all relevant comparators motivates the need for evidence syntheses that pool outcomes from different primary studies, in particular more complex forms of synthesis that reflect multiple comparisons within a single framework, such as the NMA we have conducted in WP2. The use of modelling, specifically extrapolation modelling, gives the opportunity to compare many different alternatives with DIs, which is not possible to do as part of a single within-trial evaluation. Yet the use of extrapolation modelling does not negate the need for robust primary studies that have large samples and long-term follow-ups.

***Research questions: value beyond symptom reduction and cost per unit gained***

Stakeholders asked whether economic studies can tell us if DIs can reduce relapse, risk and admission/re-admission rates; can improve attendance/engagement with health services; can reduce waiting time for treatment or improve remission and recovery rates; can help deliver treatment more quickly and speed up discharge; or can help clinicians treat more patients within a given time. Clinical and economic studies of DIs usually collect all the necessary data to answer these questions, so it will be useful to explicitly formulate questions that speak to the stakeholders' interests and report results in a way that enable us to answer these questions beyond symptom reduction (e.g. GAD-7 scores) and costs per unit of outcome gained (e.g. depression-free days or QALYs).

When stakeholders were asked about what would influence their decisions to adopt DIs other than costs and outcomes, they cited four factors: increasing choice in the way patients and service users access help, improving access/reach for underserved or underengaged populations, enabling continuity of care and accepting the 'inevitability of going digital'. These four factors can be used to steer research questions and discussion topics in future qualitative studies to inform the body of evidence on the

impact of DIs on choice, access/reach and continuity of care, as well as the impact of the ‘inevitability of going digital’ on service users who are not digital natives. These questions may be beyond the scope of standard economic evaluations but are important for decision-making on adopting DIs alongside value for money.

The current economic evidence does not consider costs associated with implementation. Although issues of budget and capacity are methodologically separate to determining cost-effectiveness,<sup>11</sup> decisions to adopt DIs are also driven by the need to deliver interventions in a resource-conscious system, such as the UK’s NHS. Beyond standard methods to establish the cost-effectiveness of DIs, future research needs to consider the actual gains that can be achieved by a system that recommends them, and the investments that may be required to achieve those gains in practice,<sup>210</sup> for example where capital investment is required to build technological infrastructure or to train the workforce in technology literacy.

### **Digital therapeutic alliance: measure and relationship with outcomes**

Future research needs to consider incorporating standardised tools that measure digital therapeutic alliance, like the one developed by Berry *et al.*,<sup>211</sup> to capture the ‘working relationship’ between users and the digital medium itself. This is grounded on our stakeholders’ interest in understanding whether or not using a digital medium mediates clinical outcomes. The value of digital technologies beyond their therapeutic content has been the objective of two groups of economic evaluations we identified in our systematic review. First, studies that compare DIs with their non-digital counterparts (e.g. Jones *et al.*<sup>76</sup>) can inform us about the added value of the digital medium all things being equal in the intervention itself (same content with and without the digital medium). Second, studies that compare DIs with ‘digital dummies’, for example a technology-aided programme with and without a therapeutic element (e.g. in Španiel *et al.*<sup>100</sup>) can inform us about the non-specific effect of the digital medium on outcomes other than the therapeutic intervention itself.

Recent literature reviews<sup>212,213</sup> suggest a relationship between digital therapeutic alliance and outcomes with DIs, perhaps indirectly via improved engagement with therapy. Designing and delivering research studies that compare DIs with appropriate alternatives to control for differences in the content of the digital medium (therapeutic vs. non-therapeutic) or the delivery of the intervention (digital vs. non-digital) can answer questions about the mediating role of the digital medium on clinical outcomes; however, such studies are resource intensive. Alternatively, future studies that compare DIs with NI or with face-to-face therapy can incorporate a measure of digital therapeutic alliance to help us understand and improve the working relationship between users and DIs, and subsequently improve outcomes that can drive value for money.

## **Decision-making for digital interventions in mental health**

Health service commissioners and providers are particularly concerned with delivering the best-quality service for the least possible cost. Economic evaluations, especially CEAs and CUAs, are important tools to help us make decisions about resource allocation to DIs based on their ‘value for money’. Figure 22 is a visual representation of how economic evaluations can inform decision-making based on the costs and outcomes of DIs against the costs and outcomes of their alternatives. The figure is a cost-effectiveness plane<sup>214</sup> whose four quadrants represent four possible combinations of relative costs and outcomes. In the south-east quadrant DIs are more effective and less costly than their alternatives. The opposite is true in the north-west quadrant, where DIs are less effective and more costly. The north-east quadrant corresponds to more effective and more costly DIs, whereas in the south-west quadrant DIs are less effective and less costly than their alternatives.

Decision-making is relatively straightforward when DIs are more effective and less costly, or so-called ‘dominant’ (south-east quadrant), as they can save money. Examples of such DIs from our review




FIGURE 22 Decision-making based on costs and outcomes of DIs compared with alternatives.

include an automated motivational text-messaging service and an internet CBT programme for smoking<sup>67,99</sup> (which dominated 'usual care') and an online self-help intervention to reduce the frequency and intensity of suicidal ideation<sup>104</sup> (which dominated the alternative of signposting participants to a website with general information about suicide). Yet, even in cases in which DIs achieve better outcomes at lower costs, their adoption may require disinvesting from alternatives that are valued and preferred by service users or professionals (e.g. face-to-face consultation with a clinician). In this case, decision-makers may opt for the status quo based on people's personal values and preferences, rather than an intervention's value for money.

When DIs are more effective and more costly than their alternatives (north-east quadrant), health-care commissioners and providers need to decide whether or not they get enough 'bang for their buck' from an intervention for it to be worth their investment, and to consider whether or not they can afford the extra cost to obtain the extra gain. This was the case in several economic evaluations of internet CBT, which was found to be more effective but also more costly than usual care for depression<sup>15</sup> and panic,<sup>95</sup> or than relaxation for OCD,<sup>42</sup> or than WL for depression.<sup>105</sup> In these cases, the decision about whether or not DIs are a cost-effective option depends on how much money we are willing, or able, to invest in them.

On the flipside, when DIs are shown to be less effective and less costly (south-west quadrant), decision-makers have to weigh up the loss in benefits against the need to deliver services within budget in a system that does not have infinite capacity such as the UK's NHS. An example from our economic modelling speaks to the relative value of UDIs for GAD, which ranked marginally lower than unsupported ones in terms of outcomes, yet their NMB was higher for no investment (£0) because of their lower intervention costs. For a health-care system that cannot afford or cannot recruit the human resources to support DIs, our economic model opens up the hypothesis (albeit with uncertainty) that, for no investment, UDIs may have better value than SDIs if the alternative is 'doing nothing'.

Finally, in the scenario in which a DI is less effective but also more costly (north-west quadrant), so the DI is 'dominated' by an alternative, it does not automatically follow that this DI is rejected, because decision-making in health care involves social and moral considerations, alongside economic ones. An example from our review is a web-based CBT self-help programme for health anxiety<sup>52</sup> that was dominated by a paper-based CBT self-help manual; the web-based CBT may still be considered for adoption if it reaches younger populations who are digital natives and may prefer to access help through a web-based programme rather than by using a printed manual.

It is important to recognise that decisions about DIs need to be made in a timely manner because delaying decisions until perfect cost-effectiveness evidence becomes available may result in HRQoL

losses and increased health-care costs. As this report was completed during the COVID-19 pandemic, when mental health and addiction were areas of increasing concern, and digital technologies became the 'default' option for health care and other activities, a major determinant of the use of DIs in the future may be necessity and established practice owing to the pandemic circumstances.

## Conclusion

The NHS investment in digital technologies is growing rapidly.<sup>215</sup> According to the National Information Board's strategy for personalised health and care 2020,<sup>216</sup> use of an online digital health service, rather than visiting a health professional, can improve patient choices, access to services, clinical outcomes and self-care. In the treatment of patients with mental health conditions, this can offer the potential to elevate a system that can face challenges in providing face-to-face appointments across all geographical locations. Digitalisation of mental health care needs to demonstrate value for money as a way of improving access to and outcomes with services. DIs are complex interventions, which require complex methodology to evaluate cost-effectiveness appropriately.<sup>217</sup>

Complexities, although not unique to DIs, do pose a challenge for the evaluation and the eventual usefulness of the evidence generated. It is difficult to conclude on the overall cost-effectiveness of DIs, given the heterogeneity of the populations, interventions, comparators and outcomes used across different studies that evaluate DIs. Moreover, a lack of data limits the extent to which conclusions can be drawn regarding particular conditions, even those as common as GAD. However, if we were to make best use of the available evidence, albeit with the uncertainty and limitations that come with it, we can, at the very least, observe trends in the costs and outcomes of DIs and identify research gaps in the context of stepped care for mental health.

With this in mind, DIs may have a place as first-line treatments instead of 'doing nothing' or doing something without an expected therapeutic benefit (e.g. monitoring or having a general discussion); however, DIs may not confer any clinical or financial value when they are used instead of or in addition to medication or individual therapy. Clinical outcomes rather than intervention costs drive 'value for money' when DIs are compared with alternative care options; to put it simply, it is better to make DIs more effective rather than cheaper than their alternatives. Future research needs to consider two ways of making DIs more effective: improving the technology and/or improving the interpersonal support offered alongside the technology. The value of integrating digital and interpersonal elements, as well as the choice of alternatives with which to compare DIs, depends on where in the stepped-care model we want DIs to fit.

Considerations other than costs and outcomes during decision-making relevant to DIs, such as geographical reach and limited workforce, are beyond the remit of standard economic evaluations. Complexity and heterogeneity are inherent features not only of DIs, but also of the methods used to evaluate them. We need to cut through this complexity and heterogeneity and make the best use of currently available evidence by classifying interventions and controls in a way that fits clinically meaningful research questions, pooling together costs and outcomes across different studies, and presenting the results in a way that speaks to what is important to decision-makers and end users. Ultimately, no individual interventions or evidence syntheses are of any value by themselves, unless they are considered in the context of a health and social care system that would invest in and use interventions (digital or non-digital) to promote and improve mental health.



# Acknowledgements

We thank our NHS colleagues, and in particular Mrs Sarah Daniel, Head of Research at Tees, Esk and Wear Valleys NHS Foundation Trust for organising workshops with stakeholders within the health service. We thank the service user representatives and academic colleagues for their thoughts on this programme of work and our findings. We thank Professor Paul McNamee, Professor Nicola Cooper, Dr Alrinda Cerga-Pashoja and Mr Daniel Horne for their guidance and support as members of our advisory/steering group.

## Contributions of authors

**Lina Gega** (<https://orcid.org/0000-0003-2902-9256>) (Reader in Mental Health and Honorary Nurse Consultant) conceived this programme of work; wrote the protocol; obtained the funding; co-ordinated and supervised all WPs; organised the steering group and incorporated its feedback; drafted the progress reports; and contributed to and checked the literature searches, screening of records, data extractions, analyses and write-up across all WPs. She developed and applied the classification system; produced the figures and tables; led the clinical and lay interpretation, presentation and discussion of the results; conducted and summarised the stakeholder consultation groups; and produced the final report.

**Dina Jankovic** (<https://orcid.org/0000-0002-9311-1409>) (Research Fellow in Health Economics) completed the data extraction, quality assessment and methodological discussion of economic studies for WP1; led the scoping, developing, coding, analysing and write-up for the modelling study for WP3; contributed to the NMA for WP2; contributed to the screening of literature for WPs 1 and 2; and led the paper submissions to peer-reviewed journals for WPs 1 and 3.

**Pedro Saramago** (<https://orcid.org/0000-0001-9063-8590>) (Research Fellow in Health Economics) led the NMA for WP2; contributed to the data extraction, quality assessment and methodological discussion of economic studies for WP1; contributed to the classification system; contributed to the scoping, developing, coding, analysing and write-up for the modelling study for WP3; contributed to the screening of literature for WPs 1 and 2; and led the submission of a paper to a peer-reviewed journal for WP2.

**David Marshall** (<https://orcid.org/0000-0001-5969-9539>) (Research Fellow in Evidence Synthesis) co-ordinated the literature searches for WPs 1–3, screened the retrieved records for WPs 1–3, contributed to the classification system for WPs 1 and 2, carried out the methodological assessment for WP2, conducted the clinical data extraction for WPs 1 and 2, and co-ordinated the referencing of the final report.

**Sarah Dawson** (<https://orcid.org/0000-0002-6682-063X>) (Senior Research Associate in Information Retrieval) conducted the literature searches for WPs 1 and 2 and updated the literature searches as needed. She contributed to the defining and refining of the inclusion/exclusion criteria for WPs 1 and 2.

**Sally Brabyn** (<https://orcid.org/0000-0001-5381-003X>) (Research Fellow in Mental Health) contributed to the data extraction for WP1 and the stakeholder seminars for WP4.

**Georgios F Nikolaidis** (<https://orcid.org/0000-0001-9008-6896>) (Research Fellow in Health Economics) conducted part of the NMA for WP2 and contributed to the write-up of the results for WP2.



## ACKNOWLEDGEMENTS

**Hollie Melton** (<https://orcid.org/0000-0003-3837-510X>) (Research Fellow in Evidence Synthesis) contributed to the screening of records for WPs 1 and 2, and to the data extraction and quality assessment of the clinical studies for WP2.

**Rachel Churchill** (<https://orcid.org/0000-0002-1751-0512>) (Chair in Evidence Synthesis) supervised the work of colleagues from the Centre for Reviews and Dissemination and from the Cochrane Common Mental Disorders Group. She is leading the planned webinar as part of WP4.

**Laura Bojke** (<https://orcid.org/0000-0001-7921-9109>) (Reader in Health Economics) supervised and contributed to the economic review for WP1; the NMA for WP2; the scoping, developing, coding, analysing and write-up of the modelling study for WP3; and the write-up of recommendations and conclusions.

## Publication

Jankovic D, Bojke L, Marshall D, Saramago Goncalves P, Churchill R, Melton H, *et al.* Systematic review and critique of methods for economic evaluation of digital mental health interventions. *Appl Health Econ Health Pol* 2021;**19**:17–27.

Saramago P, Gega L, Marshall D, Nikolaidis GF, Jankovic D, Melton H, *et al.* Digital interventions for generalised anxiety disorder (GAD): systematic review and network meta-analysis. *Front Psychiatry* 2021;**12**:726222.

Jankovic D, Saramago PG, Gega L, Marshall D, Wright K, Hafidh M, *et al.* Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis [published online ahead of print 27 December 2021]. *PharmacoEconomics Open* 2021.

## Data-sharing statement

Our data were from published literature. We will make extracted data available to the scientific community with as few restrictions as feasible, while retaining exclusive use until the publication of major outputs. Stakeholder consultation notes may not be suitable for sharing but these can be discussed with the corresponding author.

## References

1. World Health Organization. *International Classification of Diseases, Eleventh Revision (ICD-11)*. Geneva: World Health Organization; 2018.
2. National Institute for Health and Care Excellence (NICE). *Generalised Anxiety Disorder and Panic Disorder in Adults: Management*. Clinical Guideline 113. London: NICE; 2011.
3. Gega L, Gilbody S. Software-based Psychotherapy: The Example of Computerized Cognitive-Behavioral Therapy. In Aboujaoude E, Starcevic V, editors. *Mental Health in the Digital Age: Grave Dangers, Great Promise*. Oxford: Oxford University Press; 2015. pp. 196–219. <https://doi.org/10.1093/med/9780199380183.003.0011>
4. Christensen H, Batterham P, Mackinnon A, Griffiths KM, Kalia Hehir K, Kenardy J, *et al*. Prevention of generalized anxiety disorder using a web intervention, iChill: randomized controlled trial. *J Med Internet Res* 2014;**16**:e199. <https://doi.org/10.2196/jmir.3507>
5. Pham Q, Khatib Y, Stansfeld S, Fox S, Green T. Feasibility and efficacy of an mHealth game for managing anxiety: 'Flowy' randomized controlled pilot trial and design evaluation. *Games Health J* 2016;**5**:50–67. <https://doi.org/10.1089/g4h.2015.0033>
6. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? *Health Econ* 2001;**10**:179–84. <https://doi.org/10.1002/hec.584>
7. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal*. London: NICE; 2008.
8. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. *PharmacoEconomics* 1996;**9**:113–20. <https://doi.org/10.2165/00019053-199609020-00003>
9. Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English National Health Service from 2003 to 2012. *Value Health* 2019;**22**:995–1002. <https://doi.org/10.1016/j.jval.2019.04.1926>
10. Grosse SD. Assessing cost-effectiveness in healthcare: history of the \$50,000 per QALY threshold. *Expert Rev Pharmacoecon Outcomes Res* 2008;**8**:165–78. <https://doi.org/10.1586/14737167.8.2.165>
11. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal*. London: NICE; 2013.
12. Aboujaoude E, Gega L. From digital mental health interventions to digital 'addiction': where the two fields converge. *Front Psychiatry* 2019;**10**:1017. <https://doi.org/10.3389/fpsy.2019.01017>
13. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. *J Health Econ* 1999;**18**:341–64. [https://doi.org/10.1016/S0167-6296\(98\)00039-3](https://doi.org/10.1016/S0167-6296(98)00039-3)
14. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverly C, *et al*. Computerized cognitive behavior therapy for depression and anxiety update: a systematic review and economic evaluation. *Health Technol Assess* 2006;**10**(33). <https://doi.org/10.3310/hta10330>
15. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, *et al*. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. *Br J Psychiatry* 2004;**185**:55–62. <https://doi.org/10.1192/bjp.185.1.55>

16. Arnberg FK, Linton SJ, Hultcrantz M, Heintz E, Jonsson U. Internet-delivered psychological treatments for mood and anxiety disorders: a systematic review of their efficacy, safety, and cost-effectiveness. *PLOS ONE* 2014;**9**:e98118. <https://doi.org/10.1371/journal.pone.0098118>
17. Donker T, Blankers M, Hedman E, Ljótsson B, Petrie K, Christensen H. Economic evaluations of internet interventions for mental health: a systematic review. *Psychol Med* 2015;**45**:3357–76. <https://doi.org/10.1017/S0033291715001427>
18. Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the internet: a systematic review of applications, clinical efficacy and cost-effectiveness. *Expert Rev Pharmacoecon Outcomes Res* 2012;**12**:745–64. <https://doi.org/10.1586/erp.12.67>
19. Ahern E, Kinsella S, Semkovska M. Clinical efficacy and economic evaluation of online cognitive behavioral therapy for major depressive disorder: a systematic review and meta-analysis. *Expert Rev Pharmacoecon Outcomes Res* 2018;**18**:25–41. <https://doi.org/10.1080/14737167.2018.1407245>
20. Massoudi B, Holvast F, Bockting CLH, Burger H, Blanker MH. The effectiveness and cost-effectiveness of e-health interventions for depression and anxiety in primary care: a systematic review and meta-analysis. *J Affect Disord* 2019;**245**:728–43. <https://doi.org/10.1016/j.jad.2018.11.050>
21. Naidu VV, Giblin E, Burke KM, Madan I. Delivery of cognitive behavioural therapy to workers: a systematic review. *Occup Med* 2016;**66**:112–17. <https://doi.org/10.1093/occmed/kqv141>
22. Kolovos S, van Dongen JM, Riper H, Buntrock C, Cuijpers P, Ebert DD, *et al.* Cost effectiveness of guided internet-based interventions for depression in comparison with control conditions: an individual-participant data meta-analysis. *Depress Anxiety* 2018;**35**:209–19. <https://doi.org/10.1002/da.22714>
23. Paganini S, Teigelkötter W, Buntrock C, Baumeister H. Economic evaluations of internet- and mobile-based interventions for the treatment and prevention of depression: a systematic review. *J Affect Disord* 2018;**225**:733–55. <https://doi.org/10.1016/j.jad.2017.07.018>
24. Chen YF, Madan J, Welton N, Yahaya I, Aveyard P, Bauld L, *et al.* Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis. *Health Technol Assess* 2012;**16**(38). <https://doi.org/10.3310/hta16380>
25. Badawy SM, Kuhns LM. Texting and mobile phone app interventions for improving adherence to preventive behavior in adolescents: a systematic review. *JMIR Mhealth Uhealth* 2017;**5**:e50. <https://doi.org/10.2196/mhealth.6837>
26. de la Torre-Díez I, López-Coronado M, Vaca C, Aguado JS, de Castro C. Cost-utility and cost-effectiveness studies of telemedicine, electronic, and mobile health systems in the literature: a systematic review. *Telemed J E Health* 2015;**21**:81–5. <https://doi.org/10.1089/tmj.2014.0053>
27. McNamee P, Murray E, Kelly MP, Bojke L, Chilcott J, Fischer A, *et al.* Designing and undertaking a health economics study of digital health interventions. *Am J Prev Med* 2016;**51**:852–60. <https://doi.org/10.1016/j.amepre.2016.05.007>
28. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;**151**:264–9, W64. <https://doi.org/10.7326/0003-4819-151-4-200908180-00135>
29. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;**4**:1. <https://doi.org/10.1186/2046-4053-4-1>

30. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, *et al.* Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *Int J Technol Assess Health Care* 2013;**29**:117–22. <https://doi.org/10.1017/S0266462313000160>
31. Barak A, Hen L, Boniel-Nissim M, Shapira N. A comprehensive review and a meta-analysis of the effectiveness of internet-based psychotherapeutic interventions. *J Technol Hum Serv* 2008;**26**:109–60. <https://doi.org/10.1080/15228830802094429>
32. Cuijpers P, van Straten A, Andersson G. Internet-administered cognitive behavior therapy for health problems: a systematic review. *J Behav Med* 2008;**31**:169–77. <https://doi.org/10.1007/s10865-007-9144-1>
33. Hollis C, Falconer CJ, Martin JL, Whittington C, Stockton S, Glazebrook C, Davies EB. Annual research review: digital health interventions for children and young people with mental health problems – a systematic and meta-review. *J Child Psychol Psychiatry* 2017;**58**:474–503. <https://doi.org/10.1111/jcpp.12663>
34. Marks I, Cavanagh K, Gega L. *Hands-on Help: Computer-aided Psychotherapy*. London: Psychology Press; 2007. <https://doi.org/10.4324/9780203962152>
35. Mayo-Wilson E, Montgomery P. Media-delivered cognitive behavioural therapy and behavioural therapy (self-help) for anxiety disorders in adults. *Cochrane Database Syst Rev* 2013;**9**:CD005330. <https://doi.org/10.1002/14651858.CD005330.pub4>
36. Schulz R, Czaja SJ, McKay JR, Ory MG, Belle SH. Intervention taxonomy (ITAX): describing essential features of interventions. *Am J Health Behav* 2010;**34**:811–21. <https://doi.org/10.5993/AJHB.34.6.15>
37. Johansson R, Björklund M, Hornborg C, Karlsson S, Hesser H, Ljótsson B, *et al.* Affect-focused psychodynamic psychotherapy for depression and anxiety through the internet: a randomized controlled trial. *Peer J* 2013;**1**:e102. <https://doi.org/10.7717/peerj.102>
38. Teng MH, Hou YM, Chang SH, Cheng HJ. Home-delivered attention bias modification training via smartphone to improve attention control in sub-clinical generalized anxiety disorder: a randomized, controlled multi-session experiment. *J Affect Disord* 2019;**246**:444–51. <https://doi.org/10.1016/j.jad.2018.12.118>
39. Lovell K, Bower P, Gellatly J, Byford S, Bee P, McMillan D, *et al.* Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET). *Health Technol Assess* 2017;**21**(37). <https://doi.org/10.3310/hta21370>
40. Andersson E, Hedman E, Wadström O, Boberg J, Andersson EY, Axelsson E, *et al.* Internet-based extinction therapy for worry: a randomized controlled trial. *Behav Ther* 2017;**48**:391–402. <https://doi.org/10.1016/j.beth.2016.07.003>
41. Dahlin M, Andersson G, Magnusson K, Johansson T, Sjögren J, Håkansson A, *et al.* Internet-delivered acceptance-based behaviour therapy for generalized anxiety disorder: a randomized controlled trial. *Behav Res Ther* 2016;**77**:86–95. <https://doi.org/10.1016/j.brat.2015.12.007>
42. McCrone P, Marks IM, Greist JH, Baer L, Kobak KA, Wenzel KW, Hirsch MJ. Cost-effectiveness of computer-aided behaviour therapy for obsessive-compulsive disorder. *Psychother Psychosom* 2007;**76**:249–50. <https://doi.org/10.1159/000101504>
43. Andersson E, Hedman E, Ljotsson B, Wikstrom M, Elveling E, Lindefors N, *et al.* Cost-effectiveness of internet-based cognitive behavior therapy for obsessive-compulsive disorder: results from a randomized controlled trial. *J Obsessive Compuls Relat Disord* 2015;**4**:47–53. <https://doi.org/10.1016/j.jocrd.2014.12.004>

44. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial based economic evaluation for health care decision making? *Health Econ* 2006;**15**:677–87. <https://doi.org/10.1002/hec.1093>
45. Jankovic D, Bojke L, Marshall D, Saramago Goncalves P, Churchill R, Melton H, et al. Systematic review and critique of methods for economic evaluation of digital mental health interventions. *Appl Health Econ Health Policy* 2020;1–11. <https://doi.org/10.1007/s40258-020-00607-3>
46. Hodgins DC, Peden N. [Cognitive-behavioral treatment for impulse control disorders.] *Braz J Psychiatry* 2008;**30**(Suppl. 1):31–40.
47. Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. *Value Health* 2019;**22**:377–82. <https://doi.org/10.1016/j.jval.2018.10.006>
48. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. Oxford: Oxford University Press; 2015.
49. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. *Pharmacoeconomics* 2006;**24**:355–71. <https://doi.org/10.2165/00019053-200624040-00006>
50. Aardoom JJ, Dingemans AE, van Ginkel JR, Spinhoven P, Van Furth EF, Van den Akker-van Marle ME. Cost-utility of an internet-based intervention with or without therapist support in comparison with a waiting list for individuals with eating disorder symptoms: a randomized controlled trial. *Int J Eat Disord* 2016;**49**:1068–76. <https://doi.org/10.1002/eat.22587>
51. Andersson E, Ljotsson B, Hedman E, Mattson S, Enander J, Andersson G, et al. Cost-effectiveness of an internet-based booster program for patients with obsessive-compulsive disorder: results from a randomized controlled trial. *J Obsessive-Compuls Relat Disord* 2015;**4**:14–19. <https://doi.org/10.1016/j.jocrd.2014.10.002>
52. Axelsson E, Andersson E, Ljótsson B, Hedman-Lagerlöf E. Cost-effectiveness and long-term follow-up of three forms of minimal-contact cognitive behaviour therapy for severe health anxiety: results from a randomised controlled trial. *Behav Res Ther* 2018;**107**:95–105. <https://doi.org/10.1016/j.brat.2018.06.002>
53. Bergman Nordgren L, Hedman E, Etienne J, Bodin J, Kadowaki A, Eriksson S, et al. Effectiveness and cost-effectiveness of individually tailored internet-delivered cognitive behavior therapy for anxiety disorders in a primary care population: a randomized controlled trial. *Behav Res Ther* 2014;**59**:1–11. <https://doi.org/10.1016/j.brat.2014.05.007>
54. Bergström J, Andersson G, Ljótsson B, Rück C, Andréewitch S, Karlsson A, et al. Internet-versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. *BMC Psychiatry* 2010;**10**:54. <https://doi.org/10.1186/1471-244X-10-54>
55. Bolier L, Majo C, Smit F, Westerhof GJ, Haverman M, Walburg JA, et al. Cost-effectiveness of online positive psychology: randomized controlled trial. *The J Posit Psychol* 2014;**9**:460–71. <https://doi.org/10.1080/17439760.2014.910829>
56. Brabyn S, Araya R, Barkham M, Bower P, Cooper C, Duarte A, et al. The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. *Health Technol Assess* 2016;**20**(89). <https://doi.org/10.3310/hta20890>
57. Budney AJ, Stanger C, Tilford JM, Scherer EB, Brown PC, Li Z, et al. Computer-assisted behavioral therapy and contingency management for cannabis use disorder. *Psychol Addict Behav* 2015;**29**:501–11. <https://doi.org/10.1037/adb0000078>

58. Buntrock C, Berking M, Smit F, Lehr D, Nobis S, Ri per H, *et al.* Preventing depression in adults with subthreshold depression: health-economic evaluation alongside a pragmatic randomized controlled trial of a web-based intervention. *J Med Internet Res* 2017;**19**:e5. <https://doi.org/10.2196/jmir.6587>
59. Burford O, Jiwa M, Carter O, Parsons R, Hendrie D. Internet-based photoaging within Australian pharmacies to promote smoking cessation: randomized controlled trial. *J Med Internet Res* 2013;**15**:e64. <https://doi.org/10.2196/jmir.2337>
60. Calhoun PS, Datta S, Olsen M, Smith VA, Moore SD, Hair LP, *et al.* Comparative effectiveness of an internet-based smoking cessation intervention versus clinic-based specialty care for veterans. *J Subst Abuse Treat* 2016;**69**:19–27. <https://doi.org/10.1016/j.jsat.2016.06.004>
61. Dear BF, Zou JB, Ali S, Lorian CN, Johnston L, Sheehan J, *et al.* Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of anxiety: a randomized controlled trial. *Behav Ther* 2015;**46**:206–17. <https://doi.org/10.1016/j.beth.2014.09.007>
62. Ebert DD, Kählke F, Buntrock C, Berking M, Smit F, Heber E, *et al.* A health economic outcome evaluation of an internet-based mobile-supported stress management intervention for employees. *Scand J Work Environ Health* 2018;**44**:171–82. <https://doi.org/10.5271/sjweh.3691>
63. Garrido G, Penadés R, Barrios M, Aragay N, Ramos I, Vallès V, *et al.* Computer-assisted cognitive remediation therapy in schizophrenia: durability of the effects and cost–utility analysis. *Psychiatry Res* 2017;**254**:198–204. <https://doi.org/10.1016/j.psychres.2017.04.065>
64. Geraedts AS, van Dongen JM, Kleiboer AM, Wiezer NM, van Mechelen W, Cuijpers P, Bosmans JE. Economic evaluation of a web-based guided self-help intervention for employees with depressive symptoms: results of a randomized controlled trial. *J Occup Environ Med* 2015;**57**:666–75. <https://doi.org/10.1097/JOM.0000000000000423>
65. Gerhards SA, de Graaf LE, Jacobs LE, Severens JL, Huibers MJ, Arntz A, *et al.* Economic evaluation of online computerised cognitive–behavioural therapy without support for depression in primary care: randomised trial. *Br J Psychiatry* 2010;**196**:310–18. <https://doi.org/10.1192/bjp.bp.109.065748>
66. Graham AL, Chang Y, Fang Y, Cobb NK, Tinkelman DS, Niaura RS, *et al.* Cost-effectiveness of internet and telephone treatment for smoking cessation: an economic evaluation of the iQUITT Study. *Tob Control* 2013;**22**:e11. <https://doi.org/10.1136/tobaccocontrol-2012-050465>
67. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. *Eur J Health Econ* 2013;**14**:789–97. <https://doi.org/10.1007/s10198-012-0424-5>
68. Hedman E, Andersson E, Lindefors N, Andersson G, Rück C, Ljótsson B. Cost-effectiveness and long-term effectiveness of internet-based cognitive behaviour therapy for severe health anxiety. *Psychol Med* 2013;**43**:363–74. <https://doi.org/10.1017/S0033291712001079>
69. Hedman E, Andersson E, Ljótsson B, Andersson G, Rück C, Lindefors N. Cost-effectiveness of internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. *Behav Res Ther* 2011;**49**:729–36. <https://doi.org/10.1016/j.brat.2011.07.009>
70. Hedman E, Andersson E, Ljótsson B, Axelsson E, Lekander M. Cost effectiveness of internet-based cognitive behaviour therapy and behavioural stress management for severe health anxiety. *BMJ Open* 2016;**6**:e009327. <https://doi.org/10.1136/bmjopen-2015-009327>

71. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D. Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. *Br J Psychiatry* 2010;**197**:297–304. <https://doi.org/10.1192/bjp.bp.109.073080>
72. Holst A, Björkelund C, Metsini A, Madsen JH, Hange D, Petersson EL, *et al.* Cost-effectiveness analysis of internet-mediated cognitive behavioural therapy for depression in the primary care setting: results based on a controlled trial. *BMJ Open* 2018;**8**:e019716. <https://doi.org/10.1136/bmjopen-2017-019716>
73. Hunter R, Wallace P, Struzzo P, Vedova RD, Scafuri F, Tersar C, *et al.* Randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website: cost-effectiveness analysis. *BMJ Open* 2017;**7**:e014577. <https://doi.org/10.1136/bmjopen-2016-014577>
74. Joesch JM, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne P. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. *Psychol Med* 2012;**42**:1937–48. <https://doi.org/10.1017/S0033291711002893>
75. Jolstedt M, Wahlund T, Lenhard F, Ljótsson B, Mataix-Cols D, Nord M, *et al.* Efficacy and cost-effectiveness of therapist-guided internet cognitive behavioural therapy for paediatric anxiety disorders: a single-centre, single-blind, randomised controlled trial. *Lancet Child Adolesc Health* 2018;**2**:792–801. [https://doi.org/10.1016/S2352-4642\(18\)30275-X](https://doi.org/10.1016/S2352-4642(18)30275-X)
76. Jones DJ, Forehand R, Cuellar J, Parent J, Honeycutt A, Khavjou O, *et al.* Technology-enhanced program for child disruptive behavior disorders: development and pilot randomized control trial. *J Clin Child Adolesc Psychol* 2014;**43**:88–101. <https://doi.org/10.1080/15374416.2013.822308>
77. Jones RB, Atkinson JM, Coia DA, Paterson L, Morton AR, McKenna K, *et al.* Randomised trial of personalised computer based information for patients with schizophrenia. *BMJ* 2001;**322**:835–40. <https://doi.org/10.1136/bmj.322.7290.835>
78. Kass AE, Balantekin KN, Fitzsimmons-Craft EE, Jacobi C, Wilfley DE, Taylor CB. The economic case for digital interventions for eating disorders among United States college students. *Int J Eat Disord* 2017;**50**:250–8. <https://doi.org/10.1002/eat.22680>
79. Kenter RMF, van de Ven PM, Cuijpers P, Koole G, Niamat S, Gerrits RS, *et al.* Costs and effects of internet cognitive behavioral treatment blended with face-to-face treatment: results from a naturalistic study. *Internet Interventions* 2015;**2**:77–83. <https://doi.org/10.1016/j.invent.2015.01.001>
80. Kiluk BD, Devore KA, Buck MB, Nich C, Frankforter TL, LaPaglia DM, *et al.* Randomized trial of computerized cognitive behavioral therapy for alcohol use disorders: efficacy as a virtual stand-alone and treatment add-on compared with standard outpatient treatment. *Alcohol Clin Exp Res* 2016;**40**:1991–2000. <https://doi.org/10.1111/acer.13162>
81. Koeser L, Dobbin A, Ross S, McCrone P. Economic evaluation of audio based resilience training for depression in primary care. *J Affect Disord* 2013;**149**:307–12. <https://doi.org/10.1016/j.jad.2013.01.044>
82. Kolovos S, Kenter RM, Bosmans JE, Beekman AT, Cuijpers P, Kok RN, van Straten A. Economic evaluation of internet-based problem-solving guided self-help treatment in comparison with enhanced usual care for depressed outpatients waiting for face-to-face treatment: a randomized controlled trial. *J Affect Disord* 2016;**200**:284–92. <https://doi.org/10.1016/j.jad.2016.04.025>
83. König HH, Bleibler F, Friederich HC, Herpertz S, Lam T, Mayr A, *et al.* Economic evaluation of cognitive behavioral therapy and internet-based guided self-help for binge-eating disorder. *Int J Eat Disord* 2018;**51**:155–64. <https://doi.org/10.1002/eat.22822>

84. Kraepelien M, Mattsson S, Hedman-Lagerlöf E, Petersson IF, Forsell Y, Lindefors N, Kaldo V. Cost-effectiveness of internet-based cognitive-behavioural therapy and physical exercise for depression. *BJPsych Open* 2018;**4**:265–73. <https://doi.org/10.1192/bjo.2018.38>
85. Kumar S, Jones Bell M, Juusola JL. Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: a cost-effectiveness analysis. *PLOS ONE* 2018;**13**:e0190554. <https://doi.org/10.1371/journal.pone.0190554>
86. Lee YC, Gao L, Dear BF, Titov N, Mihalopoulos C. The cost-effectiveness of the Online MindSpot Clinic for the treatment of depression and anxiety in Australia. *J Ment Health Policy Econ* 2017;**20**:155–66.
87. Lee YY, Barendregt JJ, Stockings EA, Ferrari AJ, Whiteford HA, Patton GA, Mihalopoulos C. The population cost-effectiveness of delivering universal and indicated school-based interventions to prevent the onset of major depression among youth in Australia. *Epidemiol Psychiatr Sci* 2017;**26**:545–64. <https://doi.org/10.1017/S2045796016000469>
88. Lenhard F, Sregonja R, Andersson E, Feldman I, Rück C, Mataix-Cols D, Serlachius E. Cost-effectiveness of therapist-guided internet-delivered cognitive behaviour therapy for paediatric obsessive-compulsive disorder: results from a randomised controlled trial. *BMJ Open* 2017;**7**:e015246. <https://doi.org/10.1136/bmjopen-2016-015246>
89. Littlewood E, Duarte A, Hewitt C, Knowles S, Palmer S, Walker S, *et al*. A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. *Health Technol Assess* 2015;**19**(101). <https://doi.org/10.3310/hta191010>
90. McCrone P, Marks IM, Mataix-Cols D, Kenwright M, McDonough M. Computer-aided self-exposure therapy for phobia/panic disorder: a pilot economic evaluation. *Cogn Behav Ther* 2009;**38**:91–9. <https://doi.org/10.1080/16506070802561074>
91. Mihalopoulos C, Kiropoulos L, Shih ST, Gunn J, Blashki G, Meadows G. Exploratory economic analyses of two primary care mental health projects: implications for sustainability. *Med J Aust* 2005;**183**:S73–6. <https://doi.org/10.5694/j.1326-5377.2005.tb07184.x>
92. Murphy SM, Campbell AN, Ghitza UE, Kyle TL, Bailey GL, Nunes EV, Polsky D. Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial. *Drug Alcohol Depend* 2016;**161**:119–26. <https://doi.org/10.1016/j.drugalcdep.2016.01.021>
93. Naughton F, Cooper S, Foster K, Emery J, Leonardi-Bee J, Sutton S, *et al*. Large multi-centre pilot randomized controlled trial testing a low-cost, tailored, self-help smoking cessation text message intervention for pregnant smokers (MiQuit). *Addiction* 2017;**112**:1238–49. <https://doi.org/10.1111/add.13802>
94. Naveršnik K, Mrhar A. Cost-effectiveness of a novel e-health depression service. *Telemed J E Health* 2013;**19**:110–16. <https://doi.org/10.1089/tmj.2012.0081>
95. Olmstead TA, Ostrow CD, Carroll KM. Cost-effectiveness of computer-assisted training in cognitive-behavioral therapy as an adjunct to standard care for addiction. *Drug Alcohol Depend* 2010;**110**:200–7. <https://doi.org/10.1016/j.drugalcdep.2010.02.022>
96. Phillips R, Schneider J, Molosankwe I, Leese M, Froushani PS, Grime P, *et al*. Randomized controlled trial of computerized cognitive behavioural therapy for depressive symptoms: effectiveness and costs of a workplace intervention. *Psychol Med* 2014;**44**:741–52. <https://doi.org/10.1017/S0033291713001323>



97. Romero-Sanchiz P, Nogueira-Arjona R, García-Ruiz A, Luciano JV, García Campayo J, Gili M, *et al*. Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: results from a multi-center, three-armed randomized controlled trial conducted in primary care. *PLOS ONE* 2017;**12**:e0172741. <https://doi.org/10.1371/journal.pone.0172741>
98. Smit ES, Evers SM, de Vries H, Hoving C. Cost-effectiveness and cost-utility of internet-based computer tailoring for smoking cessation. *J Med Internet Res* 2013;**15**:e57. <https://doi.org/10.2196/jmir.2059>
99. Solomon D, Proudfoot J, Clarke J, Christensen H. e-CBT (myCompass), antidepressant medication, and face-to-face psychological treatment for depression in Australia: a cost-effectiveness comparison. *J Med Internet Res* 2015;**17**:e255. <https://doi.org/10.2196/jmir.4207>
100. Španiel F, Hrdlička J, Novák T, Kožený J, Höschl C, Mohr P, Motlová LB. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study. *J Psychiatr Pract* 2012;**18**:269–80. <https://doi.org/10.1097/01.pra.0000416017.45591.c1>
101. Stanczyk NE, Smit ES, Schulz DN, de Vries H, Bolman C, Muris JW, Evers SM. An economic evaluation of a video- and text-based computer-tailored intervention for smoking cessation: a cost-effectiveness and cost-utility analysis of a randomized controlled trial. *PLOS ONE* 2014;**9**:e110117. <https://doi.org/10.1371/journal.pone.0110117>
102. Titov N, Andrews G, Johnston L, Schwencke G, Choi I. Shyness programme: longer term benefits, cost-effectiveness, and acceptability. *Aust N Z J Psychiatry* 2009;**43**:36–44. <https://doi.org/10.1080/00048670802534424>
103. Titov N, Dear BF, Ali S, Zou JB, Lorian CN, Johnston L, *et al*. Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of depression: a randomized controlled trial. *Behav Ther* 2015;**46**:193–205. <https://doi.org/10.1016/j.beth.2014.09.008>
104. van Spijker BA, Majo MC, Smit F, van Straten A, Kerkhof AJ. Reducing suicidal ideation: cost-effectiveness analysis of a randomized controlled trial of unguided web-based self-help. *J Med Internet Res* 2012;**14**:e141. <https://doi.org/10.2196/jmir.1966>
105. Warmerdam L, Smit F, van Straten A, Ri per H, Cuijpers P. Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial. *J Med Internet Res* 2010;**12**:e53. <https://doi.org/10.2196/jmir.1436>
106. Wijnen BF, Lokman S, Leone S, Evers SM, Smit F. Complaint-directed mini-interventions for depressive symptoms: a health economic evaluation of unguided web-based self-help interventions based on a randomized controlled trial. *J Med Internet Res* 2018;**20**:e10455. <https://doi.org/10.2196/10455>
107. Wright B, Tindall L, Littlewood E, Allgar V, Abeles P, Trépel D, Ali S. Computerised cognitive-behavioural therapy for depression in adolescents: feasibility results and 4-month outcomes of a UK randomised controlled trial. *BMJ Open* 2017;**7**:e012834. <https://doi.org/10.1136/bmjopen-2016-012834>
108. Wu Q, Parrott S, Godfrey C, Gilbert H, Nazareth I, Leurent B, *et al*. Cost-effectiveness of computer-tailored smoking cessation advice in primary care: a randomized trial (ESCAPE). *Nicotine Tob Res* 2014;**16**:270–8. <https://doi.org/10.1093/ntr/ntt136>
109. Duarte A, Walker S, Littlewood E, Brabyn S, Hewitt C, Gilbody S, Palmer S. Cost-effectiveness of computerized cognitive-behavioural therapy for the treatment of depression in primary care: findings from the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. *Psychol Med* 2017;**47**:1825–35. <https://doi.org/10.1017/S0033291717000289>

110. El Alaoui S, Hedman-Lagerlöf E, Ljótsson B, Lindefors N. Does internet-based cognitive behaviour therapy reduce healthcare costs and resource use in treatment of social anxiety disorder? A cost-minimisation analysis conducted alongside a randomised controlled trial. *BMJ Open* 2017;**7**:e017053. <https://doi.org/10.1136/bmjopen-2017-017053>
111. Hedman E, El Alaoui S, Lindefors N, Andersson E, Rück C, Ghaderi A, *et al.* Clinical effectiveness and cost-effectiveness of internet- vs. group-based cognitive behavior therapy for social anxiety disorder: 4-year follow-up of a randomized trial. *Behav Res Ther* 2014;**59**:20–9. <https://doi.org/10.1016/j.brat.2014.05.010>
112. Kählke F, Buntrock C, Smit F, Berking M, Lehr D, Heber E, *et al.* Economic evaluation of an internet-based stress management intervention alongside a randomized controlled trial. *JMIR Ment Health* 2019;**6**:e10866. <https://doi.org/10.2196/10866>
113. Baumann M, Stargardt T, Frey S. Cost-utility of internet-based cognitive behavioral therapy in unipolar depression: a Markov model simulation. *Appl Health Econ Health Policy* 2020;**18**:567–78. <https://doi.org/10.1007/s40258-019-00551-x>
114. Gräfe V, Berger T, Hautzinger M, Hohagen F, Lutz W, Meyer B, *et al.* Health economic evaluation of a web-based intervention for depression: the EVIDENT-trial, a randomized controlled study. *Health Econ Rev* 2019;**9**:16. <https://doi.org/10.1186/s13561-019-0233-y>
115. Klein NS, Bockting CL, Wijnen B, Kok GD, van Valen E, Ri per H, *et al.* Economic evaluation of an internet-based preventive cognitive therapy with minimal therapist support for recurrent depression: randomized controlled trial. *J Med Internet Res* 2018;**20**:e10437. <https://doi.org/10.2196/10437>
116. Kooistra LC, Wiersma JE, Ruwaard J, Neijenhuis K, Lokkerbol J, van Oppen P, *et al.* Cost and effectiveness of blended versus standard cognitive behavioral therapy for outpatients with depression in routine specialized mental health care: pilot randomized controlled trial. *J Med Internet Res* 2019;**21**:e14261. <https://doi.org/10.2196/14261>
117. Lindsäter E, Axelsson E, Salomonsson S, Santoft F, Ljótsson B, Åkerstedt T, *et al.* Cost-effectiveness of therapist-guided internet-based cognitive behavioral therapy for stress-related disorders: secondary analysis of a randomized controlled trial. *J Med Internet Res* 2019;**21**:e14675. <https://doi.org/10.2196/14675>
118. O'Connor K, Bagnell A, McGrath P, Wozney L, Radomski A, Rosychuk RJ, *et al.* An internet-based cognitive behavioral program for adolescents with anxiety: pilot randomized controlled trial. *JMIR Ment Health* 2020;**7**:e13356. <https://doi.org/10.2196/13356>
119. Osborne D, Meyer D, Moulding R, Kyrios M, Bailey E, Nedeljkovic M. Cost-effectiveness of internet-based cognitive-behavioural therapy for obsessive-compulsive disorder. *Internet Interv* 2019;**18**:100277. <https://doi.org/10.1016/j.invent.2019.100277>
120. Pot-Kolder R, Veling W, Geraets C, Lokkerbol J, Smit F, Jongeneel A, *et al.* Cost-effectiveness of virtual reality cognitive behavioral therapy for psychosis: health-economic evaluation within a randomized controlled trial. *J Med Internet Res* 2020;**22**:e17098. <https://doi.org/10.2196/17098>
121. Powell J, Williams V, Atherton H, Bennett K, Yang Y, Davoudianfar M, *et al.* Effectiveness and cost-effectiveness of a self-guided internet intervention for social anxiety symptoms in a general population sample: randomized controlled trial. *J Med Internet Res* 2020;**22**:e16804. <https://doi.org/10.2196/16804>
122. Richards D, Enrique A, Eilert N, Franklin M, Palacios J, Duffy D, *et al.* A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety. *NPJ Digit Med* 2020;**3**:85. <https://doi.org/10.1038/s41746-020-0293-8>

123. Kolovos S, Van Dongen JM, Ri per H, Van Tulder MW, Bosmans JE. Cost-effectiveness of guided internet-based treatments for depression in comparison with control conditions: an individual-participant data meta-analysis. *Value Health* 2017;**20**:PA714–A715. <https://doi.org/10.1016/j.jval.2017.08.1898>
124. Saramago P, Gega L, Marshall D, Nikolaidis GF, Jankovic D, Melton H, et al. Digital interventions for generalised anxiety disorder (GAD): systematic review and network meta-analysis. *Front Psychiatry* 2021;**12**:726222. <https://doi.org/10.3389/fpsy.2021.726222>
125. McManus S, Bebbington P, Jenkins R, Brugha T. *Mental Health and Wellbeing in England: Adult Psychiatric Morbidity Survey 2014. A Survey Carried Out for NHS Digital by NatCen Social Research and the Department of Health Sciences*. Leicester: University of Leicester; 2016.
126. Revicki DA, Travers K, Wyrwich KW, Svedsäter H, Locklear J, Matterna MS, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. *J Affect Disord* 2012;**140**:103–12. <https://doi.org/10.1016/j.jad.2011.11.014>
127. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. *Cochrane Database Syst Rev* 2007;**1**:CD001848. <https://doi.org/10.1002/14651858.CD001848.pub4>
128. Hayes-Skelton SA, Roemer L, Orsillo SM, Borkovec TD. A contemporary view of applied relaxation for generalized anxiety disorder. *Cogn Behav Ther* 2013;**42**:292–302. <https://doi.org/10.1080/16506073.2013.777106>
129. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. *Lancet* 2019;**393**:768–77. [https://doi.org/10.1016/S0140-6736\(18\)31793-8](https://doi.org/10.1016/S0140-6736(18)31793-8)
130. Aboujaoude E, Gega L, Parish MB, Hilty DM. Editorial: digital interventions in mental health: current status and future directions. *Front Psychiatry* 2020;**11**:111. <https://doi.org/10.3389/fpsy.2020.00111>
131. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. *World Psychiatry* 2014;**13**:56–67. <https://doi.org/10.1002/wps.20089>
132. Richards D, Richardson T, Timulak L, McElvaney J. The efficacy of internet-delivered treatment for generalized anxiety disorder: a systematic review and meta-analysis. *Internet Interv* 2015;**2**:272–82. <https://doi.org/10.1016/j.invent.2015.07.003>
133. Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med* 2002;**21**:2313–24. <https://doi.org/10.1002/sim.1201>
134. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;**23**:3105–24. <https://doi.org/10.1002/sim.1875>
135. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;**331**:897–900. <https://doi.org/10.1136/bmj.331.7521.897>
136. Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? *Value Health* 2011;**14**:371–80. <https://doi.org/10.1016/j.jval.2010.09.001>
137. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;**366**:l4898. <https://doi.org/10.1136/bmj.l4898>

138. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* 2013;**33**:607–17. <https://doi.org/10.1177/0272989X12458724>
139. Dias S, Welton NJ, Sutton AJ, Ades AE. *NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials*. London: National Institute for Health and Care Excellence; 2014.
140. Higgins JPT, Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of Interventions*. 2nd edn. Hoboken, NJ: Wiley-Blackwell; 2020.
141. Riley RD, Kauser I, Bland M, Thijs L, Staessen JA, Wang J, et al. Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. *Stat Med* 2013;**32**:2747–66. <https://doi.org/10.1002/sim.5726>
142. van Breukelen GJ. ANCOVA versus CHANGE from baseline in nonrandomized studies: the difference. *Multivariate Behav Res* 2013;**48**:895–922. <https://doi.org/10.1080/00273171.2013.831743>
143. Winkens B, van Breukelen GJ, Schouten HJ, Berger MP. Randomized clinical trials with a pre- and a post-treatment measurement: repeated measures versus ANCOVA models. *Contemp Clin Trials* 2007;**28**:713–19. <https://doi.org/10.1016/j.cct.2007.04.002>
144. Fu R, Vandermeer BW, Shamliyan TA, O’Neil ME, Yazdi F, Fox SH, et al. Handling Continuous Outcomes in Quantitative Synthesis. In Agency for Healthcare Research and Quality, editor. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
145. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. *BMC Med Res Methodol* 2001;**1**:6. <https://doi.org/10.1186/1471-2288-1-6>
146. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. *BMJ* 2001;**323**:1123–4. <https://doi.org/10.1136/bmj.323.7321.1123>
147. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing Data and Undertaking Meta-analyses. In Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 (Updated September 2008)*. 2008. URL: <https://training.cochrane.org/handbook/current/chapter-09> (accessed 29 July 2021).
148. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Computing* 2000;**10**:325–37. <https://doi.org/10.1023/A:1008929526011>
149. Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. *J Stat Softw* 2005;**12**:1–16. <https://doi.org/10.18637/jss.v012.i03>
150. Brooks S, Gelman A. Some issues in monitoring convergence of iterative simulations. *Dimension Reduct Computat Complex Info* 1998;**30**:30–6.
151. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. *J Comput Graph Stat* 1998;**7**:434–55. <https://doi.org/10.2307/1390675>
152. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. *Stat Sci* 1992;**7**:457–72. <https://doi.org/10.2307/2246093>
153. Spiegelhalter DJ, Best NG, Carlin BR, van der Linde A. Bayesian measures of model complexity and fit. *J R Stat Soc Series B Stat Methodol* 2002;**64**:583–616. <https://doi.org/10.1111/1467-9868.00353>

## REFERENCES

154. Saramago P, Woods B, Weatherly H, Manca A, Sculpher M, Khan K, *et al*. Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. *BMC Med Res Methodol* 2016;**16**:131. <https://doi.org/10.1186/s12874-016-0224-1>
155. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. *Pharmacoeconomics* 2006;**24**:1–19. <https://doi.org/10.2165/00019053-200624010-00001>
156. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. *Med Decis Making* 2013;**33**:641–56. <https://doi.org/10.1177/0272989X12455847>
157. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. *NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials*. London: National Institute for Health and Care Excellence; 2014.
158. Andersson G, Paxling B, Roch-Norlund P, Östman G, Norgren A, Almlöv J, *et al*. Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial. *Psychother Psychosom* 2012;**81**:344–55. <https://doi.org/10.1159/000339371>
159. Christensen H, Mackinnon AJ, Batterham PJ, O’Dea B, Guastella AJ, Griffiths KM, *et al*. The effectiveness of an online e-health application compared to attention placebo or sertraline in the treatment of generalised anxiety disorder. *Internet Interv* 2014;**1**:169–74. <https://doi.org/10.1016/j.invent.2014.08.002>
160. Dear BF, Staples LG, Terides MD, Karin E, Zou J, Johnston L, *et al*. Transdiagnostic versus disorder-specific and clinician-guided versus self-guided internet-delivered treatment for generalized anxiety disorder and comorbid disorders: a randomized controlled trial. *J Anxiety Disord* 2015;**36**:63–77. <https://doi.org/10.1016/j.janxdis.2015.09.003>
161. Hazen RA, Vasey MW, Schmidt NB. Attentional retraining: a randomized clinical trial for pathological worry. *J Psychiatr Res* 2009;**43**:627–33. <https://doi.org/10.1016/j.jpsychires.2008.07.004>
162. Hirsch CR, Krahé C, Whyte J, Loizou S, Bridge L, Norton S, Mathews A. Interpretation training to target repetitive negative thinking in generalized anxiety disorder and depression. *J Consult Clin Psychol* 2018;**86**:1017–30. <https://doi.org/10.1037/ccp0000310>
163. Howell AN, Rheingold AA, Uhde TW, Guille C. Web-based CBT for the prevention of anxiety symptoms among medical and health science graduate students. *Cogn Behav Ther* 2019;**48**:385–405 <https://doi.org/10.1080/16506073.2018.1533575>
164. Jones SL, Hadjistavropoulos HD, Soucy JN. A randomized controlled trial of guided internet-delivered cognitive behaviour therapy for older adults with generalized anxiety. *J Anxiety Disord* 2016;**37**:1–9. <https://doi.org/10.1016/j.janxdis.2015.10.006>
165. Navarro-Haro MV, Modrego-Alarcón M, Hoffman HG, López-Montoyo A, Navarro-Gil M, Montero-Marin J, *et al*. Evaluation of a mindfulness-based intervention with and without Virtual Reality Dialectical Behavior Therapy® mindfulness skills training for the treatment of generalized anxiety disorder in primary care: a pilot study. *Front Psychol* 2019;**10**:55. <https://doi.org/10.3389/fpsyg.2019.00055>
166. Paxling B, Almlöv J, Dahlin M, Carlbring P, Breitholtz E, Eriksson T, Andersson G. Guided internet-delivered cognitive behavior therapy for generalized anxiety disorder: a randomized controlled trial. *Cogn Behav Ther* 2011;**40**:159–73. <https://doi.org/10.1080/16506073.2011.576699>

167. Repetto C, Gaggioli A, Pallavicini F, Cipresso P, Raspelli S, Riva G. Virtual reality and mobile phones in the treatment of generalized anxiety disorders: a phase-2 clinical trial. *Pers Ubiquitous Comput* 2013;**17**:253–60. <https://doi.org/10.1007/s00779-011-0467-0>
168. Richards D, Timulak L, Rashleigh C, McLoughlin O, Colla A, Joyce C, *et al.* Effectiveness of an internet-delivered intervention for generalized anxiety disorder in routine care: a randomised controlled trial in a student population. *Internet Interv* 2016;**6**:80–8. <https://doi.org/10.1016/j.invent.2016.10.003>
169. Robinson E, Titov N, Andrews G, McIntyre K, Schwencke G, Solley K. Internet treatment for generalized anxiety disorder: a randomized controlled trial comparing clinician vs. technician assistance. *PLOS ONE* 2010;**5**:e10942. <https://doi.org/10.1371/journal.pone.0010942>
170. Titov N, Andrews G, Johnston L, Robinson E, Spence J. Transdiagnostic internet treatment for anxiety disorders: a randomized controlled trial. *Behav Res Ther* 2010;**48**:890–9. <https://doi.org/10.1016/j.brat.2010.05.014>
171. Titov N, Andrews G, Robinson E, Schwencke G, Johnston L, Solley K, *et al.* Clinician-assisted internet-based treatment is effective for generalized anxiety disorder: randomized controlled trial. *Aust N Z J Psychiatry* 2009;**43**:905–12. <https://doi.org/10.1080/00048670903179269>
172. Topper M, Emmelkamp PMG, Watkins E, Ehring T. Prevention of anxiety disorders and depression by targeting excessive worry and rumination in adolescents and young adults: a randomized controlled trial. *Behav Res Ther* 2017;**90**:123–36. <https://doi.org/10.1016/j.brat.2016.12.015>
173. Gorini A, Pallavicini F, Algeri D, Repetto C, Gaggioli A, Riva G. Virtual reality in the treatment of generalized anxiety disorders. *Stud Health Technol Inform* 2010;**154**:39–43.
174. Gorini A, Pallavicini F, Algeri D, Repetto C, Gaggioli A, Riva G. Virtual reality in the treatment of generalized anxiety disorders. *Annu Rev CyberTherapy Telemed* 2010;**8**:31–35.
175. Pallavicini F, Algeri D, Repetto C, Gorini A, Riva G. Biofeedback, virtual reality and mobile phones in the treatment of generalized anxiety disorder (GAD): a phase-2 controlled clinical trial. *J Cyber Ther Rehabil* 2009;**2**:315–27.
176. Lorian CN, Titov N, Grisham JR. Changes in risk-taking over the course of an internet-delivered cognitive behavioral therapy treatment for generalized anxiety disorder. *J Anxiety Disord* 2012;**26**:140–9. <https://doi.org/10.1016/j.janxdis.2011.10.003>
177. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, *et al.* The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;**59**(Suppl. 20):22–33.
178. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;**166**:1092–7. <https://doi.org/10.1001/archinte.166.10.1092>
179. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. *Behav Res Ther* 1990;**28**:487–95. [https://doi.org/10.1016/0005-7967\(90\)90135-6](https://doi.org/10.1016/0005-7967(90)90135-6)
180. Kroenke K, Spitzer RL. The PHQ-9: A new depression diagnostic and severity measure. *Psychiatr Ann* 2002;**32**:509–15. <https://doi.org/10.3928/0048-5713-20020901-06>
181. Beck A, Steer R, Brown G. *Manual for Beck Depression Inventory-II (BDI-II)*. San Antonio, TX: Psychology Corporation; 1996. <https://doi.org/10.1037/t00742-000>

## REFERENCES

182. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. *J Affect Disord* 1988;**14**:61–8. [https://doi.org/10.1016/0165-0327\(88\)90072-9](https://doi.org/10.1016/0165-0327(88)90072-9)
183. Barlow DH. *Anxiety and its Disorders: The Nature and Treatment of Anxiety and Panic*. 2nd edn. New York, NY: Guilford Press; 2002.
184. Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, *et al*. Adjusting survival time estimates to account for treatment switching in randomized controlled trials – an economic evaluation context: methods, limitations, and recommendations. *Med Decis Making* 2014;**34**:387–402. <https://doi.org/10.1177/0272989X13520192>
185. Cuijpers P, Donker T, van Straten A, Li J, Andersson G. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. *Psychol Med* 2010;**40**:1943–57. <https://doi.org/10.1017/S0033291710000772>
186. Spek V, Cuijpers P, Nyklíček I, Riper H, Keyzer J, Pop V. Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: a meta-analysis. *Psychol Med* 2007;**37**:319–28. <https://doi.org/10.1017/S0033291706008944>
187. Shim M, Mahaffey B, Bleidistel M, Gonzalez A. A scoping review of human-support factors in the context of internet-based psychological interventions (IPIs) for depression and anxiety disorders. *Clin Psychol Rev* 2017;**57**:129–40. <https://doi.org/10.1016/j.cpr.2017.09.003>
188. Dear BF, Titov N, Sunderland M, McMillan D, Anderson T, Lorian C, Robinson E. Psychometric comparison of the Generalized Anxiety Disorder scale-7 and the Penn State Worry Questionnaire for measuring response during treatment of generalised anxiety disorder. *Cogn Behav Ther* 2011;**40**:216–27. <https://doi.org/10.1080/16506073.2011.582138>
189. Jankovic D, Saramago PG, Gega L, Marshall D, Wright K, Hafidh M, *et al*. Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis [published online ahead of print 27 December 2021]. *PharmacoEconomics Open* 2021. <https://doi.org/10.1007/s41669-021-00318-y>
190. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. *Br J Psychiatry* 1996;**168**:308–13. <https://doi.org/10.1192/bjp.168.3.308>
191. Ruiz MA, Zamorano E, García-Campayo J, Pardo A, Freire O, Rejas J. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. *J Affect Disord* 2011;**128**:277–86. <https://doi.org/10.1016/j.jad.2010.07.010>
192. Willan AR, Briggs AH. *Statistical Analysis of Cost-effectiveness Data*. Hoboken, NY: John Wiley & Sons, Inc.; 2006. <https://doi.org/10.1002/0470856289>
193. Kind P, Hardman G, Macran S. *UK Population Norms for EQ-5D (Working Papers 172)*. York: Centre for Health Economics, University of York; 1999.
194. Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. *Eur J Health Econ* 2010;**11**:35–44. <https://doi.org/10.1007/s10198-009-0160-7>
195. Office for National Statistics. *Consumer Price Inflation, UK: May 2015*. 2015. URL: [www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/2015-06-16](http://www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/2015-06-16) (accessed 3 April 2020).

196. Office for National Statistics. *Consumer Price Inflation, UK: May 2019*. 2019. URL: [www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/may2019](http://www.ons.gov.uk/economy/inflationandpriceindices/bulletins/consumerpriceinflation/may2019) (accessed 3 April 2020).
197. Office for National Statistics. *National Life Tables: UK*. 2019. URL: [www.ons.gov.uk/people/populationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables](http://www.ons.gov.uk/people/populationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables) (accessed 3 April 2020).
198. Michal M, Prochaska JH, Keller K, Göbel S, Coldewey M, Ullmann A, *et al*. Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: results from the thrombEVAL study program. *Int J Cardiol* 2015;**187**:614–19. <https://doi.org/10.1016/j.ijcard.2015.03.374>
199. Pharmaceutical Services Negotiating Committee. *Professional Fees (Drug Tariff Part IIIA)*. 2019. URL: <https://psnc.org.uk/dispensing-supply/endorsement/fees-allowances/> (accessed 3 April 2020).
200. OpenPrescribing.net, EDM DataLab, University of Oxford. *OpenPrescribing.net*. 2020. URL: <https://OpenPrescribing.net> (accessed March 2020).
201. NHS Improvement. *National Cost Collection 2018/19*. 2019. URL: <https://improvement.nhs.uk/resources/national-cost-collection/> (accessed 3 April 2020).
202. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. *PharmacoEconomics* 2006;**24**:1055–68. <https://doi.org/10.2165/00019053-200624110-00003>
203. Walters K, Rait G, Griffin M, Buszewicz M, Nazareth I. Recent trends in the incidence of anxiety diagnoses and symptoms in primary care. *PLOS ONE* 2012;**7**:e41670. <https://doi.org/10.1371/journal.pone.0041670>
204. Beesdo K, Pine DS, Lieb R, Wittchen HU. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. *Arch Gen Psychiatry* 2010;**67**:47–57. <https://doi.org/10.1001/archgenpsychiatry.2009.177>
205. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. *Med Decis Making* 2014;**34**:311–26. <https://doi.org/10.1177/0272989X13505910>
206. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, *et al*. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. *Health Technol Assess* 2015;**19**(14). <https://doi.org/10.3310/hta19140>
207. von Winterfeldt D. Bridging the gap between science and decision making. *Proc Natl Acad Sci USA* 2013;**110**:14055–61. <https://doi.org/10.1073/pnas.1213532110>
208. Bruine de Bruin W, Bostrom A. Assessing what to address in science communication. *Proc Natl Acad Sci USA* 2013;**110**:14062–8. <https://doi.org/10.1073/pnas.1212729110>
209. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;**3**:77–101. <https://doi.org/10.1191/1478088706qp063oa>
210. Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M, *et al*. Estimating the cost-effectiveness of implementation: is sufficient evidence available? *Value Health* 2016;**19**:138–44. <https://doi.org/10.1016/j.jval.2015.12.009>
211. Berry K, Salter A, Morris R, James S, Bucci S. Assessing therapeutic alliance in the context of mHealth interventions for mental health problems: development of the Mobile Agnew Relationship Measure (mARM) Questionnaire. *J Med Internet Res* 2018;**20**:e90. <https://doi.org/10.2196/jmir.8252>



## REFERENCES

212. Henson P, Wisniewski H, Hollis C, Keshavan M, Torous J. Digital mental health apps and the therapeutic alliance: initial review. *BJPsych Open* 2019;**5**:e15. <https://doi.org/10.1192/bjo.2018.86>
213. Tremain H, McEnery C, Fletcher K, Murray G. The therapeutic alliance in digital mental health interventions for serious mental illnesses: narrative review. *JMIR Ment Health* 2020;**7**:e17204. <https://doi.org/10.2196/17204>
214. Black WC. The CE plane: a graphic representation of cost-effectiveness. *Med Decis Making* 1990;**10**:212–14. <https://doi.org/10.1177/0272989X9001000308>
215. NHS England. *Five Year Forward View*. 2014. URL: [www.england.nhs.uk/wp-content/uploads/2014/10/5yfv-web.pdf](http://www.england.nhs.uk/wp-content/uploads/2014/10/5yfv-web.pdf) (accessed 31 January 2018).
216. National Information Board. *Personalised Health and Care 2020: Using Data and Technology to Transform Outcomes for Patients and Citizens: A Framework for Action*. London: HM Government; 2014.
217. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;**337**:a1655. <https://doi.org/10.1136/bmj.a1655>
218. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. *Stat Med* 2009;**28**:1861–81. <https://doi.org/10.1002/sim.3594>

# Appendix 1 Methods for statistical analysis and synthesis model

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

## Statistical synthesis model

Using the RE approach, the NMA ANCOVA model used takes the following form:

$$\begin{aligned}
 y_{1,i,k} &\sim N(\theta_{i,k}, \sigma_{1,i,k}^2) \\
 \theta_{i,k} &= \mu_i + \delta_{i,b,k} + \beta_{bk} \times y_{0,i,k} \\
 \delta_{i,b,k} &\sim N(d_{bk}, \tau^2) \\
 d_{bk} &= d_{Ak} - d_{Ab}, d_{AA} = 0 \\
 \beta_{bk} &= \beta_{Ak} - \beta_{Ab}, \beta_{AA} = 0.
 \end{aligned} \tag{2}$$

The set of treatments included in these trials are labelled [A, B, C, . . .], where A is the reference treatment and  $y_{1,i,k}$  and  $\sigma_{1,i,k}^2$  are the study  $i$ - and arm  $k$ -specific post-treatment measurement (the assessment ranging from 3 to 12 weeks) and their associated standard errors.  $\theta_{i,k}$  is the linear predictor that uses the identity link function, with  $\mu_i$  being the study-specific baseline parameters for the reference treatment  $b$  in each study (which is not necessarily the reference treatment of the network, i.e. treatment A) and  $\delta_{i,b,k}$  is the study-specific relative treatment effects between the treatment included in arm  $k$  and the treatment included in the baseline arm  $b$  of study  $i$ .  $\beta_{bk}$  represent the treatment-specific coefficients that adjust for the pre-treatment (i.e. baseline) measurements  $y_{0,i,k}$  under the ANCOVA model.  $\delta_{i,k,l}$  are assumed to follow a RE approach with mean  $d_{bk}$  and a between-study heterogeneity  $\tau_2$  that is assumed to be common across all treatment comparisons to assist identification. For trials that use an active control treatment (i.e.  $b \neq A$ ) the consistency assumption is imposed in the form of a set of functional relationships among basic parameters (e.g.  $d_{Ak}$ ). Note that  $\beta_{AA}$  is assumed to be zero, indicating that patients who did not receive any treatment are expected to neither improve nor worsen during the duration of treatment (i.e. null placebo effect). Finally, we assume that the effect of the baseline measurement is common across all treatments so that  $\beta_{Ak} = \beta$ , implying that, when two active treatments are compared in a trial, the baseline effects are offset. Vague prior distributions were assigned to all parameters [i.e.  $d_{Ak}, \beta \sim N(0, 10^{-6})$  and  $\tau \sim Unif(0, 10)$ ].

Meta-regression is the most commonly employed method to explore the influence of particular study-level covariates on the relative effect. A range of approaches can be used to model comparison-specific treatment-effect interactions.<sup>218</sup> In this analysis, we assumed a common effect interaction (i.e. a single interaction term was assumed to apply to all comparisons with NI), as this was deemed more clinically plausible and also less data demanding. However, this method requires that all studies report data on the covariate(s) in question. For the trials informing the NMA, complete data were obtained for disease severity (as a binary covariate mild to moderate/moderate to severe) but not for the other two potential effect modifiers. Under these circumstances, one option is to exclude studies for which data on the covariate are missing and perform a meta-regression on the subset of studies that provide covariate information; however, this approach may lead to a smaller (with fewer interventions being compared) and 'weaker' network (with less evidence informing it). Alternatively, to preserve all studies

(and treatments), we may assume that the covariate is distributed across studies in accordance with a beta distribution, the hyperparameters of which are assigned non-informative priors and are estimated in the model through the MCMC simulation to impute missing covariate information (multiple imputation procedure assuming ‘missingness’ mechanism of ‘missing at random’). The meta-regression model extends the aforementioned NMA ANCOVA model so that the linear predictor is now:

$$\begin{aligned}\theta_{i,k} &= \mu_i + \delta_{i,bk} + \beta_{bk} \times y_{0i,k} + B_{bk} \times X_i, \\ B_{bk} &= B_{Ak} - B_{Ab}, B_{AA} = 0, \\ X_i &\sim \text{Beta}(a, b).\end{aligned}\tag{3}$$

$B_{Ak}$  are again assumed independent of treatment comparison so that  $B_{Ak} = B$ , which represents the additional effect that is observed not because of the treatment, but because of the interaction of the treatment with the study-level covariate.  $X_i$  represent the study-level covariate values, and are assigned a beta distribution with hyperparameters  $a, b$ , which are estimated in the model and are assigned vague priors  $a, b \sim \text{Unif}(0, 1000)$ . As  $X_i$  are proportions, a beta distribution is perhaps the most reasonable distributional assumption. The effect modification for the reference treatment is also assumed to be zero.

### WinBUGS code for main synthesis model

The WinBUGS modelling code is provided followed by a summary table of all variables included in the data set and R code describing the specification of initial values for two chains.

#### WinBUGS model code

```
model {
  for(i in 1:NS) {
    w[i,1] <- 0
    delta[i,1] <- 0
    mu[i] ~ dnorm(0, 1.0E-6)
    for (k in 1:na[i]) {
      y1[i,k] ~ dnorm(theta[i,k], prec[i,k]) #likelihood function
      theta[i,k] <- mu[i] + delta[i,k]
      var[i,k] <- pow(se1[i,k], 2)
      prec[i,k] <- 1/var[i,k]
      dev[i,k] <- (y1[i,k] - theta[i,k]) * (y1[i,k] - theta[i,k]) * prec[i,k] #residual deviance
    }
    resdev[i] <- sum(dev[i,1:na[i]])
    for (k in 2:na[i]) {
```

```

#consistency model for treatment effects and baseline adjustment

delta[i,k] ~ dnorm(md[i,k],precd[i,k])

md[i,k]<- d[t[i,k]] - d[t[i,1]] + (b_base[t[i,k]] - b_base[t[i,1]]) * y0[i,k] + sw[i,k]

precd[i,k] <- pre * 2 * (k - 1)/k

#correction for multi-arm trials

w[i,k]<- delta[i,k] - d[t[i,k]] + d[t[i,1]]

sw[i,k]<- sum(w[i,1:k-1])/(k - 1)

}

}

#total Residual Deviance

totresdev <- sum(resdev[])

d[1]<-0

for (k in 2:NT) {

#prior on treatment effects and baseline score effects

d[k] ~ dnorm(0,1.0E-6)

b_base[k] <- b_basey

}

#prior on random treatment effect variance

tau ~ dunif(0,10)

tau.sq<- tau * tau

pre<- 1/(tau.sq)

#prior on impact of baseline score on final outcome score

b_basey ~ dnorm(0,1.0E-6)

b_base[1]<-0

# pairwise effects

```

```

for (c in 1:(NT - 1)) {
  for (k in (c + 1):NT) {
    ef[c,k] <- d[k] - d[c]
  }
}

# Treatment A baseline, based on average of the trials including No intervention
for (i in 1:NS) {
  mu1[i] <- mu[i] * equals(t[i,1],1)
}

mn.mu1<- sum(mu1[]) / 6

#Posterior distributions of absolute post-treatment scores
for (k in 1:NT) {
  T[k]<- mn.mu1 + d[k] + b_base[k]*mn.mu1
}

# ranking and prob{treatment k is the best}

for (k in 1:NT) {
  rk[k]<- NT + 1 - rank(T[,k])
  best[k]<- equals(rk[k],7)
}

```

TABLE 19 Description of data sets and variables

Object	Variable	Description
Data set descriptors/constants	na	Number of arms in studies in data set
	NS	Number of trials in data set
	NT	Number of treatments in data set
Data	y1	Data on final outcome mean score (arm level)
	y0	Data on baseline outcome mean score (arm level)
	t	Treatment code
	se1	Data on final outcome standard error of mean score (arm level)

The R code used to generate initial values (only one set shown for didactic purposes) was:

```
list(d = c(NA,0,0,0,0,0,0), mu = c(0,0,0,0,0, 0,0,0,0,0,0,0,0), b_basey = c(0), tau = c(1))
```



## Appendix 2 Outcome measures used in randomised controlled trials of digital interventions for generalised anxiety disorder

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.



TABLE 20 Outcome measures used in at least two RCTs

Study (first author and year)	Outcome measure																			
	GAD-7	PSWQ	PHQ-9	BDI/BDI-II	STAI-T	BAI	STAI-S	MADRS-S	PDSS-SR	GAD-Q-IV	QOLI	K-10	SDS	NEO-FFI-3	RRS	HADS/ HADS-A	MINI	CGI	ASI/ASI-3	CES-D
Andersson 2012 <sup>158</sup>		X		X	X	X	X	X		X	X							X		
Andersson 2017 <sup>40</sup>		X						X								X				
Christensen 2014 <sup>4</sup>	X	X															X		X	X
Christensen 2014 <sup>159</sup>	X																	X		X
Dahlin 2016 <sup>41</sup>	X	X	X			X		X		X	X									
Dear 2015 <sup>160</sup>	X		X						X					X			X			
Hazen 2009 <sup>161</sup>		X		X	X															
Hirsch 2018 <sup>162</sup>	X	X	X												X					
Howell 2018 <sup>163</sup>	X																			
Johansson 2013 <sup>37</sup>	X		X																	
Jones 2016 <sup>164</sup>	X		X																	
Navarro-Haro 2019 <sup>165</sup>	X															X				
Paxling 2011 <sup>166</sup>		X		X	X	X	X			X	X									
Pham 2016 <sup>5</sup>	X								X										X	
Repetto 2013 <sup>167</sup>	X	X			X	X	X													
Richards 2016 <sup>168</sup>	X	X		X																
Robinson 2010 <sup>169</sup>	X	X	X									X	X							
Teng 2019 <sup>38</sup>		X		X	X	X	X													
Titov 2009 <sup>171</sup>	X	X	X									X	X							
Titov 2010 <sup>170</sup>		X	X						X			X	X	X						
Topper 2017 <sup>172</sup>		X		X						X					X					
Total number of comparisons	14	14	8	6	5	5	4	4	3	4	3	3	3	2	2	2	2	2	2	2

ASI, Anxiety Sensitivity Index; ASI-3, Anxiety Sensitivity Index-3; CES-D, Center for Epidemiologic Studies Depression Scale; CGI, Clinical Global Improvement Scale; GAD-Q-IV, Generalised Anxiety Disorder Questionnaire-IV; HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale – Anxiety Subscale; K-10, Kessler Psychological Distress Scale; MADRS-S, Montgomery-Åsberg Depression Rating Scale; NEO-FFI-3, NEO Five-Factor Inventory-3; PDSS-SR, Panic Disorder Severity Scale – Self-Report version; QOLI, Quality of Life Inventory; RRS, Ruminative Response Scale; SDS, Sheehan Disability Scale; STAI-S, State-Trait Anxiety Inventory – State; STAI-T, State-Trait Anxiety Inventory – Trait.

TABLE 21 Outcome measures used in only one RCT

Study (first author and year)	Outcome measure																									
	PSWQ-A	SCID-I	CAQ	BBQ	MCQ-30	IOU	Days out of role	Mini-SPIN	GAI	GDS	WHOQOL	ACES	FFMQ	DERS	MAIA	OASIS	Q-LES-Q-SF	HAM-A	WASAS	SPSQ	DASS-21	PTQ	MASQ-D30	EDI-2-BU	QDS	
Andersson 2012 <sup>158</sup>		X																								
Andersson 2017 <sup>40</sup>			X	X	X	X																				
Christensen 2014 <sup>4</sup>							X																			
Christensen 2014 <sup>159</sup>																										
Dahlin 2016 <sup>41</sup>																										
Dear 2015 <sup>160</sup>								X																		
Hazen 2009 <sup>161</sup>																										
Hirsch 2018 <sup>162</sup>																										
Howell 2018 <sup>163</sup>																										
Johansson 2013 <sup>37</sup>																										
Jones 2016 <sup>164</sup>	X								X	X	X	X														
Navarro-Haro 2019 <sup>165</sup>													X	X	X											
Paxling 2011 <sup>166</sup>																										
Pham 2016 <sup>5</sup>																X	X									
Repetto 2013 <sup>167</sup>																		X								
Richards 2016 <sup>168</sup>																			X							
Robinson 2010 <sup>169</sup>																										
Teng 2019 <sup>38</sup>																										
Titov 2009 <sup>171</sup>																										
Titov 2010 <sup>170</sup>																				X	X					
Topper 2017 <sup>172</sup>																						X	X	X	X	
Total number of comparisons	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

ACES, Anxiety Change Expectancy Scale; BBQ, Brunnsvikien Brief Quality of Life Scale; CAQ, Cognitive Avoidance Questionnaire; DASS-21, Depression Anxiety Stress Scales – 21 items; DERS, Difficulties in Emotion Regulation Scale; EDI-2-BU, Eating Disorder Inventory-2 Bulimia; FFMQ, Five Facet Mindfulness Questionnaire; GAI, Geriatric Anxiety Inventory; GDS, Geriatric Depression Scale; IOU, Intolerance of Uncertainty Scale; MAIA, Multidimensional Assessment of Interoceptive Awareness; MASQ-D30, Mood and Anxiety Symptoms Questionnaire – Short Form; MCQ-30, Metacognition Questionnaire-30; Mini-SPIN, Mini-Social Phobia Inventory; OASIS, Overall Anxiety Severity and Impairment Scale; PTQ, Perseverative Thinking Questionnaire; QDS, Quick Drinking Screen; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; SCID-I, Structured Clinical Interview for DSM-IV Axis I Disorders; SPSQ, Satisfaction with Performance Scaled Questionnaire; WASAS, Work and Social Adjustment Scale; WHOQOL, World Health Organization Quality of Life.



## Appendix 3 Results of randomised controlled trials of digital interventions for generalised anxiety disorder synthesised in the network meta-analysis models

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

TABLE 22 Results of RCTs using the GAD-7 as outcome synthesised in the GAD-7 NMA model

Study (first author and year)	Intervention	Number of participants	Baseline GAD score		Post-treatment GAD score	
			$y_0$ , mean	$se_0$ , SE	$y_1$ , mean	$se_1$ , SE
Christensen 2014 <sup>4</sup>	UDC	111	7.00	3.80	6.10	4.10
	SDC	113	6.60	3.70	5.30	4.20
	UDI	111	6.80	3.90	6.10	4.70
	UDI	110	6.80	3.60	4.70	3.60
	SDI	113	6.20	3.90	4.60	2.90
Christensen 2014 <sup>159</sup>	SDC	7	11.70	4.80	12.00	6.50
	SDI	8	11.50	3.70	6.50	2.30
	M	6	14.80	5.20	3.80	2.80
Dahlin 2016 <sup>41</sup>	NI	51	13.51	4.14	10.72	4.20
	SDI	52	13.83	3.66	6.90	3.52
Dear 2015 <sup>160</sup>	UDI	170	12.42	4.34	6.23	4.05
	SDI	168	12.61	4.40	6.09	3.96
<sup>a</sup> Hirsch 2018 <sup>162</sup>	SDC	20	14.55	3.46	11.15	4.33
	SDI	44	14.00	3.18	11.59	4.91
Johansson 2013 <sup>37</sup>	SDC	21	12.67	2.80	8.90	4.70
	SDI	22	12.23	3.80	6.95	5.30
Jones 2016 <sup>164</sup>	NI	21	11.99	4.82	10.16	4.22
	SDI	24	11.78	4.87	6.50	4.55
Navarro-Haro 2019 <sup>165</sup>	SDI	19	14.05	4.61	9.79	5.60
	SNoDI	20	15.33	4.03	9.08	3.85
Pham 2016 <sup>5</sup>	UDC	32	10.66	4.63	9.53	4.79
	UDI	31	11.55	5.05	9.39	5.21
Repetto 2013 <sup>167</sup>	NI	4	14.25	4.57	8.75	6.19
	SDI	4	10.25	5.56	8.25	3.95
	SDI	4	16.00	8.37	6.50	4.51
Richards 2016 <sup>168</sup>	NI	67	13.19	2.78	9.13	4.13
	SDI	70	12.84	2.39	7.73	4.44

continued

TABLE 22 Results of RCTs using the GAD-7 as outcome synthesised in the GAD-7 NMA model (continued)

Study (first author and year)	Intervention	Number of participants	Baseline GAD score		Post-treatment GAD score	
			y <sub>0</sub> , mean	se <sub>0</sub> , SE	y <sub>1</sub> , mean	se <sub>1</sub> , SE
Robinson 2010 <sup>169</sup>	NI	48	12.94	4.07	11.25	4.70
	SDI	50	11.90	3.38	6.02	3.43
	SDI	47	12.45	4.14	5.55	4.73
Titov 2009 <sup>171</sup>	NI	21	13.62	3.51	12.29	4.26
	SDI	24	14.33	4.50	6.92	4.40

M, medication; SE, standard error.

a Hirsch: three-arm trial, but the results were reported in two groups by pooling the intervention groups.

TABLE 23 Results of RCTs using the PSWQ as outcome synthesised in the PSWQ NMA model

Study (first author and year)	Intervention	Number of participants	Baseline PSWQ score		Post-treatment PSWQ score	
			y <sub>0</sub> , mean	se <sub>0</sub> , SE	y <sub>1</sub> , mean	se <sub>1</sub> , SE
Andersson 2012 <sup>158</sup>	NI	27	68.52	6.24	62.88	9.39
	SDI	27	67.89	6.19	60.78	9.83
	SDI	27	69.74	5.56	61.88	7.73
Andersson 2017 <sup>40</sup>	NI	70	66.59	6.84	66.31	7.84
	SDI	70	65.60	6.20	52.92	11.16
Christensen 2014 <sup>4</sup>	UDC	111	40.30	12.00	41.00	12.30
	SDC	113	39.20	10.80	38.40	12.80
	UDI	111	40.50	12.20	39.00	13.20
	UDI	110	37.90	12.50	33.80	11.50
	SDI	113	39.50	11.60	37.40	10.60
Dahlin 2016 <sup>41</sup>	NI	51	67.45	6.77	63.35	8.4
	SDI	52	66.88	7.16	55.29	10.02
Hazen 2009 <sup>161</sup>	SDC	12	67.96	6.05	67.83	8.05
	SDI	12	71.09	4.70	62.82	8.75
<sup>a</sup> Hirsch 2018 <sup>162</sup>	SDC	20	67.10	6.54	65.80	6.84
	SDI	44	69.48	6.22	65.32	9.39
Paxling 2011 <sup>166</sup>	NI	45	69.32	6.55	69.39	7.06
	SDI	44	68.74	5.94	57.82	13.01
Repetto 2013 <sup>167</sup>	NI	4	51.25	9.85	50.00	5.29
	SDI	4	48.50	12.66	47.25	8.73
	SDI	4	41.25	13.24	48.50	12.40
Richards 2016 <sup>168</sup>	NI	67	63.48	6.95	60.33	8.79
	SDI	70	63.04	8.11	58.53	10.97
Robinson 2010 <sup>169</sup>	NI	48	65.81	10.24	64.22	11.81
	SDI	50	63.12	9.46	52.28	10.73
	SDI	47	64.02	9.27	51.45	12.28
Teng 2019 <sup>38</sup>	SDC	31	60.60	10.09	57.03	8.23
	SDI	31	59.80	8.86	53.43	11.01
	SNoDC	31	62.27	8.99	60.18	8.88

TABLE 23 Results of RCTs using the PSWQ as outcome synthesised in the PSWQ NMA model (continued)

Study (first author and year)	Intervention	Number of participants	Baseline PSWQ score		Post-treatment PSWQ score	
			$y_0$ , mean	$se_0$ , SE	$y_1$ , mean	$se_1$ , SE
Titov 2009 <sup>171</sup>	NI	21	66.33	12.70	66.14	8.70
	SDI	24	66.13	8.25	56.75	10.78
Topper 2017 <sup>172</sup>	NI	85	59.15	6.78	57.80	8.54
	SDI	84	58.73	6.96	51.87	8.85
	SNoDI	82	58.20	6.59	51.29	8.58

M, medication; SE, standard error.

a Hirsch: three-arm trial, but the results were reported in two groups by pooling the intervention groups.



## Appendix 4 Surface under the cumulative ranking curve graphs and rankograms

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.




FIGURE 23 Ranking of each intervention based on surface under the cumulative ranking curve values for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication. (continued)






FIGURE 23 Ranking of each intervention based on surface under the cumulative ranking curve values for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication. (continued)




FIGURE 23 Ranking of each intervention based on surface under the cumulative ranking curve values for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication.




FIGURE 24 Generalised Anxiety Disorder-7 rankograms: rankogram of each intervention for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication. (continued)






FIGURE 24 Generalised Anxiety Disorder-7 rankograms: rankogram of each intervention for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication. (continued)




FIGURE 24 Generalised Anxiety Disorder-7 rankograms: rankogram of each intervention for GAD-7: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDI; and (g) medication.




FIGURE 25 Penn State Worry Questionnaire surface under the cumulative ranking curves: ranking of each intervention based on surface under the cumulative ranking curve values for the PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI. (continued)




FIGURE 25 Penn State Worry Questionnaire surface under the cumulative ranking curves: ranking of each intervention based on surface under the cumulative ranking curve values for the PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI. (continued)




FIGURE 25 Penn State Worry Questionnaire surface under the cumulative ranking curves: ranking of each intervention based on surface under the cumulative ranking curve values for the PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI.





FIGURE 26 Penn State Worry Questionnaire rankograms: rankogram of each intervention for PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI. (continued)




FIGURE 26 Penn State Worry Questionnaire rankograms: rankogram of each intervention for PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI. (continued)







FIGURE 26 Penn State Worry Questionnaire rankograms: rankogram of each intervention for PSWQ: (a) NI; (b) UDC; (c) SDC; (d) UDI; (e) SDI; (f) SNoDC; and (g) SNoDI.

## Appendix 5 Assessment of between-study heterogeneity and inconsistencies

Reproduced with permission from Saramago *et al.*<sup>124</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The text below includes minor additions and formatting changes to the original text.

As only one study was performed in a population with milder disease, the NMA ANCOVA RE meta-regression model considering a binary covariate on severity (1, mild/moderate; 0, moderate/severe) did not converge for either of the end points. For comorbidities, the number of studies reporting information on the proportion of individuals within the trial with comorbidities was limited (GAD-7, 2 out of 13; PSWQ, 6 out of 14), impairing the use of multiple imputation. For this reason, we did not explore this variable further. Information on the proportion of individuals with concomitant medication was more prevalent across the evidence base (GAD-7, 9/13; PSWQ, 9/14); thus, data on concomitant medication were included as a covariate in the synthesis modelling.

Network meta-analysis models for GAD-7 and PSWQ, which account for the proportion of patients receiving concomitant medication, fit comparably with those that did not, suggesting that no improvement in model fit was achieved. The effect modification coefficient is of the expected direction [GAD-7:  $\beta_{med} = -1.8$  (95% CrI -28.6 to 24.2); PSWQ:  $\beta_{med} = -7.7$  (95% CrI -81.2 to 64.9)], suggesting that, as the proportion of patients receiving concomitant medication increases, GAD-7 and PSWQ scores are reduced. However, for both outcomes, the covariate effect is not statistically significant and highly uncertain. For both outcomes, when this covariate is included, the between-study heterogeneity parameter,  $\tau^2$ , is not reduced, suggesting that heterogeneity is not explained by this covariate. Crucially, even if the proportion receiving concomitant medication is found to be an important effect modifier, the described meta-regression model is not necessarily suited to detect this intervention-covariate interaction as patients were receiving medication before trial entry. Therefore, medication may have already exerted an effect on patients, being captured by the ANCOVA baseline adjustment component,  $\beta_k$ .

The consistency models produced lower DIC (difference in GAD-7 end point > 3 points) than the inconsistency models and, therefore, the additional model complexity that is due to the consistency assumptions is supported by the data (Table 24). The consistency plots (Figures 27 and 28) show that there are a few deviant data points for which the inconsistency models lead to higher residual deviance than the consistency models, further supporting the latter.

TABLE 24 Results from ANCOVA RE NMA consistency and inconsistency models for GAD-7 and PSWQ

Model	Dres, median (95% CrI)	DIC	$\tau^2$ , median (95% CrI)	B_base, median (95% CrI)
<b>Outcome: GAD-7</b>				
NMA ANCOVA RE: consistency model	21.28 (11.23, 36.39)	194.50	1.85 (0.004, 25.47)	-0.09 (-0.85, 0.68)
NMA ANCOVA RE: inconsistency model	23.11 (12.45, 38.73)	198.17	1.95 (0.004, 29.37)	-0.08 (-1.77, 1.65)
<b>Outcome: PSWQ</b>				
NMA ANCOVA RE: consistency model	21.33 (11.34, 36.33)	253.82	8.03 (0.02, 77.54)	0.01 (-0.45, 0.48)
NMA ANCOVA RE: inconsistency model	21.58 (11.61, 36.51)	254.27	7.06 (0.01, 73.4)	-0.01 (-1.13, 1.13)
B_base, coefficient relating to baseline score adjustment; Dres, mean residual deviance; $\tau^2$ , between-study heterogeneity.				




FIGURE 27 Consistency plot for GAD-7.




FIGURE 28 Consistency plot for PSWQ.

## Appendix 6 Costing the support for digital interventions and controls

Parts of this appendix have been reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The text below includes minor additions and formatting changes to the original text.

The cost of SDIs and SDCs was derived from (1) the cost of time spent by the facilitators of SDI/SDCs, as reported in the studies we included in our meta-analysis of RCTs on DIs for GAD, and (2) the cost of the person who provided the support. In SDCs (*Table 25*), the duration of contact varied between 5 minutes and 2.5 hours, and therapy was delivered by both clinical psychologists and non-clinical staff. In the base case, we assumed that interventions required 20 minutes of clinical psychologists' time, and additional costs were explored in scenario analyses. In SDIs (*Table 26*), the duration of one-on-one contact varied from 33.54 to 130 minutes. The vast majority of studies that reported who delivered the intervention stated that the support was provided by clinical psychologists. Hence, in the base case, the interventions were assumed to last 90 minutes and to be delivered by a clinical psychologist, and additional costs were explored in scenario analyses.

TABLE 25 Support for DCs

Study (first author and year)	Contact time	Type of therapist
Christensen 2014 <sup>4</sup>	5–20 minutes	'Casual telephone interviewers'
Christensen 2014 <sup>159</sup>	Four appointments duration, NR; three appointments duration, NR	Clinical psychologist; GP
Hazen 2009 <sup>161</sup>	5 × 30 minutes	Not reported
Hirsch 2018 <sup>162</sup>	NR	Researchers (unspecified)
Johansson 2013 <sup>37</sup>	10 × 2.3 minutes (SD 0.86 minutes)	Master's-level students in their last semester of a 5-year clinical psychologist programme

NR, not reported; SD, standard deviation.

### Note

Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.

TABLE 26 Support for DIs

Study (first author and year)	Contact time	Type of therapist
Andersson 2012 <sup>158</sup>	113 minutes (SD 41 minutes)	Therapists in their final year of a 5-year clinical psychology programme and licensed psychologist
Andersson 2012 <sup>158</sup>	92 minutes (SD 61 minutes)	Psychologists with experience guiding internet treatment for GAD, and psychology students in their final year
Andersson 2017 <sup>40</sup>	117 minutes (SD 96 minutes)	Clinical psychology students in their final year of the 5-year psychologist programme
Christensen 2014 <sup>4</sup>	5–20 minutes	'Casual interviewers'
Christensen 2014 <sup>159</sup>	Four appointments duration, NR; three appointments duration, NR	Clinical psychologist; GP
Dahlin 2016 <sup>41</sup>	78.78 minutes (range 1–226 minutes)	Clinical psychologist graduate students, supervised by clinical psychologist
Dear 2015 <sup>160</sup>	NR, not significantly different from guided CBT (below)	Qualified psychologist
Dear 2015 <sup>160</sup>	33.54 minutes (SD 18.07 minutes)	Qualified psychologist
Hazen 2009 <sup>161</sup>	2.5 hours (5 × 30 minutes)	NR
Hirsch 2018 <sup>162</sup>	NR	Researchers (unspecified)
Hirsch 2018 <sup>162</sup>	NR	Researchers (unspecified)
Johansson 2013 <sup>37</sup>	95 minutes (10 × 9.5 minutes; SD 4.0 minutes)	Master's-level students in their last semester of a 5-year clinical psychologist programme
Jones 2016 <sup>164</sup>	105–210 minutes intended	Therapist, unspecified qualifications
Navarro-Haro 2019 <sup>165</sup>	9 hours, group; 90 minutes, individual	NR
Paxling 2011 <sup>166</sup>	9 minutes (SD 52 minutes)	Therapist in the final year of psychologist training
Repetto 2013 <sup>167</sup>	NR	NR
Repetto 2013 <sup>167</sup>	NR	NR
Richards 2016 <sup>168</sup>	60–90 minutes	Psychologists with a Master's degree or higher
Robinson 2010 <sup>169</sup>	80.8 minutes (SD 22.6 minutes)	Qualified and registered clinical psychologist
Robinson 2010 <sup>169</sup>	74.5 minutes (SD 7.8 minutes)	Technician employed in an administrative role as a clinic manager
Teng 2019 <sup>38</sup>	2.5 hours (5 × 30 minutes)	NR
Titov 2009 <sup>171</sup>	130 minutes with clinical psychologist; 30 minutes with administrator	Clinical psychologist; administrator
Titov 2010 <sup>170</sup>	46 minutes (SD 16 minutes)	Clinical psychologist
Topper 2017 <sup>172</sup>	3.96 sessions (SD 1.65 minutes)	Clinical psychologist

NR, not reported; SD, standard deviation.

#### Note

Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.

## Appendix 7 Model parameters

Parts of this appendix have been adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The text below includes minor additions and formatting changes to the original text.

Table 27 shows the distribution of patients across health states after treatment. At baseline (i.e. before treatment) the distribution was assumed to be identical to NI for all comparators.

Tables 28 and 29 show the model parameter values, with measures of uncertainty.

TABLE 27 Distribution of patients across health states, after treatment

Health state	Intervention						
	NI	UDC	SDC	UDI	SDI	SNoDI <sup>a</sup>	M <sup>b</sup>
No anxiety	0	0.114	0.073	0.115	0.038	0.290	0.492
Mild anxiety	0.179	0.411	0.451	0.505	0.800	0.422	0.598
Moderate anxiety	0.786	0.380	0.428	0.351	0.162	0.288	0
Severe anxiety	0.035	0.094	0.047	0.029	0	0	0

M, medication.

a SNoDI is group therapy.

b Pharmacotherapy with SSRIs.

### Note

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The table includes minor additions and formatting changes to the original table.

TABLE 28 Model parameters, with measures of uncertainty

Parameter	Mean	Probability distribution	Source
Baseline GAD-7 score	10.68	~N(10.68, 1.83)	Chapter 4
<b>GAD-7 score after treatment</b>			
UDC	8.77	~N(8.77, 3.72)	Chapter 4
SDC	8.76	~N(8.76, 3.14)	
UDI	8.01	~N(8.01, 3.16)	
SDI	7.22	~N(7.22, 1.82)	
SNoDI	6.51	~N(6.51, 3.59)	
Medication	4.08	~N(4.08, 1.89)	

continued

TABLE 28 Model parameters, with measures of uncertainty (continued)

Parameter	Mean	Probability distribution	Source
<b>Intervention cost</b>			
NI, UDC, UDI	£0	–	Assumed
SDC	£18	–	Derived
SDI	£80	–	Derived
SNoDI	£80	–	Derived
Medication (per year)	£351.04 in year 1, £201.94 thereafter	–	Derived
<b>Health-care cost</b>		<b>Gamma (shape, scale)</b>	<b>Kaltenthaler et al.<sup>14</sup></b>
No anxiety	£86	(1.960, 0.016)	
Mild anxiety	£200	(0.848, 0.003)	
Moderate anxiety	£210	(0.295, 0.001)	
Severe anxiety	£324	(0.320, 0.0007)	
Dead	£0	–	
<b>Utilities</b>		<b>Mean (SD) used to derive beta parameters<sup>a</sup></b>	<b>Revicki et al.<sup>126</sup></b>
No anxiety	0.72	0.72 (0.10)	
Mild anxiety	0.64	0.64 (0.10)	
Moderate anxiety	0.60	0.60 (0.10)	
Severe anxiety	0.53	0.60 (0.10)	
Dead	0	–	
Age-related utility decrements	Age specific (see Table 29)		
Mortality – general population	Sex and age specific (see Table 29)		
<b>Excess mortality (RR)</b>		<b>Non-parametric CI<sup>b</sup></b>	<b>Michal et al.<sup>198</sup></b>
Mild anxiety	1.20	0.82 to 1.67	
Moderate anxiety	1.58	1.06 to 2.24	
Severe anxiety	2.17	1.47 to 3.05	

a Uncertainty in utilities was derived by fitting a beta distribution to the reported mean and standard error, using the method of moments.<sup>192</sup>

b Beta distribution applied to the risk of death in each state, then 25,000 random samples used to derive the relative risk.

#### Note

Adapted with permission from Jankovic et al.<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

TABLE 29 Age- and sex-related utility, and mortality decrements<sup>193,197</sup>

Age (years)	Mortality		Utility (SE)
	Male	Female	
0	0.004288	0.003592	–
1	0.000257	0.000228	0.94 (0.002)
2	0.000129	0.000128	0.94 (0.002)
3	0.000118	0.000096	0.94 (0.002)
4	0.000095	0.000071	0.94 (0.002)
5	0.000095	0.000072	0.94 (0.002)
6	0.000067	0.00007	0.94 (0.002)
7	0.000079	0.000063	0.94 (0.002)
8	0.000066	0.000058	0.94 (0.002)
9	0.000072	0.000063	0.94 (0.002)
10	0.000072	0.000061	0.94 (0.002)
11	0.000086	0.000074	0.94 (0.002)
12	0.000099	0.000066	0.94 (0.002)
13	0.000106	0.000074	0.94 (0.002)
14	0.000131	0.000091	0.94 (0.002)
15	0.000176	0.000107	0.94 (0.002)
16	0.000225	0.000146	0.94 (0.002)
17	0.000303	0.00015	0.94 (0.002)
18	0.000391	0.000204	0.94 (0.002)
19	0.000411	0.000187	0.94 (0.002)
20	0.000485	0.00019	0.94 (0.002)
21	0.000489	0.000213	0.94 (0.002)
22	0.000483	0.000204	0.94 (0.002)
23	0.000487	0.000196	0.94 (0.002)
24	0.000515	0.00021	0.94 (0.002)
25	0.00054	0.000252	0.94 (0.002)
26	0.000548	0.000249	0.93 (0.003)
27	0.00056	0.000269	0.93 (0.003)
28	0.000628	0.000315	0.93 (0.003)
29	0.000653	0.000304	0.93 (0.003)
30	0.000692	0.000364	0.93 (0.003)
31	0.00077	0.00037	0.93 (0.003)
32	0.000776	0.000464	0.93 (0.003)
33	0.000857	0.000466	0.93 (0.003)
34	0.000904	0.000521	0.93 (0.003)
35	0.000964	0.000552	0.93 (0.003)

continued



TABLE 29 Age- and sex-related utility, and mortality decrements<sup>193,197</sup> (continued)

Age (years)	Mortality		Utility (SE)
	Male	Female	
36	0.001083	0.000603	0.91 (0.003)
37	0.001145	0.000714	0.91 (0.003)
38	0.001142	0.0007	0.91 (0.003)
39	0.001277	0.000772	0.91 (0.003)
40	0.001413	0.000814	0.91 (0.003)
41	0.001571	0.000929	0.91 (0.003)
42	0.001693	0.001014	0.91 (0.003)
43	0.001951	0.001122	0.91 (0.003)
44	0.002024	0.001274	0.91 (0.003)
45	0.002157	0.001375	0.91 (0.003)
46	0.002296	0.00148	0.85 (0.004)
47	0.002591	0.001651	0.85 (0.004)
48	0.002747	0.001767	0.85 (0.004)
49	0.003004	0.001895	0.85 (0.004)
50	0.003224	0.002047	0.85 (0.004)
51	0.003421	0.002281	0.85 (0.004)
52	0.003744	0.002482	0.85 (0.004)
53	0.003967	0.002657	0.85 (0.004)
54	0.004248	0.002822	0.85 (0.004)
55	0.004732	0.003163	0.85 (0.004)
56	0.00514	0.003484	0.8 (0.004)
57	0.005696	0.00377	0.8 (0.004)
58	0.006252	0.00418	0.8 (0.004)
59	0.006755	0.004536	0.8 (0.004)
60	0.007549	0.004914	0.8 (0.004)
61	0.008237	0.005432	0.8 (0.004)
62	0.009032	0.006128	0.8 (0.004)
63	0.010114	0.006559	0.8 (0.004)
64	0.010879	0.007089	0.8 (0.004)
65	0.011916	0.0077	0.8 (0.004)
66	0.013085	0.008553	0.78 (0.004)
67	0.014063	0.009173	0.78 (0.004)
68	0.015525	0.010067	0.78 (0.004)
69	0.016679	0.010969	0.78 (0.004)
70	0.018153	0.012068	0.78 (0.004)
71	0.020201	0.013331	0.78 (0.004)
72	0.022407	0.015463	0.78 (0.004)

TABLE 29 Age- and sex-related utility, and mortality decrements<sup>193,197</sup> (continued)

Age (years)	Mortality		Utility (SE)
	Male	Female	
73	0.025271	0.016993	0.78 (0.004)
74	0.027758	0.01867	0.78 (0.004)
75	0.031326	0.021376	0.78 (0.004)
76	0.034938	0.024237	0.73 (0.005)
77	0.039053	0.02692	0.73 (0.005)
78	0.042973	0.030324	0.73 (0.005)
79	0.047425	0.033515	0.73 (0.005)
80	0.053347	0.037897	0.73 (0.005)
81	0.059653	0.042929	0.73 (0.005)
82	0.066297	0.048841	0.73 (0.005)
83	0.075312	0.056501	0.73 (0.005)
84	0.085068	0.063635	0.73 (0.005)
85	0.094756	0.072676	0.73 (0.005)
86	0.106853	0.082822	0.73 (0.005)
87	0.119617	0.094077	0.73 (0.005)
88	0.133736	0.106986	0.73 (0.005)
89	0.149832	0.119952	0.73 (0.005)
90	0.162588	0.13548	0.73 (0.005)
91	0.178751	0.151395	0.73 (0.005)
92	0.198581	0.167872	0.73 (0.005)
93	0.218678	0.1851	0.73 (0.005)
94	0.237316	0.204495	0.73 (0.005)
95	0.262646	0.228609	0.73 (0.005)
96	0.285623	0.247393	0.73 (0.005)
97	0.307486	0.268697	0.73 (0.005)
98	0.322356	0.288444	0.73 (0.005)
99	0.363244	0.314599	0.73 (0.005)
100	0.391216	0.336838	0.73 (0.005)
101	-	-	0.73 (0.005)

SE, standard error.

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.



## Appendix 8 Generalised anxiety disorder score trajectory in scenario analysis

Without treatment, patients' GAD symptoms were assumed to improve over time, as reported by Yonkers *et al.*,<sup>190</sup> where 15% of patients recovered in the first year, a further 10% recovered in the second year and a further 5% recovered in the third year. The treatment effect was assumed to remain constant indefinitely (i.e. any change in GAD severity remained over a patient's lifetime). In addition, in the base case, patients on treatment were assumed to improve over time at the same rate as those who had not received treatment. Five additional scenarios regarding the GAD score trajectory are summarised in *Table 30*.

TABLE 30 Generalised anxiety disorder score trajectory in scenario analysis

Period for which treatment effect lasts	GAD score trajectory with treatment over time	GAD score trajectory with 'no treatment' over time	
		Spontaneous recovery: GAD-7 scores decrease	No change: GAD-7 scores are constant
Indefinitely	Constant: GAD-7 scores remain at post-treatment level indefinitely	Scenario 1 (base case)	Scenario 4
For 1 year <sup>a</sup> then disappears	GAD-7 scores remain at post-treatment level for 1 year, then return to 'no treatment' level	Scenario 2	Scenario 5
For 1 year <sup>a</sup> then diminishes gradually for 10 years	GAD-7 scores decline over 10 years until they return to 'no treatment' level	Scenario 3	Scenario 6

a Consistent with assumptions made in Kumar *et al.*<sup>85</sup>

### Note

Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.



## Appendix 9 Health-care costs in scenario analysis

Parts of this appendix have been reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The text below includes minor additions and formatting changes to the original text.

Two alternative scenarios regarding health-care resource use informed state-specific health-care costs using alternative studies: Vera-Llonch *et al.*<sup>194</sup> and Kumar *et al.*<sup>85</sup> The cost of health care (*Table 31*) was derived by multiplying the reported resource use by the unit costs available from the NHS England tariff, year 2018/19.<sup>201</sup>

It is important to note that Vera-Llonch *et al.*<sup>194</sup> evaluated medication for GAD, and so some of the health-care costs shown in *Table 31* are likely to be associated with pharmacotherapy. We could not ascertain which resources were used for the pharmacotherapy from the available data, but we caution that the estimates derived using data from Vera-Llonch *et al.*<sup>194</sup> could overestimate health-care costs in the model.

TABLE 31 State-specific health-care costs used in scenario analyses


Source (first author and year)	Health-care resource use					Unit cost of health services (£)
	Health-care service	No anxiety	Mild anxiety	Moderate anxiety	Severe anxiety	
Kumar 2018 <sup>85</sup>	Primary care visits ( <i>n</i> )	1.2	1.7	2.2	2.4	31 (GP appointment)
	Emergency care visits ( <i>n</i> )	0.014	0.019	0.025	0.027	222
	Inpatient days ( <i>n</i> )	0.014	0.019	0.025	0.027	1603
	Total cost (£) per model cycle	188	262	341	371	–
Vera-Llonch 2010 <sup>194</sup>	Primary care visits ( <i>n</i> )	0.44	1.03	1.26	1.80	31 (GP appointment)
	Specialist visits ( <i>n</i> )					
	Psychiatrist	0.42	0.48	0.48	0.49	109 (1 hour, consultant)
	Psychologist	0.48	0.52	1.03	1.37	53 (1 hour, grade 7)
	Emergency room	0.14	0.26	0.37	0.56	222
	Other	0.33	0.37	0.58	0.52	0
	Blood counts ( <i>n</i> )	0.35	0.38	0.5	0.43	6.75
	Electrocardiography ( <i>n</i> )	0.33	0.35	0.33	0.18	58
	Thyroid function tests ( <i>n</i> )	0.33	0.33	0.36	0.35	1.84
	Inpatient days (mean)	0.12	0.18	0.37	0.49	1603
Total cost per model cycle (£)	911	1444	2531	3316	–	

### Note


Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by/4.0/>. The table includes minor additions and formatting changes to the original table.



## Appendix 10 Cumulative costs and outcomes over time



**FIGURE 29** Mean cumulative QALY gain over time. M, medication. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.



**FIGURE 30** Mean cumulative total cost over time. M, medication. Reproduced with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.





## Appendix 11 Results from scenario analyses


Parts of this appendix have been adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The text below includes minor additions and formatting changes to the original text.

### Alternative assumptions about the generalised anxiety disorder score trajectory with and without treatment


Six scenarios were explored for the GAD-7 score trajectory over time. The movement through the states and the changes in GAD-7 scores in the initial 10-year period are shown in *Figures 31–33*. After 10 years, outcomes were assumed to remain constant in all scenarios.

In *Table 32*, differences in costs and QALY gains were very small. An alternative assumption about the GAD score trajectory without treatment led to a 0.1 reduction in mean QALYs, whereas alternative assumptions about the treatment effect led to a maximum difference of 0.54 QALYs (medication when comparing no spontaneous improvement and a diminishing treatment effect, and spontaneous improvement with indefinite treatment effect).

Differences in QALY gains between different scenarios follow a logical pattern. Without treatment, the QALY gain is slightly higher when spontaneous improvement is expected. The QALY impact of all treatments is lowest when the treatment effect is assumed to disappear after 1 year, and highest when it is assumed to remain constant indefinitely.



**FIGURE 31** Movement through Markov states without treatment in the initial 10-year period, where GAD-7 scores improve over time (scenarios 1–3). Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.



**FIGURE 32** Movement through Markov states without treatment in the initial 10-year period, where GAD-7 scores are constant (scenarios 4–6). Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

In *Table 33*, total costs follow a similar pattern; when patients were assumed to improve spontaneously, the total cost of treatment was slightly higher, probably because of lower mortality. However, differences between mean costs in different scenarios were small, with the maximum difference in mean costs of £557 (medication when comparing no spontaneous improvement and a diminishing treatment effect, and spontaneous improvement with indefinite treatment effect).

Finally, although the mean NMB varied across scenarios (*Table 34*), the ranking of interventions did not.


### Alternative assumptions about the cost of health care

Two alternative costs of health care were considered, obtained from different sources. Comparison of state-specific costs are shown in *Table 35*.

The updated costs and NMB are shown in *Table 36*. The health-care costs did not affect the ranking of interventions and uncertainty (the NMB confidence intervals remain overlapping), only the magnitude of costs and the net benefit. Health-care resource use informed by Vera-Llonch *et al.*<sup>194</sup> led to the highest costs and, consequently, the lowest net benefit.

### Alternative assumptions about the cost of therapy

Two alternative costs of support in SDCs. Comparisons of different assumptions are shown in *Table 37*. The cost difference is very small (smaller than the mean cost difference between SDCs and the next most expensive or next cheapest alternative), and therefore the results were concluded to be insensitive without running additional analyses.



**FIGURE 33** Generalised Anxiety Disorder-7 scores over time, in six scenarios. Mean QALYs, costs and net benefit for each treatment in each scenario are shown in *Tables 32–34*, respectively. Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.

TABLE 32 Mean QALY gains under different model assumptions for GAD score trajectory

Intervention	Treatment effect, mean QALY gain (95% confidence interval)					
	No spontaneous improvement			Spontaneous improvement		
	Constant	Disappears after 1 year	Gradually diminishes	Constant	Disappears after 1 year	Gradually diminishes
NI	10.95 (9.22 to 12.35)			11.05 (9.37 to 12.40)		
UDC	11.46 (8.80 to 14.07)	11.31 (9.24 to 13.54)	11.31 (9.20 to 13.57)	11.54 (8.89 to 14.07)	11.41 (9.31 to 13.70)	11.42 (9.28 to 13.7)
SDC	11.47 (9.09 to 13.96)	11.30 (9.55 to 13.34)	11.31 (9.52 to 13.38)	11.55 (9.19 to 13.96)	11.41 (9.65 to 13.51)	11.42 (9.61 to 13.52)
UDI	11.69 (9.49 to 14.05)	11.46 (9.85 to 13.55)	11.48 (9.83 to 13.58)	11.76 (9.65 to 14.05)	11.57 (9.92 to 13.69)	11.58 (9.92 to 13.72)
SDI	11.85 (10.45 to 13.71)	11.56 (10.48 to 13.01)	11.57 (10.49 to 13.07)	11.92 (10.53 to 13.71)	11.67 (10.56 to 13.14)	11.68 (10.56 to 13.17)
SNoDI	12.17 (10.35 to 14.24)	11.85 (10.34 to 13.82)	11.87 (10.35 to 13.84)	12.23 (10.40 to 14.24)	11.96 (10.40 to 13.98)	11.98 (10.42 to 13.99)
M	12.88 (11.41 to 14.33)	12.38 (10.97 to 13.96)	12.42 (11.03 to 13.97)	12.92 (11.48 to 14.33)	12.50 (11.03 to 14.10)	12.53 (11.10 to 14.12)

M, medication.

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

TABLE 33 Mean total cost (£) under different model assumptions for GAD score trajectory (95% confidence interval)

Intervention	Treatment effect, mean total cost (£) (95% confidence interval)					
	No spontaneous improvement			Spontaneous improvement		
	Constant	Disappears after 1 year	Gradually diminishes	Constant	Disappears after 1 year	Gradually diminishes
NI	16,530 (0 to 99,304)			16,069 (1 to 87,123)		
UDC	16,059 (7 to 86,001)	16,617 (7 to 97,025)	16,590 (8 to 88,143)	14,822 (18 to 75,923)	16,133 (19 to 87,277)	15,992 (20 to 78,709)
SDC	15,891 (23 to 82,488)	16,542 (22 to 93,904)	16,397 (23 to 86,704)	14,623 (31 to 74,315)	16,003 (32 to 84,115)	15,881 (33 to 78,442)
UDI	15,377 (9 to 76,047)	16,349 (9 to 96,453)	16,224 (9 to 86,419)	14,114 (25 to 68,008)	15,769 (22 to 84,580)	15,715 (30 to 77,420)
SDI	16,325 (158 to 69,394)	16,608 (129 to 94,607)	16,519 (157 to 85,324)	14,298 (218 to 63,232)	15,939 (160 to 83,243)	15,675 (228 to 74,955)
SNoDI	13,500 (96 to 66,496)	16,300 (96 to 94,607)	15,995 (99 to 82,263)	12,442 (128 to 59,171)	15,867 (117 to 85,199)	15,429 (131 to 73,077)
M	13,012 (1698 to 53,201)	17,197 (1227 to 93,790)	16,821 (1616 to 75,716)	11,754 (1839 to 47,063)	16,641 (1253 to 82,556)	16,144 (1716 to 69,824)

M, medication.

**Note**  
Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

TABLE 34 Mean NMB (£) under different model assumptions for GAD score trajectory (95% confidence interval)

Intervention	Treatment effect, mean NMB (£) (95% confidence interval)					
	No spontaneous improvement			Spontaneous improvement		
	Constant	Disappears after 1 year	Gradually diminishes	Constant	Disappears after 1 year	Gradually diminishes
NI	147,661 (61,801 to 179,119)			149,671 (74,016 to 180,051)		
UDC	155,905 (72,746 to 205,462)	152,973 (69,172 to 197,625)	153,114 (76,377 to 195,729)	158,335 (81,276 to 205,462)	155,082 (79,412 to 198,816)	155,304 (85,579 to 197,580)
SDC	156,100 (79,038 to 203,339)	152,984 (71,178 to 193,926)	153,243 (77,863 to 192,218)	158,586 (88,232 to 203,339)	155,167 (83,412 to 194,860)	155,361 (86,983 to 194,260)
UDI	159,919 (88,552 to 205,226)	155,598 (72,214 to 198,097)	155,912 (80,999 to 196,581)	162,334 (97,837 to 205,226)	157,821 (84,553 to 198,986)	158,039 (91,794 to 198,295)
SDI	161,446 (104,622 to 197,813)	156,745 (77,084 to 186,877)	157,087 (85,918 to 185,869)	164,551 (111,833 to 197,813)	159,059 (89,223 to 188,411)	159,529 (97,334 to 187,107)
SNoDI	169,043 (102,566 to 208,548)	161,376 (79,787 to 202,462)	162,027 (90,262 to 201,040)	171,033 (110,947 to 208,548)	163,517 (90,086 to 203,790)	164,248 (99,994 to 203,032)
M	180,191 (125,503 to 209,180)	168,526 (86,875 to 203,686)	169,506 (104,381 to 202,389)	181,975 (131,817 to 209,180)	170,837 (100,380 to 204,893)	171,866 (112,948 to 204,345)

M, medication.

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

TABLE 35 State-specific costs obtained from different sources

Study (first author and year)	State-specific costs (£)			
	No anxiety	Mild anxiety	Moderate anxiety	Severe anxiety
Kaltenthaler 2006 <sup>14</sup> (base case)	86	200	210	324
Kumar 2018 <sup>85</sup>	188	262	341	371
Vera-Llonch 2010 <sup>194</sup>	911	1444	2531	3316

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

TABLE 36 Cost and NMB when using alternative health-care cost data

Intervention	Study (first author and year)					
	Kaltenthaler 2006 <sup>14</sup> (base case)		Kumar 2018 <sup>85</sup>		Vera-Llonch 2010 <sup>194</sup>	
	Total cost (£)	NMB (£)	Total cost (£)	NMB (£)	Total cost (£)	NMB (£)
NI	16,816 (0 to 99,741)	149,671 (74,016 to 180,051)	24,350 (15,907 to 31,631)	141,346 (113,133 to 168,088)	165,947 (84,946 to 237,267)	-209 (-79,666 to 98,286)
UDC	16,210 (7 to 86,259)	158,335 (81,276 to 205,462)	22,124 (14,004 to 31,217)	151,015 (105,954 to 195,263)	143,289 (75,350 to 257,370)	29,838 (-121,839 to 130,949)
SDC	16,121 (23 to 83,355)	158,586 (88,232 to 203,339)	22,198 (14,169 to 31,021)	151,119 (110,691 to 193,520)	141,588 (76,197 to 237,970)	31,622 (-91,709 to 127,800)
UDI	15,387 (9 to 76,428)	162,334 (97,837 to 205,226)	21,473 (13,908 to 30,711)	154,969 (117,761 to 195,429)	132,913 (75,209 to 232,125)	43,549 (-73,383 to 130,796)
SDI	16,342 (149 to 71,053)	164,551 (111,833 to 197,813)	20,627 (14,199 to 29,183)	158,224 (131,015 to 189,786)	118,687 (76,055 to 217,748)	60,181 (-55,378 to 120,708)
SNoDI	13,842 (93 to 69,453)	171,033 (110,947 to 208,548)	20,275 (13,505 to 30,176)	163,102 (128,957 to 198,212)	120,905 (73,304 to 224,888)	62,564 (-62,082 to 135,299)
M	12,968 (1,656 to 53,015)	181,975 (131,817 to 209,180)	18,931 (14,297 to 25,775)	174,836 (149,400 to 198,491)	97,493 (73,262 to 135,514)	96,277 (43,886 to 136,525)

M, medication.

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.



TABLE 37 Cost and effects when using alternative health-care cost data

Support required	Intervention cost (£)
30 minutes with psychologist (base case)	26.50
5 minutes with psychologist	4.42
5 minutes with administrative support	1.50

**Note**

Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/by-nc/4.0>. The table includes minor additions and formatting changes to the original table.

### Exclusion of digital controls (unsupported digital control and supported digital control)

In a constrained health system, patients may be referred to reputable online resources to access information about their condition. However, it is not clear to what extent this occurs in the NHS in England, and so we explored a scenario in which UDCs and SDCs are not considered as possible treatment options. Exclusion of DCs does not affect the costs, QALYs or net benefit of other treatments, only their probability of being cost-effective and the VOI. The results are shown in Figures 34 and 35. Figure 34 shows that the ranking of interventions is unchanged. The intervention most likely to be cost-effective depends on the opportunity cost; it is NI for opportunity cost £0 per QALY, SNoDIs for opportunity cost £1000 per QALY and medication for opportunity costs £2000 per QALY or greater.

Figure 35 shows EVPI<sub>P</sub> over a range of opportunity costs. The relationship between EVPI<sub>P</sub> and the opportunity cost is comparable to that in the base case; VOI is lowest when opportunity cost is £4000 per QALY. The value of uncertainty is high, a minimum of £9.9B, increasing to £12.8B and £15.1B when the opportunity cost is £15,000 and £20,000 per QALY, respectively.





FIGURE 34 Cost-effectiveness acceptability curves without DCs. M, medication. Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.



**FIGURE 35** The  $EVPI_p$  for a range of opportunity costs. Adapted with permission from Jankovic *et al.*<sup>189</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for non-commercial use, provided the original work is properly cited. See: <https://creativecommons.org/licenses/by-nc/4.0/>. The figure includes minor additions and formatting changes to the original figure.





EME  
HS&DR  
**HTA**  
PGfAR  
PHR

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care*

***Published by the NIHR Journals Library***